国立大学法人

大阪大学

微生物病研究所

2014－2015

࿒ষContents‫ٽ͂ڟ״‬ါ

History & Outline

Ĳ

‫ࢹܥ‬

OrganizationĳႤయਫ਼ಿȟႤయ‫ޗ‬਎Former Directors & Professors

Ĵ

࿨૖֥൝

Department Heads

ĵࢹ଼֥

Faculty & StudentsĶࡄ‫ڰݪ‬൲͈‫ٽ‬ါResearch & Activitiesۜஅ‫ݪࡄࢹܥ‬໐࿝ȁȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤ
୆ఘཡࢄࡄ‫ݪ‬໐࿝ȁȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤ
۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝ȁȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤȤ
ඳহۜஅછచॐࡄ‫ݪ‬ΓϋΗȜȁȤȤȤȤȤȤȤȤȤȤȤ
֒ഥૂ༭৘ࡑΓϋΗȜȁȤȤȤȤȤȤȤȤȤȤȤȤȤȤ
ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȁȤȤȤȤȤȤȤȤȤȤȤȤȤ

ۜஅછ‫ڠ‬྾‫ڠע‬ဏࣣίυΈρθଔૺ৒

ķ
Ĳĵ
ĳĵ
Ĵĳ
Ĵĵ
ĵĳ

Ķı

Office of Combined Program on Microbiology and immunology඾ུȆΗͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜĶĴ

Thailand-Japan Research Collaboration Center on Emerging and Re-emerging InfectionsఱिġĮġζΪΡϋۜஅછΓϋΗȜĶķMahidol-Osaka Center for Infectious Diseases

ΟϋΈχ·ΙϋȪिఱ๷୆໤ພࡄ‫ݪ‬ٛȫ‫ݪࡄ້ܙ‬໐࿝

Ķĸ

BIKEN Endowed Department of Dengue Vaccine Development້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭

Research FacilitiesĶĹ྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜ

Immunology Frontier Research Centerķĵࠨॳȟົ౷ȟ࠺໤

Accounts & Building Area

ķķ

մඤ଎

Map & AccessķĹນঞৢ૯ȁ࿤ോġฎ‫ٽ͂ڟ״‬ါȁHistory & Outline‫״‬‫ڟ‬ȁ઎გːාȪ1929ȫ൚শ͈ఱि֓‫ش‬ఱ‫ڠ‬Ȫ઎გ˒ාఱिೱ࣭ఱ‫ۯ֊ͅڠ‬ȫ‫ڠ‬ಿනུಿ२჊͂ळ޿ࠬୄ‫ޗڠ‬਎౓࢛ᦂඵ͉ȂఱिȂ૰࡫̦΋τρȆβΑΠ͈̈́̓‫ٸ‬ြഥஅພ͈૟ව࿝࡫̜̹̭͂̈́ͤ̾̾̽͂͂Ȃఱୃ 12 ා

͂
‫ٽ‬
ါ

͈‫۾‬൐ఱૼब͈‫̥ͣ߱ޗ‬Ȃ‫۾‬ୌȂඅͅఱिͅ๷୆໤ພͅ‫̳ͥ۾‬௙ࣣഎࡄ‫ͬ۾ܥݪ‬୭ၛ̳ͥຈါ଻ͬ୰̧Ȃ൚শ͈ఱिຸ౶মড়ന஝२჊͞ఱि़‫ފͅٮ‬ႁͬါ୏̱̹ȃ५࢛࡚൸ঙ͉Ȃ̭͈ါ୏ͅ؊̢̀ 20 ྔ‫̱ັܙͬ׫‬Ȃ̭ͦͤ͢ͅ઎გ˕ාȪ1934ȫˎ࠮Ȃఱिঌཤߊ൴ോୌ಴ˏ๔౷ͅࡄ‫ݪ‬ਫ਼ུ‫̹̱ࢥੋ̦܁‬ȃ൴ോ΅λϋΩᾼ͉Ȃ‫ͅܡ‬ಅ๶ࠫ‫ݪࡄړ‬ਫ਼Ȫಅ๶হֲ‫מ‬࿝ঙ͈‫ັܙ‬ȫ͂ఱिඅਂ๧ໂພࡄ‫ݪ‬ਫ਼Ȫඈ঎‫ັܙ͈ز‬ȫ̦̜ͤȂ‫ڰ‬อ̈́ࡄ‫ڰݪ‬൲࣐̞̹̦ͬ̽̀Ȃ̭ͦͣˎ‫ͬ۾ܥ‬໵̵̀Ȃ઎გ˕ාȪ1934ȫ˕࠮ 17 ඾ೂ႓ 270 ࣢ͤ͢ͅȂఱिೱ࣭ఱ‫້ڠ‬౾͈๷୆໤ພࡄ‫ݪ‬ਫ਼ۗଷ̦࢖ື̯ͦȂུࡄ‫ݪ‬ਫ਼̦อ௷̳ͥͅঢ̹̽ȃ̷͈ࢃ 30 ဒාͬࠐ̀Ȃࡄ‫ݪ‬໐࿝Ȃঔ୭͈௩‫ฺ̞ͅح‬൴ോ౷ߊ͉ষలͅ‫ޛ‬᳕̹͂̈́̽ȃ̹͘૧̱̞ࡄ‫ݪ‬‫ڰ‬൲ͅచ؊̱ංͥࡄ‫ݪ‬৒͂੨ঔ୭͈ା๵ਰ৘͈̹͛Ȃఱिఱ‫͈ڠ‬଑ന΅λϋΩΑൡْࣣ͈ࠗల֚ଈ̱͂̀Ȃ઎გ 42 ාȪ1967ȫ࡛ह౷ͅ֊ഢ̱̹ȃȁ໹଼ˑාȪ1993ȫ˔࠮֓‫ڠ‬໐້௺ພ͈֭଑ന΅λϋΩΑΰ͈֊ഢͬ‫ͅܥ‬Ȃ‫͈܈‬হၷȂࡄ‫́̓̈́ݪ‬ఉ̩͈৘ୡུ̧̜̬̹ͬ̀ࡄ‫ݪ‬ਫ਼້௺ພ͉֭֓‫ڠ‬໐້௺ພ֭͂ൡࣣȂࣣ໵̱Ȃ60 ා̹̥̱̞ͩͥܵͅႤঃ͈ྃͬ໾
̲̹ȃུࡄ‫ݪ‬ਫ਼͉́Ȃ̭ͦͬࠀ‫̱̀͂ܥ‬Ȃ๷୆໤ພȂ̦ͭ‫͍ݞ‬අ೰͈ඳহ৖ۛͅ‫ڠ̳ͥ۾‬ၑ‫̷͈͍ݞ‬؊ဥࡄ‫͈֚ݪ‬௄͈อജͬ଎ͤȂˎˍଲ‫ͬܮ‬ജབ̱̹૧̱̞ࡄ‫ݪ‬ఘଷͬ‫ږ‬ၛ̳͓̩Ȃ໹଼˒ාȪ1994ȫਲြ͈໐࿝ଷ
ͬഢ̱۟Ȃఱ໐࿝ଷ͈͒٨ழ࣐̹ͬ̽ȃ໹଼ 17 ාȪ2005ȫ͉ۜͅஅ‫ࢹܥ‬Ȃ୆ఘཡࢄȂ۪‫ޏ‬؊൞͈ 3 ໐࿝Ȫ15 ໦࿤ȫͅठ༎଼̳ͥ͂͂͜ͅȂඳহ଻ۜஅછ࣪໚͈̹͛ͅඳহۜஅછచॐࡄ‫ݪ‬ΓϋΗȜȪ3 ໦࿤ȫ͂ۜஅછ࣭षࡄ
‫ݪ‬ΓϋΗȜȪ2 ໐࿝ 1 ৒ȫͬ૧୭ȃ̹͘ȂΊΦθૂ༭ٜଢ଼͈ࡄ‫ٳݪ‬อͬଔૺ̳ͥ֒ഥૂ༭৘ࡑΓϋΗȜȪ3 ໦࿤ȫͬ‫ڠ‬ඤ‫ވ‬൳‫ݪࡄ֗ޗ‬ঔ୭ུ̥ͣࡄ‫ݪ‬ਫ਼້௺ঔ୭̱͂̀ൡࣣȂ̯ͣͅȂ૧‫ޟ‬Ȇठ‫ۜޟ‬அછଷգ̫̹࣭࢜ͅषࡄ
‫ݶݪ‬തȶ඾ུȆΗͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜȷͬΗͼ࣭ၛထཡ‫מ‬୆ࡄ‫ݪ‬ਫ਼ඤͅ୭౾̱̹ȃ໹଼ 21 ාȪ2009ȫ
6 ࠮͉ͅȂ໲໐‫ڠش‬ఱ૳̥ͣ‫ވ‬൳၌ဥȆ‫ވ‬൳ࡄ‫ݶݪ‬ത̱͂̀෇೰ͬ਋̫Ȃ໹଼ 22 ාȪ2010ȫ4 ࠮̥ͣ‫ڰ‬൲ͬ‫ٳ‬ইȃ̯ͣͅȂ֒ഥঊ঩࡙͈‫ږ‬༗͂౶എਫ਼ခࡀ͈‫ږ‬༗ͬ࿒എ̱̹͂ȶ୆ఘ؊൞֒ഥঊٜଢ଼ΓϋΗȜȷͬ૧୭̱̹ȃȁུࡄ‫ݪ‬ਫ਼͉Ȃ஻ၛոြۜஅછ͈‫ܖ‬யഎࡄ‫̷͈͍ͣ̈́ͅݪ‬ଷգ̞̾̀ͅࡄ‫͛ૺͬݪ‬Ȃ૧̹̈́ພࡔ޿͞ພࡔ;ͼσΑ͈อࡉȂอພ͈ι΃ΣΒθ͈ٜྶȂχ·Ιϋ͞૷౯स͈‫ٳ‬อ̈́̓Ȃِ̦࣭͈ۜஅછ‫͍ݞ‬྾‫ڠע‬໦࿤́ఉఱ͈࣓ࡃ࣐ͬ̽̀ြ̹ȃ̹͘Ȃ̦ͭࡄ‫͈ݪ‬໦࿤̤̞̀͜ͅ઎გ 11 ාȪ1936ȫͅρΐ;θͬঀဥ̱̹ࡄ‫ٳͬݪ‬ই̳ͥ̈́̓Ȃఈ͈‫̦̫ͭ̀ߐ୶ͅ۾ܥ‬்͈‫ܢ‬อࡉ͂হၷ༹͈‫ٳ‬อ഼ͅႁ̳ͥ͂͂͜ͅȂ̦ͭอ୆͈ι΃ΣΒθ͈ࡄ‫ͬݪ‬ଔૺ̱̹ȃ̭͈࿂̤ͅ
̞̀͜Ȃଲ‫̹̫ߐ୶ͅٮ‬෽ူळ༾͈อ଼̦͈ͭࢗȂ̦ͭ֒ഥঊ̦ͭ͞;ͼσΑ͈อࡉ̈́̓ఉ଼̩͈‫ͬض‬̜̬Ȃ̦ͭࡄ‫͈ݪ‬อജͅఱ̧̩࣓ࡃ̱̹ȃ̹͘Ȃඳহ଻֒ഥঊ৖͈ۛࡄ‫̞̤֚̀͜ͅݪ‬໐ࡔ֦֒ഥঊ͈
๷୆໤ພࡄ‫ݪ‬ਫ਼୭ၛဇြൾโ‫ڣ‬Ȫུ‫۾࡚܁‬γȜσȫౙၗ̷͈͂‫ܥ‬ෝٜଢ଼̈́̓࿹̹ͦࡄ‫ૺ̦ݪ‬ജಎ̜́ͥȃ༷֚Ȃུࡄ‫ݪ‬ਫ਼́ड੝ͅอࡉ̯̹ͦळ༾ဏࣣ࡛
ય͉ఘळ༾֒ഥ‫͈ڠ‬อജ͞ౙ·υȜϋࢯఘ͈‫ٳ‬อ̈́५࢛࡚൸Ȫ̪̻̬̠ͭ̓͘͞ȫ࣓̓ͅࡃ̱Ȃ࡛య͈୆ྵ‫ܖ͈ڠش‬யͬಃ̞̹ȃĲĹķĴ ා֓঍͈ಿ౳̱͂̀๶ൽ́୆ͦͥ͘ȃĲĶ प́ఱिͅ੄̀Ȃ഼ႁ͈ྎ‫۾‬ୌͬయນ̳ͥ৘ު‫͂ز‬̈́ͥȃఱୃ˒ා͉ͅমު̥ͣ਀̧ͬ֨Ȃু఺́ಋൽ͂
૞ަ͈୆‫ͅڰ‬වͥȃু़͈ͣॲͬ࢖‫ވ‬মު͞২঳
͈͒‫́ࠁ̠̞͂ૺܙ‬২ٛ‫ࡓۺ‬ȃȁ̤̈́Ȃུࡄ‫ݪ‬ਫ਼͉́஠‫ڠུ̦֥ޗ‬ఱ‫ࡄࠏڠ֭֓ڠ‬‫شݪ‬Ȫ֚໐͉ၑ‫شݪࡄڠ‬Ȃ࿪‫شݪࡄڠ‬Ȇ୆ྵ‫ܥ‬ෝࡄ‫͜شݪ‬ȫฎআ‫ه‬೾͍̈́ͣͅਘআ‫ه‬೾͈‫ͬ֗ޗ‬౜൚̳ͥ͂‫଼̞̹̜͈ͥ̀̽֗ͅऺ૽ͅވ‬ȃ
Ĳ

‫ࢹܥ‬ȁOrganizationਫ਼ಿȁDirectorయ݈֥ٛȁDelegate Assembly‫ޗ‬਎ٛȁFaculty Meetingࡄ‫ݪ‬໐࿝ȁResearch Divisionۜஅ‫ݪࡄࢹܥ‬໐࿝ȁ໦ঊळ޿‫ڠ‬໦࿤ȁ;ͼσΑۜஅଷࢄ໦࿤
ȁ໦ঊ;ͼσΑ໦࿤ȁ࿪໤ၷ༹໦࿤
ȁۜஅພఠ໦࿤
୆ఘཡࢄࡄ‫ݪ‬໐࿝ȁ໦ঊ྾‫ע‬ଷࢄ໦࿤ȁ྾‫ע‬ະ஠৖ۛࡄ‫ݪ‬໦࿤ȁুட྾‫ڠע‬໦࿤ȁळ༾‫ܥ‬ෝ໦࿤ȁ྾‫ڠاע‬໦࿤۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝ȁ֒ഥঊ୆໤‫ڠ‬໦࿤ȁ໦ঊ֒ഥࡄ‫ݪ‬໦࿤ȁอ‫܈‬ଷࢄࡄ‫ݪ‬໦࿤ȁૂ༭ഥో໦࿤
ȁळ༾ଷࢄ໦࿤

ŅŪŷŪŴŪŰůġŰŧġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦŴ
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġŃŢŤŵŦųŪŰŭŰŨźġ
ȁŅŦűŢųŵŮŦůŵġŰŧġŗŪųŢŭġŭůŧŦŤŵŪŰůŴġ
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġŗŪųŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġőũŢųŮŢŤŰŵũŦųŢűź
ȁŅŦűŢųŵŮŦůŵġŰŧġŊŮŮŶůŰűŢųŢŴŪŵŰŭŰŨź
ŅŪŷŪŴŪŰůġŰŧġŉŰŴŵġŅŦŧŦůŴŦ
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġŊŮŮŶůŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġŊŮŮŶůŰųŦŨŶŭŢŵŪŰů
ȁŅŦűŢųŵŮŦůŵġŰŧġŉŰŴŵġŅŦŧŦůŴŦ
ȁŅŦűŢųŵŮŦůŵġŰŧġńŦŭŭġŃŪŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġŊŮŮŶůŰŤũŦŮŪŴŵųź
ŅŪŷŪŴŪŰůġŰŧġńŦŭŭŶŭŢųġŢůťġŎŰŭŦŤŶŭŢųġŃŪŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġŎŪŤųŰţŪŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġňŦůŦŵŪŤŴ
ȁŅŦűŢųŵŮŦůŵġŰŧġŐůŤŰŨŦůŦġœŦŴŦŢųŤũ
ȁŅŦűŢųŵŮŦůŵġŰŧġŔŪŨůŢŭġŕųŢůŴťŶŤŵŪŰů
ȁŅŦűŢųŵŮŦůŵġŰŧġńŦŭŭŶŭŢųġœŦŨŶŭŢŵŪŰů

້௺ঔ୭ȁSpecial Research Facilitiesඳহۜஅછచॐࡄ‫ݪ‬ΓϋΗȜȁळ޿ۜஅ໦࿤
ȁ໦ঊࡔಖ‫ڠ‬໦࿤ȁ;ͼσΑ྾‫ע‬໦࿤֒ഥૂ༭৘ࡑΓϋΗȜȁ֒ഥঊ‫ܥ‬ෝٜଢ଼໦࿤
ȁΊΦθૂ༭ٜଢ଼໦࿤
ȁۜஅછιΗΊΦθࡄ‫ݪ‬໦࿤ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȁࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝ȁۜஅଷࢄ໐࿝
ȁພࡔ๷୆໤঩࡙৒
ۜஅ൲໤৘ࡑঔ୭
ۜஅછŅŏłΙΛί‫ٳ‬อΓϋΗȜ୆ఘ؊൞֒ഥঊٜଢ଼ΓϋΗȜœŦŴŦŢųŤũġńŦůŵŦųġŧŰųġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦġńŰůŵųŰŭ
ȁŅŦűŢųŵŮŦůŵġŰŧġŃŢŤŵŦųŪŢŭġŊůŧŦŤŵŪŰůŴ
ȁŅŦűŢųŵŮŦůŵġŰŧġŎŰŭŦŤŶŭŢųġőųŰŵŰŻŰŰŭŰŨź
ȁŅŦűŢųŵŮŦůŵġŰŧġŗŪųŰŭŰŨź
ňŦůŰŮŦġŊůŧŰųŮŢŵŪŰůġœŦŴŦŢųŤũġńŦůŵŦų
ȁŅŦűŢųŵŮŦůŵġŰŧġņŹűŦųŪŮŦůŵŢŭġňŦůŰŮŦġœŦŴŦŢųŤũ
ȁŅŦűŢųŵŮŦůŵġŰŧġňŦůŰŮŦġŊůŧŰųŮŢŵŪŤŴ
ȁŅŦűŢųŵŮŦůŵġŰŧġŊůŧŦŤŵŪŰůġŎŦŵŢŨŦůŰŮŪŤŴ
ŊůŵŦųůŢŵŪŰůŢŭġœŦŴŦŢųŤũġńŦůŵŦųġŧŰųġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦŴġ
ȁŅŦűŢųŵŮŦůŵġŰŧġŔűŦŤŪŢŭġőŢŵũŰŨŦůŴ
ȁŅŦűŢųŵŮŦůŵġŰŧġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦġńŰůŵųŰŭ
ȁőŢŵũŰŨŦůŪŤġŎŪŤųŰţŦŴġœŦűŰŴŪŵŰųźġŖůŪŵ
łůŪŮŢŭġœŦŴŰŶųŤŦġńŦůŵŦųġŧŰųġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦŴ
ŅŏłĮŤũŪűġŅŦŷŦŭŰűŮŦůŵġńŦůŵŦųġŧŰųġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦŴ
ńŦůŵŦųġŧŰųġňŦůŦŵŪŤġłůŢŭźŴŪŴġŰŧġŃŪŰŭŰŨŪŤŢŭġœŦŴűŰůŴŦŴ

ۜஅછ‫ڠ‬྾‫ڠע‬ဏࣣίυΈρθଔૺ৒ȁOffice of Combined Program on Microbiology and immunologyࡄ‫ݪ‬ଔૺΈσȜί‫֗ޗ‬ଔૺΈσȜίœŦŴŦŢųŤũġőųŰŮŰŵŪŰůġňųŰŶű
ņťŶŤŢŵŪŰůġőųŰŮŰŵŪŰůġňųŰŶű

٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in Overseas඾ུȆΗͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜ ŕũŢŪŭŢůťĮŋŢűŢůġœŦŴŦŢųŤũġńŰŭŭŢţŰųŢŵŪŰůġńŦůŵŦųġŰůġņŮŦųŨŪůŨġŢůťġœŦĮŦŮŦųŨŪůŨġŊůŧŦŤŵŪŰůŴ
ȁळ޿ۜஅ໐࿝
ȁŔŦŤŵŪŰůġŰŧġŃŢŤŵŦųŪŢŭġŊůŧŦŤŵŪŰůŴ
ȁ;ͼσΑۜஅ໐࿝
ȁŔŦŤŵŪŰůġŰŧġŗŪųŢŭġŊůŧŦŤŵŪŰůŴ
ఱिȽζΪΡϋۜஅછΓϋΗȜŎŢũŪťŰŭĮŐŴŢŬŢġńŦůŵŦųġŧŰųġŊůŧŦŤŵŪŰŶŴġŅŪŴŦŢŴŦŴ
ΟϋΈχ·ΙϋȪिఱ๷୆໤ພࡄ‫ݪ‬ٛȫ‫ݪࡄ້ܙ‬໐࿝ġġġġġġġġġġġġġġġġġġġġġġġġġġġŃŊŌņŏġņůťŰŸŦťġŅŦűŢųŵŮŦůŵġŰŧġŅŦůŨŶŦġŗŢŤŤŪůŦġŅŦŷŦŭŰűŮŦůŵ

‫ވ‬೒ঔ୭ȁCommon Research Facilitiesಎ؇৘ࡑ৒༶ৣ଻൳պࡓள৘ࡑ৒
ۜஅછ‫ވ‬൳৘ࡑ৒଎੥৒ńŦůŵųŢŭġŊůŴŵųŶŮŦůŵŢŵŪŰůġōŢţŰųŢŵŰųź
œŢťŪŰŪŴŰŵŰűŦġōŢţŰųŢŵŰųź
ńŦůŵųŢŭġōŢţŰųŢŵŰųźġŧŰųġŃŪŰŭŰŨŪŤŢŭġŉŢŻŢųťŰŶŴġŎŪŤųŰţŦŴ
ōŪţųŢųź

মྩ໐ȁAdministration੢ྩ߸ٛࠗ߸ࡄ‫ފݪ‬ႁ߸

ňŦůŦųŢŭġłŧŧŢŪųŴġŔŦŤŵŪŰů
łŤŤŰŶůŵŪůŨġŔŦŤŵŪŰů
œŦŴŦŢųŤũġńŰŰűŦųŢŵŪŰůġŔŦŤŵŪŰů

ଲ‫ٮ‬ΠΛίτασ‫ݶ‬തȁWorld Premier International Research Center྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜĳŊŮŮŶůŰŭŰŨźġŇųŰůŵŪŦųġœŦŴŦŢųŤũġńŦůŵŦų

Ⴄయਫ਼ಿȟႤయ‫ޗ‬਎ȁFormer Directors & ProfessorsႤయਫ਼ಿȁFormer DirectorsĲĺĴĵį˕ȽĲĺĵıįġķ੝యġ ࡣ໌ġ࿥অ჊ġȪ઎გ˕ා˕࠮ȡ઎გĲĶා˒࠮ȫ ŚŢŴũŪųŰġŌŰŵŢŬŦĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
Ĳĺĵıį˔ȽĲĺĵĴįġĸˎయġ ࣽఆġ࣏౳ġ Ȫ઎გĲĶා˔࠮ȡ઎გĲĹා˓࠮ȫġ łųŢŰġŊŮŢŮŶųŢĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
ĲĺĵĴį˓ȽĲĺĶĶįġĴˏయġ ౓࢛ġᦂඵġ Ȫ઎გĲĹා˓࠮ȡ઎გĴıාˏ࠮ȫ ŕŦůūŪġŕŢůŪŨŶŤũŪĭġŎįŅįĭġőųŰŧŦŴŴŰųġġːయġ ൥࿤ġࢭ२჊ġȪ઎გĴıාː࠮ȡ઎გĴĴාˏ࠮ȫ ŕŴŶůŦŴŢţŶųŰġŇŶūŪůŰĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ ĲĺĶĶįːȽĲĺĶĹįġĴˑయġ ‫ۀ‬൸ġਗ਼ఊ჊ġȪ઎გĴĴාː࠮ȡ઎გĴĺාˏ࠮ȫ ŋŶůŵŢųŰġŌŢŮŢũŰųŢĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ ĲĺĶĹįːȽĲĺķĵįġĴ˒యġ ഛ࿤ġࢭ‫ݛ‬ġ Ȫ઎გĴĺාː࠮ȡ઎გĵĴාˏ࠮ȫ ŕŴŶůŦũŪŴŢġłŮŢůŰĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ ĲĺķĵįːȽĲĺķĹįġĴ
ĲĺķĹįːȽĲĺĸĳįġĴ˓యġ ؈࿤ġၻ૳ġ Ȫ઎გĵĴාː࠮ȡ઎გĵĸාˏ࠮ȫ ŚŰŴũŪŰŮŪġŐŬŶůŰĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
ĲĺĸĳįːȽĲĺĸķįġĴ˔యġ ཱġ२ೋຳġ Ȫ઎გĵĸාː࠮ȡ઎გĶĲාˏ࠮ȫ ŎŪŵŴŶŰġŉŰųŪĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ˕యġ ୼ྋġਜ਼֚ġ Ȫ઎გĶĲාː࠮ȡ઎გĶĶාˏ࠮ȫ ŋŶůŪŤũŪġŌŢŸŢŮŢŵŢĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ ĲĺĸķįːȽĲĺĹıįġĴ
ĲĺĹıįːȽĲĺĹĵįġĴ
Ĳıయġ ‫ح‬൥ġঅ჊ġ Ȫ઎გĶĶාː࠮ȡ઎გĶĺාˏ࠮ȫ ŔũŪųŰġŌŢŵŰĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
ĲĲయġ ࣞ‫ޘ‬ġၑྶġ Ȫ઎გĶĺාː࠮ȡ઎გķĲාˏ࠮ȫ ŎŪŤũŪŢŬŪġŕŢŬŢũŢŴũŪĭŎįŅįĭġőųŰŧŦŴŴŰųġġ ĲĺĹĵįːȽĲĺĹķįġĴ
ĲĺĹķįːȽĲĺĹĹįġĴ
Ĳĳయġ २ႊ౓ġੇຳġȪ઎გķĲාː࠮ȡ઎გķĴාˏ࠮ȫ ŕŰŴũŪŰġŎŪŸŢŵŢůŪĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
ĲĴయġ ‫זڙ‬ġ໌ຳġ Ȫ઎გķĴාː࠮ȡ઎გķĴා˕࠮ȫ ŕŢŬŦŰġŌŢŬŶůŢŨŢĭġŅįőũŢųŮįĭġőųŰŧŦŴŴŰųġġ ĲĺĹĹįːȽĲĺĹĹįġĺ
ĲĺĹĹįĲĲȽĲĺĺıįĲı
Ĳĵయġ ൥๶ġ߼ġȪ઎გķĴාĲĲ࠮ȡ໹଼ˎාĲı࠮ȫ ŉŢūŪŮŦġŇŶūŪŰĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
ĲĶయġ ཅോġ‫ݛ‬૯౳ġȪ໹଼ˎාĲĲ࠮ȡ໹଼ˑාĲı࠮ȫ ŌŶŮŢŰġŕŰźŰŴũŪŮŢĭġŎįŅįĭġőųŰŧŦŴŴŰųġ ĲĺĺıįĲĲȽĲĺĺĴįĲı
ĲĺĺĴįĲıȽĲĺĺĸįĲı
Ĳķయġ ֵாġྶġȪ໹଼ˑාĲı࠮ȡ໹଼˕ාĲı࠮ȫ łŬŪųŢġŉŢŬŶųŢĭġŅįŔŤįĭġőųŰŧŦŴŴŰųġġ
Ĳĸయġ ୌਕġ݅໌ġ Ȫ໹଼˕ාĲı࠮ȡ໹଼ĲĴාĲı࠮ȫ ŚŰŴũŪŵŢŬŦġŏŪŴũŪŮŶůŦĭŎįŅįĭġőųŰŧŦŴŴŰųġġĲĺĺĸįĲıȽĳııĲįĲı
ĳııĲįĲıȽĳııĴįĲı
ĲĹయġ ུനġ໌ংġ Ȫ໹଼ĲĴාĲı࠮ȡ໹଼ĲĶාĲı࠮ȫ ŕŢŬŦūŪġŉŰůťŢĭġŎįŅįĭġőųŰŧŦŴŴŰųġġ
Ĳĺయġ ࿐‫ئ‬ġΗυ;ġȪ໹଼ĲĶාĲı࠮ȡ໹଼ĲĺාĲı࠮ȫ ŕŢųŰũġŌŪůŰŴũŪŵŢĭġŅįŎŦťįŔŤįĭġőųŰŧŦŴŴŰųġġĳııĴįĲıȽĳııĸįĲı
ĳııĸįĲıȽĳıĲĲįĲı
ĳıయġ ݊౓ġ૾ġȪ໹଼ĲĺාĲı࠮ȡ໹଼ĳĴාĲı࠮ȫ ŉŪŵŰŴũŪġŌŪŬŶŵŢůŪĭġŎįŅįĭġőųŰŧŦŴŴŰųġ
ĳıĲĲįĲıȽ
ĳĲయġ ࿒‫ح‬നġ‫ם‬༟ġȪ໹଼ĳĴාĲı࠮ȡġġġġġġġġġġġġġġġġġġġȫ ņŪŴŶŬŦġŎŦŬŢťŢĭġőũįŅįĭġőųŰŧŦŴŴŰųġ

‫ܥ‬
ࢹ
ȟ
Ⴄ
య
ਫ਼
ಿ
ȟ
Ⴄ
య
‫ޗ‬
਎

Ⴄయ‫ޗ‬਎ȁFormer Professors֓‫ڠ‬ฎআȁࡣ໌ġ࿥অ჊ġਫ਼ಿ֓‫ڠ‬ฎআȁ‫݌‬നġ೭ဎġ‫ܙ‬୆ಖ‫ڠ‬֓‫ڠ‬ฎാȁࣽఆġ࣏౳ġਫ਼ಿ֓‫ڠ‬ฎআȁऎ౓ġခ‫݌‬ġឦহၷࡄ‫ݪ‬໐֓‫ڠ‬ฎআȁ౓࢛ġᦂඵġਫ਼ಿ֓‫ڠ‬ฎআȁଲၻġࢡఊġळ޿‫ڠا‬໐֓‫ڠ‬ฎআȁଽ५ġၨඃġ‫܈‬হၷ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁఱ౓ġય໹ġळ޿‫ڠا‬໐֓‫ڠ‬ฎআȁ‫۾‬ġ೶অ჊ġཡ‫ڠע‬໐
֓‫ڠ‬ฎআȁଌനġୃྜġळ޿‫ڠا‬໐֓‫ڠ‬ฎআȁ૩‫ئ‬ġ߰ġ‫ܙ‬୆ಖࡔಖ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁ५࢛ġ਍ġႉ઄໐࿝֓‫ڠ‬ฎআȁ൥࿤ġࢭ२჊ġळ޿ࠬୄ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁչ൥ġଽ֚ġల֚ࠫ‫شݪࡄړ‬֓‫ڠ‬ฎআȁ‫ۀ‬൸ġਗ਼ఊ჊ġਆន;ͼσΑ໐࿝֓‫ڠ‬ฎআȁୌఆġ៍ඵġឦ໐࿝֓‫ڠ‬ฎআȁ‫ح‬൥ġ֢຃ġࠫ‫ړ‬ພၑ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁༀനġୃ຃ġࢯॸ޿୆ၑ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁঢ়ġ࿆ġႉ઄സ࿝֓‫ڠ‬ฎআȁಞ࿐ġୃ२ġ‫ܙ‬୆ಖࡔಖ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁཱġ२ೋຳġࠫ‫ړ‬ພၑ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁ؈࿤ġၻ૳ġཻ૮໐࿝֓‫ڠ‬ฎআȁ୞ષġਹ࣐ġႉ઄໐࿝֓‫ڠ‬ฎআȁഛ࿤ġࢭ‫ݛ‬ġ྾‫ڠاע‬໐࿝֓‫ڠ‬ฎআȁ୼ྋġਜ਼֚ġ‫ڠا‬ၷ༹໐࿝
֓‫ڠ‬ฎআȁ‫ؖ‬നġ஝ဎġ൲໤;ͼσΑ໐࿝ၑ‫ڠ‬ฎআȁು‫ݳ‬ġ࢕ဎġ྾‫ڠاע‬໐࿝֓‫ڠ‬ฎআȁ૬֔ġࢣ෗੩ġཡ‫ڠע‬໐࿝
֓‫ڠ‬ฎআȁ૩ġၨ౳ġࠫ‫ړ‬ພၑ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁչ൥ġ၌आఊ჊ġ ឦ໐࿝࿪‫ڠ‬ฎআȁ‫זڙ‬ġ໌ຳġอ‫֒܈‬ഥঊ໐࿝
֓‫ڠ‬ฎআȁ‫ح‬൥ġঅ჊ġۜஅພၑ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁಎႅġຮຳġࡔಖ‫ڠ‬໐࿝
֓‫ڠ‬ฎআȁ५෗ඤġࢣંġۜஅ൲໤৘ࡑঔ୭
֓‫ڠ‬ฎআȁ२ႊ౓ġੇຳġळ޿ࠬୄ‫ڠ‬໐࿝֓‫ڠ‬ฎআȁࣞ‫ޘ‬ġၑྶġ ཻ૮໐࿝֓‫ڠ‬ฎআȁ൥๶ġ߼ġ྾‫ڠاע‬໐࿝֓‫ڠ‬ฎআȁന࢛ġᲔ౳ġ ႉ઄໐࿝ၑ‫ڠ‬ฎআȁઐయġՔ२ġ ळ޿;ͼσΑ໐࿝ၑ‫ڠ‬ฎআȁಎനġඈ౳ġ ‫ڠا‬ၷ༹໐࿝֓‫ڠ‬ฎআȁ‫ؖ‬५ġฎ૽ġ ໦ঊ֒ഥࡄ‫ݪ‬໦࿤֓‫ڠ‬ฎআȁཅോġ‫ݛ‬૯౳ġ อ‫֒܈‬ഥঊ໐࿝֓‫ڠ‬ฎআȁ࿐౓ġચຳġ ႉ઄໐࿝֓‫ڠ‬ฎআȁࣞ֔ġ૧֚჊ġ ႉ઄໐࿝֓‫ڠ‬ฎআȁઐനġ৿ࢬġ ळ޿ඉள‫ڠ‬໦࿤֓‫ڠ‬ฎআȁߪఆġࠉġ;ͼσΑۜஅଷࢄ໦࿤
֓‫ڠ‬ฎআȁ५ୌġࢬ֚ġ ;ͼσΑ྾‫ע‬໦࿤ၑ‫ڠ‬ฎআȁֵாġྶġ‫ဲ܈‬ଷ֒ഥঊࡄ‫ݪ‬໦࿤Ȫ࠳ġਆន;ͼσΑ໦࿤ȫၑ‫ڠ‬ฎআȁਝ५ġഔġอ‫܈‬ଷࢄࡄ‫ݪ‬໦࿤֓‫ڠ‬ฎআȁாനġ‫ܧ‬ġ΀ζȜΐϋΈۜஅછࡄ‫ݪ‬ΓϋΗȜ֓‫ڠ‬ฎআȁષനġਹୀġ ૰ࠐ;ͼσΑ໦࿤֓‫ڠ‬ฎআȁോനġგങġ ֒ഥঊ৖ۛࡄ‫ݪ‬໦࿤֓‫ڠ‬ฎআȁॕ୼ġ୷ଂġ ळ޿ඉள‫ڠ‬໦࿤ၑ‫ڠ‬ฎআȁ଩࿤ġྶဎġ ֒ഥঊໝୋࡄ‫ݪ‬໦࿤֓‫ڠ‬ฎআȁୄ࿤ġࢤġ྾‫ڠاע‬໦࿤֓‫ڠ‬আȁȁୌਕġ݅໌ġ ۜஅ൲໤৘ࡑঔ୭
֓‫ڠ‬ฎআȁಏ࿤ġഔġ֒ഥঊ൲ఠࡄ‫ݪ‬໦࿤ၑ‫ڠ‬ฎআȁ຦୼ġ඾੄ຳġ ֒ഥঊ୆໤‫ڠ‬໦࿤ၑ‫ڠ‬ฎআȁനఆġᐤ֚ġ ;ͼσΑۜஅထཡ‫ݪࡄ້ܙ‬໐࿝֓‫ڠ‬ฎআȁઐനġൽ࣐ġ ૂ༭ഥో໦࿤
֓‫ڠ‬ฎআȁུനġ໌ংġ ळ޿ۜஅ໦࿤
֓‫ڠ‬ฎআȁ౓࢛ġೄ෗ġ ৖ۛൠङ‫ڠ‬Ȫ୆‫ުࢥڠا‬ȫ‫ݪࡄ້ܙ‬໐࿝֓‫ڠ‬ฎআȁ‫݌‬૩ġ༗ġळ༾ଷࢄ໦࿤
֓‫ڠ‬ฎআȁനᰧġგ᫜ġ ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜၑ‫ڠ‬ฎআȁུࣽġ໲౳ġ ໦ঊ୆໤‫ݪࡄ້ܙڠ‬໐࿝֓‫ڠ‬ฎআȁߧΦ‫ޡ‬ġ੓ġ ۜஅພఠ໦࿤
֓‫ڠ‬ฎআȁఱ୞ġგඃġ ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜ֓‫ڠ‬ฎআȁܹ‫ؖ‬ġୃങġ ඾ུȆΗͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜ࿪‫ڠ‬ฎআȁ‫ؖ‬໐ġੳġ୆ఘ؊൞֒ഥঊٜଢ଼ΓϋΗȜ֓‫ڠ‬ฎআȁ୆നġგၻġ ;ͼσΑ྾‫ע‬໦࿤Ĵ࿨૖֥൝ȁDepartment Heads
໹଼26ා4࠮1඾࡛ह

ĵ

ਫ਼ಿ
໗ਫ਼ಿ

‫ޗ‬਎
‫ޗ‬਎

֓‫ڠ‬ฎআ
਷֓‫ڠ‬ฎআ

࿒‫ح‬നġ‫ם‬༟ઐ‫׆‬ġ஝হ

ۜஅ‫ݪࡄࢹܥ‬໐࿝ȁ໦ঊळ޿‫ڠ‬໦࿤ȁ;ͼσΑۜஅଷࢄ໦࿤
ȁ໦ঊ;ͼσΑ໦࿤ȁ࿪໤ၷ༹໦࿤
ȁۜஅພఠ໦࿤

‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎

෠‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
਷֓‫ڠ‬ฎআཱ࢛ġհ຃‫؂‬നġోဎ
ઐ‫׆‬ġ஝হ‫ޗ‬਎֓‫ڠ‬ฎআ

५ུġٗဉ୆ఘཡࢄࡄ‫ݪ‬໐࿝ȁ໦ঊ྾‫ע‬ଷࢄ໦࿤ȁ྾‫ע‬ະ஠৖ۛࡄ‫ݪ‬໦࿤ȁুட྾‫ڠע‬໦࿤ȁळ༾‫ܥ‬ෝ໦࿤ȁ྾‫ڠاע‬໦࿤

‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎

֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ݊౓ġ૾࿐‫ئ‬ġΗυ;
ૣၻġ୓౳࿒‫ح‬നġ‫ם‬༟࣏ଳġં۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝ȁ֒ഥঊ୆໤‫ڠ‬໦࿤ȁ໦ঊ֒ഥࡄ‫ݪ‬໦࿤ȁอ‫܈‬ଷࢄࡄ‫ݪ‬໦࿤ȁૂ༭ഥో໦࿤
ȁळ༾ଷࢄ໦࿤

ȁ
‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎

ၑ‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ࿤ോġฎ‫ؖ‬നġٗ૽
ࣞாġ૝ࢨ
२࿐ġဉྶ

ඳহۜஅછచॐࡄ‫ݪ‬ΓϋΗȜȁळ޿ۜஅ໦࿤
ȁ໦ঊࡔಖ‫ڠ‬໦࿤ȁ;ͼσΑ྾‫ע‬໦࿤֒ഥૂ༭৘ࡑΓϋΗȜȁ֒ഥঊ‫ܥ‬ෝٜଢ଼໦࿤
ȁΊΦθૂ༭ٜଢ଼໦࿤
ȁۜஅછιΗΊΦθࡄ‫ݪ‬໦࿤ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȁࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝ȁȁႉ઄ۜஅછ‫ݪࡄڠ‬ΈσȜίȁȁۜஅळ༾୆໤‫ݪࡄڠ‬ΈσȜίȁȁ;ͼσΑࡄ‫ݪ‬ΈσȜίȁۜஅଷࢄ໐࿝
ȁȁΊΦθພࡔळ޿‫ݪࡄڠ‬ΈσȜίȁȁ;ͼσΑໝୋࡄ‫ݪ‬ΈσȜίȁȁۜஅછ‫ڠ‬Ȇ྾‫ڠע‬ဏࣣࡄ‫ݪ‬ΈσȜίȁພࡔ๷୆໤঩࡙৒

ΓϋΗȜಿȆ‫ޗ‬਎ၑ‫ڠ‬ฎআ

ཱ֔ġੇࢤ

‫ޗ‬਎

ၑ‫ڠ‬ฎআ

ཱ֔ġੇࢤΓϋΗȜಿȆ‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎
‫ޗ‬਎ġ
ΓϋΗȜಿȆ‫ޗ‬਎ȁၑ‫ڠ‬ฎআ
࿪‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআġၑ‫ڠ‬ฎআ

հ‫ז‬ġચဎչ୼ġୃ૽հ‫ז‬ġચဎ
ཱ֔ġੇࢤ
ཱ֔ġੇࢤ

අහ‫ޗ‬਎
අහ੎‫ޗ‬਎ȁඅහ‫ޗ‬਎
අහ੎‫ޗ‬਎੎‫ޗ‬਎අහ‫ޗ‬਎

֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ

൥‫ז‬ġဇ‫ج‬ঊ૩നġ‫ם‬঄֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ
֓‫ڠ‬ฎআ๑നġഓ࿟઀ႅġ࣠‫֔ז‬ġࢤਏȁȁȁ๑നġഓ࿟ۜஅ൲໤৘ࡑঔ୭
ۜஅછDNAΙΛί‫ٳ‬อΓϋΗȜ୆ఘ؊൞֒ഥঊٜଢ଼ΓϋΗȜঔ୭ಿȆ‫ޗ‬਎ΓϋΗȜಿȆ‫ޗ‬਎ΓϋΗȜಿȆ‫ޗ‬਎࿪‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ
࿪‫ڠ‬ฎআ

չ୼ġୃ૽
࿤ോġฎ
չ୼ġୃ૽

ۜஅછ‫ڠ‬྾‫ڠע‬ဏࣣίυΈρθଔૺ৒ȁࡄ‫ݪ‬ଔૺΈσȜίȁ‫֗ޗ‬ଔૺΈσȜί

৒ಿȆਫ਼ಿ
੎‫ޗ‬਎
੎‫ޗ‬਎

֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ
֓‫ڠ‬ฎআ

࿒‫ح‬നġ‫ם‬༟
ఆષġၻঊ
൥֔ġ༠ࣞ

඾ུȆΗͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜȁȁळ޿ۜஅ໐࿝
ȁȁ;ͼσΑۜஅ໐࿝ΓϋΗȜಿȆඅහ‫ޗ‬਎ ֓‫ڠ‬ฎআඅහ‫ޗ‬਎
ভ‫ڠ‬ฎআ
අහ‫ޗ‬਎
֓‫ڠ‬ฎআ

໌നġೄგ
ຩനġ࿆ࢨ
໌നġೄგ

ఱिȽζΪΡϋۜஅછΓϋΗȜΓϋΗȜಿȆ‫ޗ‬਎අහ੎‫ޗ‬਎਷֓‫ڠ‬ฎআ
਷֓‫ڠ‬ฎআ

ઐ‫׆‬ġ஝হ
‫ؖ‬ႅġ۪ਏ

ΟϋΈχ·Ιϋ
Ȫिఱ๷୆໤ພࡄ‫ݪ‬ٛȫ‫ݪࡄ້ܙ‬໐࿝‫ޗ‬਎֓‫ڠ‬ฎআ

઀ୌġ‫ם‬ඵಎ؇৘ࡑ৒༶ৣ଻൳պࡓள৘ࡑ৒
ۜஅછ‫ވ‬൳৘ࡑ৒৒ಿȆ‫ޗ‬਎৒ಿȆ‫ޗ‬਎৒ಿȆ‫ޗ‬਎ၑ‫ڠ‬ฎআ
ၑ‫ڠ‬ฎআ
֓‫ڠ‬ฎআ

२࿐ġဉྶ२࿐ġဉྶ‫؂‬നġోဎ

଎੥৒৒ಿȆ‫ޗ‬਎ၑ‫ڠ‬ฎআ

२࿐ġဉྶ

মྩ໐

মྩಿ

୞ாġ݅૞

ࢹ଼֥ȁFaculty & Students૖֥ȁStaff໹଼26ා4࠮1඾࡛ह‫ޗ‬਎

Professor

16‫ݪࡄ້ܙ‬໐࿝‫ޗ‬਎Endowed Chair Professor1අහ‫ޗ‬਎

SA Professor

5

੎‫ޗ‬਎

Associate Professor

14අහ੎‫ޗ‬਎SA Associate Professor

7࣒঍Associate Professor

1

අහ࣒঍

SA Associate Professor

5

੩‫ޗ‬

Assistant Professor

28‫ݪࡄ້ܙ‬໐࿝੩‫ޗ‬Endowed Chair Assistant Professor1අහ੩‫ޗ‬SA Assistant Professor

7‫ྩޗ‬૖֥

Educational Support Staff

3

ܿ੅૖֥

Technical Staff

7

মྩ૖֥

Administrative Staff

22අහࡄ‫֥ݪ‬SA Researcher48মྩȆܿ੅༞ऎ֥

Part-time General & Technical staff

39ȁࠗȁTotal

203

࿨
૖
֥
൝
ȟ
ࢹ
଼
֥

SA ȇ Specially Appointedఱ‫ڠ֭ڠ‬୆ȁGraduate Students໹଼26ා4࠮1඾࡛हฎআ‫ه‬೾

ਘআ‫ه‬೾

Doctor Course

Master Course֓‫شݪࡄࠏڠ‬Graduate School of Medicine

358ၑ‫شݪࡄڠ‬Graduate School of Science11࿪‫شݪࡄڠ‬Graduate School of Pharmaceutical Science22ভ‫شݪࡄڠ‬Graduate School of Dentistry00୆ྵ‫ܥ‬ෝࡄ‫شݪ‬Graduate School of Frontier Biosciences

8

0

ȁࠗ

ȁTotal46

11ɦ๷୆໤ພࡄ‫ݪ‬ਫ਼ͅ෻௺͈৪ͬࠗષ

ࡄ‫֥ݪ‬Ȇࡄ‫ݪ‬୆ȁResearch Fellows & Research Students໹଼26ා4࠮1඾࡛हඅ༆ࡄ‫ڠݪ‬୆Special research students

4

ࡄ‫ݪ‬୆

Research Students

5‫ݪࡄ૽࣭ٸ‬৪

Visiting Research Scholars

3඾ུ‫੅ڠ‬૦‫ޟ‬ٛඅ༆ࡄ‫֥ݪ‬ȪPDȫ

JSPS Research Fellows

1ȁࠗȁTotal13Ķࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅ‫ݪࡄࢹܥ‬໐࿝໦ঊळ޿‫ڠ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁ෠‫ڠ‬ฎআȁཱ࢛ȁհ຃੩‫ޗ‬ȁၑ‫ڠ‬ฎআȁհ෼ȁဉਜ਼੩‫ޗ‬ȁ࿪‫ڠ‬ฎআȁ૧ᚧȁೄྶඅහࡄ‫֥ݪ‬ȁΨͼ΂΍ͼ΀ϋΑฎআȁ໛֔ȁȁၑඅහࡄ‫֥ݪ‬ȁ਷֓‫ڠ‬ฎআȁȁȁȁȁȁಎఆȁ‫ج‬ংࡄ‫ݪ‬ඤယȇ൚໦࿤͉́Ȃळ޿͈ພࡔ֦ঊ̦਽৽ळ༾‫ܥ‬ෝͅ‫ͬޣג̳͖ݞ‬໦ঊτασٜ́ଢ଼̱̞̀ͥȃ࡛हૺ࣐ಎ͈ࡄ‫ݪ‬‫ه‬ఴ͉ո‫͈ئ‬೒̜ͤ́ͥȃȪˍȫȁळ޿଻ΗϋΩ·ඉள͈ࢹ௮͂‫ܥ‬ෝ͈ٜଢ଼ȁ౷‫ݩ‬ષͅంह̳ͥඉ଻໤ৗ͈ಎ́Ȅळ޿଻ΗϋΩ·ඉள͈ඉ଻͉գുഎ̩ࣞͅȂ̷̹͈͘ैဥ̧͉ͩ͛̀ळ༾Ȇດഎ໦ঊඅ։എ̜́ͥȃ൚ࡄ‫ݪ‬৒͉́Ȅຐ඾‫޿ٹ‬ٟঘඉȂΩΑΜτρඉளȂ;΀σΏν޿΀ϋΞυΠ΅ΏϋȄఱಸ޿ळ༾ٟঘ֦
ঊ̈́̓ਅș͈ळ޿ඉளͬऺၳͅဥ̞̀Ȃ൲໤Ȅழ૕Ȅळ༾Ȅ໦ঊτασ́ळ޿଻ΗϋΩ·ඉள͈ैဥ‫ͬࢹܥ‬ٜଢ଼̱̞̀ͥȃ̹͘Ȃ‫ڎ‬ඉள͈‫ܥ‬ෝΡιͼϋ໦ືٜଢ଼̤͍͢ၛఘࢹ௮ٜଢ଼̳̳ͬ͛Ȅၰ৪଼͈‫ͬض‬໵̵̀ඉள͈ࢹ௮͂‫ܥ‬ෝ͈஠ఘ௨͈ၑ
ٜͬ࿒ঐ̱̞̀ͥȃȪˎȫȁຐ඾‫ٹ‬ພఠ͈ٜଢ଼
ȁຐ඾‫̜ͥ́޿֦ࡔ͈ٹ‬ຐ඾‫͉޿ٹ‬ȂΪΠ͈ષ໐‫ܨ‬ൽۜͅஅ̱̀อै଻‫ٹ‬቞ͬ৽છે̳͂ͥພ‫̳̭ܳͬܨ‬ȃུ޿͉ΪΠ͈͙ͬ਽৽̳̦͂ͥȂ̭͈਽৽අ։଻ͬࠨ೰̳ͥ਽৽௰ါ֦͞ळ޿௰ါ֦͉ະྶ̜́ͥȃ̹͘อै଻‫ٹ‬቞͈อછι΃ΣΒθ͜ྶ̥̯̞̞ͣͦ̀̈́ͅȃ൚ࡄ‫ݪ‬৒͉́Ȃ̭͈ͦͣ͏̹͈̾݃࿚͈ٝ൞ͬං̹ͥ͛Ȃຐ඾‫̷͈͞޿ٹ‬႒‫ͬ޿׻‬ဥ̞̹൲໤ۜ
அκΟσ̤̫ͥͅພఠٜͬଢ଼̱̞̀ͥȃ଎ˍȇఉद̈́ळ༾‫ܥ‬ෝͅ‫̳͖ݞͬޣג‬ळ޿ඉளळ޿ඉள͈ఉ̩͉਽৽ळ༾͈ਹါ̈́‫ܥ‬ෝͬਘૐ̳̭ͥ͂̽̀࢘͢ͅၚഎͅैဥͬอ‫̳ͥܞ‬ȃ̳̻̈́ͩळ޿ඉள͈ैဥ‫͈ࢹܥ‬ٜଢ଼͉ळ޿ۜஅພఠ̴͈͙̈́ͣ൲໤ळ༾‫ܥ‬ෝ͈ၑٜ͜ͅ࿨ၛ
̢̞̾͂ͥȃ

ķ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଎ˎȇ;΀σΏν޿΀ϋΞυΠ΅Ώϋ͈ၛఘࢹ௮

଎ˏȇຐ඾‫޿ٹ‬ȪBordetella pertussisȫ႒‫ۯܨ͈׻‬঑෴ࠬછ޿ȪB. bronchisepticaȫ͂႒ຐ඾‫޿ٹ‬ȪB. parapertussisȫ͈ΊΦθ΍ͼΒ͂਽৽අ։଻ȃ0ES ͈ΊΦθ΍ͼΒͬ঵̾‫ۯܨ‬঑෴ࠬછ޿͉ఉਅ႒͈൲
໤ͬ਽৽ͅ঵̻Ȃ֒ഥঊ͈ഢպࠧ͞৐́ΊΦθ΍ͼΒ͈઀̯̩̹̈́̽႒ຐ඾‫͞޿ٹ‬ຐ඾‫͉޿ٹ‬਽৽ํս͜‫̩ͥ̈́ޛ‬ȃड߃͈యນഎ̈́ა໲
1. Substrate specificity of Pasteurella multocidaWR[LQIRUĮVXEXQLWVRIKHWHURWULPHULF*SURWHLQV2UWK-+)HVWHU,
6LHJHUW3:HLVH0/DQQHU8.DPLWDQL67DFKLEDQD7:LOVRQ%$6FKORVVHU$+RULJXFKL<$NWRULHV.
FASEB J)HE  
 6ZLQHDWURSKLFUKLQLWLVFDXVHGE\Pasteurella multocidaWR[LQDQGBordetellaGHUPRQHFURWLFWR[LQ+RULJXFKL<Curr Top Microbiol Immunol
 (Q]\PDWLFDFWLRQVRIPasteurella multocidaWR[LQGHWHFWHGE\PRQRFORQDODQWLERGLHVUHFRJQL]LQJWKHGHDPLGDWHGĮVXEXQLWRIWKHKHWHURWULPHULF*73DVH*T.DPLWDQL6$R67RVKLPD+7DFKLEDQD7+DVKLPRWR0.LWDGRNRUR.
)XNXL0L\D]DNL$$EH++RULJXFKL<FEBS J$XJ  
 &U\VWDOVWUXFWXUHRIClostridium perfringensHQWHURWR[LQGLVSOD\VIHDWXUHVRIEHWDSRUHIRUPLQJWR[LQV.LWDGRNRUR.1LVKLPXUD..DPLWDQL6)XNXL0L\D]DNL$7RVKLPD+$EH+.DPDWD<6XJLWD.RQLVKL<<DPDPRWR6
.DUDWDQL++RULJXFKL<J Biol Chem-XQ  
 &KDUDFWHUL]DWLRQRIWKHPHPEUDQHWDUJHWLQJ&GRPDLQLQPasteurella multocidaWR[LQ.DPLWDQL6.LWDGRNRUR.
0L\D]DZD07RVKLPD+)XNXL$$EH+0L\DNH0+RULJXFKL<J Biol Chem$XJ  
ĸࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅ‫ݪࡄࢹܥ‬໐࿝

;ͼσΑۜஅଷࢄ໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁ֓‫ڠ‬ฎআȁ‫؂‬നȁోဎ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁಎ५ȁ‫ם‬๼੩‫ޗ‬ȁȁ֓‫ڠ‬ฎআȁᗣ࿐ȁ੓֚අහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁᗣ࿐઀ຐࣣ
අහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁ໌നȁ‫ם‬ၖඅහࡄ‫֥ݪ‬ȁভ‫ڠ‬ฎআȁന౓̥͕ͥ

ȁِș͉΀ͼΒ൝͈;ͼσΑۜஅછ͈ພࡔ଻อ࡛͈໦ঊ‫͈ࢹܥ‬ٜྶͬ࿒ດ̱̞͂̀ͥȃߓఘഎ͉ͅո‫̞࣐ͥ̀̽ͬݪࡄ͈ئ‬ȃˍȅࢯ ŉŊŗ ֦ঊ͈ࡄ‫ݪ‬ȁHIV ͉ΙϋΩϋΐȜո‫ͅٸ‬΍σ͞઀൲໤ۜͅஅ଼̦ၛ̱̞̹̈́͛൲໤κΟσ̦ంह̵̴Ȃમळ̈́ພၑ‫ڠ‬എٜଢ଼̢̦࣐̈́
̞ȃ΍σ̤̞͉̀ͅȂ;ͼσΑۜஅ͈੝‫ًܢ‬೾Ȫ‫ݙ‬ഢৢȫͬஷ‫֦̳ͥٺ‬ঊ 75,0Į̦ంह̳ͥȃ͉࡛ͩͦͩͦह́͘ͅ
75,0Į͈ࢯ;ͼσΑ࢘‫ ͉ͅض‬C ྎ౤௰͈̞̩̥͈̾ͺηΦॸ̦ਹါ̜̭́ͥ͂Ȃ༷֚́;ͼσΑ͉ 75,0Į͈ດഎ̜́ͥ
΃ίΏΡ͈ࡠ̹ͣͦͺηΦॸͬ་։̵̯̀ 75,0Įͥۜ͢ͅஅဲଷ̥ͣ൪๰̱̤̀ͤȂ;ͼσΑ͂਽৽֦ঊ 75,0Į̦ૺ‫ا‬ً͈೾́ᶕ̨̜̞̭̽̀ͥ͂ͬা̱̀ြ̹ȃ̹͘Ȃୌͺές΃͈ HIV-2 ۜஅ৪̤̞͉̀ͅȂ;ͼσΑ΃ίΏΡ̴͈̥ͩˍͺηΦॸ͈֑̞̦ࠬಎ;ͼσΑၾ͂௖‫̭̳͂ͥ۾‬ȂΪΠ 75,0Į֒ഥঊ͈ఉ߿̦ࡢఘ͈ HIV ۜஅ࢘ၚ͜ͅ‫̥̭̳ͣ͂ͥޣג‬Ȃ
75,0Į̦ΪΠ͈୆ఘඤ́͜৘षͅ;ͼσΑۜஅଷࢄͅ‫ܙ‬ဓ̱̞̭̀ͥ͂ͬྶ̥̱̹ͣͅȃ଎ˍȇHIV ͈୆‫۪͂ڰ‬ඤ֦଻ࢯ;ͼσΑ֦ঊĹˎȅΊΦθ‫ݪࡄڠע‬ȁࢯ HIV ࿪ͥ͢ͅ໗ैဥ͈੄࡛͉ͅࡢఘओ̦ంह̳ͥȃۜஅ৪͈ఉ̞Ηͼ࣭͈͂‫ވ‬൳ࡄ‫́ݪ‬Ȃ໗ैဥ͈ઁ̞̈́࿪໤ൎဓ
ȪΞȜρȜιȜΡ֓ၷȫ͈‫ږ‬ၛͬ࿒ঐ̱̞̀ͥȃ̭ͦ́͘ͅ࿪૮͂ HLA-C ͈͂‫߸۾‬Ȃডৗయ৫։ુ͂ Fas ֒ഥঊ͈͂‫߸۾‬

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ͬྶ̥̱ͣͅȂ࡛ह͉ଅ‫ܥ‬ෝ։ુ͈໗ैဥͅ‫ͥͩ۾‬ఉ߿ͬౝ̱̞॑̀ͥȃˏȅHIV-1 ΊΦθ RNA ඵၾఘ‫̳ͥ۾ͅا‬ٜଢ଼ȁHIV-1 ͬ‫͚܄‬τΠυ;ͼσΑུ͈֚ङ RNA ΊΦθ͉;ͼσΑၥঊඤ́๱‫ވ‬ခഎࣣ̱ࠫ̀ͅඵၾఘͬࠁ଼̱̞̀ͥȃΊΦθඵၾఘ‫͉ا‬ΊΦθΩΛΉȜΐϋΈȂ‫ݙ‬ഢৢȂΊΦθழ̢۟̈́̓;ͼσΑ୆‫͈۪ڰ‬အș̈́౲‫́ٴ‬ਹါ̈́࿨‫̤̱̹ͤ̀ضͬڬ‬ȂHIV ΊΦθඵၾఘ‫ܥا‬੬͈ٜྶ͉ȂHIV ଷգ͈౤੣̠͂̈́ͤͥȃِș͉ HIV ၥঊ͈ۜஅ଻‫ڕ‬ංͅຈଌ̈́ၥঊ଼੃ً͈೾
̷͈ͬ‫ڎ‬౲‫́ٴ‬೪গ̵̯Ȃၥঊඤ HIV-1 ΊΦθඵၾఘ‫ેا‬ఠٜͬଢ଼̱̹ȃ̷͈ࠫ‫ض‬Ȃၥঊ଼੃ૺ࣐͈‫ڎ‬౲‫ྀͅٴ‬ΊΦθඵၾఘ‫࣐̱࣐̀̽̀ૺ̴̱̾ઁ̦੃̷଼͈͂ا‬๭‫ݙ‬ഢৢෝ͈‫ڕ‬ංͅঢ̭̦ͥ͂ྶ̥̹ͣ̈́̽ͅȪ଎ 2Aȫȃ̹͘ȂΊΦθ RNAષ͈ඵၾఘ‫ا‬ΏΈ΢σȪDLSȫ͈ຈါ਱໦ႀ֖ඤ໐͈‫ܖ؂‬చࠁ଼̞̾̀ͅඊু͈ٜଢ଼ࠏͬߐঀ̱̀મळٜ̈́ଢ଼࣐̞ͬȂಇୟ̱̹ΟȜΗͬࡓࠗͅॳ‫ ͤ͢ͅڠشܥ‬DLS ႀ֖͈ RNA ၛఘࢹ௮͈κΟςϋΈ࣐̹ͬ̽ࠫ‫ض‬Ȃ͉ࣽ́͂͘஠̩։̈́ͥȂΏνȜΡΦΛΠအࢹ௮ͬ‫̺ͭ܄‬૧̱̞ࢹ௮κΟσͬං̹ȃ̭͈ΏνȜΡΦΛΠအࢹ௮͉ DLS ஠ఘ͈ࢹ௮ͬ‫̩ܰޑ‬೰̱ȂΑΞθ͈α·Πσͬࢰ௵̳ͥ࿨‫ ̞̞̱̹͊ͩͥ̀ضͬڬ‬DLS ͈ါ̜́ͤȂ̭ͦͬດഎ̱̹͂૧ܰࢯ;ͼσΑၷ༹͉ఱ̧̈́‫خ‬ෝ଻ͬ঵̽̀
̞ͥ͂ࣉ̢̹ͣͦȪ଎ 2Bȫȃ଎ˎȇHIV ΊΦθඵၾఘड߃͈యນഎ̈́ა໲
1. Moderate restriction of macrophage-tropic human immunodeficiency virus type 1 by SAMHD1 in monocyte-derived
macrophages. Taya K, Nakayama EE, Shioda T. PLoS ONE. 2014 Mar5;9(3):e90969.
 $QDWXUDOO\RFFXUULQJVLQJOHDPLQRDFLGVXEVWLWXWLRQLQKXPDQ75,0ĮOLQNHUUHJLRQDIIHFWVLWVDQWL+,9W\SH
activity and susceptibility to HIV type 1 infection. Nakayama EE, Nakajima T, KaurG, Mimaya JI, Terunuma H,
Mehra N, Kimura A, ShiodaT. AIDS Res Hum Retroviruses. 2013 Jun;29(6):919-924.
3. Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. Likanonsakul S,
Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Srisopha S, Nitiyanontakij R, Tengtrakulcharoen P,
Tarkowski M, Riva A, Nakayama EE, Shioda T. AIDS Res Hum Retroviruses. 2013 Jan;29(1):142-50.
4. A proposal for a new HIV-1 DLS structural model. Sakuragi JI, Ode H, Sakuragi S, Shioda T, Sato H. Nucleic Aids
Res. 2012 Jun;40(11):5012-22.
 75,0ĮDQG6SHFLHV7URSLVPRI+,96,91DND\DPD((6KLRGD7Front Microbiol. 2012 Jan 24;3:13.
ĺࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅ‫ݪࡄࢹܥ‬໐࿝໦ঊ;ͼσΑࡄ‫ݪ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁȁȁ਷֓‫ڠ‬ฎআȁઐ‫׆‬ȁ஝হ੩‫ޗ‬ȁȁȁȁ֓‫ڠ‬ฎআȁȁ‫ུؖ‬ȁȁഔ੩‫ޗ‬ȁȁȁȁ֓‫ڠ‬ฎআȁȁ໛ࡔȁଢٚඅහࡄ‫֥ݪ‬ȁ෠‫ڠ‬ฎআȁȁ઀࿤ȁ૥ঊඅහࡄ‫֥ݪ‬ȁၑ‫ڠ‬ฎআȁȁ௖ᚧȁୄࣝඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁȁგനȁ૯৘අහࡄ‫֥ݪ‬ȁၑ‫ڠ‬ฎআȁȁőŶŪŨĮŃŢŴŢŨŰŪŵŪġŇųŢůŤŦŴŤ
εΑΡ·ȁȁ਷֓‫ڠ‬ฎআȁള໐ȁ૝࿟ࡄ‫ݪ‬ඤယȇ൚ࡄ‫ݪ‬৒͉́Ȃ˟߿۴‫ͼ;׶‬σΑ (HCV) ͈ळ༾͈͒૟වȂཱུ࿫ȂໝୋȂ੄ٔȂ̷̱̀อછພၑ͈໦ঊ‫ܥ‬੬͈ٜଢ଼͂Ȃ֒ഥঊহၷͅຈଌ̈́૧̱̞֒ഥঊ൵වα·ΗȜ͈‫ٳ‬อͬૺ̞͛̀ͥȃˍȅHCV の分子生物学
ȁHCV ͈ۜஅ৪͉ଲ‫ ́ٮ‬1 ‫ ؙ‬3 ୷ྔ૽͜ంह̱Ȃ̷͈ఉ̩̦ྕ଻঵௽ۜஅ͒͂֊࣐̱Ȃ۴ࣁ་ͬࠐ̀۴ळ༾‫ͬ܈‬อછ̳ͥȃ߃ාȂခ࢘̈́ HCV ͈໦ঊດഎ࿪̦‫ٳ‬อ̯ͦȂC ߿ྕ଻۴‫׶‬হၷ͉ఱ̧̩ૺ༜̱̹ȃ̱̥̱̦̈́ͣȂ‫ͅܡ‬۴ࣁ་ͬอછ̱
̞̀ͥۛ৪͞Ȃ໗ैဥฺ̠ͬ࿪सൎဓͅఛ̢̞ͣͦ̈́ࣞႢ৪ͅచ̳ͥহၷ༹͉̩̈́Ȃ̹͘Ȃ;ͼσΑͬෳੰ̧̹̱́͂̀͜Ȃ۴อ‫ܓ͈܈‬ᏼͬۖ஠ͅ໡૑̧́ͥ࿫͉̞́̈́ȃ̯ͣͅȂ࿪सఛ଻;ͼσΑ͈੄࡛͜ఱ̧̈́࿚ఴ̞͂̈́̽̀ͥȃ;ͼσΑ౩ฒৗͤ͢͜ȂHCV ͈ໝୋͅਹါ̈́਽৽֦ঊͬດഎ̱̹͂ࢯ;ͼσΑस͈༷̦Ȃ࿪सఛ଻;ͼσΑ͈੄࡛ອഽ͉գുഎͅ೩̞ȃ̷̭́Ȃِș͉ HCV ͈௩૓͞ພࡔ଻อ࡛ͅ‫۾‬ဓ̳ͥ਽৽֦ঊٜͬଢ଼̱ȂC ߿ྕ଻۴‫͈׶‬૧̱̞஻࿪ΗȜΊΛΠͬ࠿̱॑̀
̞ͥȃळ༾ͅ૟ව̱̹ HCV ͈ΊΦθ RNA ཱུ̥ͣ࿫̯̹ͦஜߐఘ౩ฒৗ͉Ȃळ༾͈ΏΈ΢σβίΙΘȜΔ͂ΏΈ΢σβίΙ
ΡβίΙΘȜΔȂ̷̱̀Ȃ;ͼσΑ̦΋ȜΡ̱̞̀ͥίυΞͺȜΔ̽̀͢ͅȂ10 ࡢ͈౩ฒৗͅ୨౯̯ͦͥȃ͕͈͂ͭ̓ RNA;ͼσΑ͉ळ༾ৗ́ໝୋ̳̦ͥȂ଼੃̱̹ HCV ΋ͺ౩ฒৗ͈֚໐͉‫̱࣐֊͒ړ‬Ȃ‫ړ‬ඤίυΞͺΕȜθ͈‫֦ا଻ڰ‬ঊ̜́ͥ PA28Ȗ͂௖ࡽैဥ̱̀໦ٜ̯ͦͥȃHCV ͈΋ͺ౩ฒৗͬอ࡛̳ͥΠρϋΑΐͿΣΛ·ζ;Α͉ȂC ߿ྕ଻۴‫ۛ׶‬৪́۷ख़̯ͦͥȂͼϋΑςϋ೷ࢯ଻Ȃডཛ۴Ȃ̷̱̀۴ळ༾‫ͬ܈‬อછ̳̦ͥȂ̭͈ζ;Α̥ͣ PA28Ȗͬࠧఅ̵̯ͥ͂Ȃ̭͈ͦͣພఠ̦ۖ஠ͅક৐̳ͥȃ̹͘ȂPA28Ȗ͈อ࡛ͬဲଷ̳ͥ͂Ȃ;ͼσΑၥঊ͈ॲ୆̦೩‫̥̭̳ͣ͂ͥئ‬Ȃ΋ͺ౩ฒৗ͈֚໐
̦ 3$Ȗջంഎͅ‫ړ‬ඤ́໦ٜ̯̭̦ͦͥ͂ȂHCV ͈ၥঊॲ୆̺̫̩́̈́Ȃພࡔ଻อ࡛͜ͅ૬̩‫۾‬ဓ̱̞̭̦̀ͥ͂ྶ̥ͣ
̹̈́̽ͅȃ̯ͣͅȂFKBP8 ͞ hBind-1 ൝͈΋Ώλβυϋ̦ NS5A ౩ฒৗ͂௖ࡽैဥ̳̭ͥ͂̽̀͢ͅȂ໦ঊΏλβυΰ̜ͥ Hsp90 ͬໝୋໝࣣఘ͒ς·σȜΠ̳̭̦ͥ͂ȂHCV ͈ໝୋͅਹါ̜̭́ͥ͂ͬྶ̥̱̹ͣͅȃ̹͘ȂHCV ͈ழ૕අ։଻
ͬࠨ೰̳ͥ਽৽֦ঊ̱͂̀Ȃ۴௫අ։എͅอ࡛̱̞̀ͥ miR-122 ͞ VLDL (Very Low-Density Lipoprotein) ‫۾‬Ⴒ֦ঊ͈ਹ
ါ଻̦༭̯̞̦࣬ͦ̀ͥȂ̷͈મळ͉ະྶ̈́ത̦ఉ̞ȃ̷̭́ȂHCV ͈ၥঊॲ୆ͅ‫۾‬ဓ̳ͥȂVLDL ‫۾‬Ⴒ֦ঊ͈ͺεςε౩ฒৗ B (ApoB) ͂ ApoE ͬ൳শࠧͅఅ
̵̯̹ळ༾‫ͬڼ‬ਏၛ̱̹̭͂ͧȂၥঊॲ୆͉࿩ 1/100 ͅࡘઁ̱̹ȃ‫ྙޟ‬૬̞̭͂ͅȂ
ApoB/ApoE ࠧఅळ༾‫ ͅڼ‬ApoA1, ApoA2,
ApoC1, ApoC2, ̜̞͉ͥȂApoC3 ͬอ̵࡛̯ͥ͂ၥঊॲ୆̦ٝ໘̳̭̥ͥ͂ͣȂਅș͈ͺεςε౩ฒৗ̦௖ࡽͅ༞̱̦ۖ̈́
ͣȂHCV ͈ۜஅ଻ၥঊॲ୆ͅ‫۾‬ဓ̱̞̭̦̀ͥ͂ྶ̥̹ͣ͂̈́̽ȃHCV ࡄ‫͈ݪ‬डఱ͈વ‫͉ٺ‬Ȃۛ৪ࠬୄಎ͈ HCV ͬ෽ူ̧́ͥळ༾෽ူࠏۜ͞਋଻ͬা̳઀߿৘ࡑ
൲໤̩̭̜ͬࠧ͂́ͥȃHCV ͈κΟσ;ͼ
σΑ̱͂̀Ȃ൳̲έρΫ;ͼσΑ௺͈඾ུෞ
‫ͼ;׶‬σΑ͈ࡄ‫̞ͥ̀͛ૺ͜ݪ‬ȃĲıˎȅΨ΅νυ;ͼσΑα·ΗȜ͈‫ٳ‬อ
HCV ͈̠͢ͅ෽ူळ༾́ໝୋ̧̞́̈́;ͼσΑۜஅછ͈ࡄ‫͉ͅݪ‬Ȃ;ͼσΑα·ΗȜ̦ਹါ̈́໌‫ͥ̈́͂ܕ‬ȃ̹͘Ȃ୶౤֓ၷ͈ါ͂̈́ͥ֒ഥঊহၷ͉ͅȂհ஠́֒ഥঊ൵ව࢘ၚ̦̞ࣞȂ֒ഥঊ൵වα·ΗȜ͈‫ٳ‬อ̦ະ‫̜ͥ́ࠧخ‬ȃِș͉अಖ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

;ͼσΆ̜ͥΨ΅νυ;ͼσΑ Autographa californica nucleopolyhedrovirus (AcNPV) ͬ၌ဥ̱̹ఉ‫ܥ‬ෝ;ͼσΑα·ΗȜ‫ٳ‬อͬૺ̞͛̀ͥȃAcNPV ͉ 134kbp ͈۪ે 2 ུङ DNA ͬΊΦθ̱͂̀঵̻Ȃۜஅळ༾͈ 30 ȡ 40ɓ̦ఉ‫ڙ‬ఘ౩ฒৗͅ౾̧
͕͈۟ͩͥ̓‫ޑ‬ႁ̈́ఉ‫ڙ‬ఘίυκȜΗȜͬခ̱̞̀ͥȃ̭͈଻ৗͬ၌ဥ̱̀ȂAcNPV ͉अಖळ༾ͬဥ̞̹ழ̢۟౩ฒৗ͈
ॲ୆ࠏ̱͂̀၌ဥ̯̞ͦ̀ͥȃ̹͘ȂAcNPV ͉अಖळ༾̴͈͙̈́ͣȂࢩํ̈́ሶ඿൲໤ळ༾ͅȂ࢘ၚ̩͢‫ٸ‬ြ֒ഥঊͬ൵ව
̧̭̦́ͥ͂฻ྶ̱Ȃ૧̱̞֒ഥঊ൵වα·ΗȜ̱͂̀͜ಕ࿒̯̞ͦ̀ͥȃAcNPV ͉ఱ̧̈́‫ٸ‬ြ֒ഥঊͬழ͙ࣺ͚̭̦͂́
̧Ȃ̱̥͜Ȃሶ඿൲໤ळ༾͉́஠̩ໝୋ̱̞̭̥̈́͂ͣȂͺΟΦ;ͼσΑα·ΗȜ൝́࿚ఴ͂̈́ͥুၛ௩૓;ͼσΑ͈੄࡛͞Ȃ;ͼσΑ౩ฒৗ͈อ࡛ͥ͢ͅခ‫̈́ٺ‬྾‫ע‬؊൞͈ည൵൝͈‫ܓ‬ᏼ̦̞̈́ȃ̹͘Ȃळ༾ඤࣺ̹৾ͤͦ͘ͅ AcNPV ΊΦθ͉Ȃ
TLR9 ջంഎͅ‫׶‬છ଻΍ͼΠ΃ͼϋͬȂ̹͘ TLR9 ๱ջంഎͅͼϋΗȜέͿυϋ (IFN) ͬည൵̱ȂAcNPV ͬζ;Α͈๽࣌ඤͅൎဓ̳ͥ͂Ȃ౿ঘ଻͈ͼϋέσ΀ϋΎ;ͼσΑ͈ۜஅ̥ͣཡࢄ̯̭ͦͥ͂ͬྶ̥̱̹ͣͅȃ̯ͣͅȂAcNPV ΊΦθͥ͢ͅ
IFN ͈ည൵͉ͅȂSTING/TBK1/IRF3 ࠐႹ̦ਹါ̈́࿨‫̹̱̥ͣͅྶ̭̞̲ͬ͂ͥ̀׵ͬڬ‬ȃ;ͼσΑۜஅ̽̀͢ͅুட྾‫ע‬͈ည൵̦ဲଷ̯̹ͦळ༾́
͉ȂAcNPV ͥ͢ͅ‫ٸ‬ြ֒ഥঊ͈อ࡛̦ᄤૺ̳̭̥ͥ͂
ͣȂۜஅळ༾අ։എͅ‫ٸ‬ြ֒ഥঊͬอ̧࡛́ͥ‫خ‬ෝ଻̦া̯̹ͦȃոષ଼͈ୡ̥ͣȂ
AcNPV ͉अಖळ༾͈́ழ۟
̢౩ฒৗ͈ఱၾอ࡛α·ΗȜ͞ሶ඿൲໤ळ༾͈͒֒ഥঊ
൵වα·ΗȜ͉͂ͤ͜͢Ȃχ
·Ιϋα·ΗȜ͞ΗȜΊΛΞͻϋΈα·ΗȜ̱͈͂̀‫خ‬ෝ଻̦াऐ̯̹ͦȃड߃͈యນഎ̈́ა໲
1. Novel permissive cell lines for a complete propagation of hepatitis C virus. Shiokawa M, Fukuhara T, Ono C,
Yamamoto S, Okamoto T, Watanabe N, Wakita T, Matsuura Y. J Virol. 2014 Mar 5. [Epub ahead of print]
2. Innate immune response induced by baculovirus attenuates transgene expression in Mammalian cells. Ono C,
Ninomiya A, Yamamoto S, Abe T, Wen X, Fukuhara T, Sasai M, Yamamoto M, Saitoh T, Satoh T, Kawai T, Ishii
KJ, Akira S, Okamoto T, Matsuura Y. J Virol. 2014 Feb;88(4):2157-67.
3. Japanese encephalitis virus core protein inhibits stress granule formation through an interaction with Caprin-1 andfacilitates viral propagation. Katoh H, Okamoto T, Fukuhara T, Kambara H, Morita E, Mori Y, Kamitani W,
Matsuura Y. J Virol. 2013 Jan;87(1):489-502.
4. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis
C virus. Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K,
Matsuura Y. J Virol. 2012 Aug;86(15):7918-33.
5. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction
with Toll-like receptor 2 and hyaluronan. Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y,
Takeuchi O, Kawai T, Akira S, Matsuura Y. J Virol. 2012 Jun;86(11):6159-70.
ĲĲࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅ‫ݪࡄࢹܥ‬໐࿝ۜஅພఠ໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁȁ֓‫ڠ‬ฎআȁȁȁȁȁȁȁ५ུȁٗဉ੩‫ޗ‬ȁȁȁΨͼ΂΍ͼ΀ϋΑฎআȁॕ֔ȁ๼გඅහ੩‫ޗ‬ȁ಄ॲ‫מ‬୆‫ڠ‬ฎআȁȁȁȁฺ࡫ȁۘඃȁ൚ࡄ‫ݪ‬৒͉́Ȃ༾ঊಖ႒ພࡔ଻‫ܙ‬୆ಖ̜́ͥΠ΅ΕίρΒζͬκΟσ̱͂̀‫ܙ‬୆ಖ͈਽৽྾‫ဲע‬ଷ‫ͅࢹܥ‬಍࿒̱̹‫ܙ‬୆ಖ྾‫ݪࡄڠע‬ȁ͂Π΅ΕίρΒζͅచ̳ͥ਽৽྾‫ݪࡄ͈ࠏע‬ȁ৾ͤͅழ̞ͭ́ͥȃˍȫΠ΅ΕίρΒζ͉͂‫̥ة‬ȉȁΠ΅ΕίρΒζછ͉Π΅ΕίρΒζࡔಖȪToxoplasma
gondiiȫ͈ۜஅ̧̭̯ͤ֨ܳͦͥ͢ͅࡔಖພ̜́ͥȃ̷͈୆‫͉۪ڰ‬Υ΋ͬਞ਽৽̱͂̀ΪΠȆΥΒη̈́̓ͬ‫͚܄‬஠͈̀ࢭ‫أ‬Ȫ‫ࠬأ‬ȫ൲໤̦ಎ‫ۼ‬਽৽̭̥͂̈́ͥ͂ͣ๱ુͅࢩ̞
਽৽֖ͬ঵̻Ȃۜஅ̱̹Υ΋͈໯༒̦ంह̱̠۪ͥ‫͈́ޏ‬΄ȜΟΣϋΈۜ͞அ̱̞̀ͥ‫ز‬಄͈୆රͬ‫ح‬෎ੜၑ̵̴୫
̳̭৾ͥ͂ͥ͢ͅȂ̴̞ͦ͜ࠐ࢛ۜஅ̽̀͢ͅΪΠۜͅஅ̳ͥȃΠ΅ΕίρΒζࡔಖ͉࠲ુ૽͉͕͈́͂ͭ̓ાࣣۜஅ
੝‫ۜͅܢ‬ཙအછે͞ςϋΩ୯͈ࠚ̞ਆಷ೾ഽ͈છેͬা̱
ະࡐ଻ۜஅ͂̈́ͥ඾გࡉພࡔఘ̜́ͤȂ஠ଲ‫ٮ‬എ͉ͅଲ‫ٮ‬
૽࢛͈ 3 ໦͈ 1 ̦ະࡐ଻ۜஅ̱̞̯̀ͥ͂ͦͥȃ਽৽྾‫ע‬ࠏ̦ୃુͅै൲̱̞̀ͥાࣣ͉́஠̩࿚ఴ͉̞̦͂̈́ͣ̈́Ȃ߃ා͈΀ͼΒȪࢃഛ଻ະ஠྾‫ע‬છ࢓߲ȫͬอછ̱̹ۛ৪
̤̞̈́̓̀ͅ΃ςΣ෹‫́ͭͣ̈́͂׶‬Π΅ΕίρΒζෞછ̦ঘ֦͈৽ါ͈̈́ͬ͜୸͛ͥȃ̹͘ළૡশ༦ఘ͉։໤̜́ͥథ
঱ͬ‫̹̞̱֚͛̈́ͅ୲ݵ‬ਅ͈྾‫ע‬ະ஠ેఠ̞̦͂̈́̽̀ͥȂ̷͈षͅළິ̦੝ۜஅ̜̹́̽ાࣣథ঱ͅΠ΅ΕίρΒζ
ࡔಖ̦ۜஅ̱ၠॲȂ̜̞͉ͥۜஅ̱̹͘͘૧୆঱̦କ൮
છȆ઀ෞછͬ୶ഛഎͅ༴̢̹ેఠ́౪୆̷̱͈ࢃ͈ୈ૰
อ֗Ȃಶ‫ܥژ‬ෝ೩‫୶ฺ̠ͬئ‬ഛ଻৖̧̭̳ۛͬ֨ܳΪΠਹ ଎ˍȁΠ΅ΕίρΒζ͉͂ȉါພࡔఘ̜́ͥȃ̭͈̠͢ͅȂ;ͼσΑۜஅછȆळ޿ۜஅછȆȪAȫΠ΅ΕίρΒζࡔಖ͈࿅৆଎ȃ୶౤໐ͅ໦๥઀‫̜ͥ́ۗܕ‬υίΠςȜȪ୤̞໐໦ȫ̦ంह̳ͥȃȪBȫ਽৽ळ༾ۜͅஅ̱̹Π΅ΕίρΒζࡔಖ૯޿ۜஅછͅ‫ࡔ̢̀ح‬ಖȪ‫ܙ‬୆ಖȫۜஅછِ͜ș͈૸߃ ͈ഩঊࡐ๷‫ޢ‬଎ȃۜஅळ༾ಎ͉́‫ܙ‬୆༾ඤȪକ૗࿦֣ȫͅంह̳ͥȃ̹͘Ȃͅంह̳ͥۜஅછ̜́ͥȪ଎ˍȫȃ൚ࡄ‫ݪ‬৒͉́ȂΠ΅ΕίρΒζ͉အș̈́΀έͿ·ΗȜ໦ঊͬ༶੄̱Ȃ਽৽྾‫ࠏע‬ͬဲଷ̱Ȃພࡔ଻ͬอ‫̞̱̥ͥ̀ͣͅྶ̭̞̱ͬ͂ͥ̀ܞ‬ȃ୶౤໐ͅྶ̥ͣ̈́υίΠςȜ௨̦෇͛ͣͦͥȪႂ࿦֣ȫȃȪCȫۜஅळ༾ಎ͈́Π΅ΕίρΒζࡔಖ͈྾‫ע‬அ૗଎ȃΠ΅ΕίρΒζࡔಖ͈ळ༾྄
౩ฒৗ GAP45 ͬ୤૗́ȂROP18 ͬႂ૗́அ૗̱̹ȃંȂROP16 ͜൳အͅυίΠςȜͅంह̳ͥ΀έͿ·ΗȜ໦ঊ̜́ͥȃˎȫΠ΅ΕίρΒζͅచ̳ͥ਽৽྾‫ࠏע‬ȁΠ΅ΕίρΒζۜஅͅచ̱̀Ȃِș਽৽͉ਅș͈྾‫ע‬฽؊̧̭̱ͬ֨ܳచࢯ̱̞̀ͥȃ๊֚ͅ྾‫ע‬฽؊͉ুட྾‫ڕ͂ע‬ං྾‫ע‬؊൞ͅఱ༆̯̦ͦͥȂΠ΅ΕίρΒζ͈ࢹ଼଼໦̦ Toll အ਋ယఘͅ෇ে̯ͦȂζ·υέ͹Ȝΐ͞ਏેळ༾͈̈́̓ুட
྾‫ע‬ळ༾̥ͣͼϋΗȜυͼ΅ϋ 12ȪIL-12ȫ͈̈́̓‫׶‬છ଻΍ͼΠ΃ͼϋ̦ఱၾͅ༶੄̯ͦͥȃ̹͘‫ڕ‬ං྾‫ ͉ࠏע‬IL-12 ͤ͢ͅঁ̯ࠣͦ I ߿྾‫ע‬؊൞̦‫̩ޑ‬ည൵̯̭̦ͦͥ͂ȂࢯΠ΅ΕίρΒζ਽৽ཡࢄ‫ͅࢹܥ‬ਹါ̜́ͥȃI ߿྾‫ע‬؊൞͈ಎ́ड͜
ਹါ̈́ίτȜμȜ̦ȂͼϋΗȜέͿυϋȖȪ,)1Ȗȫ̜́ͥȃ,)1Ȗ͉‫׶‬છ଻΍ͼΠ΃ͼΰ̜ͤȂΠ΅ΕίρΒζ͈৽ါ̈́ດ
എळ༾̜́ͥুட྾‫ע‬౜൚ळ༾ͅैဥ̳ͥ͂࿩ 2000 ਅ႒͈ ,)1Ȗည൵଻ΗϋΩ·ৗͬॲ୆̳ͥȃ,)1Ȗ͉Π΅ΕίρΒζ͈௩૓̦ဲ̢ͣͦͥȶ୓ȷैဥ͂Π΅ΕίρΒζু૸̦෫ٟ̯ͦͥȶफ़ȷैဥ̞̠͂ 2 ਅ႒͈։̈́ͥैဥͬခ̱Ȃȶ୓ȷैဥ̞͉̾̀ͅ iNOS ̱̹֚ͬٚॸ‫ا‬ಊள͈ॲ୆͞ IDO ̳ͬٚͥΠςίΠέ͹ϋ໦ٜ̦ਹါ̈́࿨‫̦̭̞̱̹͂ͥ̀ضͬڬ‬Ȃ90 ාయͅྶ̥̯̹ͣͦͅȃȁ༷֚ȶफ़ȷैဥ̞͉̾̀ͅະྶ̈́ത̦ఉ̥̹̦̽ 2000 ාయͅවͤȂΠ΅ΕίρΒζ̦ۜஅळ༾ඤ́ࠁ଼̳ͥ΂σ΄ΥρĲĳ̜́ͥȶ‫ܙ‬୆༾ȷ྄͈ࢹ௮ͬ෫ٟ̳̭ͥ͂ͅ ,)1Ȗ̦ਹါ̜̭̦́ͥ͂া̯̹ͦȪ଎ˎ Aȫȃ̹̭͈͘‫ܙ‬୆༾྄෫ٟ̦
,)1Ȗည൵଻ΗϋΩ·ৗ̜́ͥ IGTP ͂ࡤ͊ͦͥ 47kD ͈ GTPase ̷͈͞έ͹ηςȜ໦ঊ߲ȪIRG ͂ࡤ̞͊ͦ̀ͥȫ͈ంह̦ਹါ̜̹́̽ȃ,)1Ȗ͉ IRG ͈ఈͅȂ65kD ͈ GTPase έ͹ηςȜ໦ঊ̜́ͥ GBP ͬည൵̳ͥȃIRG ͬ൳̲̩ GBP ͉‫ܙ‬୆༾ͅ ,)1Ȗঁࠣջంഎͅ൲֥̯̩ͦ̀ͥȃຊ৪͉ͣ GBP ͬࠧఅ̳ͥζ;Αͬैୋ̱Ȃ୆ఘȆळ༾τασ͈́ࢯΠ΅ΕίρΒζ؊൞ͬ࠿൦̱̹ȃ୆ఘτασ͉́ȂΠ΅ΕίρΒζۜஅͤ͢ͅ GBP ࠧఅζ;Α͉ ,)1Ȗࠧఅζ;Α͂൳အ̞ࣞۜͅ਋
଻ͬা̱̹ȃ̹͘ GBP ࠧఅζ·υέ͹Ȝΐ͉ ,)1Ȗঁࠣͥ͢ͅΠ΅ΕίρΒζಖఘତ͈ࡘઁ̦વ‫ͬٺ‬਋̫̤̀ͤȂȶफ़ȷै

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ဥ͈ঐດ͂̈́ͥࡔಖ͈,)1Ȗջంഎ̈́ۜஅၚ͈೩‫̹̥̽̈́ͦͣ͛෇̦ئ‬ȃষͅ,)1Ȗঁࠣͥ͢ͅ‫ܙ‬୆༾྄ͬ࠿൦̱̹̭͂ͧȂ
GBP ࠧఅζ·υέ͹Ȝΐ͉́‫ܙ‬୆༾྄෫̴ٟ̦̭ܳͣȂ‫ܙ‬୆༾྄͉‫̥ͣͅڲ‬༗̹̞̹ͦ̀Ȫ図 2Bȫȃ̭͈̭̥ͦͣ͂ͣȂ
GBP ͉ ,)1Ȗջంഎ̈́ȶफ़ȷैဥͅਹါ̈́࿨‫̦̭̜̦͂ͥڬ‬฻ྶ̱̹ȃp47 GTPase ̜́ͥ IRG ̦ȶफ़ȷैဥͅਹါ̜̦́ͥȂ
GBP ࠧఅळ༾̤̫ͥͅ IRG ͈Π΅ΕίρΒζ͈͒൲֥͉ঁࠣࢃশ‫̹̞̱̀ઁࡘ̹̦̀ͦ̾̾ͅۼ‬ȃ̯ͣͅȂ࿤୆߿ζ;Αဇြ͈ळ༾͉́ GBP ͉ IRG ͂‫ܙ‬୆༾ષ́‫ޫވ‬हͬা̱ȂGBP ͉ IRG ͂ೄ୪എࣣ̳̭̥ࠫͥ͂ͣͅȂ,)1Ȗည൵଻
GTPase ̜́ͥ GBP ͉Π΅ΕίρΒζ‫ܙ‬୆༾྄ષ́ IRG ͂ೄ୪௖ࡽैဥ̱Ȃ̷྄͈ࢹ௮ͬ෫ٟ̳̭ͥ͂́ȶफ़ȷ‫ܥ‬ෝͬอ‫̦̭̞̱͂ͥ̀ܞ‬াऐ̯̹ͦȃȁ̹͘ GBP ͞ IRG ̦‫ܙ‬୆༾ͅ൲֥̯ͦͥι΃ΣΒθ̞̾̀ͅȂຊ৪͉ͣड߃Ȃळ༾͈ু૙ैဥͅਹါ̈́࿨‫΂̳̹ضͬڬ‬ȜΠέ͹ΐȜͅ‫۾‬Ⴒ̳ͥΗϋΩ·ৗ߲ȪAtg ໦ঊ߲ȫ̦ IRG ͞ GBP ͬ‫ܙ‬୆༾྄ͅ൲֥̳͈ͥͅਹါ̜̭́ͥ͂ͬྶ̥̱̹ͣͅȃ΂ȜΠέ͹ΐȜ‫۾‬Ⴒ໦ঊ߲̜́ͥ Atg3ȂAtg7 ͞ Atg16L1 ͬࠧఅ̳ͥळ༾̤̞͉̀ͅȂΠ΅ΕίρΒζ‫ܙ‬୆༾྄͈͒ IRG ͞
GBP ͈൲֥ၚ̦ခփͅ೩‫̱ئ‬Ȃ̷ฺ̞ͦͅ ,)1Ȗջంഎ̈́ࡔಖତ͈೩‫͜ئ‬વ‫ͬٺ‬਋̫̞̹̀ȃ༷֚Ȃ༆͈ Atg9 ͞ Atg14
ͬࠧఅळ༾͉́‫ܙ‬୆༾྄͈͒ IRG ͞ GBP ͈൲֥ၚ͉࿤୆߿ळ༾͂൳೾ഽͅ෇̹͛ͣͦȃ΂ȜΠέ͹ΐȜ̤̫ͥͅ Atg3 ͞
Atg7/Atg16L1 ͈࿨‫΂͉ڬ‬ȜΠέ͹ΌΕȜθࠁ଼̤̫ͅ
ͥ Atg8 γκυΈ̜́ͥ LC3 ͈ਘૐ͂ඵਹ྄͈͒ޫह ́ ̜ ͥȃ֚ ༷ȂAtg9 ͞ Atg14 ͉ Atg3 ͞
Atg7/Atg16L1 ΏΑΞθ͉͂஠̩ඊၛ̱̀Ȃඵਹ྄ࠁ଼
ͅ‫۾‬ဓ̳ͥຈଌ΂ȜΠέ͹ΐȜ໦ঊ߲̜́ͥȃ̭͈̭̥ͦͣ͂ͣȂ஠͉̩֚̀́̈́໐͈΂ȜΠέ͹ΐȜຈଌ໦ঊ߲̦ GBP/IRG ͈̈́̓ GTPase ͈ ,)1Ȗջంഎ̈́‫ܙ‬୆༾͈͒൲֥ͅ‫۾‬ဓ̳̭̦ͥ͂ྶ̥̹ͣ͂̈́̽Ȫ଎ˎCȫȃȁոષȂAtg3/7/16L1 ջంഎͅ ,)1Ȗည൵଻ GTPase߲ GBP ͞ IRG ̦Π΅ΕίρΒζͅచ̳ͥۜஅཡࢄ‫ܥ‬ෝͬอ‫̳ͥܞ‬ι΃ΣΒθͬત̱̹ٚȃࣽࢃ͉Ȃ,)1Ȗঁࠣͤ͢ͅ‫΂̯ͥͦا଻ڰ‬ȜΠέ͹ΐȜ‫۾‬Ⴒ໦ঊ͈‫͈ࢹܥا଻ڰ‬ٜྶ͂ ,)1Ȗ̦ည൵̳ͥ࿩ 2000 ਅ႒͈ည൵ΗϋΩ·ৗ߲ͅ‫ܥͥͦ͘܄‬ෝྚ౶͈໦ঊ߲͈
ࡢ༆͈‫ܥ‬ෝٜଢ଼ͬ೒̲̀Ȃ,)1Ȗै൲଻ळ༾ুၙഎ ଎ˎȁ,)1Ȗջంഎ̈́‫ܙ‬୆༾྄෫ٟ̤̫ͥͅ GTPase ͈࿨‫ڬ‬ȪAȫ࿤୆߿ळ༾͉́‫ܙ‬୆༾྄̦෨఑̻Ȃࢹ௮̦෫ٟ̯̞̦ͦ̀ͥȂȪBȫGBPࢯΠ΅ΕίρΒζ྾‫ע‬฽؊͈஠ယ̦ྶ̥̱̞ͣ̀ͅ ࠧఅळ༾͉́‫྄̥̈́ͣڲ‬࿂̦༗̹̞ͦ̀ͥȃ̧̹̞ȃड߃͈యນഎ̈́ა໲
1. Ohshima J, Lee Y, Sasai M, Saitoh T, Ma JS, Kamiyama N, Matsuura Y, Pann-Ghill S, Hayashi M, Ebisu S, Takeda.$NLUD6<DPDPRWR05ROHRIWKHPRXVHDQGKXPDQDXWRSKDJ\SURWHLQVLQ,)1ȖLQGXFHGFHOODXWRQRPRXV
responses against Toxoplasma gondii. J Immunol. 2014, 192: 3328-3335.
2. Yamamoto M, Okuyama M, Ma JS, Kimura T, Kamiyama N, Saiga H, Ohshima J, Sasai M, Kayama H, Okamoto T,+XDQJ'66ROGDWL)DYUH'+RULH.7DNHGD-7DNHGD.$FOXVWHURILQWHUIHURQȖLQGXFLEOHS*73DVHVSOD\VDFULWLFDOUROHLQKRVWGHIHQVHDJDLQVW7R[RSODVPDJRQGLLImmunity. 2012, 37:302-313.
3. Yamamoto M, Ma JS, Mueller C, Kamiyama N, Saiga H, Kubo E, Kimura T, Okamoto T, Okuyama M, Kayama H,
Nagamune K, Takashima S, Matsuura Y, Soldati-Favre D, Takeda K. ATF6ȕLVDKRVWFHOOXODUWDUJHWRIWKH
7R[RSODVPDJRQGLLYLUXOHQFHIDFWRU523J Exp Med. 2011, 208:1533-1546.
4. Yamamoto M, Standley DM, Takashima S, Saiga H, Okuyama M, Kayama H, Kubo E, Ito H, Takaura M, Matsuda
76ROGDWL)DYUH'7DNHGD.$VLQJOHSRO\PRUSKLFDPLQRDFLGRQ7R[RSODVPDJRQGLLNLQDVH523GHWHUPLQHV
WKHGLUHFWDQGVWUDLQVSHFLILFDFWLYDWLRQRI6WDWJ Exp Med. 2009, 206: 2747-2760.
ĲĴࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆ఘཡࢄࡄ‫ݪ‬໐࿝໦ঊ྾‫ע‬ଷࢄ໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁ֓‫ڠ‬ฎআȁ݊౓ȁȁ૾੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁհ‫ݳ‬ȁܵ૽੩‫ޗ‬ȁȁ֓‫ڠ‬ฎআȁुࡔȁਘ໹අහࡄ‫֥ݪ‬ȁ࿪‫ڠ‬ฎআȁධ౓ȁ໌੉අහࡄ‫֥ݪ‬ȁၑ‫ڠ‬ฎআȁńũŪŢŶĮŚŶŢůŨġŕŴŢŪˍȫB ळ༾໦‫ا‬Ʀ୆ంଷࢄ͈໦ঊ‫ࢹܥ‬ȁB ळ༾͉‫ٸ‬ြࢯࡔͅచ̱̀࢘‫ض‬എ̈́ࢯఘͬॲ୆̳̹ͥ͛ͅࢯఘॲ୆ळ༾ܱ͞‫ ؛‬B ळ༾ͅ໦‫̦̳ͥا‬Ȃ̷͈षͅ B ळ༾ນ࿂ષ͈ B ळ༾ࢯࡔτΓίΗȜȪBCRȫ͞ CD40 ̥͈ͣঁࠣͬຈါ̳͂ͥȃ൚໦࿤͉́Ȃ̭͈ͦͣΏΈ΢σഥోࠐႹͅ‫۾‬ဓ̳ͥਅș͈໦ঊ‫ܥ‬ෝ͈ٜଢ଼࣐̞ͬȂ‫଻ס‬྾‫͈ע‬ଷࢄ‫͈ࢹܥ‬ٜྶͬ࿒ঐ̱̞̀ͥȃඅͅȂCD40 ळ༾ඤႀ֖ࣣ̳ٛͥͅ
TRAF3 ̦ȂB ळ༾͈୆ంͅຈଌ̜̭̦́ͥ͂ྶ̥ͣ̈́ͥ͂͂͜ͅͅȂTRAF3 ࣣٛ໦ঊ̜́ͤḀ̑̾ B ळ༾τΓίΗȜΏΈ΢σ͈‫ئ‬ၠͅంह̳ͥ PKC έ͹ηςȜ໦ঊȂPKN1 ̦ AKT ͈ဲଷ֦ঊ̱͂̀ैဥ̱Ȃুࡨ฽؊଻ B ळ༾ੰ‫̓̈́ݲ‬Ȃ྾‫ۘע‬ယ଼͈ၛͅຈଌ̜̭́ͥ͂ͬࡉ੄̱̞̀ͥȃˎȫ਽৽ພࡔఘ‫ۼ‬௖ࡽैဥͥ͢ͅ྾‫ע‬ພఠอછ͈໦ঊ‫ࢹܥ‬ȽEpstein-Barr ;ͼσΑȪEBVȫ͈΋ȜΡ̳ͥ latent membraneprotein (LMP)ȁ1 ̤͍͢ 2a ̦਽৽ B ळ༾͈໦‫͂ا‬஖఼ͅဓ̢ͥ‫ޣג‬ȁEBV ͉ΪΠ B ळ༾ۜͅஅ̱ȂඅͅικςȜ B ळ༾̤̞̀ͅஆ໖̳ͥ͂ࣉ̢̞ͣͦ̀ͥȃEBV ̦ஆ໖ۜஅ̱̹ B ळ༾͉́Ȃအș̈́;ͼσΑࢯࡔ̦อ࡛̱̞̦̀ͥḀ̑̈́́͜Ȃlatent membrane protein (LMP)ȁ1 ̤͍͢ 2a ͉Ȃ̷̸ͦͦȂCD40 ͂
BCR ΏΈ΢σ‫ئ‬ၠ͈֦ঊͬࢭુഎͅ‫͈̳́ͥا଻ڰ‬ȂB ळ༾͈໦‫͂ا‬஖఼ͅ‫ͬޣג‬ဓ̢ͥ͂ࣉ̢̧̹ͣͦ̀ȃ̱̥̱Ȃinvivo ̤̫ͥͅ B ळ༾͈໦‫ͅا‬చ̱̀ȂLMP ̦͈̠̓̈́͢‫ͬޣג‬ဓ̢̥͉ͥະྶ̈́ത̦ఉ̞ȃ൚໦࿤͉́ȂLMP1 ͞
LMP2a ̦᥷ಎ૤ B ळ༾අ։എͅอ࡛̳ͥழ̢۟
ȪTgȫζ;Αͬैୋ̱ȂκΟσࢯࡔͬ྾‫̭̳́͂ͥע‬Ȃ᥷ಎ૤฽؊ͬည൵̱ȂB ळ༾͈஖఼͂໦‫࠿̞̀̾ͅا‬൦̱̹ȃ
LMP2a Tg ζ;Ά͉Ȃᦃ௫̤̞̀ͅȂୃુ̈́᥷ಎ
૤ࠁ଼̦෇༷֚͛ͣͦͥ́Ȃࢯࡔඅ։എ̈́ࢯఘॲ୆
͈೩‫̦ئ‬۷ख़̯ͦȂLMP2aȼB ळ༾͈྾‫ע‬Έυήςϋ
֒ഥঊ෻Ⴅ̥ͣࢯࡔ૶გ଻͈ະ଼੃̦ྶ̥ͣ͂̈́̽
̹ȃ̹͘Ȃᦃ௫ࠁৗळ༾͈௩‫̹͛෇ͬح‬ȃ̭͈ͦͣࠫ‫̥ͣ ض‬ȂEBV LMP2a ͉Ȃ᥷ಎ૤฽ ؊̤̫ͥͅ
BCR ૶გ଻଼੃͈ࡕྟ଻ͬ೩‫̵̯͂͂ͥ͜ͅئ‬ȂBळ༾̥ͣࠁৗळ༾͈͒໦‫ͬا‬௯ૺ̳̭̦̥̹ͥ͂ͩ̽

଎ˍ . EBV LMP2a ͥ͢ͅ B ळ༾஖఼Ჷ౵͈೩‫ ͥ͢ͅئ‬EBV ஆ໖ۜஅ଼ၛ͒
͈࣓ࡃ . EBVȁLMP2a ͥ͢ͅ BCR ΏΈ΢σ͈‫͉ا଻ڰ‬Ȃࣞ૶გ଻ B ळ༾஖఼͈Ჷ౵ͬ೩‫̵̯ͥئ‬ȃȪGerminal center: ᥷ಎ૤ȂExtrafollicular focus : ᚾ༾‫ ٸ‬B ळ༾໦‫ا‬໐պȂAcute IM: ‫଻ݢ‬ഥஅ଻ౙ‫ړ‬છȂPersistent infection: ঵௽ۜஅȂ
Lytic viral replication: ;ͼσΑဣٜۜஅȫȪ଎ˍȫȃȁ༷֚ȂLMP1 Tg ζ;Ά͉Ȃࢯࡔ྾‫᥷ͥ͢ͅע‬ಎ૤ࠁ଼̦෇̴͛ͣͦȂLMP1 ̽̀͢ͅ B ळ༾໦‫͈ا‬ஷ‫̭̭̦͂ͥܳٺ‬̦া̯̹ͦȃ‫ྙޟ‬૬̞̭͂ͅȂLMP1 Tg ဇြ͈ࣸଡळ༾ͬ࿤୆߿ζ;Αࣸଡळ༾͂͂͜ͅ֊૒̱̹ાࣣ́͜Ȃ࿤୆߿ B ळ༾͈᥷ಎ૤ࠁ଼̦ࡘઁ̱ȂLMP1ȼB ळ༾̦߃ႋ͈ B ळ༾ͅచ̱̀͜ဲଷ࢘‫ͬض‬อ‫̹̥̦̭̳̽ͩ͂ͥܞ‬ȃ೒ુ͈྾‫ע‬฽؊͉́Ȃ΢ͼȜή B ळ༾͈ఱ໐໦͉Ȃ᥷ಎ૤฽؊̀ͅੰ‫̦̯ͥͦݲ‬Ȃࣽٝྶ̥̹ͣ͂̈́̽ LMP1 ͈‫ܥ‬ෝ̦᥷ಎ૤ࠁ଼ͬဲଷ̱Ȃ̯ͣͅ LMP2a ̦ࢯࡔ૶გ଻ͅջం̵̴ۜͅஅ᥷ಎ૤ B ळ༾͈୆ంͬ੩̫̭ͥ͂́ȂΪΠ̤̫ͥͅ EBV ஆ໖ۜஅ଼͈ၛͅ
࣓ࡃ̱̞͈̥̱̞̀ͥͦ̈́͜ȃĲĵˏȫুࡨ฽؊଻̤͍͢Ȃఉ໦ঊ฽؊଻ࢯఘ͈੄࡛‫̷͈͂ࢹܥ‬୆ၑഎƦພၑഎ࿨‫͈ڬ‬ٜྶȁȁ࠲ુ૽ྎઑࠬ IgGȼικςȜ B ळ༾͉ͅȂఉ̩͈ఉ໦ঊ฽؊଻ B ळ༾̦‫̞ͥ̀ͦ͘܄‬ȃ̭͈ͦͣ྾‫ע‬Έυήςϋ֒ഥঊ͉ͅໝତ͈ఘळ༾಼་։ȪSHMȫ̦෇̭̥͛ͣͦͥ͂̈́̓ͣȂఉ໦ঊ฽؊଻ B ळ༾͉᥷ಎ૤͈́૶გ଻஖఼ͬࠐ̹‫خ‬ෝ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଻̦̜̦ͥȂ̷͈ͦͣ᥷ಎ૤฽؊ͬည̳֦ܳͥঊ̧͉͉͉̱̞̞̽ͤ͂̀̈́ȃِș͈ٜଢ଼͉́Ȃζ;ᾼ̤̫ͥζ;Α΄ϋζΰσβΑ;ͼσΑȪMHV68ȫ͈ۜஅ́ည൵̯ͦͥᦃ௫᥷ಎ૤ B ळ༾́ఉ໦ঊ฽؊଻·υȜϋ̦੄࡛̱Ȃୟޭഎͅ஖఼̯
̭ͦͥ͂ͬྶ̥̱̹ͣͅȃਅș͈ۜஅ̤̞̀ͅȂఉ໦ঊ฽؊଻ B ळ༾̦੄࡛̳ͥ‫خ‬ෝ଻͂൳শͅȂ̭͈ MHV68 ۜஅ̦ఉ໦
ঊ฽؊଻ B ळ༾੄࡛‫ͅݪࡄ͈ࢹܥ‬ഐ̱̹κΟσ̜̭̦́ͥ͂াऐ̯̹ͦȪ଎ˎȫȃȁΪΠ̤̫ͥͅఉ໦ঊ฽؊଻ࢯఘ͂ুࡨ྾‫ע‬৖͈ۛ͂‫۾‬Ⴒͬ࠿൦̳̹ͥ͛ͅȂ஠૸଻΀ςΞζΠȜΟΑȪSLEȫۛ৪̤̫ͥͅఉ໦ঊ฽؊଻ࠁৗळ༾͈੄࡛
ອഽͬྶ̥̱̹̭ͣ͂ͧͅȂ࠲ુ૽͂൳൝͈‫ࣣ́ڬ‬ఉ໦ঊ฽؊଻·υȜϋͬ‫̥̭͚ͣ͂܄‬Ȃఉ໦ঊ฽؊଻ B ळ༾͈੄࡛ອഽ͂ SLE อછ͈‫ͅۼ‬௖‫͉̈́۾‬̞͂ࣉ̢ͣͦͥȃ̱̥̱̦̈́ͣȂSLE ဇြ͈ఉ໦ঊ฽؊଻·υȜϋ͉Ȃ࠲ુ૽͈·υȜϋͤ͢͜ুࡨࢯࡔ͈͒૶გ଻̦‫خ̞ޑ‬ෝ଻̦̜ͤȂ࡛हٜଢ଼ͬૺ
̞͛̀ͥȃȁ༷֚Ȃ૷౯ζȜ΃Ȝ̯̞͂ͦ̀ͥࢯ‫ࢯړ‬ఘ͉Ȃ‫ ଻ݢ‬SLE ۛ৪̥͈ͣྎઑ
ࠬࠁৗळ༾͈͙ࣞͅອഽȪ࿩5ɓȫͅ෇̹͛ͣͦȃ̭ͦͣࢯ‫ࢯړ‬ఘ·υȜϋ͉ȂSmith ࢯࡔ̷̸͈͈̈́̓ͦͦࢯࡔͅඅ։എͅ฽؊̱̹̦Ȃఉ໦ঊ฽؊଻͉঵
̹̥̹̈́̽ȃࣽࢃ͉ȂNGSȪষଲయΏȜ·΀ϋ΍Ȝȫͬߐঀ̱Ȃ̭ͦͣুࡨࢯఘ͈੄࡛ອഽͬྶ‫̳͂͂ͥ͜ͅͅږ‬Ȃ‫·ڎ‬υȜϋ͈྾‫ע‬Έυήςϋ֒ഥঊ͈ࠏൡਏٜଢ଼̥ͣȂΪΠ̤̫ͥͅুࡨ฽؊଻ B ळ༾͈౪୆̷͈͂஖఼̾ͅ
̞͈̀໦ঊ‫ܖ‬๕ͬྶ̥̱̹̞ͣͅȃ଎ 2. MHV68 ۜஅ̤̫ͥͅᦃ௫ IgG+ ᥷ಎ૤ B ळ༾͈́ఉ໦ঊ฽؊଻·υȜϋ͈੄࡛ȃMHV68 ۜஅ́ည൵̯ͦͥᦃ௫᥷ಎ૤฽؊̀ͅȂఉ໦ঊ฽؊
଻ B ळ ༾ ̦ ࿩ 30ɓ ͅ ອ ഽ ́ ੄ ࡛ ̳ ͥ ̭ ͂ ͬȂsingle-cell ֒ഥঊ·υȜΣϋΈ͂ ELISA ͥ͢ͅ฽؊଻ίυέ͹ͼσȪऒષȈయນഎ̈́ࠫ‫͈ض‬႕ȂֲષȈࠫ‫׫̹͛͂ͬ͘ض‬Έρέ [n = 75]ȫ̀ͅྶ̥ͣͅ
̱̹ȃ̭͈ۜஅκΟσ͉Ȃఉ໦ঊ฽؊଻ B ळ༾੄࡛‫ͅݪࡄ͈ࢹܥ‬ഐ̱̞̀ͥȃड߃͈యນഎ̈́ა໲
1. Kumanogoh, A., and Kikutani H. Immunological functions of the neuropilin and plexin as receptors forsemaphorins. Nat Rev Immunol. 2013 Nov;13(11):802-14.
2. Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T, Mochizuki H, Sakoda S, Kikutani H. BAFF controls neural cell
survival through BAFF receptor. PLoS One. 2013 Jul 29;8(7):e70924.
3. Morihana T, Goya S, Mizui M, Yasui T, Prasad DV, Kumanogoh A, Tamura M, Shikina T, Maeda Y, Iwamoto Y,
Inohara H, Kikutani H. An inhibitory role for Sema4A in antigen-specific allergic asthma. J Clin Immunol. 2013
Jan;33(1):200-9.
4. Yasui T, Sakakibara-Yada K, Nishimura T, Morita K, Tada S, Mosialos G, Kieff E, Kikutani H. Protein kinase N1,
a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation. Proc Natl Acad Sci
U S A. 2012 Dec 18;109(51):21022-7.
5. Tada, S., Okuno T., Yasui T., Nakatsuji N., Sugimoto T., Kikutani H., and Sakoda S. Deleterious effects oflymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateralsclerosis. J Neuroinflammation. 2011 Feb 23;8(1):1ĲĶࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆ఘཡࢄࡄ‫ݪ‬໐࿝྾‫ע‬ະ஠৖ۛࡄ‫ݪ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎Ȫ࠳ȫġ֓‫ڠ‬ฎআȁ࿐‫ئ‬Ηυ;੎‫ޗ‬਎ġ
֓‫ڠ‬ฎআȁஜനȁဉ༟੎‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁఆષȁၻঊ੩‫ޗ‬ġඅහ੩‫ޗ‬ġġ ֓‫ڠ‬ฎআȁന፜ȁ࿹ঊġ ֓‫ڠ‬ฎআȁ૰ᚧȁํ࣐ȁ൚ࡄ‫ݪ‬໦࿤͉́Ȃ୆ఘཡࢄ‫۾̦ࢹܥ‬ဓ̳ͥအș̈́୆໤‫ڠ‬എȂ֓‫ڠ‬എ࿚ఴͬ৾ͤե̞̽̀ͥȃ̩͂ͅȂGPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͈୆଼ࣣࠐႹȆ࿶௣ࠐႹȆ୨౯ဋၗ‫ݪࡄ͈ࢹܥ‬Ȃ̷͈ͦͣ։ુͥ͢ͅ৖͈ۛอછ‫ܥ‬੬ͅ‫ݪࡄ̳ͥ۾‬ȂΌσΐఘ͈ pH ಺୯͈ι΃ΣΒθ͂୆ၑഎփ݅ͅ‫ݪࡄ̳ͥ۾‬Ȃ߃୪̱̹΂σ΄Υρ྄‫͈ۼ‬ডৗ͞ͼ΂ϋ͈࿶௣ͬংͥȶ྄୪૘໐պȷ
͈ࢹ଼֦ঊ͈൳೰͂‫ܥ‬ෝٜଢ଼ͅ‫̞࣐ͥ̀̽ͬݪࡄ̳ͥ۾‬ȃˍȫGPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͈୆଼ࣣȆ࿶௣ȆςκΟςϋΈ‫ݪࡄ͈ࢹܥ‬ȁGPI ͺϋ΃Ȝ͉ȂγΑέ͹ΙΐσͼΦΏΠȜσͅൠङ̦̦̹̾̈́̽ൠডৗ́ȂΗϋΩ·ৗ͈˟ྎ౤྄ࣣ̱ࠫ̀ͅͺϋ΃Ȝ̱͂̀൱̩ȃሶ඿൲໤͉́ 150 ਅ೾ഽ͈ GPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ̦౶̤ͣͦ̀ͤȂ୆ఘཡࢄ͞ळ༾‫ૂ͈ۼ‬༭ഥోͅਹါ̈́
͈̦͜ఉ̩‫̥͕ͥͦ͘܄‬Ȃ;ͼσΑ͞ඉள͈਋ယఘ̞͈̜̈́̽̀ͥͥ͜͜ͅȃGPI ͺϋ΃Ȝ͈අಭ͉ȂΗϋΩ·ৗͬডৗζͼ·υΡιͼϋͅޫह̵̯̭ͥ͂Ȃͺϋ΃Ȝ໐໦͈୨౯྄̥̽̀ͣ͢ͅဋၗ̱ං̭ͥ͂Ȃͺά΃σ௰͒࿶௣̵̯̭ͥ͂̈́̓́
̜ͥȃِș͉ȂGPI ͺϋ΃Ȝ͈୆଼ࣣͅ൱̩ PIGȪPhosphatidylInositol Glycanȫ֒ഥঊ߲͂ȂGPI ͺϋ΃Ȝ̦ΗϋΩ·ৗͅັ‫ً͈ࢃ̹̯ͦح‬೾ͅ൱̩ PGAPȪPost GPI-Attachment to Proteinsȫ֒ഥঊ߲͈൳೰͂‫ܥ‬ෝٜྶͅ༫‫گ‬എ৾ͤͅழͭ
̞́ͥȪ଎ˍȫȃ̭͈ͦͣࡄ‫ͤ͢ͅݪ‬Ȃఉ̩͈ΗϋΩ·ৗ̦ GPI ྄̽̀͢ͅͅͺϋ΃Ȝ̯̞̭͈ͦ̀ͥ͂୆໤‫ڠ‬എփ݅ͬྶͣ
̥̱̹̞͂ͅࣉ̢̞̀ͥȃȁȁȁȁȁȁȁȁȁȁȁȁȁȁȁ

଎ˍȇGPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͈୆଼ࣣȆ࿶௣Ȇ୨౯ဋၗ
GPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͉ȂPIG ֒ഥঊ߲͈൱̧́୆଼ࣣ̯̹ͦ GPI ̦ΗϋΩ·ৗͅັ‫̧̯ͥ́̀ͦح‬ȃ̷͈ࢃȂGPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͉Ȃ
p24 έ͹ηςȜ౩ฒৗ̦‫۾‬ဓ̳ͥ໦๥ࠐႹ̽̀͢ͅ઀༾ఘ̥ͣΌσΐఘͬࠐ̀ळ༾ນ࿂͒࿶௣̯ͦͥȃ̷ً͈೾́ȂPGAP ֒ഥঊ߲͈൱̧͢ͅ
ͤȂGPI ͺϋ΃Ȝ͈ൠङ͂ডৗ̷̸͈̦ͦͦςκΟςϋΈͬ਋̫Ȃ଼੃߿͈ GPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ̈́ͥͅȃ֚໐͈ GPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ͉Ȃ୨౯ࣖள͈൱̧́ळ༾ນ࿂̥ͣဋၗ̳ͥȃ࡛ह́͘ͅ༭̯̞࣬ͦ̀ͥ୶ഛ଻ GPI ࠧఅછ͈ୣහ֒ഥঊͬؕ૗Ȃࢃഛ଻ GPI ࠧఅછ̜́
ͥ PNH ͈ୣහ֒ഥঊͬକ૗́া̳ȃĲķˎȫGPI ࠧఅછ͈อછ‫ܥ‬੬ͅ‫ݪࡄ̳ͥ۾‬ȁِș͉‫·͈࣭ם‬σȜί͈͂‫ވ‬൳ࡄ‫ ͤ͢ͅݪ‬GPI ୆଼ࣣͅຈଌ͈֒ഥঊȂPIGM ͈։ુͥ͢ͅ୶ഛ଻ GPI ࠧఅછ (Inherited
GPI deficiency, IGD) ͬଲ‫́ٮ‬ই͛̀༭̱̹̦࣬Ȃ̷͈ࢃষଲయΏȜ·΀ϋ΍Ȝͬঀ̹ٜ̽ଢ଼࡛ͤ͢ͅह́͘ͅ GPI ‫۾‬Ⴒ֒ഥঊͬୣහ֒ഥঊ̳͂ͥ 12 ਅ͈ IGD ̦ࡉ̥̾ͤȂ૧̹̈́৖ۛౙպ̱࣭͂̀ඤ‫ވ́ٸ‬൳ࡄ‫ ( ̞̦ͥ̀̽ࢩ̦ݪ‬଎ˍ)ȃGPI ͈ۖ஠ࠧఅ͉థ୆౿ঘ͈̈́ͥ́ͅ PIG ֒ഥঊ߲̦ࡔ֦͈ાࣣ͉໐໦ࠧఅછ̜́ͤȂGPI ςκΟςϋΈͅ‫֒ͥͩ۾‬ഥঊ͈ાࣣ
͉ͅ null ་։̜ͥ͜ȃୣහ֒ഥঊ͈ਅ႒͂ࠧఅ͈೾ഽͤ͢ͅఉद̈́છેͬা̳ḁ̑̀ͭͭȂ‫׋‬൲ୈ૰อో͈વ‫৽ͬٺ‬છે̱͂Ȃশͅ܏ཞȂ਀ঐ͈։ુȂఉ௫‫ࠁܗ͈ܕ‬Ȃࣞͺσ΃ςγΑέ͹ΗȜΔࠬછฺ̠ͬȃMabry syndrome ͂ CHIME
syndrome ͈৽ါ̈́ୣහ֒ഥঊ̜́ͤȂOhtahara syndromeȂWest syndrome ்̈́̓‫ܢ‬อછ̥̀ͭͭ଻ෞછ͈֚໐ͅ IGD
̦ంह̳̭̦ͥ͂฻ྶ̱̞̀ͥȃࣞͺσ΃ςγΑέ͹ΗȜΔࠬછ͂έυȜ΍ͼΠιΠςȜ࠿औͤ͢ͅࢡಎ‫ ͈ݩ‬CD16 ͈อ࡛೩

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

‫ͬئ‬ঐດ̳̭̦ͥ͂ͅ૷౯ͅခ̜̭̦࢘́ͥ͂ྶ̥ͣ̈́ͤͅȂࣽࢃછ႕ͬਬୟ̱̀૷౯‫ܖ‬੔ͬଷ೰̱̯͉ͣͅহၷ༹͈ٜྶ
̰̱̞ͬ͛̀ͥȃ༷֚ࢃഛ଻ GPI ࠧఅછ̜́ͥอै଻࿡‫ࠬۼ‬૗ளෂછȪPNHȫ͉ GPI ͺϋ΃Ȝ߿ΗϋΩ·ৗ̜́ͥ༞ఘଷ
ࢄ֦ঊ̦ࠧఅ̱̞̹̀ͥ͛ͅȂ୤ࠬ‫̦ݩ‬༞ఘͤ͢ͅ෫ٟ̯ͦ̀Ȃဣࠬ଻ຫ̧̹̳ࠬͬࠬ‫ס‬৖̜ۛ́ͥȃࢃഛഎͅ௮ࠬۚळ
༾́ X அ૗ఘ֒ഥঊ͈ PIGA ͅඏட་։̦̤̭ͤ GPI ࠧఅळ༾̹͂̈́̽ࢃȂ໵อ̳ͥ௮ࠬۚळ༾͈͒ুࡨ྾‫ע‬എ‫ܥ‬੬̥ͣ
൪ͦ̀ GPI ࠧఅ·υȜϋ̦௩ఱ̱Ȃ̯ͣͅၻ଻ਆន଻௩૓ͬြ̳֒ഥঊ་։̦̭̭ܳͥ͂ͤ͢ͅພఠ଼̦̳ۖͥ͂ࣉ̢̤̀
ͤȂอછ‫ܥ‬੬ͬྶ̥̳̭ͣͥ͂ͬͅ࿒ঐ̱̞̀ͥȃड߃ȂPIGA ͈ඏட་։͉̩́̈́ુஅ૗ఘ֒ഥঊ PIGT ͈ 1 ͈̾ͺςσ͈֒ഥ଻་։ͅ‫̢͈༷̠֚̀͜ح‬ͺςσ͈ఘळ༾ඏட་։ͥ͢ͅ PNH ̦ࡉ̥̞̾̽̀ͥȃˏȫळ༾ඤॸ଻΂σ΄Υρ͈ pH ಺୯‫྄͍ͣ̈́ͅࢹܥ‬୪૘໐պ͈ࢹ଼֦ঊȆ‫ܥ‬ෝٜଢ଼ȁळ༾ඤ΂σ΄Υρ͉ডৗඵਹ྄̤̽̀͢ͅࡽ̞ͅ‫ڞ‬ၗْ̯̞ͦ̀ͥ໦́
̜ͤȂ̷͈‫ܥ‬ෝͬडఱࡠͅอ‫ࡥ̹̳͛ͥͅܞ‬ခ͈۪‫͞ޏ‬ΗϋΩ·ৗȆডৗ଼໦ͬ༗঵̱̞̀ͥȃ̷͈ਹါ۪̈́‫֦ޏ‬ঊ͈̦֚̾ pH ̜́ͥȃ໦๥ࠐႹ͞΀ϋΡ΍ͼΠȜΏΑࠐႹ͈΂σ΄Υρ͈ඤ͉࣌ࡥခ͈ॸ଻ pH ͅ༗̹̞ͦ̀̀Ȃ̷͈։ુ́ळ༾τασ͉́ȂΗϋΩ·ৗȆডৗ͈࿶௣ȆίυΓΛΏϋΈȆൠङਘૐવ‫΂͞ٺ‬σ΄Υρ͈ࠁఠ։ુ̦Ȃ̹͘ࡢఘτασ͉́အș̈́৖̦ۛอછ̳̭̦ͥ͂౶̞ͣͦ̀ͥȃ̷͈ਹါ଻͜ͅࢰ̴̷͈ͣͦͣ։
ુέͿΦΗͼί͈̭ܳͥι΃ΣΒθ̞͉͕̾̀͂ͭ̓ͅ฻̞̞̽̀̈́ȃ൚ΈσȜί͉ȂΌσΐ௡౾͈ pH ։ુͬা̳་։ळ༾‫ͬڼ‬੝͛̀ਏၛ̱Ȃ̷͈ୣහΗϋΩ·ৗ͈൳೰Ȇ‫ܥ‬ෝٜଢ଼ͬ༭̱̹࣬ȃࣽࢃȂ̭͈ͦͣ་։ळ༾Ȇ֒ഥঊ͈၌ဥ໼͍ͅ૧̹̈́ pH ։ુͬা̳་։ळ༾‫͈ڼ‬ਏၛٜଢ଼ͬ೒̲
̀Ȃळ༾ඤ΂σ΄Υρ͈ pH ͈಺୯‫̷͈͞ࢹܥ‬୆ၑഎփ̞݅̾̀ͤ͢ͅၑ
ٜͬ૬͛ȂpH ։ુ̦ພ֦̜́ͥ৖ۛͅచ̳ͥ૧̹̈́஻࿪͈‫ٳ‬อ͈͒ඏ෫
࢛̭͂̈́ͥ͂ͬ࿒എ̱̞͂̀ͥȃ̹͘Ȃ̭͈ࡄ‫̥ͣݪ‬෩୆̱̹ΞȜζ̱͂̀Ȃ։̹̈́̽΂σ΄Υρ྄̦߃୪̱̀ডৗ͞ͼ΂ϋͬ࿶௣̳ͥા̱͂̀߃ාಕ࿒
̯̞ͦ̀ͥȶ྄୪૘໐պȷ͈ࢹ଼֦ঊ͈൳೰Ȇ‫خ‬ণ‫ͥ͢ͅا‬൲ఠٜଢ଼̤

଎ 3ȇळ༾ඤ΂σ΄Υρ͈ pH ಺୯໦๥ࠐႹ͞΀ϋΡ΍ͼΠȜΏΑࠐႹ͈΂σ΄Υρඤ̷̸͉࣌ͦͦࡥခ͈ॸ଻ pH ͅ಺୯̯̞ͦ̀ͥȃତল̷͉̤̤͈͢ pH ͬা̳ȃ̷͍͈͢‫ܥ‬ෝٜଢ଼͜ͅႁͬව̞ͦ̀ͥȃड߃͈యນഎ̈́ა໲
1. Implication of lipid moiety in oligomerization and immunoreactivities of GPI-anchored proteins. Seong J, Wang Y,
Kinoshita T, Maeda Y. J Lipid Res. 2013 Apr;54(4):1077-91
2. Mechanism for release of alkaline phosphatase caused by glycosylphosphatidylinositol deficiency in patients withhyperphosphatasia mental retardation syndrome. Murakami Y, Kanzawa N, Saito K, Krawitz PM, Mundlos S,
Robinson PN, Karadimitris A, Maeda Y, Kinoshita T. J Biol Chem. 2012 Feb 24;287(9):6318-25.
3. Sorting of GPI-anchored proteins into ER exit sites by p24 proteins is dependent on remodeled GPI. Fujita M,
Watanabe R, Jaensch N, Romanova-Michaelides M, Satoh T, Kato M, Riezman H, Yamaguchi Y, Maeda Y,
Kinoshita T. J Cell Biol. 2011 Jul 11;194(1):61-75.
4. Peroxisome dependency of alkyl-containing GPI-anchor biosynthesis in the endoplasmic reticulum. Kanzawa N,
Maeda Y, Ogiso H, Murakami Y, Taguchi R, Kinoshita T. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17711-6.
5. GPI glycan remodeling by PGAP5 regulates transport of GPI-anchored proteins from the ER to the Golgi. Fujita M,
Maeda Y, Ra M, Yamaguchi Y, Taguchi R, Kinoshita T. Cell. 2009 Oct 16;139(2):352-65.
Ĳĸࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆ఘཡࢄࡄ‫ݪ‬໐࿝ুட྾‫ڠע‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎Ȫ࠳ȫġ੎‫ޗ‬਎ġ੩‫ޗ‬ġ֓‫ڠ‬ฎআȁૣၻȁ୓౳֓‫ڠ‬ฎআȁḶ൥ȁోढ֓‫ڠ‬ฎআȁऎ൥ȁȁ௝අහ੩‫ޗ‬Ȫ࠳ȫġġ֓‫ڠ‬ฎআȁ‫܃‬५ȁ࠲ఊȁِș͉Ȃૺ‫ا‬എͅ༗ం̯̹ͦພࡔఘͅచ̳ͥཡࢄ‫ু̜ͥ́ࢹܥ‬ட྾‫̞࣐ͥ̀̽ͬݪࡄ̞̀̾ͅע‬ȃুட྾‫͈ע‬ည൵͉ͅΩΗȜϋ෇ে਋ယఘ̦ਹါ̈́࿨‫̳̹ضͬڬ‬ȃΩΗȜϋ෇ে਋ယఘ͉Ȃळ޿Ȇ૯޿ȆࡔಖȆ;ͼσΑ̈́̓໙ࢩ̞ພࡔఘͬ෇ে̱Ȃ΍ͼΠ΃ͼϋ͞ͼϋΗȜέͿυϋ͈̈́̓‫׶‬છ଻֦ঊ͈ॲ୆ͬည൵̳ͥȃ༷֚́ȂΩΗȜϋ෇ে਋ယఘ͉۪‫ޏ‬؄அ໤ৗ͞ুࡨ
య৫໤ৗͅࢋ̽̀฽؊̱Ȃ‫׶‬છ଻৖͈ۛอછါ֦͂̈́ͥ͜ȃ̾ͤ͘Ȃুட྾‫ِ͉ע‬ș͈૸ͬ৿ͥȂِ̹͘ș͈૸ͬੱ̫̾
̞̠ͥ͂ୃ໅ၰ༷͈࿂ͬ঵̤̽̀ͤȂۜஅછ͞‫׶‬છ଻৖ۛ̈́̓အș̈́৖͈ۛอછͅ૬̩‫̞ͥ̀̽ͩ۾‬ȃ̭͈ুட྾‫̳۾ͅע‬ͥၑٜͬ૬̹͛ͥ͛Ȃِș͉ΩΗȜϋ෇ে਋ယఘ̱̹ͬٚুட྾‫ע‬؊൞͈ଷࢄ‫͈ࢹܥ‬ٜྶ͂ুட྾‫ע‬౜൚ळ༾͈૧̹̈́‫ܥ‬ෝ͈ౝ࣐̞॑ͬ̽̀ͥȃˍȅ๷઀‫ۯ‬ջంഎ̈́ NLRP3 ͼϋέρζΕȜθ͈‫ا଻ڰ‬ȁুட྾‫ͥͩ۾ͅע‬ΩΗȜϋ෇ে਋ယఘ̜́ͥ NLRP3 ͉Ȃૂ༭ഥో֦ঊ ASC ͞ίυΞͺȜΔ Caspase-1 ͂‫ ͅވ‬NLRP3
ͼϋέρζΕȜθͬࠁ଼̱Ȃ‫׶‬છ଻΍ͼΠ΃ͼϋ ,/ȕ͈ॲ୆̱ͬٚ̀‫׶‬છͬৼ̳ܳͥȃෂॸࠫએ͈̈́̓ঁࠣ଻ၥঊͥ͢ͅ
NLRP3 ͼϋέρζΕȜθ઼ً͈̈́‫͉ا଻ڰ‬೑໓͈̈́̓‫׶‬છ଻৖͈ۛอછါ֦̹͂̈́ͥ͛ȂNLRP3 ͼϋέρζΕȜθ‫ا଻ڰ‬ͬஷ‫ࣣا̳ͥٺ‬໤͈൳೰͉ਹါ̈́ࡄ‫هݪ‬ఴ̜́ͥȃِș͉Ȃ‫ࣣا‬໤ρͼήρςȜͬဥ̞̹Α·ςȜΣϋΈ࣐̞ͬȂ೑໓হၷ࿪̜́ͥ΋σΪΙϋ̦ NLRP3 ͼϋέρζΕȜθ͈‫ဲͬا଻ڰ‬ଷ̳̭ͥ͂ͬࡉ੄̱̹ȪMisawa T et al., Nat Immunol, 2013ȫȃ
๷઀‫͉ۯ‬ෂॸࠫએ͈̈́̓ঁࠣͅ؊̲̀ηΠ΋ϋΡςͺͬ๷઀‫଼ࠁۯ‬ಎ૤༷࢜͒͂࿶௣̳̭ͥ͂ͤ͢ͅȂ઀༾ఘષ͈ NLRP3 ͂ηΠ΋ϋΡςͺષ͈ ASC ͈߃୪ͬည൵̱ȂNLRP3 ͼϋέρζΕȜθ͈‫ͬا଻ڰ‬௯ૺ̳ͥȃ΋σΪΙϋ͈̈́̓ΙνȜήςϋਹࣣஷ‫ٺ‬स͉Ȃ๷઀‫ۯ‬ջంഎͅည൵̯ͦͥ઀༾ఘ͂ηΠ΋ϋΡςͺ͈߃୪̱̹ͬٚ NLRP3 ͼϋέρζΕȜθ͈‫ဲͬا଻ڰ‬ଷ̳ͥȃෂॸࠫએ͈̈́̓ঁࠣ଻ၥঊ͉ȂηΠ΋ϋΡςͺ͈అੱ̧̭̳̹ͬ֨ܳ͛Ȃळ༾ඤ
NAD+ ̦ࡘઁ̱̀ NAD+ ջం଻͈ĮΙνȜήςϋ౎ͺΓΙσ‫ࣖا‬ள̜́ͥ SIRT2 ͈‫଻ڰ‬̦೩‫̳ͥئ‬ȃSIRT2 ͈‫଻ڰ‬೩‫͉ئ‬ͺΓΙσ‫ا‬ĮΙνȜήςϋͬ௩‫̵̹̯͛ͥح‬ȂΘͼΣϋջ ం എ ̈́ηΠ΋ϋΡςͺ͈࿶ ௣ͬ ̱̹ٚ
NLRP3 ͂ ASC ͈߃୪̦ည൵̯ͦͥȃఅੱηΠ΋ϋΡςͺဇြ͈‫ॸ଻ڰ‬ளਅ͉ȂNLRP3
ͼϋέρζΕȜθ͈ೄ୪എ̈́‫ͬا଻ڰ‬ည൵̳̦ͥȂNLRP3 ͂ ASC ͈߃୪͉ͅ‫ͬޣג‬ဓ̢̞̈́ȃ̭͈ٜͦͣଢ଼̥ͣȂNLRP3 ͬ‫଻ڰ‬ॸளਅ̦ೄ୪എͅ‫ࠐ̳ͥا଻ڰ‬Ⴙͅ‫̢̀ح‬Ȃ
NLRP3 ̥ͣ ASC ͈͒ૂ༭ഥో࣐̠̹ͬ͛
͈ાͬା̢ͥ๷઀‫ۯ‬ջంഎ̈́ࠐႹ̦ NLRP3
ͼϋέρζΕȜθ͈‫ྶ̦̭͂ͥͩ۾ͅا଻ڰ‬଎ 1. NLRP3 ͼϋέρζΕȜθ͈‫ا଻ڰ‬̥̹ͣ͂̈́̽ȃȪ଎ Ĳȫˎȅ଼ࣣ 2 ུङ RNA ̦ခ̳ͥ྾‫ע‬ଷࢄैဥ̤̫ͥͅ΃ΞίΏϋ D ͈‫۾‬ဓȁুட྾‫ע‬౜൚ळ༾͈֚̾ਏેळ༾͉ȂΩΗȜϋ෇ে਋ယఘ̱ͬٚ̀΍ͼΠ΃ͼϋॲ୆͞‫ࠣঁވ‬໦ঊอ࡛ͬည൵̱Ȃडਞഎͅ T ळ༾͈‫ࢯ͞ا଻ڰ‬ఘॲ୆̞̹͂̽‫ڕ‬ං྾‫଼ͬע‬ၛ̵̯̞ͥͩ͊ুட྾‫ڕ͂ע‬ං྾‫ޘ͈ע‬ള̱͈࿨‫ͬڬ‬‫̳̹ض‬ळ༾̜́ͥȃِș͉Ȃ;ͼσΑ RNA ͬ࿅༩଼̳ࣣͥ 2 ུङ RNAȪdsRNAȫ̜́ͥ Poly IC ͥ͢ͅਏેळ༾
͈‫̳ͥ۾ͅا଻ڰ‬ٜଢ଼࣐̞ͬȂPoly IC ͤ͢ͅည൵̯֚ͦͥ໐͈ਏેळ༾͈ळ༾ঘ̦Ȃਔս͈ਏેळ༾͈‫ͅا଻ڰ‬૬̩‫۾‬ဓ̳̭ͥ͂ͬࡉ੄̱̹ȪZou J et al., Immunity, 2013ȫȃਏેळ༾̤̞͉̀ͅȂdsRNA ͬ෇ে̳ͥ RIG-I-likereceptors ̤͍͢ͺΘίΗȜ֦ঊ IPS-1 ̱̹ͬٚΏΈ΢σഥోࠐႹ̦ুட྾‫ע‬؊൞͈ည൵ͅਹါ̈́࿨‫̳̹ضͬڬ‬ȃCathepsin D ུ͉ြςΕΕȜθඤͅޫह̳ͥ໦ٜࣖள̜̦́ͥȂPoly I:C ࣺ̺ͬ৾ͤͭਏેळ༾̤̞͉̀ͅςΕΕȜĲĹθ྄͈̦అੱ̳̹ͥ͛ͅȂCathepsin D ̦ςΕΕȜθ̥ͣჃ੄̳ͥȃळ༾ৗͅၠව̱̹ Cathepsin D ͉ȂIPS-1 ࣣ̳̭͂ࠫͥ͂ͤ͢ͅȂPoly IC ͤ͢ͅည൵̯ͦͥুட྾‫ע‬؊൞ͬ௯ૺ̳ͥȃ̹͘ȂCathepsin D ͉ळ༾ঘͬည൵̳̭ͥ
͂́Ȃ‫֦ࣣࠫॸړ‬ঊ͈֚̾ HMGB1 ͈༶੄ͬ௯̳ȃঘळ༾̥ͣ༶੄̯̹ͦ HMGB1
͂ Poly IC ͉ໝࣣఘͬࠁ଼̱Ȃ࢘ၚ̩͢ਔ
ս͈ਏેळ༾ࣺ̭৾ͤͦͥ͂́͘ͅȂুட྾‫ע‬؊൞̯ͬͣͅ‫̳ͥا଻ڰ‬ȃPoly IC͉Ȃਏેळ༾̤̞̭͈̀ͅεΐΞͻήσȜίͬည൵̳̭ͥ͂ͤ͢ͅ‫ڕ‬ං྾‫଻ڰ͈ע‬‫̩ޑͬا‬௯ૺ̳̹ͥ͛Ȃ‫ޑ‬ႁ̈́χ·Ιϋ଎ 2. Poly IC ͥ͢ͅਏેळ༾͈‫ا଻ڰ‬ͺΐνΨϋΠ̱͂̀൱̩ȃ
Ȫ଎ 2ȫ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ˏȅডཛழ૕͈֋঵ͅ‫ͥͩ۾‬ζ·υέ͹Ȝΐ͈૧̹̈́࿨‫ڬ‬ȁζ·υέ͹Ȝΐ͉ȂM1 ͂ M2 ̞̠͂ઁ̩̈́͂͜ 2 ͈̾ΈσȜί̥ͣࢹ଼̯̞ͦ̀ͥȃM1 ζ·υέ͹Ȝΐ͉‫׶‬છ؊൞ͬৼ̱ܳȂळ޿͞;ͼσΑۜஅͅచ̳ͥ਽৽ཡࢄ̤̞̀ͅಎ૤എ̈́࿨‫ͬڬ‬౜̞̽̀ͥȃ༷֚́ȂM2 ζ·υέ͹Ȝΐ͉ࢯ‫׶‬છ؊൞͞ழ૕ठ୆̈́̓ͅ‫۾‬ဓ̳ͥ͂ࣉ̢̞ͣͦ̀ͥȃِș͉ȂM2 ζ·υέ͹Ȝΐ͈֚ਅ̜́ͥழ
૕ુह߿ζ·υέ͹ȜΐȪM2 အζ·υέ͹Ȝΐ͂ྴັ̫̹ȫ͈໦‫ͅا‬ຈଌ͈֒ഥঊ̱͂̀ȂTrib1 ͬ൳೰̱̹
ȪSatoh T et al., Nature, 2013ȫȃΪΠ͈ΊΦθχͼΡ‫۾‬Ⴒٜଢ଼̥ͣডৗయ৫ͅ‫̦̭͂ͥͩ۾‬াऐ̯̞ͦ̀ͥ Trib1 ͉ȂξΫ΅Ιϋς΄ȜΔ̜́ͥ COP1 ͂௖ࡽैဥ̳̭ͥ͂̽̀͢ͅΗϋΩ·ৗ໦ٜͅ‫۾‬ဓ̳ͥ໦ঊ̜́ͥȃࠬ‫͈ࠏס‬ळ༾̤̞̀ͅ Trib1 ͬࠧఅ̱̹ζ;ΑȪTrib1 ࠧఅ΅ιρζ;Αȫ͉́ȂࣸଡȂᦃ௫Ȃ෹̤͍͢ডཛழ૕̞̹͂̽အș̈́ྍકழ૕́ M2 အζ·υέ͹Ȝΐ̦ಠ̱̩ࡘઁ̳ͥȃ̭͈ழ૕ુह଻͈ M2 အζ·υέ͹Ȝΐ͈ࡘઁ͉ȂTrib1
ࠧఅ֦̳ܳͥͅഢৢ֦ঊ C/EBPĮ઼ً͈ಇୟ̧̭̯ͤ֨ܳͦͥ͢ͅȃTrib1 ࠧఅ΅ιρζ;Α͉Ȃ೒ુ͈૙মͬဓ̢
̀ব̱̞۪֗̀ͥ‫̞̤̀ͅاޏ‬Ȃডཛ໦ٜ̦ᄤૺ̱̀ডཛळ༾ুఘ͈ఱ̧̯̦֎ੀ̳ͥȃਹါ̭̈́͂ͅȂ̭͈་։
ζ;ᾼ࿤୆߿ζ;Αͤ͢಺ା̱̹ M2 အζ·υέ͹Ȝΐͬ֊૒̳̭͈ͥ͂ພఠ̦ٝ໘̳ͥȃ̹͘Ȃࣞডཛ૙ͬဓ
̢̀ব̱̹֗ Trib1 ࠧఅ΅ιρζ;Α͉ȂࣞΠςΈςΓςΡࠬછ͞ͼϋΑςϋ೷ࢯ଻͈̈́̓ιΗδςΛ·ΏϋΡυȜθ͈ພఠ ͬ อ છ ̱ ̹ȃ̭ ͦ ͣ ͈ ٜ ଢ଼ ̥ ͣȂ
Trib1 ̤͍͢ C/EBPĮͤ͢ͅ໦‫̦ا‬ଷࢄ̯̞ͦ̀ͥழ૕ુह߿ M2 အζ·υέ͹Ȝΐ̦ডཛழ૕͈֋঵͂ιΗδςΛ·Ώϋ଎ 3. M2 အζ·υέ͹Ȝΐ͈࿨‫ڬ‬ΡυȜθ͈ဲଷͅ૬̩‫ͣྶ̦̭͂ͥͩ۾‬̥̹͂̈́̽ȃȪ଎ Ĵȫȁুட྾‫͈ע‬༫‫گ‬എၑٜ͂྾‫۾ע‬Ⴒ৖͈ۛহၷ༹‫ٳ‬อ̞̠͂ΌȜσͬ࿒ঐ̱̀Ȃࣽࢃ͉ࡄ‫̯ͣͬͅݪ‬อജ̵̯̞̀
̧̹̞ȃड߃͈యນഎ̈́ა໲
1. Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, Satoh T, Mino T, Suzuki Y,
Standley DM, Tsujimura T, Rakugi H, Isaka Y, Takeuchi O, Akira S. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell. 2013 May 23;153(5):1036-49.
2. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of
mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013 May;14(5):454-60.
3. Zou J, Kawai T, Tsuchida T, Kozaki T, Tanaka H, Shin KS, Kumar H, Akira S. Poly IC triggers a cathepsin D- and
IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis. Immunity. 2013
Apr 18;38(4):717-28.
4. Satoh T, Kidoya H, Naito H, Yamamoto M, Takemura N, Nakagawa K, Yoshioka Y, Morii E, Takakura N, Takeuchi
O, Akira S. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 2013 Mar
28;495(7442):524-8.
5. Maruyama K, Fukasaka M, Vandenbon A, Saitoh T, Kawasaki T, Kondo T, Yokoyama KK, Kidoya H, Takakura N,
Standley D, Takeuchi O, Akira S. The transcription factor Jdp2 controls bone homeostasis and antibacterial
immunity by regulating osteoclast and neutrophil differentiation. Immunity. 2012 Dec 14;37(6):1024-36.
Ĳĺࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆ఘཡࢄࡄ‫ݪ‬໐࿝ळ༾‫ܥ‬ෝ໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁ֓‫ڠ‬ฎআȁ࿒‫ح‬ന‫ם‬༟ġ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ‫ུ܊‬ȁȁၮ੩‫ޗ‬ȁȁၑ‫ڠ‬ฎআȁକോȁۘ૽අහࡄ‫֥ݪ‬ȁΨͼ΂΍ͼ΀ϋΑฎআȁಎఆȁં঎ȁඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁȁȁȁȁȁȁກനȁ౺࿟ȁ൚ࡄ‫ݪ‬໦࿤͉́Ȃळ༾‫ͅۼ‬ంह̳ͥळ༾௩૓֦ঊ͞ळ༾୪಍֦ঊ̱̹ͬٚळ༾͈‫ܥ‬ෝଷࢄ‫࣐̀̽ͬݪࡄ̞̀̾ͅࢹܥ‬̞ͥȃࡄ‫৽͈ݪ‬࿨͂̈́ͥ໦ঊ͉ȂHB-EGF ̞̠͂ EGF έ͹ηςȜ྄͈ࣣࠫ߿ळ༾௩૓֦ঊ͂ΞΠρΑΩΣῧࡤ྄͊ͦͥː
ٝ۹೒߿ΗϋΩ·ৗ̜́ͥȃ̭͈ͦͣΗϋΩ·ৗ͉Ȃळ༾‫ٸ‬ζΠςΛ·Α໦ঊ̷͈͞ఈ྄ΗϋΩ·ৗȂ̜̞͉ͥळ༾ඤΏΈ΢σ໦ঊ͂ໝࣣఘͬࠁ଼̱̀Ȃळ༾௩૓͈಺୯Ȃࠁఠࠁ଼͞ழ૕͈֋঵Ȇਘ໘ͅ൱̞̞̀ͥ͂൳শͅȂ̦ͭळ༾͈௩૓Ȇ૫੕Ȇഢ֊͜ͅ૬̩‫̞ͥ̀̽ͩ۾‬ȃˍȫHB-EGF ͈࿨‫ै͂ڬ‬ဥ‫͈ࢹܥ‬ٜଢ଼
HB-EGF ͉ EGF έ͹ηςȜ͈௩૓֦ঊ́ȂEGFR ͞ ErbB4 ࣣ̱ࠫͅȂ̭ͦͣͬ‫̳ͥا଻ڰ‬ȃHB-EGF ྄͉۹೒Ριͼϋͬ‫߿྄ࣣ̺ࠫͭ܄‬ळ༾௩૓֦ঊ଼̱ࣣ̯͂̀ͦȂ྄ࣣࠫ߿̦ळ༾ນ࿂́ίυΞͺȜΔ̽̀͢ͅ୨౯̯ͦͥ͂Ȃ໦๥߿
HB-EGF ͬ୆̲ͥȃHB-EGF ͉Ȃਅș͈ழ૕Ȃळ༾ͤ͢໦๥̯ͦȂ૤௫‫ܥ‬ෝ֋঵͞૤௫༕ࠁ଼Ȃ࿒‫଼ࠁڀ‬Ȃ஻ੱহ࿴Ȃ෹༾ࠁ଼Ȃ਋ୈ၅͈಍઄Ȃນ๧๬ً࢚͈̈́̓೾̤̞̀ͅȂळ༾͈୆ంȂ௩૓ဲଷȂ֊൲Ȃ୪಍Ȃ௩૓௯ૺ̈́̓ఉद̈́‫ܥ‬ෝͬอ‫̞̱ͥ̀ܞ‬ȃ୆ఘඤً͈͕͈͂ͭ̓೾͉́໦๥߿ HB-EGF ̦‫ܥ‬ෝ̱̞̀ͥȃ྄̱̥̱ࣣࠫ߿͉໦๥߿͈ஜߐఘ̜́
̥̩ͥ͊ͤ́̈́Ȃ྄ࣣࠫ߿͈ેఠ́͜୆໤‫ͬ଻ڰ‬঵̞̭̥̽̀ͥ͂ͣȂ྄ࣣࠫ߿͈൱̩୆ၑً೾͜ంह̳ͥ‫خ‬ෝ଻̦̜ͥȃ྄߿̥ͣ໦๥߿͈͒ഢ͉͈̠۟̓͢ͅଷࢄ̯̞͈̥ͦ̀ͥȂ྄߿͂໦๥߿͈୆ၑഎ࿨‫ڬ‬Ȃ͈̠̓̈́͢‫́ࢹܥ‬ఉद̈́୆ၑ‫ڰ‬଻ͬা̳͈̥Ȃ̯͉ͣͅພ‫ͤͩ۾͈͂ܨ‬൝͈࿚ఴͅ‫̞ͥ̀͛ૺͬݪࡄ̱̀۾‬ȃ଎ˍȁ૤௫༕ࠁ଼̤̫ͥͅ HB-EGF ͈࿨‫ڬ‬૤௫༕͈ࠁ଼ً೾́ HB-EGF ͉૤ඤ྄ષ๧ͤ͢໦๥̯ͦȂ༕‫ۼ‬ৗळ༾ͅచ̷̱͈̀௩૓ͬဲଷ̳ͥ൱̧̳ͬͥȪऒ‫ئ‬଎ȫȃ̹͘༕‫ۼ‬ৗ͉ͅΰΩρϋၤॸίυΞ΂Ές΃ϋȪHSPGsȫ̦ཅີͅంह̱Ȫֲષ଎ȫȂ༕‫ۼ‬ৗ ळ ༾ͅచ̱̀ HB-EGF ̦ ୃુͅैဥ̳̹͉ͥ͛ͅȂHB-EGF ͉
HSPGs ࣣ̳͂ࠫͥຈါ̦̜ͥȃ̱̹̦̽̀ HB-EGF ࠧఅζ;Α (KO) ̺̫̩́̈́ȂHB-EGF ͈ΰΩςϋࣣࠫΡιͼϋ̩ͬࠧ་։߿ HB-EGF ͬอ࡛̳ͥΦΛ·ͼϋζ;Α (⊿HB) ͉́Ȃ༕‫ۼ‬ৗळ༾ً͈௩૓̦̭ܳͤȂ૤௫༕̦։ુͅ๬࢚̱̹ࠁఠ̈́ͥͅȪֲ‫ئ‬଎ȫȃ(Iwamoto et al, 2010)ĳı

ˎȫ̦͈ͭ՛଻‫ ̫̤ͥͅا‬ŉŃĮņňŇ ͈࿨‫ڬ‬ȁŉŃĮņňŇ ͉‫܈‬ळ༾͞‫܈‬ਔս͈‫ۼ‬ৗ́‫̩ޑ‬อ࡛̱Ȃ̦͈ͭ՛଻‫ͅا‬૬̩‫̞ͥ̀̽ͩ۾‬ȃ̦ͭळ༾͈௩૓Ȃ૫੕Ȃഢ֊̤̫ͥͅ ŉŃĮņňŇ ͈‫̳̹ض‬࿨‫ͬڬ‬મ̱̩ٜଢ଼̱Ȃ૧̹̈́‫܈‬হၷ༹͈‫ٳ‬อͬ࿒ঐ̱̞̀ͥȃ଎ˎȁঊ‫ݠ‬ᴢ‫܈̫̤ͥͅ܈‬ळ༾͂‫ۼ‬ৗ஌֋ٔळ༾͈௖ࡽैဥ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଎ˏȁ୆ఘͼιȜΐϋΈͥ͢ͅ‫܈‬ळ༾͈௩૓ͅచ̳ͥ஌֋ٔळ
༾͈࢘‫ض‬ٜଢ଼ȃȪaȫ‫܈‬ळ༾͂஌֋ٔळ༾ͬ൳শ֊૒̱̹ાࣣȂȪbȫ‫܈‬ळ༾ͬౙඊ́֊૒̱̹ાࣣ (Murata et al, 2011)ȃ

ˏȫHB-EGF ͬ໦ঊດഎ̳͂ͥࢯ‫܈‬स͈‫ٳ‬อͬଔૺ̱ȂHB-EGF ಎგࢯఘ͞ΐέΞςͺඉள་։ఘ CRM197 ͬခ଼࢘໦
̳͂ͥ၅௏̦ͭহၷ࿪͈๱ႉ઄দࡑȆႉ઄দࡑͬ৘ঔ̱̞̀ͥȃ଎ːȁ၅௏‫ࣞ́܈‬อ࡛̳ͥ HB-EGF( ऒ ) ͂‫ٳ‬อಎ͈၅௏‫܈‬হၷ࿪ BK-UMȪֲȫːȫΞΠρΑΩΣϋ໦ঊ͈ٜଢ଼
ȁΞΠρΑΩΣϋ͉Ȃඅಭഎ྄̈́ːٝ۹೒ࢹ௮ͬ঵̻Ȃఉळ༾୆໤̺̫ͅంह྄̳߲͈֚ͥΗϋΩ·ৗέ͹ηςȜ́ȂΪΠ
͉́ 30 ਅ႒ոષȂΏο;ΐο;Ψ΀͞஌ಖ́͜ 20 ਅ႒ոષంह̳ͥȃ஌ಖͬဥ̞̀ΞΠρΑΩΣϋ͈໦ঊ‫ܥ‬ෝͬ֒ഥ‫ڠ‬എٜͅଢ଼̱̞̀ͥȃड߃͈యນഎ̈́ა໲
1. Moribe H, Konakawa R, Koga D, Ushiki T, Nakamura K, Mekada E. Tetraspanin is required for generation ofreactive oxygen species by the dual oxidase system in Caenorhabditis elegans. PLoS Genet. 2012 Sep;8(9):e1002957.
2. Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H,
Murakami T, Hori S, Shitara K, Mekada E. A novel anti-human HB-EGF monoclonal antibody with multiple
anti-tumor mechanisms against ovarian cancer cells. Clin Cancer Res. 2011 Nov 1;17(21):6733-41.
3. Murata T, Mizushima H, Chinen I, Moribe H, Yagi S, Hoffman RM, Kimura T, Yoshino K, Ueda Y, Enomoto T,
Mekada E. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts
to support progression of uterine cervical cancers. Cancer Res. 2011 Nov 1;71(21):6633-42.
4. Iwamoto R, Mine N, Kawaguchi T, Minami S, Saeki K, Mekada E. HB-EGF function in cardiac valve development
requires interaction with heparan sulfate proteoglycans. Development. 2010 Jul;137(13):2205-14.
5. Ichise T, Adachi S, Ohishi M, Ikawa M, Okabe M, Iwamoto R, Mekada E. Humanized gene replacement in mice
reveals the contribution of cancer stroma-derived HB-EGF to tumor growth. Cell Struct Funct. 2010;35(1):3-13.
ĳĲࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆ఘཡࢄࡄ‫ݪ‬໐࿝྾‫ڠاע‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁ࣏ଳȁȁં੩‫ޗ‬ġ֓‫ڠ‬ฎআȁྎ‫ז‬ȁ಑ࢩ੩‫ޗ‬ġ෠‫ڠ‬ฎআȁࣝ५ȁٗঊඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁ᠟൥ȁঃႹȁ൚ࡄ‫ݪ‬໦࿤͉́Ȃພࡔఘ͂྾‫ע‬ΏΑΞθ͈͂௖ࡽैဥ̥ͣুࡨ྾‫ע‬৖͈ۛอછ‫ܥ‬੬́͘྾‫࡛ע‬યͬ໙ࢩ̩ࡄ‫̞̱ͥ̀ݪ‬ȃඅͅȂ྾‫ע‬ळ༾͈อ࡛̳ͥဲଷ‫ا‬τΓίΗȜ͂‫ا଻ڰ‬τΓίΗȜ̥ͣ̈́ͥβͺ߿τΓίΗȜ̦ພࡔఘ͂‫̧̹̱̀اૺͅވ‬྾‫ע‬ଷࢄτΓίΗȜ͉̞̥͈́̈́͂‫ب‬୰͈͂́͜Ȃβͺ߿τΓίΗȜ͂;ͼσΑȂळ޿Ȃζρςͺࡔಖ൝͈ພࡔఘ͈͂௖ࡽै
ဥ͈ٜଢ଼ͬࡄ‫̞̱ͥ̀ݪ‬ȃ̹͘Ȃুࡨ྾‫ע‬৖͉ۛ‫͈̥ۜͣة‬அ̽̀͢ͅညอ̯̭̦ͦͥ͂ఉ̞̭̥͂ͣȂພࡔఘ͈ۜஅ̦̓
͈̠͢ͅ྾‫ע‬ΏΑΞθ͈ࢭુ଻෫౦ͅ‫۾‬ဓ̱̞̥̞̀ͥ̾̀ͅࡄ‫̞̱ͥ̀ݪ‬ȃȪˍȫβͺ߿τΓίΗȜͥ͢ͅ྾‫ע‬ଷࢄ‫͈ࢹܥ‬ٜྶȁ྾‫ע‬ळ༾͉Ȃဲଷ‫ا଻ڰ͂ا‬τΓίΗȜ଼̥ͣͥਅș͈βͺ߿τΓίΗȜͬอ࡛̱̞̀ͥȪ଎ˍȫȃဲଷ‫ا‬βͺ߿τΓίΗȜ͉ȂMHC ൝͈ুࡨ໦ঊͬ෇ে̳༷֚ͥȂ‫ا଻ڰ‬τΓίΗȜ͉ুࡨ໦ঊͬ෇ে̱̞̈́ȃِș͉Ȃβͺ߿τΓίΗȜ͈ಎ͉ͅ;ͼσΑ໦ঊͬ෇ে̳͈̦̜ͥͤ͜Ȃβͺ߿τΓίΗȜ̦ພࡔఘͅచ̳ͥۜஅ೷ࢯ଻ͬࠨ೰̳ͥષ́ਹါ̈́‫ܥ‬ෝͬ౜̞̽̀
̭ͥ͂ͬྶ̧̥̱̹ͣ̀ͅȃ̷̭́൚໦࿤͉́Ȃ;ͼσΑ͉̲ͬ͛Ȃࡔಖ͞ळ޿൝͈အș̈́ພࡔఘͬດഎ̱̀ͅȂβͺ߿τΓίΗȜ̦‫෇ͬة‬ে̱Ȃ͈̠̓̈́͢‫ܥ‬ෝͬ঵̞̥̽̀ͥͬྶ̥̳̭ͣͥ͂̽̀͢ͅͅȂβͺ߿τΓίΗȜ̱̹ͬٚ྾‫ע‬؊൞ଷࢄ‫͞ࢹܥ‬਽৽ພࡔఘ௖ࡽैဥͬࡄ‫̞̱ͥ̀ݪ‬ȃȪˎȫ;ͼσΑ͈ळ༾ඤ૟ව‫͈ࢹܥ‬ٜྶȁ঵௽ۜஅ̳ͬͥ;ͼσᾼ͉Ȃဲଷ‫ا‬τΓίΗȜ͈ς΄ϋΡͬอ࡛̱྾‫ע‬؊൞ͬဲଷ̱̞͈̦̜̀ͥͥ͜ȃ‫ྙޟ‬૬̞̭͂ͅȂဲଷ‫ا‬τΓίΗȜ͈͂௖ࡽैဥͬဥ̞̀਽৽ळ༾ͅ૟ව̳ͥ;ͼσΑ͜ంह̳̭̦ͥ͂ྶ̧̥̹ͣ̈́̽̀ͅȪ଎ˎȫȃඅͅȂ
;ͼσΑ௰̥͈ٜͣଢ଼͉ٜ́ྶ̦ඳ̱̥̹̽໦ঊι΃ΣΒθ̦Ȃ྾‫ע‬τΓίΗȜ͂;ͼσΑ໦ঊ͈ٜ͂ଢ଼̽̀͢ͅྶ̥ͣ̈́̽ͅ
̧̹̀ȃ൚໦࿤͉́Ȃਅș͈ພࡔఘ͈਽৽ळ༾͈͒૟ව‫̞̀̾ͅࢹܥ‬Ȃ਽৽໦ঊ̤͍͢;ͼσΑ໦ঊ஼༷͈௰࿂̥͈ٜͣ
ྶͬ࿒ঐ̱̞̀ͥȃ଎ˍȁβͺ߿τΓίΗȜဲଷ‫ا‬τΓίΗȜ͉྾‫ע‬؊൞͈ଷࢄͅਹါ
̈́‫ܥ‬ෝͬ౜̠༷֚ (Wang et al. Nat. Immunol.
2013)Ȃພࡔఘ͉ဲଷ‫ا‬τΓίΗȜͬ၌ဥ̱̹྾‫ע‬൪๰‫ڕͬࢹܥ‬ං̧̱̹̀ȃ༷֚Ȃ‫ڰ‬଻‫ا‬τΓίΗȜ̷͉͈̠̈́͢ພࡔఘͅచ̳
ͥ೷ࢯ଻ͬ౜̠໦ঊ͂ࣉ̢ͣͦͥȃĳĳ଎ 2ȁβͺ߿τΓίΗȜ̱̹ͬٚ;ͼσΑۜஅ‫ࢹܥ‬3,/5Į͞ Siglec (MAG) ̞̹͂̽βͺ߿τΓίΗȜ͈ಎ͉ͅȂౙ੗ΰσ β Α ; ͼ σ Α (herpes simplex virus) ͞ କ ൛ ఝ ે ឃ ૮ ; ͼ σ Α(varicella-zoster virus) ͈;ͼσΑ΀ϋαυȜί໦ঊࣣ̳̭͂ٛͥ͂ͅ
̽̀͢Ȃ;ͼσΑۜஅশ྄͈ဏࣣͅ‫̦͈̞ͥ̀̽ͩ͜۾‬ంह̳ͥ(Satoh et al. Cell 2008; Suenaga et al. Proc. Natl. Acad. Sci. USA. 2010)ȃ

Ȫˏȫুࡨ྾‫ע‬৖͈ۛอછ‫ܥ‬੬͈ٜྶȁুࡨ྾‫ע‬৖͉ۛȂুࡨழ૕ͅచ̱̀྾‫ע‬؊൞̦̭ܳͥ৖̜ۛ́ͤȂুࡨ྾‫ע‬৖͈ۛࡔ֦֒ഥঊ̱͂̀৽ါழ૕ഐࣣࢯࡔ
(Major Histocompatibility Complex (MHC))ȂඅͅȂMHC ·ρΑ II ̦̽͂͜͜৖ۛۜ਋଻ͅ‫̞ͥ̀̽ͩ۾‬ȃMHC ໦ঊ͉

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

βίΙΡࢯࡔͬ T ळ༾ͅ೹া̳͈̦ͥ৽ါ̈́‫ܥ‬ෝ̜́ͤȂুࡨ྾‫ע‬৖͈ۛࡔ֦͉ T ळ༾؊൞͈։ુ͉̞̥́̈́͂ಿාࣉ̢
̧̹ͣͦ̀ȃ̱̥̱Ȃুࡨ྾‫ע‬৖̧̭̳ۛͬ֨ܳβίΙΡࢯࡔͬ‫̀͛܄‬ȂMHC ̦͈̠̓͢ͅুࡨ྾‫ע‬৖͈ۛอછͅ‫ͥͩ۾‬̥͉ջட̱͂̀ྶ̥̞ͣ́̈́ȃِș͉ȂMHC ·ρΑ II ໦ঊ̦઀༾ఘඤ͈ηΑέ΁ȜσΡ౩ฒৗࣣ̳͂ࠫͥ͂Ȃ໦ঊΏλβυῧ̷̱̀ͦͣͬ໦̵̴ٜ̯ͅळ༾‫͒ٸ‬࿶௣̳̭ͥ͂ͬྶ̥̱̹ͣͅȃ̯ͣͅȂఉ̩͈ুࡨ྾‫ע‬৖ۛͅ෇͛ͣͦͥুࡨࢯఘ
̦Ȃুࡨ྾‫ע‬৖ۛۜͅ਋଻͈ MHC ·ρΑ II ໦ঊͅ೹া̯̹ͦηΑέ΁ȜσΡ౩ฒৗͬඅ։എͅ෇ে̳̭ͥ͂ͬࡉ੄̱̹ȃ̭͈̭̥ͦͣ͂ͣȂ։ુ̈́໦ঊໝࣣఘ̜́ͥηΑέ΁ȜσΡ౩ฒৗȟ MHC ·ρΑ II ໦ঊໝࣣఘ̦ুࡨ྾‫ע‬৖͈ۛດഎ໦ঊ
̱͂̀อછͅ‫̠̞̞͂ͥ̀̽ͩ۾‬૧̹̈́ুࡨ྾‫ע‬৖͈ۛอછ‫ܥ‬੬̦ࣉ̢̹ͣͦȪ଎ˏȫȃ৘षȂুࡨ྾‫ע‬৖͉ۛۜஅ൝͈‫׶‬છ̽̀͢ͅညอ̯ͦȂুࡨ྾‫ע‬৖͈ۛດഎ௫‫ ͉́ܕ‬MHC ·ρΑ II ໦ঊ͈։ુอ࡛̦෇͛ͣͦͥȃ̷̭́Ȃུࡄ‫ݪ‬৒͉́ȂηΑέ΁ȜσΡ౩ฒৗȟ MHC ·ρΑ II ໦ঊໝࣣఘ̦͈̠̓͢ͅࠁ଼̯ͦȂুࡨ྾‫ע‬৖͈ۛอછͅ‫̥ͬͥͩ۾‬ٜྶ̳̭ͥ͂
̽̀͢ͅȂুࡨ྾‫ע‬৖͈ۛอછ‫ܥ‬੬ͬࡄ‫̞̱ͥ̀ݪ‬ȃ଎ˏȁηΑέ΁ȜσΡ౩ฒৗȟ˩ˤ˟·ρΑ II ໦ঊໝࣣఘͥ͢ͅ૧̹̈́ুࡨ྾‫ע‬৖ۛอછ‫ܥ‬੬ळ༾ඤ͈ηΑέ΁ȜσΡ౩ฒৗ͉ MHC ·ρΑ II ໦ঊࣣ̳͂ٛͥ͂ȂMHC ·ρΑ II ໦ঊ̽̀͢ͅ໦ٜ̯ͦ̈́
̞͘͘ळ༾ນ࿂ͅ࿶௣̯ͦͥ (Jiang et al. Int. Immunol. 2013)ȃ̯ͣͅȂ̷̦ͦুࡨࢯఘ͈ດഎ̱͂̀ুࡨ྾‫ע‬৖͈ۛอછͅ‫۾‬ဓ̱̞̀ͥ (Jin et al. Proc. Natl. Acad. Sci. USA. 2014)ȃ

ड߃͈యນഎ̈́ა໲
1. Autoantibodies to IgG/HLA-DR complexes are associated with rheumatoid arthritis susceptibility.
Jin H, Arase N, Hirayasu K, Kohyama M, Suenaga T, Saito F, Tanimura K, Matsuoka S, Ebina K, Shi K,
Toyama-Sorimachi N, Yasuda S, Horita T, Hiwa R, Takasugi K, Ohmura K, Yoshikawa H, Saito T, Atsumi T,
Sasazuki T, Katayama I, Lanier LL, Arase H. Proc Natl Acad Sci USA. 2014 Mar 111(10): 3787-92.
2. Herpesvirus 6 Glycoproteins B (gB), gH, gL and gQ are Necessary and Sufficient for Cell-to-Cell Fusion.
Tanaka Y, Suenaga T, Matsumoto M, Seya T, Arase H. J Virol. 2013 Oct; 87 (19): 10900-3.
3. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules.
Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, Matsumoto M, Shida K, Lanier LL, Saito T, Arase H.
Int Immunol. 2013 Apr; 25(4): 235-46.
 1HXWURSKLOLQILOWUDWLRQGXULQJLQIODPPDWLRQLVUHJXODWHGE\3,/5ĮYLDPRGXODWLRQRILQWHJULQDFWLYDWLRQ
Wang J, Shiratori I, Uehori J, Ikawa M, Arase H. Nat Immunol. 2013 Jan; 14(1): 34-40.
5. Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Suenaga T, Satoh
T, Somboonthum P, Kawaguchi Y, Mori Y, and Arase H. Proc Natl Acad Sci USA. 2010 Jan 12;107(2):866-71.
ĳĴࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝໦ঊ֒ഥࡄ‫ݪ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ġၑ‫ڠ‬ฎআȁ࿤ോȁȁฎ੎‫ޗ‬਎ġ
֓‫ڠ‬ฎআȁᩊനȁ‫֚ܮ‬੩‫ޗ‬Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁ؈ॄȁఱٚġġඅහࡄ‫֥ݪ‬ȁၑ‫ڠ‬ฎআȁ࢜֔ȁ౺๼ࡄ‫ݪ‬ඤယȇ൚ࡄ‫ݪ‬໦࿤͉́‫͈܈‬՛଻‫ฺ̠ͅا‬அ૗ఘະհ೰଻
͈ଷࢄ‫ͬࢹܥ‬Ȃळ༾ਔ‫ܢ‬ΙͿΛ·εͼϋΠଷࢄ͞ಎ૤ఘ଼੃͈
։ુ̞̠͂۷ത̥ͣࡄ‫̞̱ͥ̀ݪ‬ȃ̩͂ͅಎ૤ఘͅޫह̳ͥ
Ser/Thr ΅΢ȜΔ̜́ͥ Lats1/2 ̜̞͉ͥ GAK ̦ࢹ଼̳ͥໝࣣ
ఘ͈ȂDNA ੱ‫͈̥ͣޏ۪̠̞͂ٺ‬ΑΠτᾼచ̳ͥ؊൞͈ଷࢄ
‫ͅࢹܥ‬എͬࣆٜ̽̀ଢ଼̱̞̀ͥȃ̭ͦͣˎ͈̾ΞȜζ͉ Mdm2
͞ p53 ̱ͬٚ̀ࡽ̞ͅྟ୪ͅႲࠒ̱̞̀ͥȪ଎ˍȫȃȁȁ ȁȁ଎ˍȇLats ΈσȜί͂ GAK ΈσȜί͉ࡽ̞ͅႲࠒ̱̞̀ͥȃȪˍȫLatsȪLarge tumor suppressorȫΈσȜί
Lats1, Lats2 ͉ਅ‫́ۼ‬༗ం̯̹ͦಎ૤ఘͅޫह̳ͥ႒য̈́΅΢ȜΔ̜́ͥ
ȪToji et al., Genes Cells, 2004ȫȃLats1/2 ͉ ‫ ۗ ܕ‬΍ ͼΒ ͬ ଷ ࢄ ̳ͥ Hippo
pathway ̤̞̀ͅഢৢ֦ঊYAP/TAZͬဲଷ̳̭ͥ͂́ळ༾௩૓೪গ͂ͺεΠȜΏΑͬ௯ૺ̳ͥಎଥഎ̈́࿨‫༷̳̹֚́ضͬڬ‬Ȃळ༾ਔ‫ܢ‬ΙͿΛ·εͼϋΠଷࢄ̤̞̀͜ͅਹါ̈́‫ܥ‬ෝͬ౜̞̽̀ͥȃ̩͂ͅ Lats2 ͉‫ဲ܈‬ଷ֦ঊ p53 ͈ೄ୪എ̈́ഢৢດഎ̜́ͥ͂͂͜ͅ p53 ͈໦ٜͬဲଷ̳̭ͥ͂ͤ͢ͅ໦ႨȪMȫ‫̤ͅܢ‬̫ͥ޳൝̈́அ૗ఘ໦෻ͬଷࢄ̱̞̀ͥȃِș͉ո‫࡛͈ئ‬યͬࡉ੄̧̱̹̀ȃ❶
Lats2 ͈֒ഥঊࠧ৐ȪLats2 KOȫζ;Αͬैୋ̱ٜଢ଼̱̹ࠫ‫ض‬Ȃ႒য֒ഥঊ
Lats1 ͉͂։̈́ͤ᥷͈อ୆Ȇ໦‫ͅا‬ຈଌ̈́֒ഥঊ̜̹́̽ȃ❷Lats2 KO ͈᥷ဇ-/ြ஌֋ٔळ༾‫ڼ‬ȪLats2 MEFȫ͉́ಎ૤ఘ͈౯༌‫ا‬Ȃஅ૗ఘ͈ະାႥȂळ༾ৗ໦Ⴈ͈։ુ̦۷ख़̯̹ͦȪYabuta et al., J. Biol. Chem., 2007ȫȃ❸Lats1 ͈N ྎȪ๱΅΢ȜΔȫႀ֖ͬࠧఅ̵̯̹ζ;ΑȪLats1ǻ1ǻ1ȫ̥ͣਏၛ̱̹ MEF
͉ Lats2 ͈อ࡛೩‫ئ͂ئ‬ၠ֦ঊ YAP ͈‫ݷ‬൲։ુͬা̱̹ȃ̯ͣͅȂஅ૗ఘ໦଎ˎȇLats1ǻ1ǻ1MEF ͉அ૗ఘ͈໦෻։ુͬ
ȁȁȁ̧̭̳֨ܳȪ࿦֣ȫȃ෻։ુ͞ळ༾ৗ໦Ⴈ͈৐෴̧̭̱ͬ֨ܳȂ௷ા๱ջం଻௩૓ෝͬ‫ڕ‬ං̱̹Ȫა໲ 4Ȉ଎ 2, 3ȫȃ̭͈ͦͣࠫ‫͉ض‬ȂLats2 ͂ Lats1 ̦ळ༾௩૓͈ଷࢄ͞Ȃୃુ̈́ M ‫͈࣐ૺܢ‬ଷࢄ̱ͬٚ̀அ૗ఘͬհ೰ͅ༗̹̾͛ͅຈଌ̈́΅΢ȜΔ̜́ͥ
̭͂ͬাऐ̱̞̀ͥȃ❹ِș͉ Lats2 ̦ଷࢄ̳ͥ૧̹̈́ςϋॸ‫ا‬ΏΈ΢σࠐႹȪCLP ࠐႹȂALB ࠐႹȫͬࡉ੄̱̹ȃCLP ࠐႹ̤̞̀ͅ Lats2 ͉ট‫ٸ‬஌ચৣͥ͢ͅ DNA అੱΙͿΛ·εͼϋΠͅ؊൞̱Ȃ14-3-3 ཱུ̱ͬٚ̀࿫ဲଷͅ‫۾‬ͩͥ P-body ͈ࠁ଼ͬଷࢄ̳ͥȪOkada et al., J. Cell Sci., 2011ȫ༷֚́Ȃ❺ਘ໘ະෝ̈́ DNA అੱͬ਋̫ͥ͂ Lats2 ͈‫ࡨু͉଻ڰ‬ςϋॸ‫ͤ͢ͅا‬ષઌ̱Ȃ
p21CDKN1A ͈අ։എ̈́໐պͬςϋॸ‫̱̀ا‬ະհ೰‫ ̵̭̯ͤ͂ͥ͢ͅا‬Caspase ͅջం̱̹ͺεΠȜΏΑͬည൵̳̭ͥ͂ͬࡉ੄̱̹Ȫა໲ 2Ȉ଎ 4ȫȃఈ༷Ȃ
❻
ALB ࠐႹ͉́ M ‫ ̞̤࣐̀ͅૺܢ‬Lats2 ͉ Aurora-A ΅΢ȜΔͤ͢ͅςϋॸ‫ا‬̯ͦ̀அ૗ఘ̤͍͢ಎ؇ཚଞఘષͅޫह̱ Lats1 ͂ Aurora-B ΅΢ȜΔͬଷࢄ̱̀ୃ‫̈́ږ‬அ૗ఘ໦෻ͬ৘࣐̳ͥȪYabuta et al., Cell Cycle, 2011ȫȃ̯ͣͅȂ
❼Lats2 ͉ ASPP1-p53 ͬଷࢄ̳̭ͥ͂ͤ͢ͅఉ෼ఘȆ։ତఘ͈՛଻‫܈‬ळ༾̤̞̀ͅळ༾ঘͬည൵̱ȪAylon et al., Genes Dev., 2010ȫȂSnail ͬςϋॸ‫̳ا‬̭ͥ͂ͤ͢ͅ EMTȪષ๧‫ۼ‬ဩഢ۟ȫͬଷࢄ̱̞̀ͥȪZhang et al., EMBO J.,
2012ȫȃ

଎ˏȇLats1ǻ1ǻ1MEF ͉௷ા๱ջం଻
ȁȁȁ௩૓ෝͬခ̳ͥȃ଎ːȇLats2 ͈ুࡨςϋॸ‫ا‬Ȫ‫ا଻ڰ‬ȫ͉ȁȁȁͺεΠȜΏΑ̧̭̳ͬ֨ܳȪ୤૗ȫȃ

ĳĵ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ȪˎȫGAKȪcyclin G-associated kinaseȫΈσȜίȁِș̦อࡉ̱̹ GAK ͉ෞ૰ࠐळ༾ո‫͈ٸ‬ळ༾ৗ́·ρΑςϋ๭ໞ઀༾͈౎๭ໞͬଷࢄ྄̳̭ͥ͂́࿶௣Ȫ΀ϋΡ΍ͼ
ΠȜΏΑȫͅຈଌ̜̦́ͥȂ̭͈࡛ય͉ͅ΅΢ȜΔႀ֖͉ະါ̜́ͥȃِș͉ո‫࡛͈ئ‬યͬࡉ੄̳̭͂́ GAK ΅΢ȜΔ͈࿨‫ͬڬ‬ٜྶ̧̱̹̀ȃ❶GAK ͉ PP2A %¶Ṳ͍̑͢ cyclin GȪcyclin G1Ȃcyclin G2ȫ͂ໝࣣఘͬࠁ଼̳ͥȃGAK ͉ PP2A%¶Ȗ͈ T104 ͬςϋॸ‫ ̱ا‬PP2A ͈౎ςϋॸ‫ࣖا‬ள‫ͬ଻ڰ‬ଷࢄ̱̞̀ͥȪა໲ 5Ȉ଎ 5ȫȃ❷GAK ͉ळ༾ৗ͈͙̩́̈́ M ‫ͅܢ‬̤̞̀ಎ૤ఘ͞‫ړ‬ඤ͜ͅޫह̱ȂM ‫̞̤̀ͅܢ‬ಎ૤ఘ଼੃͂
அ૗ఘާੀȆାႥͬଷࢄ̱̞̀ͥȪShimizu et al., J. Cell Sci.,
2009ȫȃ❸GAK ͈ ΅ ΢ Ȝ Δ ‫ ࠧ ͬ ଻ ڰ‬అ ̯ ̵ ̹ KO ζ ; Α଎ 5ȇGAK ͥ͢ͅςϋॸ‫ا‬໐պ T104 ͉ %¶Ȗ͈σȜίˎͅġġġġġġġġպ౾̱Ȃ‫଻ڰ‬ଷࢄͅਹါ̜̭̦́ͥ͂াऐ̯ͦͥȃȪGAK-kdȫͬैୋ̱ٜଢ଼̱̹̭͂ͧȂ෹͈อ୆ͅ։ુͬြ̱੄ ୆ ೄ ࢃ ͅ ଚ ৻ ̱ ̀ ঘ ཌ ͅ ঢ ̽ ̹ȪTabara et al., PLoS One,
2011Ȉ଎ 6ȫȃ໦ঊດഎ࿪͈ΊέͻΙΣήȪgefitinibȫ͉ GAK
͜ EGFR ͂൳೾ഽͅஷ‫̥̭̳ͣ͂ͥٺ‬Ȃ̭͈ࠫ‫ ͉ض‬GAK ͈ஷ‫ۼ̦ٺ‬ৗ଻෹‫̠̞͂׶‬ਹඈ̈́໗ैဥͬ୆̲̞̭̀ͥ͂ͬা
ऐ̳ͥȃ༷֚́Ȃ❹Cyclin G2 ͈ KO ζ;ΑȪCcng2-/-ȫ͉ୃુͅ୆ͦ͘࠲஠ͅอ̱̹̦֗Ȃ̷͈ MEF ͅ༶ৣ஌ͬચৣ̱̀
DNA అੱͬဓ̢ͥ͂ȂDNA అੱ؊൞͈ٜੰȪȖH2AX ͈౎ςϋॸ‫ا‬ȫͅಁ‫̹ͦͣ͛෇̦װ‬Ȫა໲ 3Ȉ଎ 7ȫȃ̭͈ࠫ‫͉ض‬Ȃ
DNA ਘ໘ࢃͅ Cyclin G2 ̦ PP2A ͬȖH2AX ͒͂‫౎͍׋‬ςϋॸ‫̵̯ͥا‬ς·σȜΗȜ̱͂̀‫ܥ‬ෝ̱Ȃਘ໘ۖၭশͅ DNA అੱ؊൞ͬഐ୨ٜͅੰ̱̀ୃુ̈́ેఠͅ࿗̳ਹါ̈́࿨‫ͬڬ‬౜̞̭̽̀ͥ͂ͬাऐ̱̞̀ͥȃ଎ 6ȇGAK ͈΅΢ȜΔࠧఅ͉ζ;Αథॾ‫͈ܢ‬෹‫ܥ‬ෝ଼͈੃ͅ։ુͬြ̳ȃ଎ 7ȇCyclin G2 ࠧఅळ༾͉́༶ৣ஌ȪIRȫ༶ৣೄࢃͅ
ġġġġġġġġςϋॸ‫ ̹̯ͦا‬H2AXȪȖ+$;ႂ૗ȫ͈౎ςϋġġġġġġġġॸ‫̦ا‬ಁ‫̳ͥװ‬Ȫ24h, 32hȫȃड߃͈యນഎ̈́ა໲
1. Shao D, Zhai P, Del Re DP, Sciarretta S, Yabuta N, Nojima H, Lim DS, Pan D, Sadoshima J. A functional
interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response. Nat Commun. 2014
Feb 14;5:3315.
2. Suzuki H, Yabuta N, Okada N, Torigata K, Aylon Y, Oren M, Nojima H. Lats2 phosphorylates p21/CDKN1A after
UV irradiation and regulates apoptosis. J Cell Sci. 2013 Oct 1;126(Pt 19):4358-68.
3. Naito Y, Yabuta N, Sato J, Ohno S, Sakata M, Kasama T, Ikawa M, Nojima H. Recruitment of cyclin G2 to
SURP\HORF\WLFOHXNHPLDQXFOHDUERGLHVSURPRWHVGHSKRVSKRU\ODWLRQRIȖ+$;IROORZLQJWUHDWPHQWZLWKLRQL]LQJ
radiation. Cell Cycle. 2013 Jun 1;12(11):1773-84.
4. Yabuta N, Mukai S, Okamoto A, Okuzaki D, Suzuki H, Torigata K, Yoshida K, Okada N, Miura D, Ito A, Ikawa M,
Okabe M, Nojima H. N-terminal truncation of Lats1 causes abnormal cell growth control and chromosomal
instability. J Cell Sci. 2013 Jan 15;126(Pt 2):508-20.
5. Naito Y, Shimizu H, Kasama T, Sato J, Tabara H, Okamoto A, Yabuta N, Nojima H. Cyclin G-associated kinase
UHJXODWHVSURWHLQSKRVSKDWDVH$E\SKRVSKRU\ODWLRQRILWV% ȖVXEXQLWCell Cycle. 2012 Feb 1;11(3):604-16.
ĳĶࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝อ‫܈‬ଷࢄࡄ‫ݪ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁȁ‫ؖ‬നȁٗ૽੎‫ޗ‬਎ȁྴനȁ࿆෗੎‫ޗ‬਎ȁ઀आ५୷प

අහࡄ‫֥ݪ‬ȁ‫࠲ࡔک‬ఊ჊ȁȶ̦ͭȷ͉ȂΊΦθͅ୆̲ͥအș̈́་։̧ͬ֨߄̱͂̀อ୆̱Ȃૺ‫̱ا‬Ȃ̷̱̀՛଻‫̳ͥا‬ȃ̷ً͈೾̤̞̀ͅȂȶ̦ͭဲଷ֒ഥঊȷ͈‫ܥ‬ෝࠧఅ་։ͥ͢ͅळ༾͈ະঘ‫͞ا‬Ȃȶ̦ͭࡔ֒ഥঊȷ͈‫ا଻ڰ‬་։Ȫȶ̦ͭ֒ഥঊȷ͈͒་։ȫͥ͢ͅळ༾ࠁৗ͈ఱ̧̈́ഢ̦۟୆̲ͥȃະঘ‫̦ͭ̀̽͢ͅا‬ཡࢄ‫͈̱̀͂ࢹܥ‬ͺεΠȜΏΑ͞Ⴧ‫̦ا‬ٝ๰̯ͦȂࠁৗഢ۟̽̀͢ͅু
ၙഎ௩૓ෝ͈‫ڕ‬ංȂळ༾‫ۼ‬΋ηνΣΉȜΏοϋ͈෫౦Ȃळ༾ࠁఠ͈་‫ا‬Ȃ‫ܖ‬ৗ໦ٜࣖள͞௩૓֦ঊ͈໦๥ᄤૺȂ૫੕Ȇഢ֊ෝ͈‫ڕ‬ං͈̦̈́̓ͭ՛଻‫ࠁا‬ৗ̦ည൵̯ͦͥȃ൚ࡄ‫ݪ‬৒͉́Ȃࢃ৪͈ࠁৗഢ۟ͅ‫ͥͩ۾‬ȶ̦ͭࡔ֒ഥঊȷུ͈ြ͈
୆ၑ‫ܥ‬ෝ͂ଷࢄ‫̴ͬ͘ࢹܥ‬ၑٜ̱Ȃ̷͈‫ا଻ڰ‬་։̦ͥͭ͢ͅࠁৗอ࡛͈໦ঊ‫ܖ‬๕͈ٜྶ͂૧̹̦̈́ͭহၷດഎ͈‫ͬఽٳ‬࿒ঐ̱̹ࡄ‫̞ͥ̀͛ૺͬݪ‬ȃ̭ͦ́͘ͅȂΪΠ͈̦ͭ͂͜૬̩‫ͥͩ۾‬ΙυΏϋ΅΢ȜΔ߿̦ͭࡔ֒ഥঊ c-Src ͈อ୆Ȇ໦‫ا‬Ȇழ૕ࢹಃ̤̫̈́̓ͥͅ୆ၑ‫ܥ‬ෝȂ̷̤͍͈͢಺୯‫̧̹̱̥̀ͣͅྶͬࢹܥ‬ȃ࡛ह͉Ȃ̦ͭ‫ا‬κΟσळ༾͞৘ष͈ΪΠ̦ͭळ༾̈́̓ͬဥ̞̀Ȃc-Src ̦ͥͭ͢ͅ՛଻‫͈ا‬ळ༾ඤࠐႹ̷͈͂ଷࢄ‫͈ࢹܥ‬஠ယٜྶͬ࿒ঐ̱̹ࡄ‫̞ͥ̀͛ૺͬݪ‬ȃ
I. c-Src ͈‫ܥ‬ෝ͂ଷࢄ‫ࢹܥ‬ȁୃુळ༾͉́Ȃc-Src ͉අ։എ̈́ଷࢄ֦ঊ Csk ̽̀͢ͅςϋॸ‫̹̯ͦا‬ະ‫́߿଻ڰ‬ంह̱Ȃ௩૓֦ঊ͞ळ༾‫ٸ‬ζΠςΛ·Α̈́̓ఉအ̈́ळ༾‫ࠣͅঁٸ‬؊൞̱̹শͅ‫̳ͥا଻ڰ‬ȃ̷͈‫ئ‬ၠ́ȂMAPK ࠐႹ͈̈́̓‫ͬا଻ڰ‬̱ٚ̀֒ഥঊ͈อ࡛ͬည൵
̱̹ͤȂRho GTPase ͬ‫̱̀ا଻ڰ‬ळ༾ࣸ‫͈ڒ‬ठ༎ͬည൵̳ͥȃ̷͈ࠫ‫ض‬Ȃळ༾୪಍Ȇ‫׋‬൲ෝ͈‫ا଻ڰ‬Ȃ໦‫ا‬Ȃ௩૓Ȃ୆ంȂ̯͉ͣͅࠁৗഢ͈۟ည൵̈́̓ఉအ̈́୆ၑ‫ܥ‬ෝͬอ‫̳ͥܞ‬Ȫ଎ˍȫȃΪΠ͈̦͉ͭ́ c-Src ֒ഥঊুఘ͉ͅ་։͉࠿੄̯ͦ̀
̞̞̦̈́Ȃအș̦̈́ͭळ༾́ Src ͈౩ฒၾ͞‫̦଻ڰ‬ષઌ̱̞̀ͥ
̭̦͂෇̞͛ͣͦ̀ͥȃ̷͈௩ఱ̱̹΅΢ȜΔ‫ ̀̽͢ͅ଻ڰ‬Src
͈ఉအ̈́‫ܥ‬ෝ̦௩໙̯̦ͦ̀ͭ՛଻‫ࠁا‬ৗ̦ည൵̯ͦͥ͂ࣉ̢ͣ
̞ͦ̀ͥȃ߃ාِș͉Ȃc-Src ͈̦ͭ‫ا‬ෝ̦Ȃळ༾྄η·υΡιͼϋͅంह྄̳ͥͺΘίΗȜΗϋΩ·ৗ Cbp ̽̀͢ͅଷࢄ̯̭ͦͥ͂
ͬࡉ੄̱Ȃ̷͈ଷࢄΏΑΞθ͈෫౦̦͂ͭ‫۾͈͂ا‬Ⴒ଻̞̾̀ͅ
ٜଢ଼ͬૺ̞͛̀ͥȃII. c-Src ̦ͥͭ͢ͅࠁৗอ࡛‫͈ࢹܥ‬ٜଢ଼
ȁc-Src ̦ͥͭ͢ͅࠁৗอ࡛ͅঢͥळ༾ඤࠐႹͬඅ೰̳̹ͥ͛ͅȂඊুͅ‫ٳ‬อ̱̹ c-Src ̦ͥͭ͢ͅ‫ا‬ည൵ࠏͬဥ̞̀࿌္എٜ̈́ଢ଼

଎ˍ. c-Src ͈‫ܥ‬ෝ͂‫଻ڰ‬ଷࢄ‫ࢹܥ‬ͬૺ̞͛̀ͥȃίυΞ΂η·Αٜଢ଼̥ͣȂ૧̹̈́ Src ‫ئ‬ၠ֦ঊ̱͂
̀ Rho ͈‫ͬا଻ڰ‬ည൵̳ͥ Arhgef5 ͬ൳೰̱Ȃ̷͈ KO ζ;Αैୋ൝ͤ͢ͅ‫ܥ‬ෝٜଢ଼ͬૺ̞͛̀ͥȃ̹͘ȂmiRNA ͈ͺτͼٜଢ଼̥͉ͣȂc-Src ̦ͥͭ͢ͅ‫ࠁا‬ৗ͈อฺ࡛̽̀ͅ๤‫ڛ‬എࡠ̹ͣͦਅ
႒͈ miRNA ͈อ࡛̦་൲̳̭ͥ͂ͬࡉ̞̺̱Ȃ̷͈ͦͣດഎ֒
ഥঊͬໝତਅ൳೰଼̳̭̱̞ͥ͂ࢗ̀ͥͅȃ̷ͦͣ৽ါ̈́ດഎ֒
ഥঊ̦ c-Src ͈ષၠ̤͍͢‫ئ‬ၠ͈ΏΈ΢σ໦ঊȪFGFR3, mTOR,
ILK ̈́̓ȫ̜̭̥́ͥ͂ͣȂc-Src ̦ miRNA ̱ͬٚ̀ু͈ͣΏΈ΢σഥోࠐႹͬΙνȜΣϋΈ̳̭ͥ͂̽̀͢ͅȂ̦ͭ‫ࠁا‬ৗ͈อ࡛ͬεΐΞͻῄ΋ϋΠυȜσ̳̞̠ͥ͂૧̱̞ଷࢄΏΑΞθ͈ంहͬྶ̥̱̹ͣͅȪ଎ˎȫȃ࡛हȂFí6UF ‫ ͥ͢ͅا଻ڰ‬miRNA อ࡛͈ଷࢄ‫͈ࢹܥ‬ٜଢ଼ͬૺ̞͛̀ͥȃĳķ଎ˎȅmiRNA ̳ͬٚͥ Src ̦ͥͭ͢ͅࠁৗอ࡛ଷࢄ‫ࢹܥ‬

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

III. ࢃ‫΀ܢ‬ϋΡΕȜθȟςΕΕȜθ̳ͬٚͥ௩૓ΏΈ΢σ͈ٜଢ଼
ȁc-Src ͈ດഎ໦ঊౝً͈॑೾́Ȃࢃ‫΀ܢ‬ϋΡΕȜθȟςΕΕȜθͅඅ։എͅޫह̳ͥ૧྄̹̈́ͺΘίΗȜ౩ฒৗ p18 ͬ൳೰̱Ȃ̷͈‫ܥ‬ෝٜଢ଼ͬૺ̞͛̀ͥȃ̭ͦ́͘ͅȂp18 ̦ p14/MP1 ͂ໝࣣఘͬࠁ଼̳̭ͥ͂̽̀͢ͅȂmTORC1 ̦ࢃ‫΀ܢ‬ϋΡΕȜθȟςΕΕȜθષ́‫̹̳͛ͥͅا଻ڰ‬ຈଌ͂̈́ͥ௷ા̱͂̀‫ܥ‬ෝ̳̭ͥ͂ͬྶ̥̱̹ͣͅȃ̹͘Ȃp18 KO ζ;Α̦ςΕΕȜθ଼͈੃ͅਹඈ̈́։ુͬা̱̀థ୆౿ঘ̭̥͂̈́ͥ͂ͣȂςΕΕȜθ଼੃ً೾̤̫ͥͅ p18 ͈࿨‫̦ڬ‬ಕ࿒̯ͦȂ̷͈षͅ‫ܥ‬ෝ̳ͥ
p18-mTORC1 ࠐႹ͈ດഎ໦ঊ͈൳೰͂‫ܥ‬ෝٜଢ଼ͬૺ̞͛̀ͥ
Ȫ଎ˏȫȃ̯ͣͅȂp18-mTORC1 ࠐႹ̦Ȃळ༾͈௩૓଼͞ಿȂ‫ ͍ݞ‬Src ͈̦̈́̓ͭ֒ഥঊ̳̦ͬٚͥͭ‫̞̤̀͜ͅا‬ຈଌ͈࿨‫ͬڬ‬౜̠̭̥͂ͣȂ̷͈௩૓ΏΈ΢σࠐႹ̤̫ͥͅ‫ܥ‬ෝ̞̾ͅ଎ˏȅ૧̹̈́ࢃ‫΀ܢ‬ϋΡΕȜθ྄ͺΘίΗȜ౩ฒৗ p18 ͈‫ܥ‬ෝ̀͜໦ঊτασ͈ٜ́ଢ଼ͬૺ̞͛̀ͥȃड߃͈యນഎ̈́ა໲
1 : Nada S, Mori S, Takahashi Y, Okada M. p18/LAMTOR1: a late endosome/lysosome-specific anchor protein for themTORC1/MAPK signaling pathway. Methods Enzymol. 2014;535:249-63
2 : Soma-Nagae T, Nada S, Kitagawa M, Takahashi Y, Mori S, Oneyama C, Okada M. The lysosomal signaling anchor
p18/LAMTOR1 controls epidermal development by regulating lysosome-mediated catabolic processes. J Cell Sci.
2013 Aug 15;126(Pt 16):3575-84.
3 : Kajiwara K, Yamada T, Bamba T, Fukusaki E, Imamoto F, Okada M, Oneyama C. c-Src-induced activation ofceramide metabolism impairs membrane microdomains and promotes malignant progression by facilitating thetranslocation of c-Src to focal adhesions. Biochem J. 2014 Feb 15;458(1):81-93
4 : Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M.
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic
pathways. Oncogene. 2011 Aug 11;30(32):3489-501.
5 : Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S, Tarakhovsky A, Okada M. The lipid raft-anchoredadaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell. 2008 May 23;30(4):426-36.
ĳĸࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝ૂ༭ഥో໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁࣞாȁ૝ࢨ੩‫ޗ‬ȁ֓‫ڠ‬ฎআȁ࿐࡫‫ࢫࢼؚ‬੩‫ޗ‬ȁ֓‫ڠ‬ฎআȁඤ൥ȁંൽඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁ‫܀‬ȁȁ‫י‬Ⴙȁȁȁȁȁȁȁȁȁȁȁȁ
අහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁ५୼ȁఱঃඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁᮁȁȁ֋ᦫඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁ৹ႅȁȁసࡄ‫ݪ‬ඤယȇୃુழ૕Ȇ௫‫ܕ‬ȟ‫ࢹ͈ۗܕ‬ಃ̤̞͉̀ͅȂழ૕අ։എۚळ༾ͥ͢ͅழ૕ळ༾͈ॲ୆̦ຈଌ̜̦́ͥȂ൳শ̭͈ۚͅळ༾ͬಎ૤̱̹͂Ȃழ૕۪‫ࢹ͈ޏ‬ಃ̦̭ͦͣۚळ༾ΏΑΞθͬ֋঵̱̞̩̀ષ͉́ਹါ
̜́ͥȃழ૕۪‫͈ޏ‬ါள̱͂̀Ȃ‫̜ͤ́ۯ̦͈̳ࠬ̈́ͬڒུࣸܖ‬Ȃࠬ‫ࢹۯ‬ಃ̦̫͕͈̈́ͦ͊͂ͭ̓௫‫ܕ‬Ȇ‫଼͉ࠁ͈ۗܕ‬ஷ‫̯ͥͦٺ‬ȃِș͈ࡄ‫ݪ‬৒͉́Ȃ̭͈̠̈́͢ୃુ௫‫ܕ‬Ȇ‫ۯ̫̤ࠬͥۗͅܕ‬૧୆͂ழ૕ۚ
ळ༾͈ۚळ༾଻͈֋঵‫͈̞̀̾ͅࢹܥ‬໦ঊ‫ͬࢹܥ‬ٜྶ̱Ȃඅͅພఠࠁ଼͈͂‫͉̞̤̀ͤͩͅ۾‬ਆនͅಕ࿒̱̀Ȃ̦ͭۚळ༾͈อ୆ȟ௩૓ȟ֋঵͈ι΃ΣΒθ͂Ȃ̷ͦͬ঑঵̳ͥ୆ఠ‫ڠ‬എഐਫ਼ȪΣΛΙȫٜͬଢ଼̱Ȃ̦ͭͬआহ̳ͥহၷ༹͈‫ٳ‬อ࣐̞ͬ̽̀ͥȃࡄ‫͉ݪ‬ఱ̧̩໦̫ո‫ࣜˎ͈ئ‬࿒ͤ͢ͅ৘ঔ̱
̞̀ͥȃ
ԅ. ୃુழ૕̤͍̦ͭ͢ழ૕̤̫ͥࠬͅ‫ۯ‬ςκΟςϋΈ͈໦ঊ‫ܥ‬੬͈ٜྶȁˍȫȁอٔഎࠬ‫ۯ‬૧୆͈໦ঊι΃ΣΒθȁ(Tie1, Tie2 ਋ယఘ͈‫ا଻ڰ‬Ȃະ‫͈ا଻ڰ‬໦ঊ‫) ࢹܥ‬ȁˎȫȁࠬ‫ۚۯ‬ळ༾͈อ୆͂୆ၑഎȟພഎࠬ‫۾଼͈͂ࠁۯ‬Ⴒȁˏȫȁࠬ‫͍̤͢ا੃଼ۯ‬൲୓ྤΩΗȜΣϋΈ͈ٜྶȪephrinB2/EphB4Ȃapelin/APJȫȁːȫȁࠬ‫ۯ‬ଷࢄͥ͢ͅΡρΛΈΟςΨςȜΏΑΞθ͈ࢹಃ
Ԇ. ̦ͭۚळ༾̤͍͢ୃુழ૕ۚळ༾͈ழ૕ඤ֋঵‫͈ࢹܥ‬ٜྶȁˍȫȁۚळ༾͈͒ςίυΈρηϋΈ‫͈ࢹܥ‬ٜଢ଼ȁˎȫȁۚळ༾͈໦Ⴈͬଷࢄ̳ͥ DNA ໝୋ֦ঊ GINS ̤͍͢ Galectin-3 ͈‫ܥ‬ෝଷࢄȁˏȫȁ̦ͭۚळ༾֋঵̥̥ͩͥͅΣΛΙࢹ଼ळ༾͈൳೰͂ΣΛΙ͈෫౦଎ˍȁࠬ‫ࢹܥا੃଼͈ۯ‬ਅș͈ࠬ‫ۯ‬ພ͈হၷ̤̞̀ࠬͅ‫ͼ͈ا੃଼ۯ‬ϋΩ·Π͉ఱ̧̞ȃِș͉༃ळ༾ (MC) ̦໦๥̳ͥ angiopoietin-1ȪAng1ȫ͉ࠬ‫ۯ‬ඤ๧—༃ळ༾‫ۼ‬୪಍ͬည൵̱̀ࢹ௮എͅհ೰̈́ࠬ‫଼ͬࠁۯ‬ည൵̳ͥ‫ٽ‬ැͬ൵̧̺̱̹ȪTakakura, Immunity 1998ȫȃ̹͘௮ࠬۚळ༾ (HSC) ဇြ Ang1 ͉ࠬ‫ۯ‬૧୆ͬည൵̱̾̾ȪTakakura, Cell 2000ȫȂ૧୆ࠬ‫͈ۯ‬൫ً଻ͬဲଷ̳̭ͥ͂ͬࡉ̞̺
̱̹ȪYamada, J Exp Med 2006ȫȃࠬ‫ۯ‬૧୆ً͈೾́ඤ๧ळ༾ષ͈ Tie2 ͈‫ ͤ͢ͅا଻ڰ‬apelin ̦໦๥̯ͦȂࠬ‫͈ࠂۯ‬ఊ̞Ȃ൫ً଻͈ဲଷ̯̹ͦࠬ‫( ଼̯ͥͦࠁ̦ۯ‬Kidoya, EMBO J 2008, Blood 2000)ȃ̷̱̀ apelin ͬਆន઼ً́ͅอ̵࡛̯ͥ͂Ȃਆនࠬ‫̱ا੃଼̦ۯ‬Ȃ࿪स௣ో଻ͬ٨஝̳ͥ̈́̓Ȃఈ͈‫܈‬হၷ͈࢘‫̹̱̺̞ࡉ̭ͬ͂ͥ͛ࣞͬض‬ȪKidoya, Oncogene 2012ȫȃ

ĳĹ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଎ˎȁࠬ‫ۯ‬૧୆͂ࠬ‫ۯ‬ඤ๧ۚळ༾
ࠬ‫ۯ‬૧୆ً͈೾͉́Ȃอ̱̹ٔࠬ‫୶͈ۯ‬൮ͬ֊൲̱̀΄ͼΘϋΑ̱͂̀‫ܥ‬ෝ̳ͥ tip ळ༾Ȃ̷͈෸ࢃ̥ͣ௩૓̱̀ࠬ‫ۯ‬૝ಿͅ‫ ͥͩ۾‬stalk ळ༾Ȃ̷̱̀डࢃͅ༃ळ༾‫ͅۯ̹̱ࠬ੃଼ฺ̠ͬا‬໦‫ ̵̯ͥا‬phalanx ळ༾̞̠͂Ȃઁ̩̈́͂͜ˏਅ͈ඤ๧ळ༾̦ంह̳̭̦ͥ͂ྶ̧̥̯̹ͣͦ̀ͅȃِș͉ඤ๧ळ༾͈ಎۚͅळ༾အळ༾ͬอࡉ̱̹̭͂ͅၛ‫( ̱ݗ‬Naito,
EMBO J 2012)Ȃ̭͈̠̈́͢ඤ๧ळ༾͈։ਅ଻ळ༾໦‫̫̤ۚͥͅا‬ळ༾ΏΑΞθ͈୆ၑഎ̤͍͢ພഎփٜ݅ͬྶ̱̞̀ͥȃ଎ˏȁ̦ͭۚळ༾͈ࠬ‫ۯ‬ΣΛΙِș͉Ȃুࡨໝୋಎ͈ۚळ༾ͅ‫ވ‬೒̱̀อ࡛̳ͥ DNA ໝୋ֦ঊȂPSF1͈ อ ࡛ ͬ ၌ ဥ ̱ ̀ ̦ ͭ ۚ ळ ༾ȪCSCȫͬ ௴ ̢ (Nagahama, Cancer Res2010)ȂCSC ̦ਆនඤ଼੃ࠬ‫ͬۯ‬୆ఠ‫ڠ‬എഐਫ਼ȪΣΛΙȫ̱̞̭͂̀ͥ͂
ٜͬྶ̱̹ (Matsui, Am J pathol 2013)ȃ̷̱̀ࠬ‫ۯ‬ΣΛΙ̤̫ͥͅȂ̦ͭۚ ळ ༾ ͈ ۚ ळ ༾ ଻ ֋ ঵ ͅ CD44 ̦ ‫ ۾‬ဓ ̱ ̀ ̞ ͥ ̭ ͂ ͬ ࡉ ̞ ̺ ̱ ̹ȪKinugasa, Stem Cells 2014ȫȃ

ड߃͈యນഎ̈́ა໲
1. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug
resistance of malignant cancer cells in the tumor microenvironment. Kinugasa Y, Matsui T, Takakura N. Stem Cells.
2014 Jan;32(1):145-56.
2. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin.
Muramatsu F, Kidoya H, Naito H, Sakimoto S, Takakura N. Oncogene. 2013 Jan 24;32(4):414-21.
3. A role for endothelial cells in promoting the maturation of astrocytes through the apelin/APJ system in mice.
Sakimoto S, Kidoya H, Naito H, Kamei M, Sakaguchi H, Goda N, Fukamizu A, Nishida K, Takakura N.
Development. 2012 Apr;139(7):1327-35.
4. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels.
Naito H, Kidoya H, Sakimoto S, Wakabayashi T, Takakura N. EMBO J. 2012 Feb 15;31(4):842-55.
5. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy.
Kidoya H, Kunii N, Naito H, Muramatsu F, Okamoto Y, Nakayama T, Takakura N. Oncogene. 2012 Jul 5;31
(27):3254-64.
ĳĺࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities۪‫ޏ‬؊൞ࡄ‫ݪ‬໐࿝ळ༾ଷࢄ໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ȁฎআȪၑ‫ڠ‬ȫȁ२࿐ȁဉྶ੩‫ޗ‬ȁฎআȪ֓‫ڠ‬ȫȁ५ॄȁఱ༟੩‫ޗ‬ȁฎআȪ࿪‫ڠ‬ȫȁ஑࡫ȁဢ࿸අහࡄ‫֥ݪ‬ȁฎআȪ࿪‫ڠ‬ȫȁ໹നȁဈٚȁఉळ༾୆໤ͬࢹ଼̳͈֚֚ͥ̾̾ळ༾͉Ȃ౾̥̹۪ͦ‫ޏ‬ȪγσκϋȆ௩૓֦ঊ͈̈́̓ঁࠣ໤ৗȂਔս͈ळ༾͞‫ۼ‬ৗ͈͂௖ࡽैဥ̈́̓ȫͅഐ୨ͅ؊൞̳̹͈ͥ͛ΏΈ΢σഥోΏΑΞθͬခ̱̞̀ͥȃ̷͈෫౦͉Ȃ̦ͭळ༾ͅങ߿എͅ۷ख़̯ͦͥ
̠̈́͢ਔս͈͂಺გͬ֝౎̱̹ྫಉ੬̈́ळ༾௩૓̈́̓Ȃ̯̰̈́͘͘৖͈ۛࡔ֦͂̈́ͥȃজ̹̻͈ࡄ‫ݪ‬৒͉́Ȃळ༾͈௩૓Ȃ໦‫ا‬Ȃ‫׋‬൲̈́̓Ȃ̯̰̈́͘͘ळ༾࡛યͬଷࢄ̳ͥΏΈ΢σഥో͈ॽழ͙̞̾̀ͅȂ໦ঊȆळ༾τασ̥ͣ஌ಖ͞ζ;Αͬဥ̞̹୆໤ࡢఘτασ́༫‫گ‬എٜ̈́ଢ଼ͬૺ̞͛̀ͥȃඅ࡛ͅह͉Ȃ(1) ౩ฒৗ͈‫ݙخ‬എ̈́ॸ‫ا‬ਘૐͥ͢ͅॸ‫ا‬ΑΠτΑ؊൞ΏΈ΢σഥోȂ(2) ळ༾ඤζΈΥΏ;θ͈ଷࢄ͂ΏΈ΢σഥోଷࢄȂ͈ඵതͬ৽ါ̈́ࡄ‫هݪ‬ఴ̱͂̀৾ͤழ̞ͭ́ͥȃȪˍȫ౩ฒৗ͈‫ݙخ‬എ̈́ॸ‫ا‬ਘૐͥ͢ͅॸ‫ا‬ΑΠτΑ؊൞ΏΈ΢σഥోȁఉळ༾୆໤͈੝‫ܢ‬อ୆͞อ̦ͭ̈́̓ͅਹါ̈́ Wnt ΏΈ΢σഥో͈૧ܰଷࢄ֦ঊ̱͂̀ȂΙ΂τΡ΅Ώϋ႒‫׻‬౩ฒৗ͈Τ·τ΂τΡ΅ΏϋȪNRX: nucleoredoxinȫͬࡉ̫̹̾ȃNRX ͉ Wnt ΏΈ΢σഥోͅຈଌ͈ DishevelledȪDvlȫࣣ̱ࠫ̀ͅȂ̷͈‫ܥ‬ෝͬဲଷ̳ͥ൱̧ͬ̾͜ȃ̷͈༷֚́Ȃ̭͈ NRX-Dvl ͈ࣣ͉ࠫȂNRX ͈໦ঊඤ S–S ࣣ͈ࠫࠁ଼ͥ͢ͅ‫ݙخ‬എ̈́ॸ‫̀̽͢ͅا‬ଷࢄ̯̞̭ͦ̀ͥ͂͜ྶ̥̹ͣ͂̈́̽ȃ̾ͤ͘ȂNRX ͉τΡΛ·Αેఠ؊൞଻ͅ Wnt ΏΈ΢σഥోͬ಺୯̳ͥ
‫ܥ‬ෝͬ౜̞̽̀ͥȃ̹͘ȂΙ΂τΡ΅Ώϋͬ၌ဥ̱̀Ȃळ༾ඤ́ S–S ࣣࠫͬࠁ଼̳ͥ౩ฒৗͬ࿌္എͅౝ̳॑ͥ৘ࡑࠏͬ
‫ٳ‬อ̱̹ȃ̷ͦͬဥ̞̀Ȃ૧ܰ S–S ౩ฒৗ̱͂̀Γζέ΁ςϋΏΈ΢σഥోͅ൱̩CRMP2 ̈́̓ͬࡉ̫̞̾̀ͥȃΓζέ΁ς
ϋঁࠣ؊൞଻ًͅॸ‫ا‬କள̦ॲ୆̯ͦȂ̷̦ͦ CRMP2 ͬॸ‫ ̱̀ا‬S–S ࣣ̹ࠫ́ࠫ͊ͦγκඵၾఘͬै̵̭ͣͥ͂ͬྶͣ
̥̱̹ͅȃ̭͈‫ݙخ‬എ̈́ CRMP2 ॸ‫̦ا‬Γζέ΁ςϋঁࠣͥ͢ͅ৊॑฽อ؊൞ͬಏ̱̞̭ٚ̀ͥ͂ͬอࡉ̱̹ȪFig. 1ȫȃ

Fig. 1: CRMP2 oxidation in Semaphorin signaling(A) Repulsive guidance of axons by Semaphorin 3A (Sema3A). (B) Increase of H2 O 2 in growth cones of neurons by Sema3A. (C)Schematic illustration of the mechanism of Semaphorin signaling via CRMP2 oxidation. Sema3A stimulation generates H 2O2 and oxidizes
CRMP2. Oxidized CRMP2 transiently forms protein complexes with TRX, which induces CRMP2 phosphorylation by GSK3.

ĴıȪˎȫळ༾ඤζΈΥΏ;θ͈ଷࢄ͂ΏΈ΢σഥోଷࢄȁळ༾ඤ́ S–S ࣣࠫͬैͥ౩ฒৗ̱͂̀ȂΙυΏϋγΑέ͹ΗȜΔΡιͼϋͬ঵̾‫ܥ‬ෝྚ౶໦ঊ PRL ͬࡉ̫̹̾ȃPRL ͉՛଻ഽ͈̞̦ࣞͭ́ࣞอ࡛̱̤̀ͤȂ̦ͭഢ֊ͬ௯̳̭̦͂౶̞ͣͦ̀ͥȃজ̹̻͉ PRL ͈ࣣࠫ౩ฒৗ͈ౝ࣐̞॑ͬȂ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

Magnesium-Exporting proteinȪMagExȫ͂ࡤ྄͐౩ฒৗͬ൳೰̱̹ȃMagEx ͉ Mg2+ ͬෳ੄̳̭ͥ͂́ळ༾ඤ Mg2+ ͈ଷࢄ࣐̤ͬ̽̀ͤȂPRL ̷͈ࣣ͈͂ࠫ̽̀͢ͅ‫ܥ‬ෝ̦ဲଷ̯̹ͦȃ̭͈ࣣ͉ࠫ PRL ͈ॸ‫ેࡓۺا‬ఠջం଻̭̤ܳ̽̀ͤͅȂ
PRL ͉ळ༾ඤζΈΥΏ;θၾͬ಺୯̱̞̭̦̀ͥ͂ྶ̥̹ͣ͂̈́̽ȃ̹͘Ȃࡢఘτασ̤̞̀ͅȂඤह଻ MagEx ͉ಸ͈ષ๧ळ༾ͅ‫̩ޑ‬อ࡛̱̤̀ͤȂ̷͈ळ༾྄͈‫ܖ‬௰໐ͅޫह̱̞̹̀ȃMagEx ͈֒ഥঊࠧఅζ;Αͬैୋ̱̹̭͂ͧȂಸ̥͈ͣζΈΥΏ;θ‫ݟ‬ਓ̦ఱ̧̩ཐ̬̞̹ͣͦ̀ȃ̯ͣͅȂMagEx ͉ভ͈΀΢ισৗͬैͥષ๧ळ༾Ȫ΀΢ισٔळ༾ȫ͜ͅ‫ޑ‬̩อ࡛̱ȂMagEx ֒ഥঊࠧఅζ;Ά͉΀΢ισৗࠁ଼ະ஠̦୆̲̞̹̀ȪFig. 2ȫȃMagEx ͥ͢ͅ Mg2+ ෳ੄̦஠૸͞ޫ
ਫ਼̤̫ͥͅζΈΥΏ;θၾ͈ഐ୨̈́ଷࢄͅਹါ̜́ͤȂ̷͈։ુ̦̯̰̈́͘͘৖͈ۛࡔ֦̞̭̦̈́̽̀ͥ͂ͅྶ̥ͣ̈́̽̀ͅ
̧̹ȃ

Fig. 2: Redox regulation of the intracellular Mg2+ level by MagEx(A) MagEx stimulates Na+ /Mg 2+ -exchange and decreases the intracellular Mg2+ level. PRL directly binds to MagEx and inhibits its
Mg2+-transporting function in a manner dependent on its redox state. Oxidized PRL is reversibly reduced by S–S bond-reducing enzymes,
such as Trx and Trp32. (B) Localization of endogenous MagEx at the basolateral membrane of the epithelial cells in the intestine.

ड߃͈యນഎ̈́ა໲
1. Basolateral Mg2+ extrusion via CNNM4 mediates transcellular Mg2+ transport across epithelia: a mouse model.
Yamazaki D, Funato Y, Miura J, Sato S, Toyosawa S, Furutani K, Kurachi Y, Omori Y, Furukawa T, Tsuda T,
Kuwabata S, Mizukami S, Kikuchi K, Miki H. PLoS Genet. 2013 Dec;9(12):e1003983.
2. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. Morinaka A,
Funato Y, Uesugi K, Miki H. Oncogene. 2011 Oct 6;30(40):4208-18.
3. Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse. Morinaka A,
Yamada M, Itofusa R, Funato Y, Yoshimura Y, Nakamura F, Yoshimura T, Kaibuchi K, Goshima Y, Hoshino M,
Kamiguchi H, Miki H. Sci Signal. 2011 Apr 26;4(170):ra26.
 1XFOHRUHGR[LQVXVWDLQV:QWȕFDWHQLQVLJQDOLQJE\UHWDLQLQJDSRRORILQDFWLYHGLVKHYHOOHGSURWHLQ)XQDWR<Terabayashi T, Sakamoto R, Okuzaki D, Ichise H, Nojima H, Yoshida N, Miki H. Curr Biol. 2010 Nov 9;20
(21):1945-52.
5. Par1b/MARK2 phosphorylates kinesin-like motor protein GAKIN/KIF13B to regulate axon formation. Yoshimura
Y, Terabayashi T, Miki H. Mol Cell Biol. 2010 May;30(9):2206-19.
ĴĲࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesඳহۜஅછచॐࡄ‫ݪ‬ΓϋΗȜ‫ޗ‬਎ȁȁȁȁၑ‫ڠ‬ฎআȁȁཱ֔ȁੇࢤඅහ‫ޗ‬਎ȁȁ֓‫ڠ‬ฎআȁȁ࿐ఆȁ‫ैם‬අහ੎‫ޗ‬਎ȁฎআ ĩ ࢥ‫ ڠ‬ĪȁΣςͺϋȆζςȜȆΩρΛ·ΩΛ·ȆΉςΰυ੩‫ޗ‬ȁȁȁȁฎআ ĩ ၑ‫ ڠ‬Īȁခྎȁ૝ঊ੩‫ޗ‬ȁȁȁȁฎআ ĩ ֓‫ ڠ‬Īȁ൐‫܅‬ȁහࢬඅහࡄ‫֥ݪ‬ȁฎআ ĩ ၑ‫ ڠ‬Īȁส࿐ȁୃങඅහࡄ‫֥ݪ‬ȁőũįŅ
ġġġġġΐοΞͻΑχρȆτΟͻȆ΀Οͽρ໦ঊࡔಖ‫ڠ‬໦࿤ࡄ‫ݪ‬ΈσȜίȁଲ‫͈࢛૽ٮ‬࿩ 4 ‫̦ڬ‬ζρςͺၠ࣐౷֖ͅ‫ݳ‬ਯ̱Ȃා‫ ̷̤͢ͅۼ‬200 ྔ૽̦ঘཌ̳̹ͥ͛Ȃζρςͺ͉૽႒डఱ͈ഌ͂ࡤ
̞͊ͦ̀ͥȃ̹͘Ȃၠ࣐౷֖͈஠֖̤̞̀ͅȂ࿪सఛ଻ζρςͺ̦੄࡛̱̤̀ͤȂζρςͺచॐ̦ࣾඳ̜̈́ͤ̾̾ͥͅȃਲ̽̀Ȃ
χ·Ιϋ͞ࢯζρςͺ࿪स͈‫ٳ‬อ͉޽‫هݪࡄ͈ݢ‬ఴ̜́ͥȃ൚ࡄ‫ݪ‬໦࿤͉́ζρςͺχ·Ιϋ͈‫ٳ‬อ࣐̠ͬ͂͂͜ͅȂ໦ঊळ༾୆໤‫ڠ‬എ਀༹ͬဥ̞̀Ȃζρςͺࡔಖ͈‫ܙ‬୆ഐ؊୽ၞ͈ٜଢ଼࣐̞ͬ̽̀ͥȃȪˍȫழ̢۟ SERA ౩ฒৗͥ͢ͅζρςͺχ·Ιϋ͈‫ٳ‬อȁِș͉̭ͦ́͘ͅ෎ఝ෎ζρςͺࡔಖ͈ SERA5(Serine Repeat Antigen, 120kD) ࢯࡔ໦ঊͅ಍࿒̱̀χ·Ιϋ‫ٳ‬อͬૺ̧̹͛̀ ( ໲ࡃ 1, 2)ȃ;΄ϋΘ͈ζρςͺࣞഽၠ࣐౷֖ͅਯ͚঱ൺͬచય̱͂̀‫಺ڠע‬औ࣐̹ͬ̽ࠫ‫ض‬ȂSERA5 ͈ N- ྎ౤Ριͼϋͅచ̳ͥࢯఘ‫ͬث‬঵̾঱ൺ͉஠̩อ෎̴̱̤ͬ̀ͣȂ঱ൺ͈ࠬಎζρςͺࡔಖၚ͂ࢯ SERA-IgG ࢯఘ‫ྶ̀͛ޭͅث‬ၸ̈́໅͈௖‫̹ͦͣ͛෇̦߸۾۾‬ȃழ̢۟ SERA5 ͈ N- ྎ౤ΡιͼϋΗϋΩ·ৗȂSE36Ȃ͂କॸ‫ا‬ͺσηΣ;θΊσͬईࣣ̱̹ζρςͺχ·Ιϋႉ઄হࡑୋस (BK-SE36) ͬ ( ़ ) िఱ๷୆໤ພࡄ‫ݪ‬ٛ͂‫ފ‬ႁ̱̀୆ॲ̱Ȃ2010 ා̥ͣ 2011 ා̥̫̀ͅ
;΄ϋΘ̤̞̀ͅ 140 ྴ͈๢ࡑ৪̦४‫̹̱ح‬ల Ib ௖ႉ઄দࡑͬ৘ঔ̱̹ȃ଼૽౳੫ͬచય̱̹͂ΑΞȜΐ 1 ́հ஠଻ͬ‫ږ‬෇̱Ȃ̷͈ࢃͅ6-20 प͈৹ා௄ͬచય̱̹͂ΑΞȜΐ 2̯́ͣͅհ஠଻ͬ‫̹̱෇ږ‬ȃ̭͈ͦͣ୪ਅ৪̷͈ͬࢃˍා‫̹̽ͩͅۼ‬̀ζρςͺۜஅ͈ે‫ͬޙ‬۷ख़̱̹ࠫ‫ض‬Ȃχ·Ιϋͬ୪ਅ̱̥̹̈́̽చચ߲ͅ๤͓̀ 72ɓ(p=0.003) ͈อછཡࢄ࢘‫̱෇ږͬض‬̹ ( ໲ࡃ 2)ȃζρςͺχ·Ιϋ͈‫ٳ‬อͬࣾඳ͈̱̞̈́͂̀ͥ͜৽̹ͥၑဇ͉ࢯࡔ֒ഥঊ͈ఉ߿଻̜̦ͥͅȂSERA ֒ഥঊ͉ࢯࡔ་։ͬা̴̯ࢯࡔఉ߿͜ޭ͛̀ઁ̩̈́ ( ໲ࡃ 4)Ȃࢩ̩࢘‫ܢ̦ض‬ఞ̧́ͥȃࣽࢃ̯ͣࣞͅষ͈ႉ઄দࡑͬ৘ঔ̱̀ၠ࣐౷
֖́၌ဥ̯ͦͥχ·Ιϋ͈‫ٳ‬อͬૺ͛ͥȃ଎ 1ȇ;΄ϋΘཤ໐ͺΩΛΙ̜ͥͅພ͈֭
ఞࣣ৒ȇਹછζρςͺ͈ঊ‫ͬރ‬Ⴒ̹ͦ༦૶ో .
ঘཌ৪͈ఱఉତ̦ 5 पո‫͈ئ‬ঊ‫ ރ‬.

଎ 2ȇSE36 ζρςͺχ·Ιϋ̽̀͢ͅည൵̯̹ͦ
ࢯ SERA ࢯఘͥ͢ͅζρςͺࡔಖफ़྽͈ैဥത

Ĵĳ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଎ 3ȇSE36 ζρςͺχ·Ιϋহࡑୋसȇ( ़ ) िఱ๷୆໤ພࡄ‫ݪ‬ٛ۷‫إ‬঳ࡄ‫ݪ‬ਫ਼ͅ
̤̞̀ GMP ૄ࠯ͬਖ਼৿̱̀୆ॲ̯̹ͦȃ଎ 4ȇKaplan-Meier ίυΛΠͥ͢ͅχ·Ιϋ୪ਅ߲Ȃ๱୪ਅ߲͈ζρςͺอછ͈๤‫ڛ‬Ȫˎȫζρςͺࡔಖ͈ૺ‫ًا‬೾͈ٜྶȁζρςͺࡔಖ͉Ȃໝॠ̈́୆‫۪ڰ‬Ȃ਽৽྾‫ע‬؊൞͈ٝ๰
‫ࢹܥ‬Ȃ਽৽අ։଻̈́̓ȂξΣȜ·̈́අಭͬତఉ̩ခ̳ͥȃ̭͈ͦͣ‫ܖ‬๕͂̈́ͥ໦ঊ‫̹̳̥͛ͥͣͅͅྶͬࢹܥ‬Ȃ‫ړ‬ΊΦθȂ΂σ΄ΥρΊΦθ͈ٜඋ͞ࢯࡔ໦ঊ͈ఉ߿ٜଢ଼̈́̓Ȃ֒ഥঊ෻Ⴅૂ༭̥͈ͣͺίυȜΙ࣐̞ͬ̽̀ͥ ( ໲ࡃ 4Ȅ5)ȃ̭͈ͦͣࡄ‫͉ض଼͈̥ͣݪ‬χ·Ιϋ‫ٳ‬อ͈࡛ા́͜ခ
࢘ͅ၌ဥ̯̞ͦ̀ͥȃ଎ 5ȇͺά΋ίρΑΠΊΦθ΋ȜΡ͈ 30 ֒ഥঊͥ͢ͅࠏൡਏȇΪΠͬ਽৽̳͂ͥ 4 ਅ͈ζρςͺࡔಖ͉ౙࠏൡ߲ͬࠁ଼̱̞̈́ȃ਽৽ഢ̦۟ૺ‫ً͈ا‬೾̤̞̀ͅ‫ة‬ഽ͜୆̲̞̀ͥȃड߃͈యນഎ̈́ა໲
1. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured
N-terminal repetitive sequence. Yagi M, Bang G, Tougan T, Palacpac NMQ, Arisue N, Aoshi T, Matsumoto Y, Ishii
KJ, Egwang TG, Druilhe P, Horii T. PLoS One. 2014 Jun 2;9(6):e98460.
2. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
Palacpac NM, Ntege E, Yeka A, Balikagala B, Suzuki N, Shirai H, Yagi M, Ito K, Fukushima W, Hirota Y, Nsereko
C, Okada T, Kanoi BN, Tetsutani K, Arisue N, Itagaki S, Tougan T, Ishii KJ, Ueda S, Egwang TG, Horii T. PLoS
One. 2013 May 28;8(5):e64073.
3. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhumanprimate models. Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, Ishii KJ, Horii T. Hum Vaccin
Immunother. 2013 Jan 4;9(2):283-90.
4. Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5.
Tanabe K, Arisue N, Palacpac NM, Yagi M, Tougan T, Honma H, Ferreira MU, Färnert A, Björkman A, Kaneko A,
Nakamura M, Hirayama K, Mita T, Horii T. Vaccine. 2012 Feb 21;30(9):1583-93.
5. The Plasmodium apicoplast genome: conserved structure and close relationship of P. ovale to rodent malaria
parasites. Arisue N, Hashimoto T, Mitsui H, Palacpac NM, Kaneko A, Kawai S, Hasegawa M, Tanabe K, Horii T.
Mol Biol Evol. 2012 Sep;29(9):2095-9.
ĴĴࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities֒ഥૂ༭৘ࡑΓϋΗȜ֒ഥঊ‫ܥ‬ෝٜଢ଼໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ġĩ ࠳ Īġ࿪‫ڠ‬ฎআȁչ୼ȁୃ૽අහ੎‫ޗ‬਎ġĩ ࠳ Īġ ࿪‫ڠ‬ฎআȁ֙౓ȁիঊ੩‫ޗ‬ġ֓‫ڠ‬ฎআȁ൥ࡔȁટࣞ੩‫ޗ‬ġၑ‫ڠ‬ฎআġ‫ݠ‬നȁহ຃
੩‫ޗ‬ġĩ ࠳ Īġ ୆ྵ‫ڠش‬ฎআġ ऎ൥ȁဉ࢖ȁΪΠ͞ζ;Α͈ΊΦθίυΐͿ·Π̦֚؊͈ۖၭ̢̹࡛ͬࠞह͉́Ȃ૽ࢥഎ֒ͅഥঊͬௌै̱̹֒ഥঊழ̢۟൲໤̦Ȃ৖ພ͈ࡄ‫ܖ͞ݪ‬யഎ̈́୆໤‫ͅݪࡄڠ‬ਹါ̈́࿨‫̜̱̹ͥ̾̾ضͬڬ‬ȃِș͉୆ఘτασ͈́֒ഥঊ‫ܥ‬ෝٜଢ଼ΜȜσͬ‫ٳ‬อ̱̀୆૓୆໤‫ڠ‬໦࿤͈́ࡄ‫̠࣐͂͂ͬ͜ͅݪ‬Ȃ֒ഥঊழ̢۟൲໤͈ैୋ঑‫̞࣐ͥ̀̽ͬ׳‬ȃࡄ‫ݪ‬ඤယ
ȁِș͉ଲ‫΂̫̀ߐ୶ͅٮ‬χϋ·ρΊ͈ GFP ֒ഥঊͬழ͙ࣺ̺ͭΈςȜϋζ;Αͬैୋ̳ͥ͂͂͜ͅȂ̷͈Φ;Χ;ͬ୆̥̱̀਋ୈ͈ι΃ΣΒθ͞୆૓ळ༾଼͈ͤၛ̻ͬࡄ‫ ( ̞̱ͥ̀ݪ‬଎ 1 ȡ 3)ȃ̭ͦ́͘ͅୈ௏අ։എ̈́઀༾ఘΏλβυϋ߲(CLGN, CALR3, PDILT) ͈ΦΛ·ͺ;Π (KO) ζ;Αͬैୋ̱Ȃ̷̦ͦͣୈঊ྄ΗϋΩ·ৗ (ADAM3) ͈຦ৗ‫ۯ‬ၑͅຈଌ́
̜̭ͥ͂ȂADAM3 ͬ৐̹̽ KO ୈঊ͉ঊ‫̥ͣݠ‬၅‫̴̧࣐́ͅ֊ͅۯ‬ဎ଻ະළ̭̈́ͥ͂ͬͅྶ̧̥̱̹ͣ̀ͅ ( ଎ 2, #5)ȃड߃͉́ GPI ͺϋ΃ȜΗϋΩ·ৗ̜́ͥ TEX101 ̦ ADAM3 ͈ంहͅຈଌ̜̭́ͥ͂ͬྶ̥̱̹ͣͅ (#3)ȃ̹͘Ȃِș̦ոஜ൳೰̱̹ୈঊ௰͈ဏࣣ֦ঊ̜́ͥ IZUMO1(Nature, 2005) ࠖͅ࢕ΗϋΩ·ৗͬັ‫̹̱ح‬ΠρϋΑΐͿΣΛ· (Tg) ζ;Αୈঊ͈ρͼήͼιȜΐϋΈ۷ख़ͤ͢ͅȂ਋ୈ ( ୈঊ - ၅ঊ͈ဏࣣ ) ͈੊‫͈ۼ‬۷ख़଼̱̹ࢗͅ ( ଎ 3, #4)ȃĴĵ଎ˍȫ൮໐͈୶ఘ̦ GFPȂ๶໐͈ηΠ΋ϋΠςͺ̦ RFP ́ρασ̯̹ͦΠρϋΑΐͿΣΛ·ζ;Αୈঊ͈ৢ૯ȃ୶ఘ฽؊ͤ͢ͅ୶ఘඤ͈ GFP ͬ༶੄̳ͥ
̭͂́Ȃୈঊ͉਋ୈ‫خ‬ෝ̈́ͥͅȃ଎ˎȫADAM3 ̦ક৐̱̹ Pdilt ΦΛ·ͺ;Πζ;Αୈঊ͉ঊ‫̥ͣݠ‬၅‫̴̧࣐́֊͒ۯ‬Ȃဎ଻ະළ͈ࡔ֦͂̈́ͥȃ଎ˏȫ၅ळ༾྄ષࣣ̱̹ࠫͅ Red-IZUMO1 ΠρϋΑΐͿΣΛ·ζ;Αୈঊ͈ৢ૯ȃ୶ఘ฽؊ͤ͢ͅGFP ͬક৐̱̹ୈঊ (2, 3) ͉ IZUMO1Ȫ୤૗ࠖ࢕ȫ͈ޫह̦་‫̳ͥا‬ȃ၅ঊ͂ဏࣣ̱̹ୈঊ͈‫୒͉ړ‬૗ࠖ࢕ͬ೮̱ (4)Ȃဏࣣೄࢃ͈ୈঊ͈ࠖ࢕ક৐̦Ȃဏࣣ͈අ։തͬা̱̞̀ͥȃ଎ːȫِș̦ਏၛ̱̹ GFP ࠖ࢕ͬ঵̾ρΛΠ ES ळ༾ͬζ;Α᥷๕༾͒ಕව̱̀ैୋ̱̹ζ;Α͂ρΛΠ͈΅ιρ൲໤ȃ࿉૗͈ฒ̞໐໦̦ζ;ΑȂခ૗໐໦̦ρΛΠဇြ͈ळ༾́ࢹ଼̯ͦ
̞̀ͥȃȁ̭͈ఈ͜ͅȂِș͉อ୆ࢥ‫̹̱ঀߐͬڠ‬ͺίυȜΙ̥ͣ୆ྵ͈आ࡙ͅทͥΙλτϋΐϋΈ̈́ࡄ‫ͬݪ‬࿒ঐ̱̞̀ͥȃτϋΙ
;ͼσΑα·ΗȜͬဥ̞̭ͥ͂́థ๕͈͙֒ͅഥঊௌै̧༹༷́ͥͬࣉմ̱ (Nat Biotechnol, 2007)Ȃథ๕අ։എͅ sFLT1 ͬอ࡛̳̭ͥ͂́ළૡࣞࠬգછ࢓߲͈κΟσζ;Α͈‫ٳ‬อ଼̱̹ࢗ͜ͅ (PNAS, 2011)ȃ̹͘Ȃඊুͅਏၛ̱̹ρΛΠ ES ळ༾

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ͬဥ̞̀ζ;ΑļρΛΠ΅ιρ൲໤ͬဥ̞̹௫‫ܕ‬ठ୆֓‫ ( ͞ݪࡄڠ‬଎ 4, Genes Cells, 2011)ȂmiRNA ࠧఅζ;Αͬဥ̞̹non coding RNA ͈୆ఘ‫ܥ‬ෝٜଢ଼̈́̓৾ͤͅழ̞ͭ́ͥ (#2)ȃड߃͉́Ȃ૧̹̈́֒ഥঊ٨་ܿ੅̱͂̀ಕ࿒ͬਬ̞͛̀ͥCRISPR/Cas ΏΑΞθͬဥ̞̀Ȃ֒ഥঊ٨་ζ;ΑȆρΛΠ͈ैୋ଼̱̹ࢗͅ (#1)ȃࣽࢃ͜Ȃ֒ഥঊழ̢۟൲໤ैୋ͈࢘
ၚ‫ͬا‬࿒ঐ̱̀‫ٳ‬อȆࡄ‫̩̞̀͛ૺͬݪ‬ȃ଎ˑȫ
A. Τ·τͺȜΔ‫ ̞͈ࣞ଻ڰ‬gRNA ෻Ⴅͬ۰༒ͅ
಺͓̹ͥ͛ͅȂGFP ͬঐດ̱̹ͅ෽ူळ༾࠿೰ࠏ
ͬࢹಃ̱̹ȃ
B. pCAG-EGxxFP ͅ Cetn1 ֒ഥঊႀ֖ͬொව̱̹
ίρΑηΡͅ‫̢ح‬ȂgRNA ͂ Cas9 Τ·τͺȜΔͬ൳শͅอ࡛̳ͥ pX330 ͬ HEK293T ळ༾͒֒ഥ
ঊ൵වࢃ 48 শ‫ৢ࢕͈ࠖۼ‬૯ ( ષȇGFPȂ‫ئ‬ȇྶণ࿤ )ȃ
C. GFP ࠖ࢕̦۷ख़̧̹́ pX330-Cetn1#1 ίρΑηΡ ͬ ۪ ે ͈ ͘ ͘Ȃζ ; Α ਋ ୈ ၅ ͒ ಕ ව ̱ ̀Ȃ
Cetn1 ֒ഥঊࠧఅζ;Αͬैୋ̱̹ȃ
D. CRISPR/Cas9 ͈අಭ̱͂̀ȂPAM ෻Ⴅ ( ୤ল )ͤ͢ 3 ‫ܖ؂‬ષၠ́ DNA ඵུङ୨౯̭̳ͬܳȃ̷͈ࠫ‫ض‬Ȃ8 ‫ࠧܖ؂‬৐͈་։ζ;Α̦ං̹ͣͦȃ(WT; ࿤୆߿Ȃem4; ་։߿ )ࡄ‫ݪ‬঑‫׳‬ȁ‫ڠ‬ඤ̴͈͙̈́ͣࢩ̩‫֒͜ͅٸڠ‬ഥঊழ̢۟൲໤͈ैୋ঑‫ͬ׳‬Ȃۜஅ൲໤৘ࡑঔ୭͂‫ވ‬൳࣐̞́̽̀ͥȃ̭ͦ͘ ́ ͅ Π ρ ϋ Α ΐ Ϳ Σ Λ · ζ ; ΑȂΦ Λ · ͺ ; Π ζ ; Α ͉ ̷ ͦ ̸ ͦ 400 ρ ͼ ϋ ͬ ಼ ̢ ͥ ै ୋ ৘ ୡ ̦ ̜ ͥ(http://www.tgko.biken.osaka-u.ac.jp/tgko/sum/index)ȃ̯ͣ֒ͅഥঊழ̢۟൲໤ͬਹါ̈́ࡄ‫ݪ‬঩࡙̱͂̀༗ం̳ͥ࿒എ
́Ȃ1000 ρͼϋոષ͈਋ୈ၅͞ୈঊ͈ൄࠫ༗ం͜঑‫׳‬৘ୡͬခ̱̞̀ͥȃड߃͈యນഎ̈́ა໲
1. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA.
Mashiko D, Fujihara Y, Satouh Y, Miyata H, Isotani A, Ikawa M. Sci Rep. 2013 Nov 27;3:3355.
2. MiR-200b and miR-429 Function in Mouse Ovulation and Are Essential for Female Fertility. Hasuwa H, Ueda J,
Ikawa M, Okabe M. Science. 2013 Jul 5;341(6141):71-3.
3. Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Fujihara Y,
Tokuhiro K, Muro Y, Kondoh G, Araki Y, Ikawa M, Okabe M. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8111-6.
4. Visualization of the moment of mouse sperm-egg fusion and dynamic localization of IZUMO1. Satouh Y, Inoue N,
Ikawa M, Okabe M. J Cell Sci. 2012 Nov 1;125(Pt 21):4985-90.
5. Testis specific PDILT is required for quality control of sperm membrane protein ADAM3 and male fertility.
Tokuhiro K, Ikawa M, Benham AM, Okabe M. Proc Natl Acad Sci U S A. 2012 March 6;109 (10):3850-3855.
ĴĶࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities֒ഥૂ༭৘ࡑΓϋΗȜ֒ഥૂ༭ࡄ‫ݪ‬ΈσȜίࡄ‫ݪ‬ΈσȜί੎‫ޗ‬਎ȁၑ‫ڠ‬ฎআȁ२ႊȁ‫ڡ‬঎ȁ੏۪‫́ࠏܕ‬අ։എͅอ࡛̱̞̀ͥ৖ۛͅ‫۾‬ဓ̳ͥ֒ഥঊ̞̾̀֒ͅഥঊழ̢۟൲໤ͬ‫̹͛܄‬κΟσ൲໤ͬ၌ဥ̱̀໦ঊ
୆໤‫ڠ‬എٜଢ଼࣐̞ͬ̽̀ͥȃඅͅȂ૤ະ஠͈࿩฼ତͬ୸͛ͥ૤ऒ৒͈‫ڐ‬ಫະ஠͈ພఠٜྶ͂อછι΃ΣΒθ͈ٜଢ଼ͬૺ͛
ͥ͂͂͜ͅȂࠬ‫ۯ‬අ։എͅอ࡛̳ͥ֒ഥঊ͈อ࡛಺୯‫͈ࢹܥ‬ٜྶ࣐̞ͬ̽̀ͥȃˍȫ૙‫ۜ؂‬਋଻ࣞࠬգΘȜσρΛΠͬဥ̞̀‫ڐ‬ಫະ஠͈ങ߿എພఠκΟσΉȜΑͬैୋ̱̹ȃ̷͈ٜଢ଼̥ͣࣞࠬգۛ৪́
௩‫̳ࠬͥح‬ୄඤ֦଻ΐΆΗςΑအ໤ৗ͈ Na+/Ca2+ exchanger ͅచ̳ͥ‫͞ޣג‬૙‫ۜ؂‬਋଻֦ঊ̱͂̀΃σΣΙϋ̦૤ऒ৒஌֋‫ဲ͈ا‬ଷͥ͢ͅऒ৒‫ڐ‬ಫ‫ܥ‬ෝ͈٨஝ͤ͢ͅ‫ڐ‬ಫະ஠͈อછ̦ဲଷ̯̹ͦȪ3ȫȃ̹͘Ȃ‫ڐ‬ಫະ஠͈ۛ৪͞κΟσρΛΠ͉́ IL-16 ͈ࠬಎෛഽ̦ષઌ̱̤̀ͤȂ૤௫අ։എͅ IL-16 ͬอ̵࡛̯ͥ͂૤ऒ৒̤̫ͥͅ஌֋‫اࣁ͂ا‬ഽ͈ષઌ̦͙ͣͦȪ଎ 1ȫȂIL-16 ̦‫ڐ‬ಫະ஠ͅఱ̞ͅ‫̹̱੄ࡉ̭̞̱ͬ͂ͥ̀ޣג‬Ȫ1ȫȃˎȫࠬ‫ۯ‬໹‫޼ڲ‬ळ༾̤̫ͥͅழ૕අ։എ֒ഥঊอ࡛಺୯‫͈ࢹܥ‬ٜଢ଼ͬΪΠࠬ‫ۯ‬໹‫޼ڲ‬Į ͺ·ΙϋȪ6PĮ$ȫͅ‫̞࣐̱̀۾‬Ȃඅ։଻ͬਹါ̈́ैဥ̳ͥႀ֖ͬ൳೰̳ͥ͂͂͜ͅȪ଎ 2ȫȂ‫׶଻ݢ‬છশً֚ͅഎͅ‫ޑ‬อ࡛̱Ȃພఠ՛‫͈͂ا‬௖‫̜̦଻۾‬ͥ֒ഥঊζȜ΃Ȝ͈ 6PĮ$͈อ࡛‫̷͈͂ࢹܥ‬ພ་͈́อ࡛͈փٜ݅ͬଢ଼̱̞̀ͥȃ଎ 1ȁĮ0+& ίυκȜΗȜ‫ ́ئ‬IL-16 ͬ૤௫අ։എͅ‫ޑ‬อ̵࡛̯̹ΠρϋΑΐͿΣΛ·ζ;ΑȪTGȫ̤̫ͥͅ૤௫͈๬ఱ‫ا‬Ȫऒ଎ȫ͂૤ऒ৒̤̫ͥͅ஌֋‫͈ا‬ᄤૺȪֲ଎ȫͬা̳ȃ଎ 2ȁࠬ‫ۯ‬໹‫޼ڲ‬Į ͺ·Ιϋ֒ഥঊίυκȜΗȜͅ‫ܖ؂‬་։ͬ঵͈̾͜Ȫಎ؇ֲ͂ȫ͉ୃુȪऒȫͅచ̱̀ζ;Αథ঱́ఱ൲ྤȪ$Rȫ͈́อ࡛͈͙̦ஷ‫͈̯́ͥͦٺ‬Ȃ̭͈ͦͣ‫͈ܖ؂‬ၰ෻Ⴅ̦ࠬ‫ۯ‬ழ૕අ։എ֒ഥঊอ࡛ͅຈ
ଌ̜́ͥȃड߃͈యນഎ̈́ა໲
1. Tamaki S, Mano T, Sakata Y, Miwa T, et.al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening inheart failure with preserved ejection fraction. PLoS One. 2013 Jul 19;8(7):e68893.
 7VXNDPRWR<0DQR76DNDWD<0LZD7HWDO$QRYHOKHDUWIDLOXUHPLFHPRGHORIK\SHUWHQVLYHKHDUWGLVHDVHE\angiotensin II infusion, nephrectomy, and salt loading. Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1658-67.
3. Kamimura D, Ohtani T, Miwa T, et al.Ca2+ Entry mode of Na+/Ca2+ exchanger as a new therapeutic target forheart failure with preserved ejection fraction. European Heart J. 2012, 11, 1408-1416.
Ĵķ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

Ĵĸ

ࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities֒ഥૂ༭৘ࡑΓϋΗȜΊΦθૂ༭ٜଢ଼໦࿤
ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎ġၑ‫ڠ‬ฎআġհ‫ז‬ȁચဎ
‫ޗ‬਎Ȫ࠳ȫġ ࿪‫ڠ‬ฎআġ
ࣞ࿐ȁో࿟
੩‫ޗ‬ġ
ฎআȪၑ‫ڠ‬ȫġ ࢃ൥ȁೄ‫ݛ‬੩‫ޗ‬ġฎআȪ࿪‫ڠ‬ȫġȁಎఆȁઌఊ੩‫ޗ‬Ȫ࠳ȫġ ฎআȪ࿪‫ڠ‬ȫġȁ୼‫ئ‬ȁၑ඾૽ȁ൚໦࿤͉́Ȃఱ߿ࠗॳ‫̱ঀߐͬܥ‬Ȃఱၾ͈֒ഥঊȆΊΦθૂ༭ͅచ̳ͥఱܰ࿅̥̾࿌္എٜ̈́ଢ଼̥ͣ୆ྵ࡛ય͞
୆໤͈ૺ‫͈ا‬ٜྶͬ࿒ঐ̳ࡄ‫̞࣐ͥ̀̽ͬݪ‬ȃ̹͘ȂΨͼ΂ͼϋέ΁ζΞͻ·Α͞໦ঊ୆໤‫ڠ‬ဥ͈ΕέΠ;Ϳͺ͈‫ٳ‬อ࣐̞ͬ̽̀ͥȃ̯ͣͅȂΊΦθૂ༭ٜଢ଼ဥ΋ϋάνȜΗΏΑΞθͬ‫׋‬ဥ̱Ȃ‫ڠ‬ඤ͈֒ഥঊȆΊΦθ‫ݪࡄ߸۾‬৪ࠗͅॳ‫ܥ‬঩࡙ͬ೹‫̳͂͂ͥ͜ͅރ‬ȂΊΦθૂ༭ٜଢ଼͞΋ϋάνȜΗΏΑΞθ͈၌ဥ༹༷̞͈̾̀ͅ‫ࡄ֗ޗ‬ਘ࣐̞ͬ̽̀ͥȃȪˍȫఱܰ࿅ΊΦθૂ༭ٜଢ଼ȁ࡛ह́͘ͅତఉ̩͈୆໤ਅ͈ΊΦθ෻Ⴅ̦ࠨ೰̯̞̦ͦ̀ͥȂ̭͈ͦͣΊΦθ෻Ⴅ̷ͦ͞ͅັଟ̳ͥ֒ഥঊȂΗ
ϋΩ·ৗȂRNA ͈̈́̓ૂ༭̞̾̀ͅȂΨͼ΂ͼϋέ΁ζΞͻ·Α͞໦ঊૺ‫̓̈́ڠا‬အș̈́਀༹ͬߐঀ̱̹࿌္എ
ٜ̈́ଢ଼࣐̞ͬ̽̀ͥȃ൳শͅȂఱܰ࿅ΊΦθૂ༭ٜଢ଼ͅຈါ̈́ΕέΠ;Ϳͺٜ͞ଢ଼ͺσΌςΒθ͈ࡄ‫ٳݪ‬อ࣐̞ͬ̽̀ͥȃِș͉༗ం෻Ⴅࠨ೰ΕέΠ;Ϳͺ CONSERV ͬ‫ٳ‬อ̱Ȃळ޿̥ͣΪΠͅঢͥအș̈́୆໤ 266 ਅ͈ΊΦθ෻Ⴅ͈ٜଢ଼̥ͣȂ͕̳͓͈͂ͭ̓̀୆໤͈ΊΦθͅ༗ం̯̞ͦ̀ͥະ་෻Ⴅͬࡉ੄̱̹Ȫ଎ˍȫȃ̹͘Ȃͼϋέσ
΀ϋΎ;ͼσΑ͈ૺ‫ͬا‬࿌္എ̈́ΊΦθ෻Ⴅٜଢ଼́೏̞̽̀ͥȪ଎ˎȫȃ଎ˍȁ266 ਅ͈ΊΦθ෻Ⴅٜଢ଼ͤ͢ͅྶ̥̹ͣ͂̈́̽
஠୆໤͈ΊΦθ͈༗ం෻ႥȃĴĹ଎ˎȁͼϋέσ΀ϋΎ;ͼσΑΊΦθ͈࿌္എ̈́ૂ༭ٜଢ଼ȃȪˎȫষଲయΏȜ·΀ϋ΍Ȝͥ͢ͅΊΦθૂ༭ٜଢ଼ȁ߃ා৘ဥ‫̹̯ͦا‬ষଲయΏȜ·΀ϋ΍Ȝ͉́Ȃ1 ୆໤͈ΊΦθ஠ఘͬࠨ̭͛ͥ͂͜‫خ‬ෝ͕̈́̓ఱၾ͈‫ܖ؂‬෻Ⴅ֚ͬഽͅࠨ೰̧̳̭̦ͥ͂́ͥȃ൚ࡄ‫ݪ‬৒͉ষଲయΏȜ·΀ϋ΍Ȝ̦੄ႁ̳ͥཛྷఱ̈́ΟȜΗၾ͈ΊΦθૂ༭ٜଢ଼ͅచ

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

؊̳͓̩Ȃٜଢ଼ΕέΠ;Ϳͺ͈‫ٳ‬อ̤͍ٜ͢ଢ଼ΏΑΞθ͈ࢹಃ࣐̞ͬ̽̀ͥȃࢹಃ̱̹ٜଢ଼ΏΑΞθͬဥ̞̀Ȃພࡔ๷୆໤̈́̓အș̈́୆໤͈૧ܰΊΦθ෻Ⴅࠨ೰͞๤‫ڛ‬ΊΦθٜଢ଼ͬ๷୆໤ພࡄ‫ݪ‬ਫ਼ඤ͞‫ڠ‬ඤ‫ݪࡄڎ͈ٸ‬৒͂‫ވ‬൳࣐̞́̽̀ͥȪ଎ˏȫȃ଎ˏȁষଲయΏȜ·΀ϋ΍Ȝͥ͢ͅΊΦθٜଢ଼ȃ
1 ͈ٝΏȜ·΀ϋΏϋΈ́ΊΦθ͈͕͖஠ႀ֖ͬ
ٜඋ̳̭̦ͥ͂‫خ‬ෝȃ଎ːȁ֒ഥૂ༭৘ࡑΓϋΗȜࠗॳ‫ܥ‬ΏΑΞθ͈ٜଢ଼΍ȜΨȜȪऒȫ͂ఱယၾΑΠτȜΐȪֲȫȃȪˏȫ‫ڠ‬ඤ‫ވ‬൳၌ဥ͈ΊΦθૂ༭ٜଢ଼ဥ΋ϋάνȜΗΏΑΞθ͈‫׋‬ဥȁΊΦθૂ༭ٜଢ଼ဥ͈ࠗॳ‫ܥ‬ΏΑΞθȪ଎ːȫͬ‫׋‬ဥ̱Ȃ‫ڠ‬ඤ͈၌ဥ৪͒೹‫̞̱ͥ̀ރ‬ȃུΏΑΞθ͉́Ȃ֒ഥૂ༭ٜଢ଼ͅຈଌ͈ଲ‫ٮ‬ಎͅ࢖‫̞̯ͥ̀ͦٳ‬အș̈́ΟȜΗαȜΑͬව਀̱Ȃુͅड૧͈ેఠͅু൲എͅ༗̹̠ͦͥ͢֋
঵‫ۯ‬ၑ̱̦̈́ͣ၌ဥ৪ͅ೹‫̞̱ͥ̀ރ‬ȃड߃͈యນഎ̈́ა໲
1. Tachibana S, Sullivan SA, Kawai S, Nakamura S, Kim HR, Goto N, Arisue N, Palacpac NM, Honma H, Yagi M,
Tougan T, Katakai Y, Kaneko O, Mita T, Kita K, Yasutomi Y, Sutton PL, Shakhbatyan R, Horii T, Yasunaga T,
Barnwell JW, Escalante AA, Carlton JM, Tanabe K. Plasmodium cynomolgi genome sequences provide insight into
Plasmodium vivax and the monkey malaria clade. Nat Genet. 2012 Sep;44(9):1051-5.
2. de Silva UC, Tanaka H, Nakamura S, Goto N, Yasunaga T. A comprehensive analysis of reassortment in influenza A
virus. Biol Open. 2012 Feb 23;1(4):385-90.
3. Yamashita A, Kawashita N, Kubota-Koketsu R, Inoue Y, Watanabe Y, Ibrahim MS, Ideno S, Yunoki M, Okuno Y,
Takagi T, Yasunaga T, Ikuta K. Highly conserved sequences for human neutralization epitope on hemagglutinin of
influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem
Biophys Res Commun. 2010 Mar 19;393(4):614-8.
4. Nakamura S, Yang CS, Sakon N, Ueda M, Tougan T, Yamashita A, Goto N, Takahashi K, Yasunaga T, Ikuta K,
Mizutani T, Okamoto Y, Tagami M, Morita R, Maeda N, Kawai J, Hayashizaki Y, Nagai Y, Horii T, Iida T, Nakaya
T. Direct metagenomic detection of viral pathogens in nasal and fecal specimens using an unbiased high-throughput
sequencing approach. PLoS One. 2009;4(1):e4219.
5. Yamashita A, Goto N, Nishiguchi S, Shimada K, Yamanishi H, Yasunaga T. Computational search forover-represented 8-mers within the 5'-regulatory regions of 634 mouse testis-specific genes. Gene. 2008 Dec 31;427(1-2):93-8.
Ĵĺࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities֒ഥૂ༭৘ࡑΓϋΗȜۜஅછιΗΊΦθࡄ‫ݪ‬໦࿤ࡄ‫ݪ‬ΈσȜί‫ޗ‬਎Ȫ࠳ȫġၑ‫ڠ‬ฎআȁཱ֔ȁੇࢤ‫ޗ‬਎Ȫ࠳ȫġၑ‫ڠ‬ฎআȁհ‫ז‬ȁચဎඅහ‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁ๑നȁഓ࿟੩‫ޗ‬Ȫ࠳ȫȁฎআȪၑ‫ڠ‬ȫȁࢃ൥ȁೄ‫ݛ‬੩‫ޗ‬Ȫ࠳ȫȁฎআȪ࿪‫ڠ‬ȫȁಎఆȁઌఊࡄ‫ݪ‬ඤယ
ˍȅRAPID (Robotics Assisted Pathogen IDentification)ȁ໲໐‫ڠش‬જ͈ȶۜஅછࡄ‫࣭ݪ‬षΥΛΠχȜ·ଔૺίυΈρθȷඤ̤̞̀ͅȂࡔ֦ະྶۜஅછ႕͈޽‫૷ݢ‬౯ȶRAPIDȷ͈ఘଷͬၑࡄ΂ηΛ·Α‫ܖ‬๕ࡄ‫ݪ‬ႀ֖͂‫ވ‬൳́ࢹಃ̱̞̀ͥȃͺΐͺȆͺές΃͈ 8 ύ࣭ͅै̹ͣͦۜ
அછࡄ‫ݶݪ‬ത͂Ⴒࠈ̱Ȃ޽‫ͬݢ‬ါ̳ͥͺ;ΠήτȜ·ΉȜΑ̥͈ͣພࡔఘ࠿੄ͬদ͙̞̀ͥȃˎȅ‫ڎ‬ਅۜஅછ͈ιΗΊΦηΛ·૷౯အș̈́ۜஅછͬιΗΊΦηΛ·ٜଢ଼́૷౯̧̥̠̥́ͥ̓Ȃ༹༷აٜ͞ଢ଼༹ͬࡄ‫̞̱ͥ̀ݪ‬ȃ̹͘૽਷‫ވ‬೒ۜஅછ͈୶࣐ࡄ‫̱̀͂ݪ‬൲໤ဇြদၳ̥ͣພࡔఘͬౝ̱̞॑̀ͥȃˏȅۜஅછอછশ͈ಸඤळ޿஽ٜଢ଼
ಸඤळ޿஽̦အș̈́৖̤̞ۛ̀ͅਹါ̈́࿨‫̦̜̥ͥ̾̾ͤ̈́ͣͅྶ̦̭̞̱̹͂ͥ̀ضͬڬ‬Ȃِș͉‫ئ‬ၓછอછশ͈ಸඤळ޿஽ͬࡄ‫̞̱ͥ̀ݪ‬ȃ͈̠̓͢ͅಸඤळ޿஽̦၄ͦȂ͈̠̓ٝ͢ͅ໘̳͈̥ͥȂΪΠ͂ಸඤळ޿Ȃພࡔ
ఘ͈ 3 ৪‫ͬ߸۾͈ۼ‬ٜଢ଼̱̞̀ͥȃːȅ૧ܰພࡔఘ࠿੄༹͈‫ٳ‬อ̯ͣ̈́ͥࣞ࢘ၚ̥̾࿌္എ̈́૧ܰພࡔఘ࠿੄༹͈‫ٳ‬อͬ࿒ঐ̱ȂພࡔఘΊΦθͬ௩໙༹̳༷ͥ͞γΑΠΊΦθ͈ੰ‫ٳ༹ͬ̓̈́ݲ‬อ̱̞̀ͥȃ
DNA/RNA ಒ੄ষଲయΏȜΉϋ΍ȜΟȜΗٜଢ଼଎ˍȇষଲయΏȜΉϋ΍Ȝͥۜ͢ͅஅછ͈ιΗΊΦηΛ·૷౯଎ˎȇ൚໦࿤ͅ൵ව̯̹ͦষଲయΏȜΉϋ΍Ȝȇ
Roche 454 GS Junior Bench Top System, illumina MiSeq Personal Sequencer, Pacific Biosciences RS System

ĵı

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

଎ˏȇ;ͼσΑۜஅ႕́࠿੄̯̹ͦ୆໤ਅ͈໦ື

଎ːȇRAPID ͈ດ੔ίυΠ΋Ȝσड߃͈యນഎ̈́ა໲
1. Masahata K, Umemoto E, Kayama H, Kotani M, Nakamura S, Kurakawa T, Kikuta J,Gotoh K, Motooka D, Sato S,
Higuchi T, Baba Y, Kurosaki T, Kinoshita M, ShimadaY, Kimura T, Okumura R, Takeda A, Tajima M, Yoshie O,
Fukuzawa M, Kiyono H,Fagarasan S, Iida T, Ishii M, Takeda K. Generation of colonic IgA-secreting cellsin the
caecal patch. Nat Commun. 2014 Apr 10;5:3704.
2. Yonogi S, Matsuda S, Kawai T, Yoda T, Harada T, Kumeda Y, Gotoh K, Hiyoshi H, Nakamura S, Kodama T, Iida
T. BEC, a novel enterotoxin of Clostridium perfringensfound in human clinical isolates from acute gastroenteritis
outbreaks. InfectImmun. 2014 Mar 24.
3. Imai A, Gotoh K, Asano Y, Yamada N, Motooka D, Fukushima M, Kanzaki M, Ohtani T, Sakata Y, Nishi H, Toda
K, Sawa Y, Komuro I, Horii T, Iida T, Nakamura S, Takashima S. Comprehensive metagenomic approach fordetecting causativemicroorganisms in culture-negative infective endocarditis. Int J Cardiol. 2014 Mar 15;172(2):e288-9.
4. Seki M, Gotoh K, Nakamura S, Akeda Y, Yoshii T, Miyaguchi S, Inohara H, Horii T, Oishi K, Iida T, Tomono K.
Fatal sepsis caused by an unusual Klebsiellaspecies that was misidentified by an automated identification system.
J Med Microbiol. 2013 May;62(Pt 5):801-3
5. Monira S, Nakamura S, Gotoh K, Izutsu K, Watanabe H, Alam NH, Nakaya T, Horii T, Ali SI, Iida T, Alam M.
Metagenomic profile of gut microbiota in childrenduring cholera and recovery. Gut Pathog. 2013 Feb 1;5(1):1.
ĵĲࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝ႉ઄ۜஅછ‫ݪࡄڠ‬ΈσȜίˍࡄ‫ݪ‬ΈσȜίඅහ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁȁ૰౓ȁȁმඅහࡄ‫֥ݪ‬ȁ਷֓‫ڠ‬ฎআȁा֔ȁဈٚࡄ‫ݪ‬ඤယ
ȁ൚ࡄ‫ݪ‬ΈσȜί͉́ࡤ‫ۜͅܕݟ‬அ̳ͥ΋υ΢;ͼσΑ͈̠̻Ȃඅͅਹછ‫ܕݟࡤ଻ݢ‬છ࢓߲΋υ΢;ͼσΑ
(SARS ΋υ΢;ͼσΑ :SARS-CoV) ̞̾̀ͅࡄ‫̞࣐ͥ̀̽ͬݪ‬ȃSARS ΋υ΢;ͼσΑ͉ۜஅळ༾ඤ́ 9 ͈̾;ͼσΑဇြ͈ mRNA ଼ࣣ̳ͬͥȃ๱ࢹ௮ΗϋΩ·ৗ (nsp ΗϋΩ·ৗ ) ͉;ͼσΑΊΦθ͈࿩ 2/3 ͬ୸͛Ȃ;ͼσΑ͈ໝୋͅ‫۾‬ဓ̳̥̩ͥ͊ͤ́̈́Ȃळ༾ͅအș̈́‫ͬޣג‬ဓ̢̭̦ͥ͂౶̞ͣͦ̀ͥȃNsp ΗϋΩ·ৗ͉Ȃࣣࠗ 16 ࡢॲ୆̯ͦȂ̷͈ಎ́͜අͅ nsp1 ΗϋΩ·ৗ̞͈ٜ̾̀ͅଢ଼࣐̞ͬ̽̀ͥȃNsp1 ΗϋΩ·ৗ͉ळ༾ৗඤ́ 40S ςδ
ΖȜθࣣ̱͂ࠫ̀਽৽͈ΗϋΩ·ৗ଼ࣣͬඅ։എͅஷ‫̳ͥٺ‬ȃ̯ͣͅȂςδΖȜθ͈ࣣ̱͂ࠫͬٚ̀ mRNA ͈໦ٜͬ௯ૺ̳ͥȃ̭͈ඵ͈̾ैဥͤ͢ͅ਽৽͈ΗϋΩ·ৗ଼ࣣͬ‫ޑ‬ႁͅဲଷ̳ͥȃNsp1 ΗϋΩ·ৗ͉ু૸͈ RNA ΊΦθಎͅంह̳ͥ๱ཱུ࿫ႀ֖ (UTR) ͂අ։എࣣ̳̭ࠫͥ͂́ͅȂ;ͼσΑဇြ RNA ͂਽৽ဇြ RNA ͈ߊ༆࣐̞ͬȂ਽৽͈ RNA ̥͈ͣΗϋΩ·ৗ଼ࣣ͈͙ͬ஖఼എͅဲଷ̳ͥȃ̯ͣͅȂজ̹̻͈ΈσȜί͉́Ȃఈ͈ nsp ΗϋΩ·ৗ̞͈ٜ̾̀ͅଢ଼ͬૺ̭͛ͥ͂́ȂSARS ΋υ΢;ͼσΑ͈ພࡔ଻อ࡛‫ܥ‬੬͈஠ཞͬྶ̥̱̠̱̞̳ͣ͂̀͘͢ͅȃ̹͘Ȃ2013 ාͅಎ൐́อ୆̱̹ MERS ΋υ΢;ͼσᾼ̞ٜ̾̀͜ଢ଼ͬଔ̱ૺ̞̭̳͛̀ͥ͂ͧ́ȃ଎ȇSARS ΋υ΢;ͼσΑ nsp1 ΗϋΩ·ৗͥ͢ͅ shutoff ͈κΟσȃ
Nsp1 ΗϋΩ·ৗ͉Ȃ40S ςδΖȜθࣣ̱͂ࠫ̀ΗϋΩ·ৗ଼ࣣஷ‫ ͂ٺ‬RNA ໦ٜͬ௯ૺ̳ͥȃ༷֚Ȃ;ͼσΑဇြ͈ RNA ͅచ̱͉̀ȂUTR ࣣ̳̭͂ࠫͥ͂́Ȃ਽৽ဇြ͈ RNA ͈͂ߊ༆ͬ
࣐̞Ȃ਽৽ဇြ͈ RNA ͅచ̱̀஖఼എͅဲଷ࣐̠ͬȃड߃͈యນഎ̈́ა໲
1. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specifictranslational shutoff of host mRNA. Tanaka T, Kamitani W, DeDiego ML, Enjuanes L, Matsuura Y. J Virol. 2012
Oct;86(20):11128-37.
2. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Kamitani W, Huang
C, Narayanan K, Lokugamage KG, Makino S. Nat Struct Mol Biol. 2009 Nov;16(11):1134-40.
3. Suppression of host gene expression by nsp1 proteins of group 2 bat coronaviruses. Tohya Y, Narayanan K,
Kamitani W, Huang C, Lokugamage K, Makino S. J Virol. 2009 May;83(10):5282-8.
4. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits
eIF2alpha phosphorylation. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. PLoS Pathog. 2009
Feb;5(2):e1000287.
ĵĳࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝ႉ઄ۜஅછ‫ݪࡄڠ‬ΈσȜίˎࡄ‫ݪ‬ΈσȜίઉ̞͒‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁఱ୞ȁგඃඅහ࣒঍ȁȁ֓‫ڠ‬ฎআȁྶനȁࢨࢤඅහࡄ‫֥ݪ‬ȁ֓‫ڠ‬ฎআȁಅඤȁȁ౭

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ࡄ‫ݪ‬Ȇ‫ڰ‬൲ඤယȁ൚ࡄ‫ݪ‬ΈσȜί͉́Ȃˍȫ෹‫ͼ͞޿ݩ׶‬ϋέσ΀ϋΎ޿Ȫb ߿޿Ȃྫ᧰྄߿޿ͬ‫͚܄‬ȫ൝ͥ͢ͅ૟ਥ଻ळ޿ۜஅછȂळ޿଻෹‫૷͈׶‬౯Ȇພఠٜଢ଼Ȃထཡͅ‫ˎݪࡄ̳ͥ۾‬ȫගτϋ΍‫ۜ޿ݩ‬அછ͈‫ڠע‬Ȇພఠࡄ‫ݪ‬Ȃˏȫ૧ܰχ·Ιϋࢯࡔ͈‫ٳ‬อȂːȫ࿪सఛ଻޿֭ͥ͢ͅඤۜஅచॐۜ͞அછ૷౯͈̹͈͛਀༹‫ٳ‬อ̭͂ͦͬ၌ဥ̱̹ႉ઄ࡄ‫ݪ‬Ȃˑȫພࡔळ޿͈ΗϋΩ·ৗ໦๥ι΃ΣΒθͅ‫ݪࡄ̳ͥ۾‬Ȃ̈́̓ͬಎ૤̱͂̀Ȃ̯ͣͅΗͼ࣭൝͈࣭‫ݪࡄٸ‬৪͂͜‫ވ‬൳̱̀ႉ઄Ȇ࢖ਤ‫מ‬୆ષਹါ̈́အș̈́ۜஅછͅచ̱̀Ȃ‫ڠע‬Ȃႉ઄ࡄ‫ܖ͞ݪ‬யࡄ‫ݪ‬എͺίυȜΙͬߐঀ̷̱͈̀อછȆພఠι΃ΣΒθͬྶ̥̳̭ͣͥ͂́ͅȂহၷȆထཡ༹͈‫ږ‬ၛͬ࿒ঐ̳͓̩ࡄ‫̳̞̭̤̀̽̈́ͬ͘ݪ‬ȃड߃͉࡛࣐́෹
‫޿ݩ׶‬χ·Ιϋ͈྾‫଻ࡔע‬ບ‫ث‬΍υΊȜΠζȜ΃Ȝ͈೹մ͞൐ධͺΐͺ́࿚ఴ̞͂̈́̽̀ͥගτϋ΍‫ۜ޿ݩ‬அͥ͢ͅଡ྄‫׶‬อછι΃ΣΒθȪ଎ȫͬྶ̥̱̞̳ͣ̀͘ͅȃȁ̹͘൚ࡄ‫ݪ‬ΈσȜί͉ఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼Ȇ֓‫ڠ‬໐ͥ͢ͅ෎ఝۜஅછ֓঍ࡄਘ΋ȜΑ‫̤ͤ̀̽ͩࠈͅא׋‬Ȃ̭ͦ́͘ͅఉ̩͈ۜஅછͬ঎̳৹਀֓঍଼͈࣐̞̳֗ͬ̽̀͘ȃ଎ȇΗͼ̤̫ͥͅගτϋ΍‫ۜ޿ݩ‬அછȁอછι΃ΣΒθ (Emerg Infect Dis 2011, J Infect Dis 2014)ड߃͈యນഎ̈́ა໲
1. Hamaguchi S, Hirose T, Matsumoto N, Akeda Y, Irisawa T, Seki M, Hosotsubo H, Yamamoto K, Tasaki O, Oishi K,
Shimazu T, Tomono K. Neutrophil extracellular traps in bronchial aspirates: a quantitative analysis. Eur Respir J.
2014 (In press)
2. Tamura K, Matsubara K, Ishiwada N, Nishi J, Ohnishi H, Suga S, Ihara T, Chang B, Akeda Y, Oishi K; Japanese
IPD Study Group. Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valentpneumococcal conjugate vaccine following invasive pneumococcal disease. Vaccine. 2014 (In press).
3. Takeuchi D, Akeda Y, Nakayama T, Kerdsin A, Sano Y, Kanda T, Hamada S, Dejsirilert S, Oishi K. The
Contribution of Suilysin to the Pathogenesis of Streptococcus suis Meningitis. J Infect Dis. 2014 (In press).
4. Kerdsin A, Dejsirilert S, Sawanpanyalert P, Boonnark A, Noithachang W, Sriyakum D, Simkum S, Chokngam S,
Gottschalk M, Akeda Y, Oishi K. Sepsis and spontaneous bacterial peritonitis in Thailand. Lancet. 2011 Sep 3;378(9794):960.
5. Kerdsin A, Dejsirilert S, Puangpatra P, Sripakdee S, Chumla K, Boonkerd N, Polwichai P, Tanimura S, Takeuchi D,
Nakayama T, Nakamura S, Akeda Y, Gottschalk M, Sawanpanyalert P, Oishi K. Genotypic profile of Streptococcus
suis serotype 2 and clinical features of infection in humans, Thailand. Emerg Infect Dis. 2011 May;17(5):835-42.
ĵĴࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝ۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȪۜஅळ༾୆໤‫ݪࡄڠ‬ΈσȜίȫࡄ‫ݪ‬ΈσȜίඅහ‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁȁȁȁȁȁȁ൥‫ז‬ဇ‫ج‬ঊඅහ੩‫ޗ‬ȁΨͼ΂΍ͼ΀ϋΑฎআȁଫࡔȁȁရඅහ੩‫ޗ‬ȁ֓‫ڠ‬ฎআȁȁȁȁȁȁȁઐఆȁఽఱඅහࡄ‫֥ݪ‬ȁၑ‫ڠ‬ฎআȁ࿳౓ȁٗࢩࡄ‫ݪ‬ඤယȇ൚ࡄ‫ݪ‬ΈσȜί͉́ळ޿ඉள͂਽৽ळ༾͈௖ࡽैဥͬࡄ‫ݪ‬చય̱̞͂̀ͥȃఉ̩͈ळ޿ඉள͉๷ၾ́਽
৽ͅ౿ঘ̈́̓ఱ̧̈́‫ͬޣג‬ဓ̢̞̠ͥ͂අಭͬ঵̾ȃळ޿ඉள̦̭͈̠̈́͢‫ޑ‬ႁ̈́ैဥͬอ‫̧ͥ́ܞ‬ၑဇ͈֚̾͂
๊̱֚̀എͅࣉ̢̞͈͉ͣͦ̀ͥȂఉ̩͈ळ޿ඉள̦๷ၾ́͜਽৽͈‫ܥ‬ෝ໦ঊͅඅ։എͅैဥ̳ͥࣖள̜̞́ͥ͂
̠̭̜͂́ͥȃ̠֚̾͜ਹါ̈́ळ޿ඉள͈අৗ̱͂̀Ȃैဥ̳ͥ‫ܖ‬ৗ࢘ͅၚ̩͢ΗȜΊΞͻϋΈ̳ͥ‫̻̳ͩ̈́ࢹܥ‬ࢦྥ̈́࿶௣‫̾ͬ͜ࢹܥ‬ાࣣ̦ఉ̞̭̦͂‫̬ͥͦͣݷ‬ȃ̷͈࿶௣‫͉ࢹܥ‬Ȃ͂͂͜͜ळ༾̦‫ུܖ‬എȆ୆ၑഎ̞̽̀͜ͅ
྄ͥ࿶௣ࠏ͞΂σ΄Υρ͈‫ܥ‬ෝ̠̩ͬ͘၌ဥ̱̞̀ͥાࣣ̦ఉ̞ȃਲ̽̀ळ޿ඉள͈࿶௣ࠐႹ͈ࡄ‫͉ݪ‬Ȃඉளͥ͢ͅພఠอ࡛‫͈ࢹܥ‬ٜྶ̞̠͂փ݅ͅ‫̢̀ح‬Ȃਲြ౶̞̥̹ͣͦ̀̈́̽਽৽ळ༾͈‫ུܖ‬എ́ਹါ̱̩͙̈́ͬྶ̥ͣͅ
̧́ͥ‫خ‬ෝ଻͜๩̞͛̀ͥȃ̭͈̠̈́͢ࡄ‫ٸ͉ݪ‬ြພࡔ֦ঊ͈૟වͅచ̳ͥ਽৽͈ཡࢄΏΑΞθͬၑٜ̱ଷࢄ̳ͥ
ષ́͜ਹါ̜́ͥȃ൚ࡄ‫ݪ‬ΈσȜί͉Ȃಸ‫ۯ‬ષ๧ळ༾Ψςͺͬࢦྥͅ೒ً̱̀δΜςΤΑ૙ಎඉ̧̭̳ͬ֨ܳδΜςΤΑ૰ࠐඉளໝࣣఘͬࡄ‫ݪ‬చય̱͂̀Ȃུඉள͈ࢹ௮͂‫ܥ‬ෝ͈໦ঊτασ͈ٜଢ଼ͬಎ૤࣐̞̽̀ͥͅȃδΜςΤΑ૰ࠐඉளໝࣣఘȪB ߿ 16S ඉளȫ͈ಸ‫ۯ‬ષ๧Ψςͺ೒ً‫͈ࢹܥ‬κΟσ଎‫࣌ۯ‬௰͈δΜςΤΑ૰ࠐඉளໝࣣఘȪB ߿ 16S ඉளȫ͉ȂHA ଼໦ͤ͢ͅಸ‫ۯ‬ષ๧ळ༾྄ષ͈΄ρ·ΠȜΑ‫܄‬ခൠङࣣ̱ࠫͅȂtranscytosis ͤ͢ͅ‫ܖ‬ೲ྄௰͒֊࣐̳ͥȃ̷͈ࢃȂ‫ܖ‬ೲ྄௰̥ͣໝࣣఘಎ͈ HA ͉ E-cadherin ࣣ̱͂ࠫȂळ༾‫ۼ‬Ψςͺͬ෫ٟ̳ͥȃུैဥ̯ͤͣ͢ͅͅఉ̩͈ඉளໝࣣఘ̦ळ༾‫̥ͣࠤۼ‬ఘඤͅ૟ව̳ͥ͂ࣉ̢ͣͦͥȃड߃͈యນഎ̈́ა໲
1. Amatsu S1, Sugawara Y1, Matsumura T, Yutani M, Kitadokoro K, and Fujinaga Y. Crystal structure of botulinum
whole hemagglutinin reveals a huge triskelion-shaped molecular complex. J Biol Chem. 2013; 288; 49: 35617-25.
1These authors contributed equally.
2. Fujinaga Y, Yo Sugawara, Takuhiro Matsumura. Uptake of Boulinum Neurotoxin in the Intestine. Curr Top
Microbiol Immunol. 2013; 364: 45-59 [ 総説 ]3. Sugawara Y, Fujinaga Y. The botulinum toxin complex meets E-cadherin on the way to its destination. Cell Adh
Migr. 2011; 5(1): 34-36. [ 総説 ]4. Sugawara Y, Matsumura T, Takegahara Y, Jin Y, Tsukasaki Y, Takeichi M, Fujinaga Y. Botulinum HA disrupts theintercellular epithelial barrier by directly binding E-cadherin. J Cell Biol. 2010; 189 (4), 691-700
5. Jin Y1, Takegahara Y1, Sugawara Y, Matsumura T, Fujinaga Y. Disruption of the epithelial barrier by botulinum
hemagglutinin (HA) proteins - Differences in cell tropism and the mechanism of action between HA proteins oftypes A or B, and HA proteins of type C. Microbiology. 2009; 155(Pt 1): 35-45. 1These authors are contributed
equally.
ĵĵࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟࣞພࡔ଻ۜஅછࡄ‫ݪ‬໐࿝;ͼσΑࡄ‫ݪ‬ΈσȜίࡄ‫ݪ‬ΈσȜίඅහ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ૩നȁ‫ם‬঄

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ȁίρΑङ RNA ;ͼσΑ͈ఉ̩͉Ȃۜஅࢃ‫ًܢ‬೾ͅ਽৽ळ༾ඤ྄ࠏͬఱܰ࿅ͅठࢹಃ̱Ȃໝୋ΂σ΄Υρ͂ࡤ͊ͦͥ૧ܰ΂σ΄Υρ̩ͬ̾ͥȃ̷͈ࢹ௮ఘ͉઀༾ఘ (ER) ߃ཌྷͅࠁ଼̯ͦȂ̷̭́;ͼσΑΊΦθ͈ໝୋ͂ၥঊࠁ
଼̦࣐̞ͩͦ̀ͥȃ̭͈ໝୋໝࣣఘࠁ଼͉Ȃအș̈́ळ༾ඤΑΠτΑ؊൞̥͈ͣٝ๰ͬ‫خ‬ෝ̱ͅȂಿ‫ু̹ͤͩͅۼܢ‬૸͈֒ഥঊͬໝୋ̵̯̹ͥ͛ͅຈଌ̈́ࢹ௮໤̜́ͥ͂ࣉ̢̞ͣͦ̀ͥȃ൚ࡄ‫ݪ‬ΈσȜί͉Ȃ;ͼσΑ̦ळ༾ৗͅ૧ܰ΂σ΄Υρͬࠁ଼̱ळ༾ඤͅȶ௏૙̠ȷ໦ঊ‫̭̳̥ͬ͂ͥͣͅྶͬࢹܥ‬࿒എ̱͂̀ࡄ‫ͬݪ‬ജ‫̞̱ͥ̀ٳ‬ȃड߃Ȃِș͉ C ߿۴‫ͼ;׶‬σΑ (HCV) ‫͍ݞ‬έρΫ;ͼσΑۜஅळ༾ඤ͈;ͼσΑໝୋໝࣣఘͬୈୋ̱೰ၾίυΞ΂η·Αٜଢ଼࣐̞ͬȂۜஅ̽̀͢ͅඅ։എͅς·σȜΠ̯̩ͦ̀ͥ਽৽֦ঊ߲ͬఉତ൳೰̱̹ȃِș͉Ȃ̭ͦͣ਽৽֦ঊ߲̦Ȃ͈̠̓͢ͅ;ͼσΑໝୋໝࣣఘࠁ଼͈‫ٳ‬ই͂֋঵ͅ‫ܙ‬ဓ̱̞̥̀ͥྶ̥̱ͣͅȂ૧̹̈́਽৽—ພࡔఘ͈௖ࡽջం‫۾‬߸ͬ࠿̳̭॑ͥ͂̽̀͢ͅȂ;ͼσΑ͂਽৽ळ༾̦‫ވ‬୆̳̭ͥ͂ͬ‫خ‬ෝ̵̯ͥͅ໦ঊ‫͈ࢹܥ‬ٜྶͬ࿒ঐ̱̞̀ͥȃ̹͘Ȃໝୋໝࣣఘ̷͈͈͈͜ࠁ଼‫̴͙͈ͣ̈́ࢹܥ‬Ȃ;ͼσΑၥঊࠁ଼྄̤̫ͥͅ൲ఠ‫ࢹܥ‬Ȃ;ͼσΑۜஅ̽̀͢ͅ
ည൵̯ͦͥ਽৽΂ȜΠέ͹ΐȜ‫͈ࢹܥ‬୆ၑ‫ڠ‬എ̈́փ̞ٜ݅̾̀͜ͅଢ଼࣐̞ͬȂඳহ଻ྌ͉૧‫ޟ‬Ȇठ‫ͼ;ޟ‬σΑ଻৖͈ۛଷࢄ༹‫ٳ‬อͅࠒ̦ͥ໦ঊ‫ܖ‬๕͈‫ږ‬ၛͬ࿒ঐ̱̞̀ͥȃ଎ : ;ͼσΑໝୋໝࣣఘȁέρΫ;ͼσΑۜஅ Vero ळ༾͈ࠖ࢕ࡐ๷‫ޢ‬௨ (A-D) ͂ഩঊࡐ๷‫ޢ‬௨ (E,F)ȃ;ͼσΑۜஅ 24 শ‫ࢃۼ‬ͅळ༾ͬࡥ೰̱๱ࢹ௮౩ฒৗࢯఘ (anti-NS2BȂζΔϋΘ )Ȃࢹ௮౩ฒৗࢯఘ (anti-EȂΈςȜϋ ) ࢯఘ̤͍͢ DAPI( Ώͺϋ ) ́அ૗̱̹ȃۜஅळ༾͉́‫̷͈͊ͅړ‬ೄࠂ 5-10mm ͈୆ఘ྄́ս̹ͦ͘;ͼσΑࢯࡔု଻͈ࢹ௮ఘ̦࠿੄̯ͦͥȃໝୋໝࣣఘ͈
ਔ‫׻‬໐͉ͅ઀༾ఘအࢹ௮̦̜ͤȂඤ໐ͅ;ͼσΑအၥঊ͈ಇୟ̦۷ख़̯̹ͦȃड߃͈యນഎ̈́ა໲
1. Fujita, N.†, Morita, E. †, Itoh, T., Tanaka, A., Nakaoka, M., Osada, Y., Umemoto, T., Saitoh, T., Nakatogawa, H.,
Kobayashi, S., Haraguchi, T., Guan, J.L., Iwai, K., Tokunaga, F., Saito, K., Ishibashi, K., Akira, S., Fukuda, M.,
Noda, T., Yoshimori, T. Recruitment of the autophagic machinery to endosomes during infection is mediated byubiquitin. J Cell Biol. 2013 †These authors contributed equally
2. Morita, E., Arii J, Christensen D, Votteler J, Sundquist WI. Attenuated protein expression vectors for use in siRNA
rescue experiments. Biotechniques. 2012 Aug;0(0):1-5.
3. Morita, E., Sandrin, V., McCullough, J., Katsuyama, A., Hamilton, IB., Sundquist, WI. ESCRT-III protein
requirements for HIV-1 budding. Cell Host Microbe. 2011, 3:235-42.
4. Morita, E., Colf, LA., Karren, MA., Sandrin, V., Rodesch, CK., Sundquist, WI. Human 5. ESCRT-III and VPS4
proteins are required for centrosome and spindle maintenance. Proc Natl Acad Sci U S A. 2010 107(29):12889-94.
5. Bajorek, M. †, Morita, E. †, Skalicky, JJ, Morham, SG., Babst, M., Sundquist, WI. Biochemical analyses of human
IST1 and its function in cytokinesis. Mol Biol Cell. 2009, 20(5):1360-73. †These authors contributed equally.
ĵĶࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟۜஅଷࢄࡄ‫ݪ‬໐࿝ΊΦθພࡔळ޿‫ݪࡄڠ‬ΈσȜίࡄ‫ݪ‬ΈσȜίඅහ‫ޗ‬਎ȁȁ֓‫ڠ‬ฎআȁ๑നȁഓ࿟අහ੩‫ޗ‬ȁȁ࿪‫ڠ‬ฎআȁઐനȁਹܵඅහࡄ‫֥ݪ‬ȁńũŰůŤũŢůŰŬġŕũŦŦŵũŢŬŢŦŸĭġőũįŅ

ȁ൚ࡄ‫ݪ‬ΈσȜί͉́ȂΪΠͅພ‫̳̭ܳͬܨ‬ळ޿̞̾̀ΊΦθഎͺίυȜΙͤ͢ͅࡄ‫̞࣐ͥ̀̽ͬݪ‬ȃˍȅພࡔळ޿͈ۜஅȆอພι΃ΣΒθ͈ࡄ‫ݪ‬ȁພࡔळ޿Ȃඅͅজ̹̻̦஠ΊΦθ෻Ⴅͬࠨ೰̱̹ಸ‫׶‬Ϋής΂͈ۜஅȆอພι΃ΣΒθ͈஠ཞͬ໦ঊτασٜ́ྶ̳ͥȃ̷͈षȂພࡔఘ͈̜ͥ
අ೰͈ພࡔ֦ঊȪ̢̹͂͊ඉளȫ͈ٜଢ̴଼̺̫͂̓ͣ͘ͅȂζͼ·υͺτͼٜଢ଼͞ͼϋέ΁ζΞͻ·Αͬߐঀ̱ȂΊΦθಎ͈஠֒ഥঊ͈൲̧ͬ
ᅛ១̳̭ͥ͂ͤ͢ͅȂພࡔఘ̦਽৽͂௖ࡽैဥ̳ͥष͈ພࡔఘ͈֒ഥঊ
อ࡛͈Θͼ΢ηΒθͬྶ̥̱̞̩ͣ̀ͅȃ̭͈̠̈́͢ͺίυȜΙͤ͢ͅȂࡢș͈֒ഥঊȆ౩ฒ̺̫̭̺͈͉̞ͩͥ́̈́ͅȂ஠ΊΦθૂ༭ͬ‫ڰ‬ဥ̱̹૧̱̞ພࡔळ޿‫ڠ‬Ȇ୆໤‫ͬڠ‬࿒ঐ̳ȃ̹͘Ȃං଼ͣͦͥ‫̹̞̿ܖͅض‬૧ܰ̈́হၷ༹͞ထཡ༹Ȃଇ௸૷౯༹͞۰օ࠿औ༹͈‫ٳ‬อ͜ુͅণ࿤ͅව
̞̩ͦ̀ȃ

଎ 1. ພࡔळ޿͈ΊΦθٜଢ଼ . ಸ‫׶‬Ϋής΂͈஠ΊΦθ෻Ⴅͬࠨ೰̱̹ȃಸ‫׶‬Ϋής΂͉̲̳ͬ͛͂ͥΫής΂௺ळ޿͈ΊΦθ͉ˎࡢ͈۪ેஅ૗ఘ̭ͤ̈́ͥ͂ͬ͢ྶ̥̱̹ͣͅȃˎȅ΀ζȜΐϋΈۜஅછ͈੄࡛ι΃ΣΒθ͈ࡄ‫ݪ‬ȁ࡛हȂۜஅછͅ‫̱̀۾‬ଲ‫ٮ‬എͅಕ࿒̯̞ͦ̀ͥ࿚ఴ͈͉͌͂̾΀ζȜΐϋΈۜஅછ͈੄࡛̜́ͥȃ૧̹̈́ۜஅછ
̦੄࡛̱̩̀ͥࡔ֦͉ͅ২ٛഎȆࠐफഎ̈́ါ֦͂͂͜ͅȂພࡔఘ̷͈͈͈͜་‫̢ͥͦͣࣉ̦ا‬ȃ΀ζȜΐϋΈۜஅછ͈੄࡛ι΃ΣΒθ̞̾̀ͅ໦ঊτασٜ́ྶ̯̹ͦ႕͉ພࡔळ޿̤̞͉̺͕̩̀͂ͭ̓̈́͘ͅȂ̭ͦͬྶ̥ͣͅ
̱̞̩̭͉̀͂ࣽࢃ͈૧ܰ̈́΀ζȜΐϋΈۜஅછ͈੄࡛ͅ๵̢̹ͥ͛ͅਹါ̜́ͥȃজ̹̻͉΀ζȜΐϋΈۜஅછ͈੄࡛ι΃ΣΒθٜଢ଼͈౤੣̱͂̀Ȃ߃ාଲ‫ٮ‬എτασ́ၠ̵࣐͙̞ͬ̀ͥಸ‫׶‬Ϋής΂͈૧߿ၠ࣐‫̦ڼ‬ਲြ͈޿‫̥͈̠֑̠͈ͬ̓͂͢ͅڼ‬ΊΦθૂ༭ٜͬ͂͜ͅଢ଼࣐̞ͬ̽̀ͥȃˏȅ୆̧໤̱͈͂̀ພࡔळ޿
ȁພࡔळ޿͈ࡄ‫͉̞̤̀ͅݪ‬Ȃळ޿̦ພ‫̠̞̳̭͂ܳͬܨ‬௰࿂̦අͅಕ
࿒̯ͦͥȃ̱̥̱̦͈̈́ͣ͌͂̾୆̧໤̱͂̀ࡉ̹ાࣣȂ਽৽͈͂௖ࡽ
ैဥ̞͈̾̀ͅ౶ࡉ͞ΊΦθ̞͈̾̀ͅૂ༭̦ࣞഽͅಇୟ̯̞ͦ̀ͥ໦Ȃພࡔळ޿͉ྛႁഎ̈́ࡄ‫ऺݪ‬ၳ̢̜̞́ͥ͂ͥȃ̢̹͂͊Ȃಸ‫׶‬Ϋής΂͉ III ߿໦๥௡౾ͬ̾͜ȃIII ߿໦๥௡౾͉ळ޿̦૯‫ړ‬ळ༾͂ྟ୪ͅ௖ࡽै
ဥ̳̹͈ͬͥ͛ळ޿௰͈௡౾̜́ͥȃ૽ఘ͉ಸ‫׶‬Ϋής΂ུ͈ြ͈ୁ௳
۪‫̥̞͉ͣ̈́́ޏ‬Ȃಸ‫׶‬Ϋής΂ུ͉ြ͈ୁ௳۪‫ޏ‬Ȫ٬ဢȫ́ III ߿໦๥௡౾ͬঀ̥͈̽̀̈́ͭͣ૯‫ړ‬୆໤͂ྟ୪̈́௖ࡽैဥ̱̞̭̦ͬ̀ͥ͂ထ
ே̯ͦͥȃ̭͈̠͢ͅȂ̭̤ͦ́͘͜ͅພࡔ଻ࡄ‫͈ݪ‬۷ത̥ͣಇୟ̯ͦ
̧̹̀౶ࡉͬঝ࢛ͅȂພࡔळ޿͈ুட۪‫̫̤ͥͅޏ‬୆‫̱̥ͣͅྶ۪ͬڰ‬̧̞̹̞̀ȃ

଎ˎȅDNA ζͼ·υͺτͼͥ͢ͅພࡔळ޿͈
֒ഥঊτΩȜΠς͈ٜଢ଼ȃːȅΊΦθૂ༭ͅ‫̩̿ܖ‬ळ޿ۜஅછ͈ଇ௸૷౯༹͈‫ٳ‬อȁळ޿ۜஅછ͈ଇ௸૷౯༹͈‫ٳ‬อͬ࿒ঐ̱̹ఱܰ࿅‫ܖ؂‬෻Ⴅٜଢ଼ͥ͢ͅພࡔळ޿͈ଇ௸൳೰ΏΑΞθ͈ࢹಃ࣐ͬ̽
̞̀ͥȃड߃͈యນഎ̈́ა໲
1. Okada R, Zhou X, Hiyoshi H, Matsuda S, Chen X, Akeda Y, Kashimoto T, Davis BM, Iida T, Waldor MK, Kodama
T. The Vibrio parahaemolyticus effector VopC mediates Cdc42-dependent invasion of cultured cells but is not
required for pathogenicity in an animal model of infection. Cell Microbiol. 2014 Jun;16(6):938-47.
2. Matsuda S, Okada N, Kodama T, Honda T, Iida T. A cytotoxic type III secretion effector of Vibrio parahaemolyticus
targets vacuolar H+-ATPase subunit c and ruptures host cell lysosomes. PLoS Pathog. 2012 Jul 19;8(7):e1002803.
3. Hiyoshi H, Kodama T, Saito K, Gotoh K, Matsuda S, Akeda Y, Honda T, Iida T. VopV, an F-actin-binding type III
secretion effector, is required for Vibrio parahaemolyticus-induced enterotoxicity. Cell Host Microbe. 2011 Oct
20;10(4):401-9.
4. Monira S, Nakamura S, Gotoh K, Izutsu K, Watanabe H, Alam NH, Endtz HP, Cravioto A, Ali SI, Nakaya T, Horii
T, Iida T, Alam M. Gut microbiota of healthy and malnourished children in Bangladesh. Front Microbiol. 2011 Nov
21;2:228.
5. Gotoh K, Kodama T, Hiyoshi H, Izutsu K, Park KS, Dryselius R, Akeda Y, Honda T, Iida T. Bile acid-induced
virulence gene expression of Vibrio parahaemolyticus reveals a novel therapeutic potential for bile acid sequestrants.
PLoS One. 2010 Oct 13;5(10):e13365.
ĵķࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟۜஅଷࢄࡄ‫ݪ‬໐࿝
ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

;ͼσΑໝୋࡄ‫ݪ‬ΈσȜίࡄ‫ݪ‬ΈσȜίඅහ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁȁ઀ႅȁȁ࣠අහ࣒঍ȁȁ਷֓‫ڠ‬ฎআȁ߄֔ȁဈఊࡄ‫ݪ‬ඤယ
ˍȫਆនဣٜ଻τ΂;ͼσΑͬဥ̞̹‫܈‬হၷͅ‫ݪࡄ̳ͥ۾‬ȁሶ඿႒΂σΕτ΂;ͼσΑȪMRVȫ͉Ȃ10 ໦୯͈ 2 ུङ RNAͬΊΦθ̱͂̀঵̻Ȃτ΂;ͼσΑ‫͈ش‬κΟσ;ͼσΑ̱͂̀ࡄ‫̳̞̯̀ͦ͘ݪ‬ȃMRV ͉ Ras ࠐႹ̦‫̹̱ا଻ڰ‬ਆនळ༾́஖఼
എͅ௩૓̱Ȃਆនळ༾ͬဣٜ̳̭̥ͥ͂ͣȂ൮ᴢ໐‫܈‬Ȃఱಸ‫܈‬Ȃ඿‫܈‬Ȃᦙ௫‫܈‬൝͈হၷͬ࿒എ̱̹͂Ȃਆនဣٜ଻;ͼσΑ̱͂̀ࡄ‫̳̞́ͭ͘ૺ̦ݪ‬ȃMRV ͈‫܈‬হၷࡄ‫͉ݪ‬Ȃ̭ͦ́͘࿤୆߿͈
MRV ͬဥ̧̞࣐̱̹̦̀ͩͦ̀͘Ȃफ़ਆន࢘‫͈ض‬۷ത̥ͣ٨ၻ
̦བ̞̳ͦ̀͘͘ȃজో͉ MRV ́؊ဥ̦ࣾඳ̜̹́̽;ͼσΑ֒ഥঊ͈٨་ܿ੅ȪςΨȜΑΐͿΥΞͻ·Αࠏȫͬ൵වȆߐঀ̳̭ͥ͂́Ȃ֒ഥঊ٨་ MRV ͬै੄̱Ȃͤ͢հ஠́হၷ࢘‫͈ࣞض‬̞ਆនဣٜ଻ MRV ͈‫ٳ‬อࡄ‫̳̞࣐̀̽ͬ͘ݪ‬ȃ଎ˍȁτ΂;ͼσᾼ̤̫ͥςΨȜΑΐͿΥΞͻ·Αࠏˎȫࣞພࡔ଻τ΂;ͼσᾼ‫ݪࡄ̳ͥ۾‬ȁ΋;κς͉ SARS ΋υ΢;ͼσΑȂΣΩ;ͼσΑȂ΀δρ;ͼσΑȂ‫ࡂޚ‬ພ;ͼσΑ̈́̓ఉ̩͈౿ঘഎۜஅͬ
̧̭̳֨ܳ૽਷‫ވ‬೒ۜஅછ͈τΔσδͺ̱͂̀ಕ࿒̯̞̳ͦ̀͘ȃ1968 ාͅ΋;κς̥ͣ໦ၗ̯̹ͦ Pteropine
orthoreovirusȪPRVȫ̞͉̾̀ͅȂ̭ͦ́͘ΪΠ͞൲໤͈৖͈ۛ͂‫۾‬Ⴒ଻͉༭̵̯̞̱̹̦࣬ͦ̀ͭ́͘Ȃ2007 ාȂ൐ධͺΐͺ́ਹඈ̈́ࡤ‫ܕݟ‬છેͬ೮̱̹ۛ৪̤̞̀ͅȂPRV ۜஅȪMelaka ‫ڼ‬ȫ̦੝͛̀༭̯̱̹࣬ͦ͘ȃ̭͈༭࣬ոࣛȂఈ͈ͺΐͺ੨࣭̤̞̀͜ͅȂ൳အ͈ۜஅ৪̦௖ষ̞́༭̯࣬ͦȂ඾ུ࣭ඤ̤̞͉̀ͅȂজో͈ΈσȜί̦Ȃ൐ධͺΐͺ̥ͣ‫ࢃ࣭ܦ‬Ȃਹඈ̈́‫ܕݟࡤ଻ݢ‬છેͬ೮̱̹ۛ৪̥ͣȂPRV ͈໦ၗ࣐̞̱̹ͬ͘ȃ̭͈ͦͣ༭͉࣬Ȃ
΋;κς࡙̳ͬܳ͂ͥτ΂;ͼσΑ̦ਅ͈༃ͬ‫̢ק‬ȂΪΠۜͅஅഥ෥̱̹ࠫ‫͂ض‬ଔख़̯ͦȂ૧‫ۜޟ‬அછ̱͈͂̀
PRV ͈ۜஅଷࢄ‫ܖ‬๕͈‫ږ‬ၛ̦བ̞̳ͦ̀͘͘ȃজో͉ȂPRV ̤̫ͥͅထཡȆহၷ༹͈‫ږ‬ၛͬ࿒ঐ̱ȂPRV ͈ໝୋ‫ࢹܥ‬Ȃພఠอ࡛‫ܥ‬੬͈ٜྶ࣐̞̳ͬ̽̀͘ȃड߃͈యນഎ̈́ა໲
1. A plasmid-based reverse genetics system for mammalian orthoreoviruses driven by a plasmid-encoded T7 RNApolymerase. Komoto S, Kawagishi T, Kobayashi T, Ikizler M, Iskarpatyoti J, Dermody TS, Taniguchi K. J Virol
Methods. 2014 Feb;196:36-9.
 1RQVWUXFWXUDOSURWHLQıVPHGLDWHVUHRYLUXVLQGXFHGFHOOF\FOHDUUHVWDQGDSRSWRVLV%RHKPH.:+DPPHU.
Tollefson WC, Konopka-Anstadt JL, Kobayashi T, Dermody TS. J Virol. 2013 Dec;87(23):12967-79.
3. The reovirus sigma1s protein is a determinant of hematogenous but not neural virus dissemination in mice. Boehme
KW, Frierson JM, Konopka JL, Kobayashi T, Dermody TS. J Virol. 2011 Nov;85(22):11781-90.
4. An improved reverse genetics system for mammalian orthoreoviruses. Kobayashi T, Ooms LS, Ikizler M, Chappell
JD, Dermody TS. Virology. 2010 Mar 15;398(2):194-200.
5. Identification of functional domains in reovirus replication proteins muNS and mu2. Kobayashi T, Ooms LS,
Chappell JD, Dermody TS. J Virol. 2009 Apr;83(7):2892-906
ĵĸࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟۜஅଷࢄࡄ‫ݪ‬໐࿝ۜஅછ‫ڠ‬Ȇ྾‫ڠע‬ဏࣣࡄ‫ݪ‬ΈσȜίࡄ‫ݪ‬ΈσȜί੎‫ޗ‬਎ġ
අහ࣒঍ġඅහࡄ‫֥ݪ‬ġඅහࡄ‫֥ݪ‬ġฎআ ĩ ၑ‫ ڠ‬Īȁ‫֔ז‬ȁࢤਏȁȁฎআ ĩ ၑ‫ ڠ‬Īȁ‫ཱݛ‬ȁ౺ঊłůťųŦŦġŎŢųŪŦġŉŶţţŦųĭġőũįŅ
řŶŢůġŕũŢůũġŃŶŪĭġőũįŅ

අහࡄ‫֥ݪ‬ȁఱாՏܲঊ
අහࡄ‫֥ݪ‬ȁ५നȁٗయȁພࡔ޿̦ພ‫̧͉̹̳̭͛ܳ֨ͬͅܨ‬Ȃळ޿̥ͣ਽৽ळ༾͒ಕව̯ͦͥພࡔ֦ঊ߲͂Ȃ̷͈̹͈͛࿶௣ΏΑΞθ̦ಎ૤എ̈́࿨‫̳̱̹͘ضͬڬ‬ȃজో͉ΪΠͅ෹‫̧̳̭ܳ֨ͬ׶‬τΐ΂Υρ̞̠͂ພࡔ޿ͬκΟσ̱͂̀Ȃ࿶௣ΏΑΞθ̜́ͥ IV ߿໦๥௡౾ (T4SS) ͂Ȃພࡔ֦ঊ̜́ͥ΀έͿ·ΗȜΗϋΩ·ৗ͈൱̧ͬ໦ঊȆࡔঊτασ́ྶ̥ͣͅ
̱̠̱̞̳͂̀͘͢ȃȪˍȫIV ߿໦๥௡౾͈ࢹ௮͂‫ܥ‬ෝȁτΐ΂Υρ͉ IV ߿໦๥௡౾ͬ၌ဥ̱̀Ȃτΐ΂Υρ஠ΗϋΩ·ৗ͈֚‫̠̞͂৻ڬ‬ཛྷఱ̈́ତ͈΀έͿ·ΗȜΗϋΩ·ৗͬ਽৽ळ༾ৗ
ಎ͒࿶௣̱̞̳̀͘ȃພࡔ଻ఱಸ޿͞΍σκΥρ̦̈́̓঵̾ III ߿໦๥௡౾͉͂։̈́ͤȂIV ߿໦๥௡౾͈৘ఘ͞໦๥ι΃ΣΒθ͉͕͂ͭ̓ྶ̵̥̯̞ͣͦ̀ͭ͘ͅȃِș͉ IV ߿໦๥͈໦ঊ‫͈ࢹܥ‬ٜྶͬ࿒ঐ̱̀Ȃ໦๥௡౾͈‫ܥ‬ෝȆࢹ௮ٜଢ଼ͬ೒̷̲͈̀৘ఘͅทͤ

଎ 1 DotD ͉ఉအ̈́ळ޿໦๥ࠏͅ༗ం̯ͦͥ
ࢹ௮κΙȜέͬ঵̾ȂT4SS ‫྄ٸ‬΋ͺΗϋΩ·ৗ̜̹̞́ͥ͂ࣉ̢̞̳̀͘ȃȪˎȫ΀έͿ·ΗȜ͈‫ܥ‬ෝ̷͈͂ଷࢄ
ȁ΀έͿ·ΗȜΗϋΩ·ৗ͈‫ܥ‬ෝͬ౶̭͉ͥ͂Ȃळ޿ͥ͢ͅພࡔ଻
͈໦ঊ‫ܖ‬๕ͬၑٜ̳̹ͥ͛ͅຈଌ̳́ȃজో͉ఈͅ୶ߐ̫̀τΐ΂Υρ͉́ड੝͈΀έͿ·ΗȜ RalF ͬ൳೰̱̹ఈȂड߃͉́ E3 ξΫ΅Ιϋς΄ȜΔ̱͈͂̀‫ܥ‬ෝͬ঵̾ LubX ̦Ȃ৘͉༆͈΀έͿ·ΗȜ͈໅͈শ‫ۼ‬എଷࢄͬংͥȂ̭ͦ́͘ͅ႕͙̞ͬ̈́Ηͼί͈΀έͿ·ΗȜΗϋΩ·ৗȂιΗ΀έͿ·ΗȜ̧̜̭̞̳́ͥ͂ͬ̾͂͛̀͘ȃ଎ 2ȁ΀έͿ·ΗȜͬଷࢄ̳ͥιΗ
΀έͿ·ΗȜ LubX

Ȫˏȫτΐ΂Υρ͂ুட਽৽̜́ͥুဇ୆‫଻ڰ‬ͺιȜΨȁτΐ΂Υρ͈අಭ͈͉͌͂̾Ȃুட਽৽ͺιȜΨ͈͂௖ࡽैဥ͈Ⴄঃ͈̥̈́́ȂΪΠͅచ̳ͥພࡔ଻ͬ‫ڕ‬ං̧̱̹̭̜̳̀͂ͤ͘ͅȃ̭͈̠̈́͢ພࡔ޿౪୆͈ι΃ΣΒθͬྶ̥̳̹ͣͥ͛ͅȂτΐ΂Υρ͂ুட਽৽͈௖ࡽैဥ
͈ٜଢ଼ͬૺ̞̳͛̀͘ȃड߃͈యນഎ̈́ა໲
1. Hubber A, Kubori T, *Nagai H. Modulation of the ubiquitination machinery by Legionella. Curr Top Microbiol
Immunol. 2014:376, 227-247
2. Hori JI, Pereira MS, Roy CR, *Nagai H, Zamboni DS. Identification and functional characterization of K(+)
transporters encoded by Legionella pneumophila kup genes. Cell Microbiol. 2013: 15, 2006-2019
3. Nagai H and Kubori T. Dot/Icm type IVB secretion systems of Legionella and other gram-negative bacteria. Front
Microbiol.,2011: 2,136.
4. Kubori T, Shinzawa N, Kanuka H, Nagai H. Legionella metaeffector exploits host proteasome to temporally regulate
cognate effector. PLoS Pathog. 2010;6(12),e1001216.
5. Nakano N, Kubori T, Kinoshita M, Imada K, Nagai H. Crystal structure of Legionella DotD: insights into therelationship between type IVB and type II/III secretion systems. PLoS Pathog. 2010;6(10),e1001129.
ĵĹࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜȟພࡔ๷୆໤঩࡙৒ġພࡔ๷୆໤঩࡙৒ġࡄ‫ݪ‬ΈσȜίඅහ‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁ๑നȁഓ࿟࣒঍ġ֓‫ڠ‬ฎআȁ঱ޮȁා؇

ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ȁພࡔळ޿͈ਓਬȆ༗ంȆ೹‫̞࣐ͥ̀̽ͬރ‬ȃུࡄ‫ݪ‬ਫ਼̤̫ͥͅ޿‫ڼ‬༗ంমު͈Ⴄঃ͉ࡣ̩Ȃ1934 ා๷ࡄ୭ၛ͂൳শͅ
ळ޿ࠬୄ‫ڠ‬໐࿝ඤ́ΑΗȜΠ̱Ȃ࿩ 40 ාࢃͅ໲໐જ̥ͣࡄ‫ݪ‬ਫ਼້౾ঔ୭̱͂̀෇‫ͬخ‬਋̫̹ȃ2002 ා̥͉ͣ໲‫ش‬જ͈΢Ώο΢σΨͼ΂ςΕȜΑίυΐͿ·Πͅ४ْ̱Ȃ2005 ාȂۜஅછ࣭षࡄ‫ݪ‬ΓϋΗȜඤ͈ພࡔ๷୆໤঩࡙৒̱͂̀պ౾̫̹̿ͣͦȃۜஅછ༹͈٨ୃฺ̽̀ͅႉ઄໦ၗ‫ͬڼ‬༗ం̱̞࣭̈́ඤ͈ঔ୭̦௩̢̹̭̥͂̈́̓ͣȂ̷͈਋̫०͂̈́ͥພࡔ๷୆໤༗ంঔ
୭̱͂̀ಎ‫ړ‬എ̈́‫ܥ‬ෝͬ౜̠̭̦͂‫ܢ‬ఞ̯̞ͦ̀ͥȃႤঃഎ̈́ࠐ֌̥̭ͣͦ́͘ಸ‫ۜۯ‬அࡔ֦޿ͬಎ૤ͅ޿‫͈ڼ‬ਓਬȆ༗ం̧࣐̹̦ͬ̽̀Ȃࣽࢃ͉ಸ‫ۜۯ‬அ๷୆໤ͅࡠ̴ͣਹါ̈́ພࡔळ޿ͬ࿌္̱̞̩༷̀ૻ̜́ͥȃ̹֓͘ၷ࡛ા̥͈ͣ௖౴
͞ջှͅ؊̲̀ࡔ֦ພࡔఘ͈൳೰͞߿༆ٜଢ଼࣐̞࡛̈́̓͜ા͒έͻȜΡΨΛ·̳ͥ͂͂͜ͅȂ޿‫ڼ‬༗ం༹̞͈̾̀ͅૂ༭೹
‫̞࣐ͥ̀̽ͬރ‬ȃ೹‫ ͉ڼ޿ރ‬HPȪhttp://rceid.biken.osaka-u.ac.jpȫ́࢖‫̞̯ͥ̀ͦٳ‬ȃĵĺࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ‫ڠ‬Ȇ྾‫ڠע‬ဏࣣίυΈρθଔૺ৒ۜஅછ‫ڠ‬Ȇ྾‫ڠע‬ဏࣣίυΈρθଔૺ৒ࡄ‫ݪ‬ΈσȜίࡄ‫ݪ‬ଔૺΈσȜίȁ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁఆષȁၻঊ‫֗ޗ‬ଔૺΈσȜίȁ੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ൥֔ȁ༠ࣞȁ൚ଔૺ৒͉́Ȃ๷୆໤ພࡄ‫ݪ‬ਫ਼͂྾‫ڠע‬έυϋΞͻͺΓϋΗȜ̷̸̞̠͂ͦͦۜஅછ‫ڠ‬Ȃ྾‫͈ڠע‬ΠΛίτασ͈ࡄ‫ݪ‬ਫ਼̦໼ၛ̳ͥခ၌۪̈́‫ͬޏ‬डఱࡠͅ୆̥̱Ȃۜஅછ‫ڠ‬Ȃ྾‫͈ڠע‬ဏࣣࡄ‫͈ݪ‬௯ૺॐْܑͬȂ̷ͦͬ৘க̳ͥȃࡄ‫ݪ‬ଔૺުྩȇࡄ‫ݪ‬ଔૺΈσȜί͉́Ȃˍȅུࡄ‫ݪ‬ਫ਼͈৽टྀ́ා 9 ࠮ͅ‫ٳ‬ट̱̞̜̲̱̀ͥͩۜ͘அછȆ྾‫ע‬έ΁Ȝρθ ( ࣭ष‫ڠ‬ٛ ) ْܑ͈Ȃ‫א׋‬ȃˎȅུࡄ‫ݪ‬ਫ਼̤̞̀ͅ࠮֚ͅഽ࣐̞ͩͦ̀ͥࡄ‫ݪ‬อນٛȪਬ౴ٛȫْܑ͈Ȃ‫א׋‬ȃˏȅུࡄ‫ݪ‬ਫ਼̤̞̀ͅාˍ࣐̞ٝͩͦ̀ͥఱਬ౴ٛȆުୡอນْܑ͈ٛȂ‫א׋‬ȃȁ̭͈ͦͣުྩͬ೒̱̀Ȃ๷୆໤ພࡄ‫ݪ‬ਫ਼ඤ͈ࡄ‫ݪ‬৒‫ފݪࡄ͈ۼ‬ႁȂૂ༭࢐۟Ȃ૽ऺ࢐ၠͬ௯ૺ̱Ȃࡄ‫ͬޏ۪ݪ‬ା̢Ȃۜஅછ‫ڠ‬Ȇ྾‫̠࣐ͬا଻ڰ͈ڠע‬ȃ‫֗ޗ‬ଔૺުྩȇ‫֗ޗ‬ଔૺΈσȜί͉́Ȃۜஅછ‫ڠ‬Ȇ྾‫͈ݪࡄڠע‬ဏࣣͬଔૺ̳̹ͥ͛ͅȂˍȅࡄ‫؍شݪ‬౯എ̈́ఱ‫֭ڠ‬໗ίυΈρθ͈ၛ̻ષ̬Ȃ̷͈̹͈͛΃ς΅νρθ͞΋ϋΞϋΜ͈ै଼Ȃ൳໗ίυΈρθ͈‫א׋‬
ˎȅఱ‫֭ڠ‬୆༡ਬ͈ࢩ༭Ȫ୰ྶ͈ٛ‫ٳ‬ट൝ȫȂව‫΂͈ࢃڠ‬ς΀ϋΞȜΏοϋˏȅۜஅછ‫ڠ‬Ȇ྾‫֗ޗڠע‬ίυΈρθȂඅུͅࡄ‫ݪ‬ਫ਼͈඾ུ - Ηͼۜஅછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜͬဥ̞̹ఱ‫֭ڠ‬୆͈٬‫ٸ‬৘౷ࡄਘ൝ْܑ͈‫͍ݞ‬৘ঔ൝࣐̠ͬȃȁ̭͈ͦͣުྩͬ೒̱̀Ȃ๷୆໤ພࡄ‫ݪ‬ਫ਼ͬಎ૤̱̹ͅఘࠏഎ̥̾ྛႁഎ̈́ۜஅછ‫ڠ‬Ȇ྾‫؍شݪࡄ͈ڠע‬౯എఱ‫ڠ‬֭‫͈֗ޗ‬იழ͙ै࣐̠ͤͬȃࡄ‫ݪ‬ΈσȜί੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁఆષȁၻঊࡄ‫ݪ‬ΞȜζȁ྾‫ע‬ະ஠৖ۛࡄ‫ݪ‬໦࿤ͬ࠳හ̱Ȃparoxysmal nocturnal hemoglobinuria (PNH) ΈσȜί͈ςȜΘȜ̱͂̀ո‫ࡄ͈ئ‬‫̞̱ͥ̀ͬݪ‬ȃȪમळ͉ષܱࡄ‫ݪ‬৒͈βȜΐ४ચȫˍȅࢃഛ଻ glycosylphosphatidylinositol (GPI) ࠧఅછȪอै଻࿡‫ࠬۼ‬૗ளෂછ PNHȫ͈อછ‫ܥ‬੬ˎȅ୶ഛ଻ GPI ࠧఅછ͈Α·ςȜΣϋΈ͂อછ‫ܥ‬੬͈ٜྶड߃͈యນഎ̈́ა໲
1. PIGA mutations cause early-onset epileptic enceohalopathies and distinctive features. M. Kato* H. Saitsu* Y.
Murakami* K. Kikuchi, Watanabe, M. Iai, K. Miya, R. Matsuura, R. Takayama, C. Ohba, M. Nakashima,Y.
Tsurusaki, N. Miyake, S. Hamano, H. Osaka, K. Hayasaka, T. Kinoshita, N. Matsumoto. Neurology. 2014 in press(*equally contribution).
2. Mutations in PGAP3 impair GPI-anchor maturation and lead to intellectual disability with hyperphosphatasia andadditional phenotypic features. Howard MF* Murakami Y* Pagnamenta AT, Haas CD, Fischer B, Hecht J, Keays
DA, Knight SJL, Kölsch U, Krüger U, Leiz S, Maeda Y, Mitchell D, Mundlos S, Philipps JA, Robinson PN, Kini U,
Taylor JC, Horn D, Kinoshita T, Krawitz PM. Am J Hum Genet.2014;94(2)278-87(*equally contribution).
3. Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with Westsyndrome and hyperphosphatasia with mental retardation syndrome. Chiyonobu T, Inoue N, Morimoto M, KinoshitaT, Murakami Y. J Med Genet. 2014; 51(3): 203-7.
4. Case report with vitamin B6 responsive epilepsy due to inherited GPI deficiency. Kuki, I., Y. Takahashi, Okazaki,
Ebara, N. Inoue, T. Kinoshita, Y. Murakami. Neurology. 2013;81(16):1467-9.
5. Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal
nocturnal haemoglobinuria. Murakami Y, Inoue N, Shichishima T, Ohta R, Noji H, Maeda Y, Nishimura J,
Kanakura Y, Kinoshita T. Br J Haematol. 2012 Feb;156(3):383-7.
Ķıࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activitiesۜஅછ‫ڠ‬Ȇ྾‫ڠע‬ဏࣣίυΈρθଔૺ৒
ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

ΊΦθ୆‫ݪࡄڠا‬ΈσȜίࡄ‫ݪ‬ΈσȜί੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ൥֔ȁ༠ࣞ੩‫ޗ‬ȁȁၑ‫ڠ‬ฎআȁ൥നȁຮষ֒ഥঊजඅ։എ୆‫ڠا‬എΊΦθ‫ܥ‬ෝٜଢ଼༹͈‫ٳ‬อ̷͈͂؊ဥ
ȁഢৢ͞΀άΐͿΥΞͻΛ·ଷࢄ͉̲̳ͬ͛͂ͥΊΦθ‫ܥ‬ෝอ࡛͈໦ঊ‫͈ࢹܥ‬ٜଢ଼͉ȂਲြȂ৽֒ͅഥ‫ڠ‬എٜଢ଼͞দࡑ‫ۯ‬ඤ͈́୆‫ڠا‬എٜଢ଼̽̀͢ͅૺ̧̹͛ͣͦ̀ȃ̱̥̱Ȃ̭̠̱̹਀༹͉́໦ঊ‫͈ࢹܥ‬ٜྶ̦ࣾඳ̜̥́ͥȂ̧̹̱́͂̀͜਱ාౙպ͈ಿ̞শ‫̦ۼ‬ຈါ̜̹́̽ȃ̭̠̱̹ે‫ͬޙ‬་̢̹ͥ͛Ȃඅ೰ΊΦθႀ֖·υζΙϋࢹ௮͈ non-biased ٜ ଢ଼ ͬ ࿒ ঐ ̱Ȃ૧ ܰ ༷ ༹ ა ͂ ̱ ̀Ȃinsertional chromatin immumoprecipitation (ChIP) (iChIP) ༹ ͂engineered DNA-binding molecule-mediated ChIP (enChIP) ༹̥ͣࢹ଼̯ͦͥ֒ഥঊजඅ։എ ChIP ༹ͬ‫ٳ‬อ̱̹ȃȁiChIP ༹͉Ȃ(i) ळ޿͈ DNA ࣣࠫ౩ฒ̜́ͥ LexA ͈ࣣࠫ෻Ⴅ (LexA BE) ͬȂٜଢ଼చયΊΦθႀ֖߃ཌྷͅொව̱
̹ळ༾ͬਏၛȂ(ii) ΗΈͬັ̫̹ LexA DNA ࣣࠫΡιͼϋ (LexA DB) ͈ષܱळ༾͈͒อ࡛Ȃ(iii) ຈါ̦̜ͦ͊ȂγσθͺσΟΪΡ൝́·υΑςϋ·ࢃȂ಼‫إ‬෨ੜၑ̹͉͘ଷࡠࣖளੜၑ൝ͤ͢ͅΊΦθ DNA ͬ౯༌‫ا‬Ȃ(iv) ષܱΗΈͬ෇ে̳ͥࢯఘͥ͢ͅ྾‫ע‬ೆࣛͤ͢ͅȂLexA DB ̦ࣣ̱̹ࠫ DNA- ౩ฒໝࣣఘͬౙၗȂ(v) ·υΑςϋ·̴͉̱ͬȂໝࣣఘಎ͈౩ฒৗȆDNAȆRNA ͬ൳೰Ȃ̞̠͂਀ਜ਼ͥ͢ͅȪ଎ऒȫȃȁenChIP ༹ ͉Ȃ(i) zinc-finger ౩ ฒ ৗ ͞ transcription activator-like (TAL) effector ౩ ฒ ৗȂະ ‫ ߿ ଻ ڰ‬Cas9 ౩ ฒ ৗ(dCas9) ͂΄ͼΡ RNA (gRNA) ͈ໝࣣఘͬဥ̞̹ CRISPR ΏΑΞθ൝̥ͣ̈́ͥΗΈັ̧ດഎ DNA ෻Ⴅࣣࠫ໦ঊ͈
ٜଢ଼చયळ༾͈͒อ࡛Ȃ(ii) ຈါ̦̜ͦ͊ȂγσθͺσΟΪΡ൝́·υΑςϋ·ࢃȂ಼‫إ‬෨ੜၑ̹͉͘ଷࡠࣖளੜၑ൝
ͤ͢ͅΊΦθ DNA ͬ౯༌‫ا‬Ȃ(iii) ષܱΗΈͬ෇ে̳ͥࢯఘ
ͥ͢ͅ྾‫ע‬ೆࣛͤ͢ͅȂDNA- ౩ฒໝࣣఘͬౙၗȂ(iv) ·υΑςϋ·̴͉̱ͬȂໝࣣఘಎ͈౩ฒৗȆDNAȆRNA ͬ൳೰Ȃ̞̠͂਀ਜ਼ͥ͢ͅȪ଎ֲȫȃȁ֒ഥঊजඅ։എ ChIP ༹͉Ȃ(I) ٜଢ଼చયΊΦθႀ֖ࣣ̳ࠫͥͅ໦ঊ̦ȂDNAȂRNAȂ౩ฒৗ൝Ȃ໦ঊਅͅ‫̴ͣͩ۾‬൳೰̧́ͥȂ(II) ೩΋άȜତ͈ΊΦθႀ֖ࣣ̳ࠫͥͅ໦ঊ͈
൳೰̦‫خ‬ෝ̜́ͥȂ̞̹͂̽‫ܡ‬ం༹͈༷͉ͅྫ̞࿹̹ͦඅ
ৗͬ঵̞̽̀ͥȃ֒ഥঊजඅ։എ ChIP ༹ͬဥ̞̭ͥ͂́Ȃඅ ೰ Ί Φ θ ႀ ֖ ͅ ࠫ ࣣ ̳ ͥ ྚ ౶ ͈ ໦ ঊȪ౩ ฒ ৗȂDNAȂ
RNAȂ̷͈ఈȫ͈࿌္എ൳೰̦‫خ‬ෝ̜́ͥȃȁ࡛हȂ֒ഥঊजඅ։എ ChIP ༹ͬဥ̞̀Ȃ(a) ςϋΩ‫ݩ‬໦‫ا‬ည൵Ȇ֋঵Ȃ(b) ቔ‫ژ‬਋ယఘ͈อ࡛ଷࢄȂ(c) ͼϋΑτȜΗȜ‫ܥ‬ෝȂ(d) DNA ඵਹङ୨౯͈෇ে‫̷͍ݞ‬͈ਘ໘Ȃ(e) ΀άΐͿΥΞͻΛ·‫ܥ‬੬ͥ͢ͅ‫ဲ܈‬ଷ֒ഥঊ͈
อ࡛ဲଷ̞̹͂̽‫ྙޟ‬૬̩̥̾ਹါ̈́୆ྵ࡛ય͈໦ঊ‫͈ࢹܥ‬ٜྶͬ࿒ঐ̱̀ࡄ‫̞ͥ̀͛ૺͬݪ‬ȃड߃͈యນഎ̈́ა໲

଎ . ֒ഥঊजඅ։എ·υζΙϋ྾‫ע‬ೆ༹ࣛ
iChIP ༹͂ enChIP ༹̥ͣࢹ଼̯ͦͥȃ

1. Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated chromatin
immunoprecipitation (enChIP). Fujita T, Asano Y, Ohtsuka J, Takada Y, Saito K, Ohki R, Fujii H. Sci Rep. 2013
Nov 8;3:3171.
2. Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding
molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Fujita T, Fujii H. Biochem Biophys
Res Commun. 2013 Sep 13;439(1):132-6.
3. Direct identification of insulator components by insertional chromatin immunoprecipitation. Fujita T, Fujii H. PLoS
One. 2011;6(10):e26109
4. Insertional chromatin immunoprecipitation: a method for isolating specific genomic regions. Hoshino A, Fujii H.
J Biosci Bioeng. 2009 Nov;108(5):446-9.
5. Regulation of Fas-mediated immune homeostasis by an activation-induced protein, Cyclon. Saint Fleur S, Hoshino
A, Kondo K, Egawa T, Fujii H. Blood. 2009 Aug 13;114(7):1355-65.
ĶĲࡄ‫ڰݪ‬൲͈‫ٽ‬ါȁResearch & Activities୆૓ळ༾ΈσȜίࡄ‫ݪ‬ΈσȜί੎‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ࿤ॄȁୃ๼ˍȅ୆૓ळ༾͈΀άΐͿΥΞͻ·Αȁୈ௏୆૓ळ༾අ։എ֒ഥঊ͈ఉ̩͉τΠυεΖΰȂ֒ഥঊඤ໐ͅ CpG-rich ႀ֖ͬ঵̾ȃ֒ഥঊඤ໐͈ιΙσ‫̦ا‬ఘळ༾͈́อ࡛ͬဲ̢Ȃ୆૓ळ༾͈́౎ιΙσ‫̦ا‬อ࡛ͅຈါ
̜̭́ͥ͂ͬྶ̥̱̹ͣͅȃ࡛हȂΪΑΠϋιΙσ‫ا‬ਘૐ͜‫͛܄‬Ȃ୆૓ळ༾໦‫΀̫̤ͥͅا‬άΐͿΥΞͻ΃σଷࢄ‫͈ࢹܥ‬ٜଢ଼࣐̞ͬ̽̀ͥȃˎȅୈঊ‫͈ړ‬ξΣȜ·̈́ࢹ௮ȁሶ඿൲໤ୈঊ‫͉ړ‬Ȃ฼ତఘΊΦθ̦ίυΗηϋ̽̀ࣞ͢ͅ

଎ȇES ळ༾̥ͣ neural crest ͈໦‫ږ͈ࠏا‬ၛȃES ळ༾ͬྫࠬୄ෽ူ̳̭ͥ͂́Ȃ૰ࠐષ๧̥ͣ̈́ͥ sphere ࠁ଼࣐̞ͬȂ̯ͣͅ BMP4 ੜၑͤ͢ͅ neural crest ळ༾ͬ໦‫̵̯ا‬Ȃࣸٔळ༾͈໦‫ͬا‬া̱̹ȃഽͅާੀ̱̤̀ͤȂ֚໐ͅΪΑΠϋ̦ॼͥȃୈঊ·υζΙϋ͈ಎ́Ȃఘळ༾߿͈ΪΑΠϋͬ঵̾ႀ֖͈ਹါ଻ٜͬ
ଢ଼̱̞̀ͥȃ
ˏȅES ळ༾ͬဥ̞̹ Neural Crest ۚळ༾͈ਏၛ͂ठ୆֓ၷ͈͒؊ဥ
ES ळ༾̥ͣ neural crest ۚळ༾ͬ‫ږ‬ၛ̱Ȃအș̈́ळ༾ͅ໦‫̵̯ا‬Ȃठ୆֓ၷ͈͒؊ဥͬদ͙ͥȃड߃͈యນഎ̈́ა໲
Inoue H, Ohnishi Y, Nakajima M, Kakudo M, Nozaki M. A novel function of EpCAM in oral squamous cell carcinoma
cells under anchorage-independent conditions. Int J Oncol. 2011 Dec; 39 (6): 1401-5.

Ķĳ٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in Overseas
ࡄ
‫ݪ‬
‫ڰ‬
൲
͈
‫ٽ‬
ါ

඾ུȆΗͼ૧‫ޟ‬Ȇठ‫ۜޟ‬அછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜΓϋΗȜಿඅහ‫ޗ‬਎ȁ໌നȁೄგȁۜஅછ͉Ȃχ·Ιϋ͈‫ٳ‬อ͞ࢯ୆໤ৗ͈̈́̓‫ڠا‬ၷ༹͈อోͤ࣪͢ͅ໚̧̹́͂ࣉ̢̹ͣͦশ‫̹̜̦̽ܢ‬ȃ̱̥̱Ȃ߃ා૧̹ͅ੄࡛̱̹အș̈́ۜஅછ ( ૧‫ۜޟ‬அછ ) ͞Ȃ‫࣪ͅܡ‬໚̱̹͂ࣉ̢̞̹͈͈ͣͦ̀͜ठြ ( ठ‫ۜޟ‬அછ )ͬ௖ষ̞́ࠐࡑ̱Ȃۜஅછͅచ̳ͥ২ٛഎະհ̦ଲ‫ٮ‬എ̧̭̹ܳ̽̀ͅȃ̹͘Ȃ̦࣭͉ͩ́ۜஅછࡄ‫ݪ‬ႀ֖͈ࡄ‫ݪ‬৪ະ௷͂͜௖̽̀͘Ȃ֚௄‫̧̞̦ͥ̀̀̽ࣞۜ͘ܥܓ‬ȃ̯ͣͅఉ̩͈ۜஅછ͉࣭‫ͬޏ‬ယօͅ‫̢ק‬Ȅ‫ڐͅ௸ݢ‬ఱ̳ͥম͜ೇ̱̩̩̈́Ȃ࣭֚ౙඊ̷͉͈́૟ව͈ထཡ͞ଷࢄ͉ࣾඳ̜̭́ͥ͂͜ྶ̥̜ͣ́ͥȃ

٬
‫ٸ‬
ࡄ
‫ݪ‬
‫ݶ‬
ത

RCC-ERI ̥ͣ༗࠲જ΅λϋΩΑͬབ͚ȃֲ௰ͅ NIH ͈࠺໤̦ࡉ̢ͥ

ȁ̭͈အ̈́෸ࠊ͈‫ئ‬Ȃ໹଼ 17 ාȪ2005 ාȫഽͅอ௷̱̹໲໐‫ڠش‬જ͈ȶ૧‫ޟ‬Ȇठ‫ۜޟ‬அછࡄ‫ݶݪ‬തࠁ଼ίυΈρθȷ̤̫ͥͅ٬‫ݶݪࡄٸ‬ത͈̱֚̾͂̀Ȃఱिఱ‫͉ڠ‬Ηͼ࣭ؐ༗࠲જ֓‫ފ͈ޫڠش‬ႁͤ͢ͅ඾ུȆΗͼ૧‫ޟ‬Ȇठ‫ۜޟ‬அછ‫ވ‬൳ࡄ‫ݪ‬ΓϋΗȜȪRCC-ERI: Research Collaboration Center on Emerging and Re-emerging Infectionsȫȷͬ୭౾̱̹ȃུίυΈρθ͉໹଼ 22 ාȪ2010 ාȫ̥ͣۜஅછࡄ‫࣭ݪ‬षΥΛΠχȜ·ଔૺίυΈρθȪJapan Initiative for Global
Research Network on Infectious Diseases ƣJ-GRIDƤ) ̧֨ͅࠑ̦ͦల 2 έͿȜΒ̦ૺ࣐ಎ̜́ͥȃȁΨϋ΋·߃ࣕΦϋΗής̜ͥͅ༗࠲જȆ֓‫ޫڠش‬ȆΗͼ࣭ၛထཡ‫מ‬୆ࡄ‫ݪ‬ਫ਼ȪNIHȫඤ͈ RCC-ERI ͉ͅȂ࿩
600m2 ͈έυͺͅ P2ȆP3 τασ͈Ψͼ΂ΧΎȜΡచॐͬঔ̱̹৘ࡑ৒ͅ‫̢ح‬Ȃ‫ڎ‬ਅ৘ࡑ‫̦ܕܥ‬୭౾̯̞ͦ̀ͥȃ
RCC-ERI ͉́ NIH ͈ࡄ‫ݪ‬৪͂ྟ୪ͅႲࠈ̱Ȃ૧‫ޟ‬Ȇठ‫ۜޟ‬அછଷգͬ࿒ঐ̱̹ࡄ‫ͬݪ‬ജ‫ͅރ̳͂ͥٳ‬Ȃ̦࣭̤͍ͩ͢Ηͼ͈৹਀ۜஅછࡄ‫ݪ‬৪଼͈֗৾ͤͅழ̞ͭ́ͥȃRCC-ERI ͉ळ޿ۜஅછȂ;ͼσΑۜஅછ͈ 2 ໐࿝ఘଷͤ͢
̈́ͤȂ૧‫ޟ‬Ȇठ‫ۜޟ‬அછ͈੄࡛শ͉ͅཡ‫ע‬ષຈါ̈́ૂ༭͈อ૞Ȃহၷ࿪͞χ·Ιϋ‫ٳ‬อ͈̯̰̈́̓̈́͘͘చॐ̦ଇ
௸̢࣐ͥͅఘଷͬ‫ږ‬ၛ̱̞̀ͥȃȁ̯ͣͅࡄ‫͈ݪ‬ႊͬ߃ႋ͈ J-GRID ‫ݶ‬ത࣭͞ඤ‫ڎ‬ఱ‫͈ۜ۾ܥݪࡄ͞ڠ‬அછȟ๷୆໤‫ݪࡄڠ‬৪͜ͅࢩ̬͓̩ͥȂࡄ‫ݪ‬৪΋ϋΕȜΏͺθ͈ࠁ଼ͬ଎ͤȄఉ̩͈ఱ‫ݪࡄ͈ڠ‬৪͈ॷ൳ͬං̞̀ͥȃRCC-ERI ͉ΈυȜΨσͅഥ෥̳ͥۜஅ
છ͈ଷࢄ̫̹࢜ͅ‫ވ‬൳ஜ஌‫ܖ‬౷̱͂̀၌ဥ̱̞̹̺̩̭̦̀͂‫خ‬ෝ̞͂̈́̽̀ͥȃBSL-2 ৘ࡑ৒BSL-3 ৘ࡑ৒ĶĴ٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in Overseasळ޿ۜஅ໐࿝
ࡄ‫ݪ‬ΈσȜίඅහ‫ޗ‬਎ȁȁভ‫ڠ‬ฎআġඅහ੩‫ޗ‬ȁȁฎআ ĩ ֓‫ ڠ‬Īġඅහࡄ‫֥ݪ‬ȁฎআ ĩ ۪‫ ڠޏ‬Īġ෩ࡍࡄ‫֥ݪ‬ȁฎআ ĩ ෎ఝ֓‫ ڠ‬Īġ෩ࡍࡄ‫֥ݪ‬ȁฎআ ĩ ֓‫ ڠ‬Īġຩനȁ࿆ࢨ‫ؖ‬നȁგ‫ݛ‬֔ષ࠲ఊ჊ŎŢŵũŶŬŰųůġŏŢĮŖţŰŭ
ŘŢųŢŸŢůġŘŰůŨţŰŰŵ

ȁΗͼِ࣭̤͍̦࣭ؐͬ͢‫͚܄‬ͺΐͺ੨࣭̱̱́͊͊อ୆̳ͥळ޿ۜஅછͅਹത̤̞ͬ̀Ȃ‫ۜڎ‬அછ͈໦ঊ‫಺ڠע‬औȂ૷౯༹͈‫ٳ‬อȂ֓‫ڠ‬എȆ২ٛഎထཡ༹༷͈‫ٳ‬อ͂৘கͬȂΗͼ༗࠲જ֓‫ޫڠش‬ထཡ‫מ‬୆ࡄ‫ݪ‬ਫ਼͈ࡄ‫ݪ‬৪͂‫ފ‬ႁ̱̾̾Ȃࡄ‫ڰݪ‬൲ͬଔૺ̳ͥȃ
ȁ2010〜2014 ාഽ̥̫̀ͅ৘ঔಎ͈ȶۜஅછࡄ‫࣭ݪ‬षΥΛΠχȜ·ଔૺίυΈρθȷ̤̞͉̀ͅȄ৽̹ͥࡄ‫ݪ‬చયͬ΋τρ‫͍ݞ‬΋τρ޿̱͖̽̀ͅࡄ‫ͬݪ‬࣐̞̽̀ͥȃΗͼ͉́Ȅ෎ఝ̞̠͂౷ଽ‫ڠ‬എၑဇ̥ͣȄအș̈́ಸ‫ۜۯ‬அછ̦ອอ̱̀
̤ͤȄࣽࢃ̷͈͂ͦͣ͜ਹါ଻͉௩̳ম͉
̜̽̀͜ࡘͥম͉̩̈́Ȃࣽࢃ͂͜อജഎͅ
ࠑ௽̳ͥȃȁΗͼ́Ȅ̞ࣞঘཌၚͬা̳ۜஅછ̱͂̀
͉ࡣ̩̥ͣ෹‫׶‬Ȃࠫ‫ړ‬Ȃ‫ئ଻ݢ‬ၓછ൝̦‫ݷ‬̬̞ͣͦ̀ͥȃड߃͉́Ȅਲြພࡔ଻̦৻
̞̯̞̹͂ͦ̀ήΗτϋ΍‫̠͈͢ͅ޿ݩ‬૧̹̈́ພ߿͂๤‫ڛ‬എ̞ࣞ౿ঘၚͬা̳૧‫ۜޟ‬அછ͈੄࡛̦ಕ࿒̯̞ͦ̀ͥȃ̭͈ͦͣळ
޿ۜஅછͅచ̳ͥ࿒෻̱ͤͬ̾̾Ȃ̷͈ͦͣထཡ࣓ͅࡃ̧́ͥࡄ‫ݪ‬ΞȜζͬ୭೰̱Ȃ‫ވ‬൳ࡄ‫͈ݪ‬৘ͬ‫̭̬ͬ͂ͥݷ‬࿒ດ̳͂ͥȃ˩˨˲˝߿̥ͣࡉ̹Ηͼ࣭ඤ̤̫ͥͅ
΋τρ޿ O1 ͈౷ၑഎ‫ڐ‬८͂ࠐশഎ་‫( ا‬2007 ා ~2010 ා )৽̈́ࡄ‫هݪ‬ఴˍȫଇ௸૷౯ LAMP ༹ͬߐঀ̱̹΋τρၠ࣐͈ଷࢄȇΗͼȆηλϋζȜ࣭‫̫̤ͥͅޏ‬΋τρࢡอ౷ఝ̤̫ͥͅদ͙
ˎȫ΋τρ޿ၠ࣐‫͈ڼ‬έ͹ȜΐΨς΀ȜΏοϋͅ‫̩̿ܖ‬૧ܰၠ࣐͈࿌္എٜଢ଼ͅ‫ݪࡄ̳ͥ۾‬ˏȫພࡔ଻τϋ΍‫͈޿ݩ‬۰օଇ௸૷౯༹͈‫ٳ‬อ͂؊ဥͅ‫ݪࡄ̳ͥ۾‬ːȫΗͼ̤̫ͥͅພࡔ଻τϋ΍‫ۜ޿ݩ‬அછ͈໦ঊ‫ڠע‬എࡄ‫ݪ‬ड߃͈యນഎ̈́ა໲
1. Okada K, Roobthaisong A, Swaddiwudhipong W, Hamada S, Chantaroj S. Vibrio cholerae O1 Isolate with Novel
Genetic Background, Thailand-Myanmar. Emerg Infect Dis. 2013 19(6):1015-17.
2. Takeuchi D, Akeda Y, Nakayama T, Kerdsin A, Sano Y, Kanda T, Hamada S, Dejsirilert S, Oishi K. The
Contribution of Suilysin to the Pathogenesis of Streptococcus suis Meningitis. J Infect Dis. 2013 first published online.
3. Okada K, Roobthaisong A, Nakagawa I, Hamada S, Chantaroj S. Genotypic and PFGE/MLVA analyses of Vibrio
cholerae O1: geographical spread and temporal changes of isolates during the 2007-2010 cholera outbreaks in
Thailand. PLoS One. 2012 7(1):e30863.
4. Takeuchi D, Kerdsin A, Pienpringam A, Loetthong P, Samerchea S, Luangsuk P, Khamisara K, Wongwan N,
Areeratana P, Chiranairadul P, Lertchayanti S, Petcharat S, Yowang A, Chaiwongsaen P, Nakayama T, Akeda Y,
Hamada S, Sawanpanyalert P, Dejsirilert S, Oishi K. Population-Based Study of Streptococcus suis Infection in
Humans in Phayao Province in Northern Thailand. PLoS One. 2012 7(2):e31265.
5. Okada K, Chantaroj S, Taniguchi T, Suzuki Y, Roobthaisong A, Puiprom O, Honda T, Sawanpanyalert P. A rapid,
simple, and sensitive loop-mediated isothermal amplification method to detect toxigenic Vibrio cholerae in rectal
swab samples. Diagn Microbiol Infect Dis. 2010 66(2):135-9.
Ķĵ٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in Overseas;ͼσΑۜஅ໐࿝
ࡄ‫ݪ‬ΈσȜίඅහ‫ޗ‬਎ġඅහ੎‫ޗ‬਎ġඅහ࣒঍ġ෩ࡍࡄ‫֥ݪ‬ġ෩ࡍࡄ‫֥ݪ‬ġ෩ࡍࡄ‫֥ݪ‬ġ෩ࡍࡄ‫֥ݪ‬ġ֓‫ڠ‬ฎআġ໌നȁೄგ֓‫ڠ‬ฎআġུఆȁგ঄਷֓‫ڠ‬ฎআġ നಎȁ੓ၑ‫ڠ‬ฎআġŏŪŵŤũŢŬŢųůġŏŰųŢůŢŵŦ
ၑ‫ڠ‬ਘআġńũųŪŴġŗŦųŢŵũŢŮūŢŮųŢŴ
ၑ‫ڠ‬ਘআġŖųŢůŢůġŕŶŮŬŰŴŪŵ
ၑ‫ڠ‬ਘআġŎŪŤũŪŵŵųŢġŃŰŰůŤũŢů

٬
‫ٸ‬
ࡄ
‫ݪ‬
‫ݶ‬
ത

ȁ;ͼσΑۜஅ໐࿝͉́ȂΗͼ̤͍̦࣭ͩͬ͢‫͚܄‬ͺΐͺ੨࣭́ۜஅ̦߫ͤ༐ٍ̯̞ͦ̀ͥ෾ٚ଻ۜஅછȂࠬ‫ס‬෾ٚ଻ۜஅછȂ̤͍͢ಸ‫ۜۯ‬அછͬࡄ‫ݪ‬చયͅ NIH ͈ࡄ‫ݪ‬৪͂‫ވ‬൳ࡄ‫ͬݪ‬ଔૺ̱̞̀ͥȃȁٍ෾ٚ଻ۜஅછ͉́Ηͼͬ‫͚܄‬෎ఝȂՏ෎ఝ౷֖ͅ྘‫̳ͥװ‬Ι·ϋΈΣͺͬచય̱͂Ȃུ;ͼσΑ͈‫ڠע‬എȂ໦ঊ୆໤‫ڠ‬എȂ̤͍͢྾‫ڠע‬എ‫ܖ‬யࡄ‫ͬݪ‬ଔૺ̱̞̀ͥȃࠬ‫ס‬෾ٚ଻ۜஅછ͉́ȂHIV ۜஅછ / ΀ͼΒͬచય̱͂ȂΗͼͬই̳͛͂ͥ൐ධͺΐͺ੨࣭ͅ྘‫ ̳ͥװ‬HIV-1 CRF01_AE ‫ͼ;͈ڼ‬σΑ‫ڠ‬എඅಭȂ਽৽‫଻ס‬྾‫ע‬؊൞Ȃ࿪सఛ଻‫ڕ‬ං‫ܖ͈̞̀̾̓̈́ͅࢹܥ‬யഎࡄ‫ͬݪ‬ଔૺ̱̞̀ͥȃಸ‫ۜۯ‬அછ͉́Ȃۛ৪̤͍۪͢‫ޏ‬କ̥ͣ࠿੄̯ͦͥΦυ
;ͼσΑ̤͍͢ A ߿۴‫ͼ;׶‬σΑ͈໦ঊ‫ڠע‬ٜଢ଼̥ͣȂΗͼ́ၠ࣐̳ͥ;ͼσΑ͈֒ഥ‫ڠ‬എ̈́අಭͬྶ̥̳ͣͅ
ͥ͂‫ͅވ‬Ȃ̷͈ଷࢄ༹͈‫ٳ‬อͬଔૺ̱̞̀ͥȃ଎ 1.ȁΙ·ϋΈΣͺ;ͼσΑȪCHIKVȫ͈֒ഥঊࢹ௮͂ࡄ
‫هݪ‬ఴȃCHIKVȪBSL3ȫ͉ίρΑˍུङ RNA ͬ֒ഥঊͅ
̾͜ೄࠂ࿩ 60-70 nm ͈‫ͼ;ࠁݩ‬σΆ̜ͥȃࢹ௮ΗϋΩ·͈஠ႀ֖ͬอ࡛̳̭ͥ͂̽̀͢ͅȂࠁఠ‫ڠ‬എ͜ͅȂࢯࡔ଻̤̞̀͜ͅΥͼΞͻή̈́ CHIKV ͂་̞ͩͣ̈́ಎߗၥঊ
Ȫvirus-like particles, VLPsȫͬॲ୆̵̧̯̭̦ͥ͂́ͥȃ̹͘Ȃ྄ΗϋΩ· E3, E2, 6k, ̤͍͢ E1 ͬอ࡛̳ͥα·ΗȜȂτϋΙ;ͼσΑΩΛΉȜΐϋΈα·ΗȜȂ̤͍͢τεȜΗȜ̱͂̀σΏέͿρȜΔͬอ࡛̳ͥα·ΗȜͬ൳শͅ 293˰ळ༾ͅΠρϋΑέͿ·Ώοῢ̱ΏνȜΡτϋΙ;ͼσΑȪBSL2ȫͬैୋ̱̹ȃ̭ͦͬဥ̞̹ಎგ৘ࡑ̦‫خ‬ෝ̜̭̦́ͥ͂া̯̹ͦȪ໲ࡃ 3ȫȃड߃͈యນഎ̈́ა໲
1. Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected
Thai individuals. Chaitaveep N, Utachee P, Nakamura S, Chuenchitra T, Ekpo P, Takeda N, Pattanapanyasat K,
Kameoka M. Microbes Infect. 2014 Feb;16(2):142-52.
2. CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in
northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow
progressors. Sapsutthipas S, Tsuchiya N, Pathipavanich P, Ariyoshi K, Sawanpanyalert P, Takeda N,
Isarangkura-na-ayuthaya P, Kameoka M. PLoS One 2013; 8: e53920.
3. Development of a Pseudotyped Lentiviral Vector--Based Neutralization Assay for Chikungunya Virus Infection.
Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S. J Clin Microbiol 2013; 51: 1389-95.
4. Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells. Li YG,
Siripanyaphinyo U, Tumkosit U, Noranate N, A AN, Pan Y, Kameoka M, Kurosu T, Ikuta K, Takeda N,
Anantapreecha S, Virol J 2012; 9: 114.
5. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE
envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specificfor the CD4 binding domain. Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P,
Ikuta K, Auwanit W, Kameoka M. J Virol 2010; 84: 4311-20.
ĶĶ٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in OverseasζΪΡϋ Į ఱिۜஅછΓϋΗȜȪŎŐńŊŅȫ
ࡄ‫ݪ‬ΈσȜίΓϋΗȜಿġ ‫ޗ‬਎Ȫ࠳ȫġġඅහ੎‫ޗ‬਎ġġ෩ࡍࡄ‫֥ݪ‬ġġ෩ࡍࡄ‫֥ݪ‬ġġ෩ࡍࡄ‫֥ݪ‬ġ਷֓‫ڠ‬ฎআġ਷֓‫ڠ‬ฎআġ֓‫ڠ‬ฎআġၑ‫ڠ‬ਘআġၑ‫ڠ‬ਘআġઐ‫׆‬ȁ஝হ
‫ؖ‬ႅȁ۪ਏ
ŐųŢűŪŮġőŶŪűųŰŮ
őŢůūŢűŰųůġńũŢŪŤũŢůŢ
ŏŢůŵŢųŢŵġńũŢůŵŢŸŢŵ

ȁ෎ఝ౷ٍ֖̤̫ͥͅ෾ٚ଻৖͉ۛȂ߃ා͈౷‫أݩ‬౰‫ฺ̞ͅا‬Ȃ̷͈ၠ࣐౷֖ͬ‫ڐ‬ఱ̱̞̀ͥȃΗͼ࣭ؐ́࿚ఴ͂
̞̈́̽̀ͥȂΟϋΈ෎ / ΟϋΈ੄ࠬ෎͞Ι·ϋΈϋμ෎ٍ͈̈́̓෾ٚ଻͈;ͼσΑ଻৖ۛͅ‫̱̀۾‬Ȃଇ௸૷౯΅ΛΠ͈‫ٳ‬อȂΪΠٍ͍̤̫̈́ͣͥͅͅ;ͼσΑ໦ື಺औȂ̷̱̀อછι΃ΣΒθ͈ٜྶ̫̹࢜ͅࡄ‫̠࣐ͬݪ‬ȃඅͅႉ઄࠿ఘͬဥ̞̹ٜଢ଼ͬζΪΡϋఱ‫ڠ‬෎ఝ֓‫ڠ‬໐͂‫ވ‬൳́ଔૺ̳ͥȃ̭͈ͦͣ‫ވ‬൳ࡄ‫ͬݪ‬೒̱̀ȂζΪΡϋఱ‫ڠ‬෎ఝ֓‫ڠ‬໐ِ̤͍̦࣭͈ۜ͢அછࡄ‫ݪ‬৪଼͈֗͜ͅႁͬಕ̪ȃ৽̈́ࡄ‫هݪ‬ఴˍȫΗͼٍ̤̫̤͍ͥ͢ͅΪΠٍ̤̫ͥͅ
෾ٚ଻;ͼσΑ͈૟֪ે‫಺͈ޙ‬औȃˎȫΟϋΈ;ͼσΑ͂Ι·ϋΈϋμ;ͼσᾼచ̳ͥΪΠ̤͍͢ζ;ΑκΦ·υȜ΢σࢯఘ͈ैୋ͂Ȃ̷͈଻ેٜଢ଼ȃˏȫैୋ̱̹κΦ·υȜ΢σࢯఘͬဥ̞̹૷౯΅ΛΠ‫ٳ‬อȃड߃͈యນഎ̈́ა໲
1. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.Chaichana P,
Okabayashi T, Puiprom O, Sasayama M, Sasaki T, Yamashita A, Ramasoota P, Kurosu T, Ikuta K.PLoS One. 2014
Mar 18;9(3):e92173.
2. Antibody germline characterization of cross-neutralizing human IgGs against 4 serotypes of dengue virus.
Pitaksajjakul P, Benjathummarak S, Pipattanaboon C, Wongwit W, Okabayashi T, Kuhara M, Misaki R, Fujiyama
K, Ramasoota P. Biochem Biophys Res Commun. 2014 Mar 14.
3. Detection and characterization of enteric viruses in flood water from the 2011 thai flood. Ngaosuwankul N,
Thippornchai N, Yamashita A, Vargas RE, Tunyong W, Mahakunkijchareon Y, Ikuta K, Singhasivanon P,
Okabayashi T, Leaungwutiwong P. Jpn J Infect Dis. 2013;66(5):398-403
4. Characterization of chikungunya virus infection of a human keratinocyte cell line: role of mosquito salivary glandprotein in suppressing the host immune response.
Puiprom O, Morales Vargas RE, Potiwat R, Chaichana P, Ikuta K, Ramasoota P,Okabayashi T. Infect Genet Evol.
2013 Jul;17:210-5.
5. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies
derived from dengue patients at acute phase of secondary infection.Sasaki T, Setthapramote C, Kurosu T, Nishimura
M, Asai A, Omokoko MD, Pipattanaboon C, Pitaksajjakul P, Limkittikul K, Subchareon A, Chaichana P,
Okabayashi T, Hirai I, Leaungwutiwong P, Misaki R, Fujiyama K, Ono K, Okuno Y, Ramasoota P, Ikuta K.
Antiviral Res. 2013 Jun;98(3):423-31.
Ķķ٬‫ݶݪࡄٸ‬തȁResearch Collaboration Center in Overseas
ΟϋΈχ·ΙϋȪिఱ๷୆໤ພࡄ‫ݪ‬ٛȫ‫ݪࡄ້ܙ‬໐࿝ࡄ‫ݪ‬ΈσȜί‫ݪࡄ້ܙ‬໐࿝‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁȁ઀ୌȁ‫ם‬ඵ‫ݪࡄ້ܙ‬໐࿝੩‫ޗ‬ȁ༗࠲‫ڠ‬ฎআȁ५ಎȁකঃ

٬
‫ٸ‬
ࡄ
‫ݪ‬
‫ݶ‬
ത

ȁ़๊֚౬༹૽िఱ๷୆໤ພࡄ‫ݪ‬̥ٛͣఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼͈͒‫້ͤ͢ͅܙ‬Ȃ2011 ාഽ̥ͣΗͼ࣭͈ؐζΪΡϋఱ‫ڠ‬෎ఝ֓‫ڠ‬໐ඤͅȂΟϋΈχ·ΙϋȪिఱ๷୆໤ພࡄ‫ݪ‬ٛȫ‫ݪࡄ້ܙ‬໐࿝̦อ௷̱̹ȃȁΟϋΈ෎͉Ȃ෎ఝ౷֖ͅࢩ̩ၠ࣐̱Ȃˍ඾ͅ࿩ 30 ྔ૽͈૧̹̈́ۛ৪อ୆̦ଔ೰̯ͦͥडਹါٍ͈෾ٚ଻;ͼσΑ৖̜ۛ́ͥȃਹછ߿͈ΟϋΈ੄ࠬ෎͉Ȃഐ୨̈́হၷ̦࣐̫ͩ̈́ͦ͊౿ྵၚ̦ 20% ͅષઌ̳ͥȃ̱̥̱Ȃ෇‫خ‬χ·Ιϋ͉̩̈́අ։എࢯ;ͼσΑस͜‫ږ‬ၛ̯̞̞ͦ̀̈́ȃχ·Ιϋ͉ड͜ຽ༑എ̈́ထཡ਀౲̜́ͤȂ̷͈‫ٳ‬อ͉‫ྩݢ‬͈‫ه‬ఴ̜́ͥȃȁ൚ࡄ‫ݪ‬໐࿝͉́ȂȪˍȫΟϋΈ෎ȆΟϋΈ੄ࠬ෎͈อછ‫ܥ‬੬̤͍͢ཡࢄ‫ͬࢹܥ‬ٜྶ̳ͥࡄ‫ݪ‬ȂȪˎȫΟϋΈ;ͼσΑ͈ພࡔ଻Ȃഥ෥͞ૺ‫ͅވ͂ݪࡄ̳ͥ۾ͅا‬ȂȪˏȫਅș͈୽ၞͥ͢ͅΟϋΈχ·Ιϋ‫ٳ‬อ͈‫ܖ‬யࡄ‫̞࣐ͥ̀̽ͬݪ‬ȃߓఘഎ͉ͅȂΟϋΈۛ৪ࠬ‫͞ס‬໦ၗ;ͼσΑͬဥ̞̀྾‫ע‬؊൞ͬ಺͓ͥ͂‫ͅވ‬Ȃழ̢۟ܿ੅ͬဥ̞̀ΟϋΈ;ͼσΑၥঊນ࿂౩ฒ͈‫ܥ‬ෝ͞྾‫ͬ଻ࡔע‬ٜଢ଼̱̞̀ͥȃ̭͈ͦͣࡄ‫ͤ͢ͅݪ‬Ȃχ·Ιϋ͈ཡࢄ࢘ႁͬບ‫̳ͥث‬྾‫ڠע‬എঐດ͈ଔ೰͞ৗ͈̞ࣞχ·Ιϋࢯࡔ͈ैୋͬ࿒ঐ̱̞̀ͥȃଲ ‫ ٮ‬੝ ͈ Ο ϋ Έ χ · Ι ϋ ࢘ ႁ ບ ‫ث‬Ȫ2012 ාȫ͈ ࠫ ‫ض‬ȂWHO ̦ଔ੻̳ͥ Vero ळ༾ͬဥ̞̹ಎგদࡑ͈٨ၻ̦ຈါ
͂࡞̠̹ͩͦͥ̈́̽͢ͅȃِș͉Ȃ)FȖτΓίΗȜͬခ̳ͥ K562 ळ༾ͬဥ̞̹ͺΛΓͼࠏͬ‫ږ‬ၛ̱Ȃཡࢄͅ‫ͥͩ۾‬ࢯఘ‫̩̱ୃͤͬ͢ث‬ນ̳দ͙࣐̞ͬ̽̀ͥȃΟϋΈۛ৪ࠬୄͬဥ̞ͥ͂Ȃષ଎͈̠͢ͅΟϋΈ 1 ߿;ͼσΑۜஅळ༾ତ̦చચȪ103 PFU/mlȫͤ͢೩̞ಎგ‫͂଻ڰ‬Ȃ̞ͤࣞ͢௩
‫̦଻ڰޑ‬ෛഽջంഎͅা̯̹ͦȃ̷̱̀Ȃ༞ఘջం଻͂๱
ջం଻͈ၰ৪͈ࢯఘ͈ంह̦෇̹͛ͣͦȃΟϋΈ 1 ߿;ͼσΑͬࢯࡔ̱͂̀ैୋ̱̹ζ;ΑκΦ·υȜ΢σࢯఘ͉Ȃఉ̩̦ಎგ͂௩‫͈଻ڰޑ‬ၰ৪ͬෛഽջం
എͅা̱̹̦ȪNEAbȫȂಎგ‫͙͈ͬ଻ڰ‬া̳ࢯఘȪNAbȫ
͞௩‫͙͈ͬ଻ڰޑ‬া̳ࢯఘȪEAbȫ͜෇̹͛ͣͦȃχ·Ιϋ‫ٳ‬อͬࣾඳ̱̞̀ͥͅવ‫ ͈ٺ‬1 ̾ͅ௩‫͈଻ڰޑ‬ည൵ͥ͢ͅਹછ‫࠼͈ا‬ැ̦̜̦ͥȂNAb ͬఉ̩ည൵̳ͥ΀άΠȜίͬ঵̾ࢯࡔ̦Ȃͤ͢հ஠́࢘‫ض‬എ̈́χ·Ιϋ‫ٳ‬อ࣓ͅࡃ̳
ͥ͂ࣉ̢̞̀ͥȃड߃͈యນഎ̈́ა໲
1. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II
and displaying strongly neutralizing but not enhancing activity. Yamanaka A, Kotaki T, Konishi E. J Virol. 2013
Dec;87(23):12828-37.
2. Genetic and evolutionary analysis of cell-fusing agent virus based on Thai strains isolated in 2008 and 2012.
Yamanaka A, Thongrungkiat S, Ramasoota P, Konishi E. Infect Genet Evol. 2013 Oct;19:188-94.
3. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains ofdengue virus type 1 or 3 DNA vaccines in mice. Sjatha F, Takizawa Y, Kotaki T, Yamanaka A, Konishi E. Microbes
Infect. 2013 Nov;15(12):828-36.
4. Memory B cells: a proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine.
Konishi E. Expert Rev Vaccines. 2013 Aug;12(8):871-3.
5. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet
available. Ishikawa T, Yamanaka A, Konishi E. Vaccine. 2014 Mar 10;32(12):1326-37.
Ķĸঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭ۜஅ൲໤৘ࡑঔ୭
ࡄ‫ݪ‬ΈσȜίঔ୭ಿġ࿪‫ڠ‬ฎআġչ୼ȁୃ૽੩‫ޗ‬ġ୆ྵ‫ڠش‬ฎআġ ऎ൥ȁဉ࢖੩‫ ޗ‬ĩ ࠳ Īġ ၑ‫ڠ‬ฎআġ‫ݠ‬നȁহ຃

අහ੎‫ޗ‬਎ ĩ ࠳ Īġ ࿪‫ڠ‬ฎআȁ֙౓ȁիঊ੩‫ ޗ‬ĩ ࠳ Īġ֓‫ڠ‬ฎআȁ൥ࡔȁટࣞȁۜஅછ͉Ȃພࡔఘ̷͈͂ۜஅచય̜́ͥ਽৽͈͂௖ࡽ‫଼ͤ͢ͅ߸۾‬ၛ̳ͥȃ̱̹̦̽̀Ȃۜஅછ͈อછι΃ΣΒθ͂ພఠ̷̤͍͈͢হၷ༹ͬࡄ‫͉̹̳͛ͥͅݪ‬Ȃພࡔఘুఘ͈ٜଢ଼͂਽৽௰͈ཡࢄ‫͈ࢹܥ‬ٜଢ଼̦ਹါ̭͉̈́͂ুྶ
̜̦́ͥȂ̯ͣͅ൩͙ࣺͭ́ພࡔఘ͂਽৽ࡢఘ͈͂௖ࡽैဥٜͬଢ଼̳̭ͥ͂͜ຈါ̯͂ͦͥȃ̭͈̹͉͛ͅႉ઄́
͈ΟȜΗ͈ಇୟ͂͂͜ͅȂ൲໤৘ࡑٜͥ͢ͅଢ଼͂࠿બ͉Ȃഐ൚̈́యఢ৘ࡑ༹༷̦̞̹̈́͛Ȃະ‫خ‬๰͈͈̜́ͥ͜ȃ൚ࡄ‫ݪ‬ਫ਼͉́Ȃ୭ၛ൚੝ͤۜ͢அછࡄ‫͈ݪ‬ಎ͈́൲໤৘ࡑ͈ਹါ଻ͬ෇ে̳ͥ͂͂͜ͅȂ̷͈ͦͣ৘ࡑ̦հ஠́ୃ
‫̥̱͜ͅږ‬ഐୃ࣐̭̦ͩͦͥ͂ͅຈါ̜́ͥ͂ࣉ̢̞̀ͥȃུঔ୭͉Ȃ࣭ඤ́࿷͈֚ۜஅ൲໤৘ࡑঔ୭̱͂̀઎გ
42 ාͅ୭ၛ̯ͦȂশయͅ௲؊̱̹‫ͬא׋‬࿒ঐ̱̾̾Ȃۜஅછࡄ‫̞̤̀ͅݪ‬ఱ̧̈́࿨‫ͬڬ‬౜̞௽̫Ȃࣽ඾ͅঢ̽̀
̞ͥȃȁঔ୭͉ఱ̧̩ 2 ͈̾ߊ֖Ȃӱۜஅব֗৘ࡑߊ֖ (BSL2, BSL3)ȂӲSPF ব֗৘ࡑߊ֖Ȃͅ໦̧̫̭̦ͥ͂́ͥȃۜஅব֗৘ࡑߊ֖͈͒໤ৗ͈੄̱ව͉ͦȂpass-through Ηͼί͈ࣞգ૊‫ܨ‬྽޿‫ͬܕ‬೒̢̱̱̥࣐̞̀̈́ΏΑΞθ̞̈́̽̀ͥͅȃ̹ۜ͘அব֗৘ࡑߊ֖͉Ȃߗ಺ۖ๵֮͂͂͜ͅգͅ༗̭̾͂́؄அ͈ςΑ·ͬड઀ࡠͅဲ̢Ȃ̯ͣͅෳ‫ܨ‬
͉ HEPA έͻσΗȜᚹً̯̭ͦͥ͂́Ȃ‫ٸ‬໐͈͒ພࡔఘ͈ၗ८ͬཡ̞̞́ͥȃષܱ͈ΏΑΞθͤ͢ͅȂۜஅ൲໤͈ব֗͂৘ࡑ̦հ஠̢࣐ͥͅঔ୭̞͂̈́̽̀ͥȃȁ৘ष͈ঔ୭ঀဥ̜̹͉̽̀ͅȂӱ‫߱֗ޗ‬ႯȂӲ൲໤৘ࡑْࠗ੥͈೹੄͂ૣऔȂӳ೰‫ܢ‬എ̈́๷୆໤‫ڠ‬എκΣΗςϋΈ
൝ͤ͢ͅȂഐୃ̈́൲໤͈ব֗͂৘ࡑ഼̦࣐̠̞ͩͦͥ͛̀ͥ͢ȃঔ୭ࢹ଼ȁA ൓ȇࣞഽհ஠ব֗৘ࡑߊ֖Ȫ଎ 1ȫȂۜஅব֗৘ࡑߊ֖ȂSPF ব֗৘ࡑߊ֖Ȃ;΍Άব֗৒ȁB ൓ȇSPF ব֗৘ࡑߊ֖
ࡄ‫ٽݪ‬ါ
ȁۜஅછͅࡠ̴ͣ୆ྵ‫̞̤̀ͅݪࡄڠش‬Ȃ໦ঊτασ͈́ࡄ‫ͬض଼ݪ‬൲໤ࡢఘτασ́৘ࡑȆ࠿બ̳̹͈ͥ͛֒ഥ
ঊழ̢͙۟൲໤͈ਹါ଻̦ఱ̧̈́๤ਹͬ୸̠̞͛ͥ̈́̽̀ͥ͢ͅȃ൚ঔ୭͉́֒ഥૂ༭৘ࡑΓϋΗȜ͂‫ވ‬൳̱̀Ȃ୆૓ࢥ‫ڠ‬Ȇอ୆ࢥ‫ܖͬڠ‬๕̱̹͂֒ഥঊழ̢۟൲໤͈ैୋܿ੅͈ࡄ‫ݪ‬Ȇ‫ٳ‬อ࣐̠ͬ͂͂͜ͅȂӱΠρϋΑΐͿΣΛ
·൲໤͈ैୋȂӲΦΛ·ͺ;ΠȆΦΛ·ͼϋ൲໤͈ैୋȂӳࡐ๷਎ୈͥ͢ͅࠏൡ֋঵ȂӴ൲໤ࠏൡ͈ൄࠫ༗ం̈́̓Ȃड୶౤͈ܿ੅ͬဥ̞̹൲໤৘ࡑ͈̹͈͛ࡄ‫ݪ‬঑‫̞࣐ͥ̀̽ͬ׳‬Ȫນ 1ȫȃນ1) ঔ୭̤̞̀ͅैୋȆ༗ం̯̹ͦζ;Α͈ࠏൡତ଎ˍȫࣞഽհ஠൲໤ব֗৘ࡑ৒ȪA ൓ 1 ‫ٴ‬ȫΨͼ΂ΓȜέΞͻτασ 3 ͈ۜஅ৘ࡑ̢̦࣐ͥ
ࣞഽ‫ࡏܓ‬ພࡔఘ൲໤৘ࡑ৒̜́ͥȃུ৘ࡑ৒͈
၌ဥͤ͢ͅȂଅછ࢓଻੄ࠬ෎͈ພࡔఘౙၗ଼ࢗͅ ̱Ȃ· υ ͼ Μ έ Ϳ σ Π μ ΋ ή ພȂATLȂ
AIDS ͈̈́̓ພࡔ֦ঊͅ‫̳ͥ۾‬൲໤৘ࡑ̦հ஠
̥̾‫̢࣐ͥͅڲ׫‬ȃ

ĶĹ

‫ۼܢ‬
ĲĺĺĶĮĳıııĳııĲĮĳııĴ
ĳııĵĮĳııķ
ĳııĸĮĳııĺ
ĳıĲıĮĳıĲĲ
ĳıĲĳĮĳıĲĴ
ŵŰŵŢŭ

ŕŨζ;Α
ĳĳĹ
Ĳıĵ
ĵĴ
ĳĳ
ĴĲ
ĵĲ
ĵķĺ

ŌŐζ;Α
Ķı
Ķĸ
ķĺ
ĸĵ
ĸĺ
ĲĶĺ
ĵĹĹ

ൄࠫ༗ం
ĳķĲ
ĵĵĴ
ĴĴĲ
ĳĲķ
ĳĳı
Ĵĸĸ
ĲĹĵĹ

Tg,ΠρϋΑΐͿΣΛ·ȈKO,ΦΛ·ͺ;Πঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭ঔۜஅછˠ˪˝ΙΛί‫ٳ‬อΓϋΗȜ୭‫ٽ‬ࡄ‫ݪ‬ΈσȜίΓϋΗȜಿġĩ ࠳ Ī ‫ޗ‬਎ġ ၑ‫ڠ‬ฎআȁ࿤ോȁȁฎ੩‫ޗ‬ġ֓‫ڠ‬ฎআȁ؈ॄȁఱٚ੎‫ޗ‬਎ġĩ ࠳ Īġ֓‫ڠ‬ฎআȁᩊനȁ‫֚ܮ‬ါȁພࡔఘ͈঵̾ພࡔ଻֒ഥঊ̦ۜஅచય͈਽৽ळ༾̤̞̀ͅอ࡛̯̭ͦͥ͂̽̀ۜ͢ͅஅછ଼͉ၛ̳ͥȃۜஅછ͈อછ‫͂ࢹܥ‬ພఠ͈ၑٜ͉Ȃۜஅછ͈ཡࢄ༹͂হၷ༹͈‫ٳ‬อͅਹါ̜́ͥȃ̷͈̹͉͛ͅȂພࡔఘ͈֒ഥঊ̦਽৽͈
ळ༾ಎ́อ࡛̯ͦ̀ພࡔ଻ͬอ‫ॽ̳ͥܞ‬ழ͙̺̫̩́̈́Ȃ਽৽௰͈ཡࢄ‫̞֒̀̾͜ͅࢹܥ‬ഥঊτασٜ́ଢ଼̳̭ͥ
̦͂ຈါ͂̈́ͥȃ̳̻̈́ͩȂພࡔఘুఘ͈֒ഥঊȪΊΦθȫ͈͙̩́̈́Ȃ਽৽֒ഥঊȪΊΦθȫ͈ۜஅͅ؊൞̱̹
֒ഥঊอ࡛ΩΗȜϋ͈་൲ͬમळٜͅଢ଼̳̭̦ͥ͂‫ͥͦͣ͛ݥ‬ȃȁུΓϋΗȜ͉Ȃ̭͈࿒എͬో଼̳̹࣭ͥ͛ͅඤ́࿷͈֚ۜஅછͬచય̱̹͂ DNA ΙΛίΓϋΗȜ̱͂̀໹଼ 16ාഽͅอ௷̱̹ঔ୭̜́ͥȃུঔ୭͈́ࡄ‫ٳݪ‬อ͉ո‫̥༷͈ͣ࢜̾ˎ͈ئ‬ଔૺ̱̞̀ͥȃȪˍȫȁDNA ΙΛίȪDNA ζͼ·υͺτͼȫͬဥ̞̹֒ഥঊอ࡛͈༫‫گ‬എȆ࿌္എٜ̈́ଢ଼ȇȁུΓϋΗȜͅ୭౾̱̹ࣞྟഽ಼઀߿ DNA ͺτͼٜଢ଼ΏΑΞθͬߐঀ̱̀ΪΠȂζ;ΑȂۜஅఘ͈̈́̓֒ഥঊ͈
อ࡛ΩΗȜϋͬତྔࡢ͈֒ഥঊ͈อ࡛་൲ͬ൳শͅ۷ख़̱̦ٜ̈́ͣଢ଼
̳ͥȃ֚૗߿ DNA ζͼ·υͺτͼȪͺέͻιΠςΛ·Α২ȫ̤͍͢ඵ૗߿ DNA ζͼ·υͺτͼȪͺΐρϋΠ২ȫȂΐͿΦΩȜσ஖าͺτͼȪ२຅τͼπϋ২ȫ̴͈̞̞ٜͦ̾̀͜ͅଢ଼̦ଔૺ̧̠́ͥ̈́͢ఘ
ଷͬົ̞̞̀ͥȃΠρϋΑ·ςίΠȜθٜଢ଼̽̀͢ͅࡄ‫ݪ‬చય̱͂̀
ࣆࣺ̹ͤͦ֒͘ഥঊ̞͉̾̀ͅȂςͺσΗͼθ őńœ ٜଢ଼͞΢Φ΃;ϋΗȜ̽̀͢ͅࡢș͈দၳ̤̫ͥ֒ͅഥঊอ࡛ၾ͈་൲ͬમळٜͅଢ଼
̧́ͥΏΑΞθ͜๵̢̞̀ͥȃ༷֚ȂۜஅȆ྾‫ע‬ΏΑΞθ͈஖఼എΠρϋΑ·ςίΠȜθٜଢ଼༹͈‫ٳ‬อུ͜ΓϋΗȜ͈ࡄ‫ݪ‬ΞȜζ͈͌͂̾଎ˍȇࣞྟഽ಼઀߿ DNA ͺτͼٜଢ଼ΏΑΞθ̱͂̀ଔૺ̱̞̀ͥȃ֚႕̱͂̀ȂDNA ζͼ·υͺτͼٜଢ଼ͬ؊ဥ
̱̀Ȃ૧̹̈́ࠬ‫ ס‬RNA ૷౯ΏΑΞθͬࢹಃ̱Ȃ̷ͦͬඳহ଻ࠬ‫׶ۯ‬͈ພ֦֒ഥঊٜଢ଼͞૷౯ζȜ΃Ȝ൳೰̈́̓ͅ؊ဥ̳̞̠ͥ͂৘ဥഎ̈́
ࡄ‫͜ݪ‬ജ‫̞̱ͥ̀ٳ‬ȃȁȁȁȁ
Ȫˎȫȁৗၾ໦ଢ଼‫ͬܕ‬ဥ̞̹ΗϋΩ·ৗอ࡛͈༫‫گ‬എȆ࿌္എٜ̈́ଢ଼ȇȁ֒ഥঊอ࡛ͤ͢ͅॲ୆̯ͦͥΗϋΩ·ৗ͈༫‫گ‬എٜ̈́ଢ଼͜ਹါ̈́‫ه‬ఴ̜́ͥȃུΓϋΗȜͅ୭౾̱̹ 0606 ߿ৗၾ໦ଢ଼௡౾ͬߐঀ̱̀
ΪΠȂζ;ΑȂۜஅఘ̦̈́̓ॲ୆̳ͥΗϋΩ·ৗ‫͈ۼ‬௖ࡽैဥ͞ਘૐ
൲ఠ͈ٜ̈́̓ଢ଼ͬଔૺ̳ͥȃड߃͉́Ȃৗၾ໦ଢ଼௡౾ͬဥ̞̹ۜஅછ
͈૷౯ܿ੅̦̈́̓ૺ̞࡛ͭ́ͥેͬ‫͙ۻ‬Ȃड୶౤͈ࡄ‫ͅݪ‬చ؊̧́ͥ
ΏΑΞθ͜๵̢̭ͥ͂́Ȃඊু̈́ۜஅఘ࠿౶ΏΑΞθ͈‫ٳ‬อ͜ণ࿤ͅ

଎ˎȇ0606 ߿ৗၾ໦ଢ଼௡౾

වͦ̀ࡄ‫̞ͥ̀͛ૺͬݪ‬ȃड߃͈యນഎ̈́ა໲
1. Nagi-Miura N, Okuzaki D, Torigata K, Sakurai MA, Ito A, Ohno N, Nojima H. CAWS administration increases the
H[SUHVVLRQRILQWHUIHURQȖDQGFRPSOHPHQWIDFWRUVWKDWOHDGWRVHYHUHYDVFXOLWLVLQ'%$PLFHBMC Immunol.
2013 Sep 24;14:44.
 0XVR(2NX]DNL'.RED\DVKL6,ZDVDNL<6DNXUDL0$,WR$1RMLPD+)LFROLQLVXSUHJXODWHGLQOHXNRF\WHV
DQGJORPHUXOLIURPPLFURVFRSLFSRO\DQJLLWLVSDWLHQWVAutoimmunity. 2013 Dec;46(8):513-24.
 2NX]DNL'.LPXUD6<DEXWD12KPLQH71RMLPD+/HXNR&DWFKDTXLFNDQGHIILFLHQWWRROIRUWKHSUHSDUDWLRQRIOHXNRF\WHH[WUDFWVIURPEORRGBMC Clin Pathol. 2011 Aug 17;11:9.
 2NX]DNL')XNXVKLPD77RXJDQ7,VKLL7.RED\DVKL6<RVKL]DNL.$NLWD71RMLPD+*HQRSDODQRYHOKROORZILEUHDUUD\IRUIRFXVHGPLFURDUUD\DQDO\VLVDNA Res. 2010 Dec;17(6):369-79.
 7RXJDQ72NX]DNL'1RMLPD+&KXP51$DOORZVSUHSDUDWLRQRIDKLJKTXDOLW\F'1$OLEUDU\IURPDVLQJOHFHOOTXDQWLW\RIP51$ZLWKRXW3&5DPSOLILFDWLRQNucleic Acids Res. 2008 Sep;36(15):e92.
Ķĺঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭୆ఘ؊൞֒ഥঊٜଢ଼ΓϋΗȜࡄ‫ݪ‬ΈσȜίɃ֒ഥঊ٨་൲໤ैୋ໐࿝Ʉ
ȁ‫ޗ‬਎Ȫ࠳ȫġ࿪‫ڠ‬ฎআġչ୼ȁୃ૽ȁඅහ੎‫ޗ‬਎ġ෠‫ڠ‬ฎআġ५ᣵȁ֚ຳȁඅහ੩‫ޗ‬ġ୆ྵ‫ڠش‬ฎআġ ષനȁȁ੕Ƀ൲໤֋঵Ȇ‫ۯ‬ၑ໐࿝Ʉȁઉ̞͒‫ޗ‬਎ġ֓‫ڠ‬ฎআġ५ఆȁࡄ֚ȁඅහ੎‫ޗ‬਎Ȫ࠳ȫġ࿪‫ڠ‬ฎআġ֙౓ȁիঊȁ੩‫ޗ‬Ȫ࠳ȫġၑ‫ڠ‬ฎআġ‫ݠ‬നȁহ຃
Ƀ୆ఘ؊൞ٜଢ଼໐࿝Ʉ
ȁ‫ޗ‬਎Ȫ࠳ȫġ֓‫ڠ‬ฎআġૣၻȁ୓౳ȁ‫ޗ‬਎Ȫ࠳ȫġ֓‫ڠ‬ฎআġ࣏ଳȁȁંȁ‫ޗ‬਎Ȫ࠳ȫġ֓‫ڠ‬ฎআġ࿐‫ئ‬Ηυ;Ƀ୆ఘ؊൞ٜଢ଼໐࿝Ʉ
ȁ‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁȁȁ݊౓ȁȁ૾ȁ‫ޗ‬਎Ȫ࠳ȫġ ၑ‫ڠ‬ฎআȁȁȁ࿤ോȁȁฎȁ‫ޗ‬਎Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁȁȁࣞாȁ૝ࢨȁ‫ޗ‬਎Ȫ࠳ȫġ ၑ‫ڠ‬ฎআȁȁȁ‫ؖ‬നȁٗ૽ȁ੩‫ޗ‬Ȫ࠳ȫġ ֓‫ڠ‬ฎআȁȁȁ൥ࡔȁટࣞɃ‫ވ‬൳ࡄ‫ݪ‬ଔૺ໐࿝Ʉ
ȁઉ̞͒‫ޗ‬਎ġ ၑ‫ڠ‬ฎআȁȁȁ‫܊‬ாဢ֚჊ȁઉ̞͒‫ޗ‬਎ġ ֓‫ڠ‬ฎআȁȁȁ‫݌‬നȁૺ઎ȁ੩‫ޗ‬Ȫ࠳ȫġ ၑ‫ڠ‬ฎআȁȁȁࢃ൥ȁೄ‫ݛ‬ȁ੩‫ޗ‬Ȫ࠳ȫġ ୆ྵ‫ڠش‬ฎআȁऎ൥ȁဉ࢖ȁ୆ఘ͉ఉ̩͈֒ഥঊ͈൱̧̽̀͢ͅࢭુ଻̦༗̹̞͈֚ͦ̀ͥ̾ΏΑΞθ̜́ͤȂ֒ഥঊ͈‫ܥ‬ෝ։ુ̦ఉ̩͈৖
ພͅ‫۾‬ဓ̱̞̀ͥȃਲ̽̀Ȃ૧̹̈́হၷ༹͈‫ٳ‬อ͈̹͉͛ͅ৖ພͅ‫۾‬Ⴒ̳ͥ֒ഥঊ͈‫ܥ‬ෝ̷͈͂ͦͣ௖ࡽ‫ͬ߸۾‬౶̭̦ͥ͂ਹါ̜́ͥȃ̱̥̱Ȃྚ̺ఉ̩͈֒ഥঊ͈‫ܥ‬ෝ͉ະྶ̜́ͤȂ৖ພͅ‫۾‬ဓ̳ͥ֒ഥঊ͈࿨‫̦ڬ‬ఘࠏഎٜͅ
ଢ଼̯̹ͦ႕͉ઁ̞̈́ȃȁ֒ഥঊ‫ܥ‬ෝ͈ٜଢ଼͉֒ͅഥঊ٨་൲໤̦ޭ͛̀ခဥ̜́ͤȂ৖ພ͈อછ‫̱̥̀ͣͅྶͬࢹܥ‬ခ࢘̈́হၷ༹ͬ‫ږ‬ၛ̳̹͉ͥ͛ͅȂழ૕എ֒ͅഥঊ٨་൲໤ͬैୋ̳ͥ͂͂͜ͅȂِ̦࣭ඊু͈୆໤঩࡙ͬ‫ږ‬༗̳̭̦ͥ͂‫̜ͥ́ྩݢ‬ȃ̳́ͅ੨‫͉࣭́ٸ‬஻࿪ͅ‫̳ͥ۾‬౶എ़ॲࡀ͈‫ږ‬༗ͬැ൮ͅఱၾ͈֒ഥঊ٨་ζ;Α͈ैୋίυΐͿ·Π̦ই̽̀͘
̤ͤȂ்ِ̦࣭̤̞̀͜ͅ‫ͅݢ‬ఘࠏഎ̈́ఘଷͬା๵̱̫̞̈́ͦ͊̈́ͣ̈́ȃȁ̷̭́Ȃ̭ͦ́͘ͅఉ̩͈֒ഥঊ٨་ζ;Αͬैୋ̱̹৘ୡ͈ཅີ̈́ఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼Ȫ๷ࡄȫȂ൐‫ނ‬ఱ
‫ݪࡄڠش֓ڠ‬ਫ਼Ȫ֓‫ࡄش‬ȫȂߧུఱ‫ڠ‬୆ྵ঩࡙ࡄ‫ݪ‬Ȇ঑‫׳‬ΓϋΗȜȪ୆ྵ঩࡙ΓϋΗȜȫ̦ඊুͅ‫ٳ‬อ̱̹࿹̹ͦ
ܿ੅ͬ௖ࡽͅ೹‫̠ࣣ̱͂͂͜ͅރ‬Ȃచયͬࣆ̭͙̦ͤ̈́ͣ࢘ၚഎ̥̾ࠏൡഎ֒ͅഥঊ٨་ζ;Αͬैୋ̳ͥȃ̯ͣͅȂ̷̸͈ͦͦ̾͜࿹̹ͦພఠٜଢ଼ΏΑΞθͬ௖ࡽ၌ဥ̳̭ͥ͂́Ȃِ̦࣭͈୆ྵ‫ݪࡄ͈ڠش‬͈อജͅ঩̳ͥயͬಃ̩ȃ֓‫̦͉ͭ́ࡄش‬྾‫̳֒ͥ۾ͅע‬ഥঊ߲̞̾̀ͅȂ̷̱̀୆ྵ঩࡙ΓϋΗȜ͉́ඳহ৖ۛͅ‫̳ͥ۾‬֒ഥঊ߲̞̾̀ͅȂ̷̱̀๷ࡄ͉́୆૓։ુȆۜஅȆͺτσΆȜ྾‫̳֒ͥ۾ͅע‬ഥঊ߲̞̾ͅ
̀έ΁Ȝ΃Α̜ͬ̀̀ࡄ‫̠࣐ͬݪ‬ġĩ ଎ ĲĪȃ̹͘‫͈̾͜۾ܥڎ‬ಿਫ਼̤ͬࡽ̞ͅ၌ဥ̱̦̈́ͣȂ̷̸̦ͦͦඅ‫̹̱ا‬໦࿤͈֒ഥঊ٨་ζ;Α͈ैୋ࣐̠ͬȃං̹ͣͦ֒ഥঊ٨་ζ;Α͉‫۾ܥڎ‬̦Ⴒࠈ̱̹࢘ၚഎٜ̈́ଢ଼ΏΑΞθ̥̫̭ͥ͂ͅ
ͤ͢ͅ৖ພ͈͂Ⴒ‫̳̥ͥͣͅྶͬ۾‬ȃ଎ Ĳȁະළછ͈ٜྶ̫̹࢜ͅΑΠρΞΐȜड߃͈యນഎ̈́ა໲
1. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA.
Mashiko D, Fujihara Y, Satouh Y, Miyata H, Isotani A, Ikawa M. Sci Rep. 2013 Nov 27;3:3355.
2. MiR-200b and miR-429 Function in Mouse Ovulation and Are Essential for Female Fertility. Hasuwa H, Ueda J,
Ikawa M, Okabe M. Science. 2013 Jul 5;341(6141):71-3.
3. Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Fujihara Y,
Tokuhiro K, Muro Y, Kondoh G, Araki Y, Ikawa M, Okabe M. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8111-6.
4. Visualization of the moment of mouse sperm-egg fusion and dynamic localization of IZUMO1. Satouh Y, Inoue N,
Ikawa M, Okabe M. J Cell Sci. 2012 Nov 1;125(Pt 21):4985-90.
5. Testis specific PDILT is required for quality control of sperm membrane protein ADAM3 and male fertility.
Tokuhiro K, Ikawa M, Benham AM, Okabe M. Proc Natl Acad Sci U S A. 2012 March 6;109 (10):3850-3855.
ķıঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭ঔ๷ࡄηνȜΐͺθ

୭
‫ٽ‬

৒ȁȁಿ

ࢩ༭տ֥ಿ ĩ ࠳ Ī ‫ޗ‬਎ȁၑ‫ڠ‬ฎআȁ࿤ോȁฎါঔ୭‫ٽ‬ါ
ȁఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼͉ಅ๶ࠫ‫ݪࡄړ‬ਫ਼͂ఱिඅਂ๧ໂພࡄ
‫ݪ‬ਫ਼ͬ໵̵̀઎გ˕ා (1934) ͅ୭ၛ̯̹ͦȃ஻ၛ 70 ਔාܱͬැ
̱̀๷ࡄηνȜΐͺθͬ୭౾ْ̳̭̦̯ͥ͂ࠗͦȂ2010 ා 12 ࠮
17 ඾͈‫܁ٳ‬৆ͬ̽̀͜ୃ৆ͅ‫̹̱܁ٳ‬Ȫ଎ˍȫȃ‫ڠ‬ඤ৪Ȃ‫ٸڠ‬৪͂͜ͅ໹඾͈ಱ 9:00~17:00 ́͘ুဇͅ੄ව̧ͤ́ͥȪවાྫၳȫȃ̹͘਋ັ́༿ྴನͅྴஜܱͬව̳ͦࣧ‫̈́ل‬ΩϋέτΛΠ̦ίτΔϋΠ̯ͦͥȃ̳́ͅ‫ˍ܁ٳ‬ාոඤ֚ͅ୷ྴոષ͈ြང৪͈ྴஜͬ
༿ྴನܱͅश̯̹ͦȃȁ๷ࡄ͈อટ͉઎გ 4 ාȪ1929ȫ̯̥͈͖ͥͅȃఱि֓‫ش‬ఱ‫ڠ‬Ȫ઎଎ˍȇ‫܁ٳ‬৆ஜ͈๷ࡄηνȜΐͺθ

გ 6 ාఱिೱ࣭ఱ‫ۯ֊ͅڠ‬ȫ͈නུಿ२჊Ȇ‫ڠ‬ಿ͂౓࢛ᦂඵȆळ޿ࠬୄ‫ޗڠ‬਎͉Ȃఱि͞૰࡫̦΋τρȆβΑΠ͈̈́̓‫ٸ‬ြഥஅພ͈૟ව࿝࡫̜̹̭͂̈́ͤ̾̾̽͂ͬ૤෻̱̞̹̀ȃఱୃ 12 ා͈‫۾‬൐ఱૼब͈‫̜̀̽߱͜ޗ‬Ȃ‫۾‬ୌȪඅͅఱिȫͅ๷୆໤ພͅ‫̳۾‬ͥ௙ࣣഎࡄ‫ͬ۾ܥݪ‬୭ၛ̳ͥຈါ଻ͬࢩ̩୰̞̀ٝͤȂ൚শ͈ఱिຸ౶মড়ന஝२჊͞ఱि़‫͉ͅٮ‬ୟޭഎ̈́‫ފ‬ႁͬါ୏̱̹ȃ५࢛࡚൸ঙ͉Ȃ̭͈ါ୏ͅ؊̢̀ 20 ྔ‫׫‬Ȫ࡛ह͈ତ‫ͅ׫ؙ‬௖൚ȫͬ‫̱ັܙ‬Ȃ̭ͦͤ͢ͅ઎გ 9 ාȪ1934ȫ2 ࠮Ȃఱिঌཤߊ൴ോୌ಴ 3๔౷ͅࡄ‫ݪ‬ਫ਼ུ‫̹̱ࢥੋ̦܁‬ȃ൴ോ΅λϋΩᾼ͉‫ͅܡ‬ಅ๶ࠫ‫ړ‬ࡄ‫ݪ‬ਫ਼Ȫಅ๶হֲ‫מ‬࿝ঙ͈‫ັܙ‬ȫ͂ఱिඅਂ๧ໂພࡄ‫ݪ‬ਫ਼Ȫඈ঎‫ັܙ͈ز‬ȫ̦̜ͤ‫ڰ‬อ̈́ࡄ‫ڰݪ‬൲࣐̞̹̦ͬ̽̀Ȃ̭ͦͣˎ‫۾ܥ‬ͬ໵̵̀઎გ 9 ාȪ1934ȫ9 ࠮ 17 ඾ೂ႓ 270 ࣢ͤ͢ͅȂఱिೱ࣭଎ˎȇಅ๶ࠫ‫ݪࡄړ‬ਫ਼͈ۭโ̤͍͢ಅ๶হֲ‫מ‬࿝ঙ͈ȁȁȁ‫ޝ‬௨Ȫऒȇల Ĳı యȂֲȇల ĲĲ యȫఱ‫້ڠ‬౾͈๷୆໤ພࡄ‫ݪ‬ਫ਼ۗଷ̦࢖ື̯ͦȂུࡄ‫ݪ‬ਫ਼̦อ௷̳ͥ
ͅঢ̹̽ȃȁ๷ࡄηνȜΐͺθ͈ಎ͉ͅಅ๶ࠫ‫ݪࡄړ‬ਫ਼͈୭ၛͅ଄ႁ̯̹ͦಅ๶হֲ‫מ‬࿝ঙȪऒȇల 10 యȂֲȇల 11 యȫ͈‫ޝ‬௨Ȫ଎ˎȫ͞ΡͼΜͤ͢‫̹̯ͦັܙ‬΋Λγ͈ࡐ๷‫ޢ‬Ȫ଎ˏȫȂ٬ဢ൴ୋȪඅಕȫ͈ͼϋέσ΀ϋΎȪ଎ːȫ͂
SARS ;ͼσΑȪ଎ˑȫ͈࿅߿̦̈́̓ജা̯̞ͦ̀ͥȃȁમळ͉γȜθβȜΐȪhttp://museum.biken.osaka-u.ac.jp/ȫͬ४ચ͈̭͂ȃ଎ˏȇ΋Λγ͈ࡐ๷‫ޢ‬଎ːȇ٬ဢ൴ୋ͈ͼϋέσ΀ϋΎ;ͼσΑ͈࿅߿଎ˑȇ٬ဢ൴ୋ͈ ŔłœŔ ;ͼσΑ͈࿅߿ķĲঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭

ಎ؇৘ࡑ৒
৒ȁȁಿ

‫ޗ‬਎ȁȁၑ‫ڠ‬ฎআȁ२࿐ȁဉྶ੎‫ޗ‬਎ȁ࿪‫ڠ‬ฎআȁ൐५ȁ૯ඵ੩‫ޗ‬ġၑ‫ڠ‬ฎআȁḶ൥ȁ֚૝අහ੩‫ޗ‬Ȫ࠳ȫġ ၑ‫ڠ‬ฎআȁ૩ઐȁ๼‫ܮ‬ȁಎ؇৘ࡑ৒͉઎გˏːාஜࢃȂ৘ࡑ‫̦ܕܥ‬ະ௷̱̞̹̀শ‫ͅܢ‬Ȃ‫ވ‬೒́ঀဥ̧́ͥ‫ݪࡄڎͬܕܥ‬৒̥ͣ঵̻‫ͤܙ‬Ȃ௖ࡽ͈༒ܽͬ଎ͥ࿒എ́୭ၛ̯̹ͦȃ࡛ह͉́Ȃအș̈́ୈྟȆࣞ଻ෝ̈́ࡄ‫̦ܕܥݪ‬୭౾̯ͦȂ̞̾́͜ঀဥ‫خ‬ෝ̈́ેఠ̞̈́̽̀ͥͅȃ৽ါ̈́ࡄ‫͉̱̀͂ܕܥݪ‬Ȃ໦ၗဥ಼‫׿‬૤‫ܥ‬Ȃ൫ً߿̤͍͢௢औ߿ഩঊࡐ๷‫ޢ‬Ȃ໦ঊ‫ۼ‬௖ࡽैဥٜଢ଼ΏΑΞθȪBiacoreȫȂΓσΕȜΗȜȂίρΑηΡু൲໦ၗ௡౾ȂDNA ΏȜΉϋ΍ȜȂৗၾ໦ଢ଼௡౾̦̈́̓୭
౾̯̞ͦ̀ͥȃ̷ͦͅ‫̢̀ح‬Ȃ‫ס‬ఘಊள͈‫ুͬݯރ‬൲‫̹̱ا‬ఱ߿ळ༾༗ంΗϋ·৒Ȃඅ೰‫ڠا‬໤ৗͬ৾ͤե̠̹͈͛৘ࡑ৒̈́̓ۖ͜๵
̱̞̀ͥȃ౜൚͈ܿ੅৪͉‫͈ܕܥ‬༗৿Ȇ‫ۯ‬ၑ̺̫̩́̈́Ȃ૧වࡄ‫ݪ‬৪ͅచ̱͈̀‫֗ޗ‬Ȇ߱Ⴏͬ໦౜̱̞̀ͥȃ̹͘ȂΓσΕȜΗȜͥ͢ͅळ༾͈໦ْȂৗၾ໦ଢ଼௡౾ͥ͢ͅ౩ฒৗ͈൳೰Ȃഩঊࡐ๷‫͢ͅޢ‬ͥ۷ख़Ȃ̤͍͢ȂDNA ΏȜΉϋ΍Ȝͥ͢ͅ‫ܖ؂‬෻Ⴅࠨ೰̞͉̾̀ͅȂ਋ుުྩ̱͂̀Ȃࡄ‫ݪ‬৪̥ͣջှ̯̹ͦ΍ϋίσ͈ٜଢ଼ͬయ࣐̱̀
̞ͥȃ৘ࡑ‫ף͉ܕܥ‬șໝॠ‫̤̱ͤ̀ا‬Ȃࡄ‫ݪ‬৪ࡢ૽͉́ఉਅ႒͈৘
ࡑ‫ͬܕܥ‬ௌै̧̩̩̹́̈́̈́̽̀ͥ͛Ȃ̭͈ͦͣ਋ుުྩ͉ࡄ‫ݪ‬ਫ਼̤̞̀ͅਹါ̈́࿨‫̞̱̹ͥ̀ضͬڬ‬ȃ༶ৣ଻൳պࡓள৘ࡑ৒৒ȁȁಿ‫ޗ‬਎ȁȁၑ‫ڠ‬ฎআȁ२࿐ȁဉྶ੎‫ޗ‬਎ȁ࿪‫ڠ‬ฎআȁ൐५ȁ૯ඵȁ൚৘ࡑ৒͉֓‫ڠ‬എࡄ‫̞̤̀ͅݪ‬༶ৣ଻൳պࡓளͬဥ̞ͥ৘ࡑ࣐̠̹͈ͬ͛
ঔ୭̱͂̀Ȃࡄ‫ݪ‬ਫ਼͈଑ന΅λϋΩΑ֊ഢฺ̞ͅȂ઎გ 42 ාͅࡄ‫ݪ‬ਫ਼ུ‫ͅ܁‬߃୪̱ RI ‫ވ‬൳৘ࡑ৒̱͂̀୭౾̯̹ͦȃ઎გ 54 ා͉ͅཤ‫ވٴˍ܁‬൳ྫ޿ RI
৘ࡑ৒Ȃ઎გ 58 ාۜͅஅછ‫ވ‬൳৘ࡑ൓ RI ৘ࡑ৒Ȃ໹଼ 10 ාͅධ‫܁‬౷‫ٴˍئ‬Cs ΄ϋζ஌ચৣ৒Ȃ̯ͣͅ໹଼ 19 ා͉֒ͅഥૂ༭৘ࡑΓϋΗȜ RI ৘ࡑ৒

137̦‫̹̽ͩح‬ȃ̹͘Ȃ໹଼ 22Ȃ23 ාഽ͉ͅჇ‫ ̹͈͛اݤ‬RI ‫ވ‬൳৘ࡑ৒Ȃཤ‫܁‬ˍ‫ވٴ‬൳ྫ޿ RI ৘ࡑ৒Ȃ֒ഥૂ༭৘ࡑΓϋΗȜ RI ৘ࡑ৒ͬ෱গ̱Ȃ૧̱̩྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜ൓˕‫ ͅٴ‬RI ৘ࡑ৒ͬ୭౾̱̹ȃ̹͘Ȃධ‫܁‬͈٨ಃฺ̞ͅȂ137Cs ΄ϋζ஌ચৣ৒͉ཤ‫֊ͅٴˍ܁‬୭̱̹ȃ༶ৣ஌‫ۯ‬ၑߊ֖ඤ͉ͅ༶ৣ଻൳պࡓளಡ௬৒Ȃ෱‫ܤ‬໤༗‫ۯ‬৒Ȃ૆‫ا‬୭๵‫ঀ͍ݞ‬ဥ̳ͥાਫ਼́
̜ͥ৘ࡑ৒͂‫ڎ‬ਅࡄ‫ݪ‬࿒എ̵̜̹ͩͅ༶ৣ஌௶೰‫ܕܥ‬৒Ȃ෽ူ৒൝̦୭̫ͣ
̞ͦ̀ͥȃ༶ৣ஌‫ۯ‬ၑߊ֖͈͒වప৒͉ࡢ૽஌ၾࠗ๔࣢ͤ͢ͅਬಎ‫ۯ‬ၑ̯̤ͦ̀ͤȂ༶ৣ଻൳պࡓள͈ঀဥ͈ܱ჏൝͜΋ϋάνȜΗ‫ۯ‬ၑ̯ͦȂհ஠଻ͬ༗঵̱̞̀ͥȃ໹଼ 25 ාഽ͈ഴ჏̯̹ͦ༶ৣ஌ުྩਲম৪͉ 246 ྴ̜̹́̽ȃķĳঔ୭‫ٽ‬ါȁResearch Facilities້௺ࡄ‫ݪ‬ঔ୭ȟ‫ވ‬೒ࡄ‫ݪ‬ঔ୭ঔۜஅછ‫ވ‬൳৘ࡑ৒

୭
‫ٽ‬

৒ȁȁಿ

‫ޗ‬਎ȁ֓‫ڠ‬ฎআȁ‫؂‬നȁోဎါȁ൚৘ࡑ৒͉ 1983 ාͅଅછ࢓଻੄ࠬ෎ȪHFRSȫ;ͼσΑͬ৾ե̠ঔ୭͂
̱̀࠺ಃ̯̹ͦȃΪΠ྾‫ע‬ະ஠;ͼσΑȪHIVȫͬ‫̀͛܄‬Ȃ‫ࡏܓ‬ഽ͈̞ࣞȪ·ρΑ 3ȫພࡔ๷୆໤ͬ৾եུ̠ࡄ‫ݪ‬ਫ਼͈́ࡄ‫͓̳͉̀ݪ‬൚৘ࡑ৒࣐́ͩͦ̀
̞ͥȃ൚৘ࡑ৒͉໹࿂ୟ 550 Ԧͬခ̳ͥˏ‫́࠺ٴ‬Ȃ୆໤‫ڠ‬എब‫ٺ‬ȪΨͼ΂ΧΎȜΡȫͬཡগ̳̠ͥ͢୭̯̞ࠗͦ̀ͥȃ‫ڎ‬৘ࡑ৒͉΀ͺυΛ·ͤ͢ͅ‫ٸ‬໐͂‫ڞ‬ၗ̯ͦȂ৘ࡑ৒ඤ͉́‫ٸ‬ĺඤ͈‫ܨ‬ၠͬ‫ږ‬༗̱̞̀ͥȃۜஅછ৘ࡑ
ௌै͉հ஠΅λΫΥΛΠඤ࣐̞́Ȃෳ‫଻͉ࣞܨ‬ෝέͻσΗȜ̽̀͢ͅᚹً
྽޿̯ͦͥȃ‫ڎ‬৒ͅ΂ȜΠ·τȜήͬ୭౾̱Ȃ৘ࡑঀဥ໤͉ۖ஠྽޿ͬঔ
̱̹ࢃͅ෱‫̞̱ͥ̀ܤ‬ȃఉအ̈́ພࡔఘͬ൳শ৾ͤͅե̢̠ͥ͢໹଼ 17 ාഽ
̥ͣ 3 ා̥̫̀஠࿂എ̈́٨ਘ࣐̞ͬȂ໐‫ؚ‬ତͬ 1.5 ෼ͅ௩̱̹͞ȃȁۜஅછ‫ވ‬൳৘ࡑ৒͈ঀဥ૭୏੥ͬ೹੄̱ພࡔఘ൝հ஠‫ۯ‬ၑտ֥ٛ́ઇ෇
̯̹ͦ৘ࡑ৒ঀဥ৪͈ତ͉໹଼ 24 ාഽ 45 ྴȂ25 ාഽ 53 ྴ̜̹́̽ȃঀဥພࡔఘ͉ HIVȂͼϋέσ΀ϋΎ;ͼσΑȂSARS ;ͼσΑ͈̈́̓;ͼσΑ͈ఈȂΑ·τͼάȜພࡔఘ́͘ఉ‫ͅܚ‬ളͥȃ

଎ȁ੥ȁ৒
৒ȁȁಿ

‫ޗ‬਎ȁฎআȪၑ‫ڠ‬ȫȁ२࿐ȁဉྶȁ๷ࡄ଎੥৒͉๷୆໤‫ڠ‬Ʀ྾‫ͬڠע‬ಎ૤ͅƥ‫۾‬Ⴒ̳ͥळ༾‫ڠ‬ƥ֒ഥ‫ڠ‬ƥழ૕‫ڠ‬ƥอ୆‫ڠ‬ƥ୆‫ڠا‬ƥ࿪ၑ‫ڠ‬ƥພၑ‫ڠ‬ƥळ޿‫ڠ‬Ȃਆន‫ڠ‬൝͈଎੥Ȇ‫੅ڠ‬ॠধͬ৽ͅਓਬ̱̞̀ͥȃಎ́͜‫ܙ‬୆ಖ‫͈߸۾ڠ‬௬੥͉Ȃఈ‫̜ͤ́͘۾ܥ‬ਫ਼௬̯̞̞ͦ̀̈́͜
͈͜ఉ̩Ȃ‫ڠ‬ඤ‫͈ٸ‬ఉ༷࿂̥ͣ၌ဥ̯̞ͦ̀ͥȃȁဏࣣ߿୆ྵ‫ڠش‬௙ࣣࡄ‫ݪ‬൓૧‫ฺ̞ͅא‬Ȃ2007 ා 12 ࠮̥ͣධ‫ ܁‬1F ͅ‫ب‬଎੥৒ͬ‫ٳ‬৒̱̞̹̦̀Ȃ2010 ා 7 ࠮Ȃఛૼ٨ਘࢥম̦ਞၭུ̱̹‫ ܁‬1F ͅ૧୭̯̹ͦ଎੥৒͒֊ഢ̱̹ȃ‫ب‬଎੥৒͉๱ુͅ਀‫̹̹̺͛̽ޛ‬Ȃ൚ࡄ‫ݪ‬ਫ਼́อ࣐̯̹ͦո‫੅ڠ͈ٸ‬ॠধ̞͉̾̀ͅȂ1991 ාոࣛอ࣐໦̥͈ͣਫ਼௬̹͂̈́̽ȃ࡛ह͈௬੥ତ͉࿩ 1 ྔ 4 ୷ॗȂ೰‫ܢ‬എͅ਋ව̱̞̀ͥॠধ͉Ȃ؎໲ধ࿩ 18 ΗͼΠσȂგ໲ধ࿩ 23 ΗͼΠσ̜́ͥȃ2010 ාոஜ͈ॠধ͉Ȃཤ‫܁‬
1F ͈੥ࡩͅภ‫̞̱ͥ̀ݑ‬ȃȁ଎੥৒́ਫ਼௬̱̞̀ͥ঩ၳ͉Ȃ້௺଎੥‫΂͈܁‬ϋρͼϋ࿒჏ΏΑΞθͅഴ჏̯̤ͦ̀ͤȂ࣭ၛૂ༭‫ݪࡄڠ‬ਫ਼͈ILL(Interlibrary Loan) ΏΑΞθ̽̀͢ͅ஠࣭͈ఱ‫ڠ‬଎੥‫͈͂܁‬௖ࡽ၌ဥ̦‫خ‬ෝ̞̈́̽̀ͥͅȃ଎੥৒‫א׋‬տ֥̱͂̀Ȃ‫ޗ‬਎ 2 ྴȂ੎‫ޗ‬਎ 2 ྴ̦‫͈א׋‬හͅ൚̹ͤȂ৘ष͈૖ྩ͉ 1 ྴ͈૖֥࣐̞ͤͩͦ̀ͥ͢ͅȃķĴ‫۾‬Ⴒঔ୭ȁRelated Facilityଲ‫ٮ‬ΠΛίτασࡄ‫ݶݪ‬ത྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜɜུ‫ݶ‬ത͈අ૗͂փ݅
ȁ྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜȪImmunology Frontier ResearchCenter : IFReCȫ͉Ȃଲ‫ٮ‬ΠΛίτασ͈ȶ࿒ͅࡉ̢ͥ‫ݶ‬തࠁ଼ȷͬ࿒എ̱̹͂Ȃ໲໐‫ڠش‬જ͈ȶଲ‫ٮ‬ΠΛίτασࡄ‫ݶݪ‬തίυΈρθȷͅन఼̯ͦ໹଼19ා10࠮1඾ͅอ௷̱Ȃ྾‫͈ݪࡄڠע‬ల֚૽৪̜́ͥૣၻ୓౳‫ޗ‬਎̦‫ݶ‬തಿͅਖහ̱̱̹͘ȃȁ྾‫͉͂ڠע‬๷୆໤ۜஅِ̥ͣș͈ఘͬ৿ͥ୆ఘཡࢄ͈ι΃ΣΒθͬࡄ‫ڠ̳ͥݪ‬࿚ఘࠏ̳́ȃ྾‫ע‬ΏΑΞθ͉ۜஅ̱̹ພࡔఘ
ͬ਽৽̥ͣෳੰ̳ͥષ́ຈଌ̜́ͤȂ྾‫ע‬ΏΑΞθ͈։ુ͉Ȃুࡨ྾‫ע‬৖ۛȂ֊૒༌‫୲ݵ‬ȂͺτσΆȜ฽؊̞̹͂̽အș̈́৖͈ۛࡔ֦̳͂̈́ͤ͘ȃȁ྾‫͉ڠע‬Ȃ඾ུ̦ςȜΡ̧̱̹̀ႀ֖͈̜֚̾́ͤȂ̷͈ఉ̩ͬ५ఆဎ֚ࡓ௙ಿ͞‫ུ܅‬಑२ࡓ௙ಿ͉̲̳ͬ͛͂ͥఱिఱ‫ڠ‬͈ࡄ‫ݪ‬৪଼̦̱ଛ̧̬̱̹̀͘ȃIFReC͉Ȃ̭̠̱̹྾‫ࡄڠע‬‫ͤͬ͢ݪ‬อജ̵̯̹ͥ͛Ȃ྾‫ͼ͂ڠע‬ιȜΐϋΈȪْ௨‫ا‬ȫܿ੅Ȃ̯ͣͅΨͼ΂ͼϋέ΁ζΞͻ·ΑȪ୆ఘૂ༭‫ڠ‬ȫ͈͂ဏࣣࡄ‫ͬݪ‬೒̱̀Ȃ൲໤୆ఘඤȪin vivoȫ̤̫ͥͅ྾‫ע‬฽؊ͬ‫خ‬ণ‫ا‬Ȃ̜̞͉ͥထ௶̳̭ͥ͂ͥ͢ͅ྾‫͈ࠏע‬൲എ̈́஠ཞͬྶ̥ͣ
̳̭ͥ͂ͬͅ࿒എ̱̞̳͂̀͘ȃIFReĆ͉Ȃ20ྴոષ͈ଲ‫ٮ‬ΠΛίτασ͈৽හࡄ‫ݪ‬৪ͬಎ૤ͅȂଲ‫ͅٮ‬႒͈̞̈́ࡄ‫ݶݪ‬ത͈ࢹಃͬ࿒ঐ̱̞̳̀͘ȃࡄ‫ݪ‬৒྾‫ע‬ΈσȜί࣭षন࿚տ֥ٛ‫ݶ‬തಿ໗‫ݶ‬തಿ

‫א׋‬տ֥ٛ

య݈֥ٛুட྾‫ڠע‬Ȫૣၻ ୓౳ȫ৘ࡑ྾‫ڠע‬Ȫा࢛ ঎໲ȫൠङ྾‫ڠע‬Ȫ࿐‫ ئ‬Ηυ;ȫ྾‫ע‬ΏΈ΢σȪ୔൥ ၦȫۜஅພఠȪߧΦ‫ ޡ‬੓ȫ

໦‫ا‬ଷࢄȪࣱॄ ౶ฎȫ྾‫ڠاע‬Ȫ࣏ଳ ંȫςϋΩ‫ݩ‬໦‫ا‬ȪFritz Melchersȫ

྾‫ܥע‬ෝൡࢄ‫ڠ‬Ȫ‫ ུ܅‬಑२ȫζρςͺ྾‫ڠע‬ȪCevayir Cobanȫ

྾‫ܥע‬ෝൡࢄ‫ڠ‬Ȫ٨ୃ ࢭࢫȫχ·Ιϋ‫ڠ‬Ȫ୞֔ ࠲ȫු྄྾‫ڠע‬Ȫಅന ࠩȫ྾‫ע‬ΥΛΠχȜ·Ȫ‫ل‬५ġႁ଼ȫ໦ঊ྾‫ע‬ଷࢄȪ݊౓ ૾ȫ྾‫ܙע‬୆ಖ‫ڠ‬Ȫ५ུ ٗဉȫ྾‫ע‬୆‫ڠا‬Ȫಿന ਹ֚ȫͼιȜΐϋΈΈσȜί1ळ༾1໦ঊͼιȜΐϋΈȪ࿮ന ຮဎȫ‫ڠا‬໦ঊͼιȜΐϋΈȪ݊౷ გ࿟ȫ୆ఘ‫ܥ‬ෝͼιȜΐϋΈȪ‫ ؖ݌‬༿૶ȫ୆ఘέ΁ΠΣ·ΑȪNicholas Isaac Smithȫ

྾‫ע‬ळ༾୆໤‫ڠ‬Ȫ୞֔ ࿹ȫ྾‫ע‬؊൞Θͼ΢η·ΑȪႝ࿐ ֚ฎȫ‫ڠ֓ړ‬Ȫศᚧ ਜ਼ȫෞȽ྾‫ࠏע‬௖ࡽैဥȪBen Seymourȫ

Ψͼ΂ͼϋέ΁ζΞͻ·ΑΈσȜίૂ༭ΏΑΞθȪศ ཅȫْܑ৒মྩ໐࿝ಿȟْܑ৒ಿ
মྩ৒ಿ

ķĵ

௙ྩΓ·Ώοϋ
ٛࠗΓ·Ώοϋ

྾‫ע‬ΏΑΞθ‫ڠ‬ȪDaron M. Standleyȫ

‫۾‬
Ⴒ
ঔ

ɜࡄ‫ݪ‬ඤယȆ‫ܢ‬ఞ଼̯ͦͥ‫ض‬୭ȁ̭ͦ́͘྾‫ͅ৽͉ݪࡄ͈ڠע‬Ȃఘඤͤ৾ͤ͢੄̱̹ळ༾͞෽ူ̱̹ळ༾ͬဥ̧̞࣐̱̹̀ͩͦ̀͘ȃ̭͈̠̈́͢
ࡄ‫༹͉༷ݪ‬Ȃ྾‫ͅڠע‬အș̈́౶ࡉ̹̱̱̹̦ͬͣ͘͜Ȃພࡔఘۜஅͅచ̳ͥ྾‫ע‬؊൞͈ࠫ‫ͬض‬ထ௶̱Ȃ྾‫ע‬؊൞͈஠ఘ௨ͬຝৢ̳ͥ౲‫̵̞̱ͭ̀͘ో͉́͘ͅͅٴ‬ȃ̭̠̱̹‫ه‬ఴͬ࣪໚̳̹͉ͥ͛ͅȂ྾‫ע‬ळ༾͈ͼιȜΐϋΈ͞໦ঊͼιȜΐϋΈ͈‫ٳ‬อ͂୆ఘૂ༭‫ڠ‬ȪΨͼ΂ͼϋέ΁ζΞͻ·Αȫ͈൵ව͉ຈါະ‫̳́ࠧخ‬ȃȁ̯ͣͅȂ୆ఘඤ(in vivo)͈́྾‫ע‬ΏΑΞθ͈‫ܥ‬ෝၑٜͬࡄ‫͉̹̳͛ͥͅݪ‬ȂͼιȜΐϋΈܿ੅͈࢜ષ̺̫́̈́
̩Ȃ໤ၑ‫ڠ‬Ȇ΋ϋάνȜΗ΍ͼ΀ϋΑ͈̈́̓͂྾‫͈ڠע‬ဏࣣࡄ‫̳ͦͣ͛͘ݥ̦ݪ‬ȃIFReĆ͉ଲ‫ٮ‬ΠΛί·ρΑ͈ࡄ‫ݪ‬৪ͬಎ‫̱͂ړ‬Ȃ྾‫ͼ͂ڠע‬ιȜΐϋΈܿ੅ƦΨͼ΂ͼϋέ΁ζΞͻ·Α͈͂‫ވ‬൳ࡄ‫ͬݪ‬೒̱̀Ȃ྾‫͈ע‬௖ࡽैဥȂ྾‫ע‬ळ༾‫͈ا଻ڰ‬Θͼ΢ηΒθͬၑٜ̱Ȃ૧̱̞୽ၞͅ‫̹̞ۜ̿ܖ‬அછχ·Ιϋ͈‫ٳ‬อ͞Ȃအș̈́ۜஅછ͞‫܈‬ͅచ̳ͥ྾‫ע‬ၷ༹͈΋ϋΓίΠ஻੄Ȃুࡨ྾‫ע‬৖͈ۛহၷ༹͈‫ٳ‬อͬ࿒ঐ̱̞̳̀͘ȃķĶࠨॳȁAccounts‫א׋‬๯࢐ັ߄ਓව
Ȫౙպȇ୷‫׫‬ȫߊȁȁȁ໦

໹଼ĳĲාഽ

໹଼ĳĳාഽ

໹଼ĳĴාഽ

໹଼ĳĵාഽ

໹଼ĳĶාഽ

૽ȁ࠯ȁ๯ĹĶĺĭķĸĴ

ĹĹĸĭĲĶı

ĹķĴĭĲķĹ

ĹĸĸĭĶĹĲ

ĺĴĳĭĺĸĺ

໤ȁ࠯ȁ๯ĶĵĹĭĺĵĸ

ĸıĵĭĵıĹ

ĶķĸĭĲĵĴ

ĵĸĸĭĹıĺ

ĶĳĸĭĸĹĴ

ࠗĲĭĵıĹĭķĳı

ĲĭĶĺĲĭĶĶĹ

ĲĭĵĴıĭĴĲĲ

ĲĭĴĶĶĭĴĺı

Ĳĭĵķıĭĸķĳ

̷͈ఈਓවȪౙպȇ୷‫׫‬ȫߊȁȁȁ໦

໹଼ĳĲාഽ

໹଼ĳĳාഽ

໹଼ĳĴාഽ

໹଼ĳĵාഽ

໹଼ĳĶාഽ

਋ుࡄ‫ݪ‬๯൝ĲĭıĵıĭĲĹı

ĺıĹĭĹķĲ

ĸĲĲĭĸĸĳ

ķĴĵĭĶķĶ

ķıĲĭĺĸķ

੻‫߄້ܙڠ‬ĴĵĴĭĸĸĳ

ķĹĺĭķĶĵ

ĸķĶĭĸĸĸ

ĸĴıĭĹķĹ

ĳķĳĭĸĲķ

̷ȁ͈ȁఈ

ĳĭıĺı

ĵĭĶıķ

ĵĭıĹĳ

ĵĭĳĹĴ

ĵĭĵĳķ

ĲĭĴĹķĭıĵĳ

ĲĭķıĴĭıĳĲ

ĲĭĵĹĲĭķĴĲ

ĲĭĴķĺĭĸĲķ

ĹķĺĭĲĲĹ

ࠗ༞੩߄൝ਓවȪ‫ۼ‬୪ࠐ๯ͬ‫͚܄‬ȫȪౙպȇ୷‫׫‬ȫ
ߊȁȁȁ໦

ķķ

໹଼ĳĲාഽ

໹଼ĳĳාഽ

໹଼ĳĴාഽ

໹଼ĳĵාഽ

໹଼ĳĶාഽ

໲໐‫ڠش‬જ‫ݪࡄڠش‬๯༞੩߄ķĹĹĭĺĺĺ

ĵĶĴĭĸĵĵ

ĵķķĭĳĲĳĵĴĺĭĳĹı

ĵĴķĭıĳı࢚୆Ⴛ൱જ‫ݪࡄڠش‬๯༞੩߄ĲĲĹĭĸĹĺ

ĲıĸĭķĴĳ

ĹĸĭĺĲĴ

ĲĴıĭķķĺ

ĳĵĶĭıĵı

࢚୆Ⴛ൱જჇ૽༗࠲মު
ଔૺ๯൝༞੩߄

ĲĴĭĺĹĹ

ııııΈυȜΨσńŐņίυΈρθ
ࠗĩࡄ‫ݶݪ‬തࠁ଼๯൝༞੩߄ĪĲĳıĭıĴĸ

ĹĶĭĵĵĲ

ĸĵĭĺĺĳĸķĭķĶĲıࠗĺĵĲĭĹĲĴ

ķĵķĭĹĲĸ

ķĳĺĭĲĲĸ

ķĵķĭķıı

ķĹĲĭıķı

ົ౷ȟ࠺໤ȁBuilding Areaົ౷ġȤȤġĴķĭıĴķԦ

ӳ

ࠨ
ॳ
ȟ
ົ
౷
ȟ
࠺
໤

࠺໤ġȤȤġ࠺࿂ୟġĹĭĸıĳԦȁ‫װ‬࿂ୟġĴĺĭĺĵĶԦ

ӷ

ӽ

Ӽ

Ӷ

ӹ
ӹ

Ӹ

Ӵ

ӵ

Ӻ

ӱུ‫܁‬ȪऒȫӺဏࣣ߿୆ྵ௙ࣣࡄ‫ݪ‬൓ȪֲȫӱӻӲධȁ‫܁‬

Ӳӷۜஅછ‫ވ‬൳৘ࡑ৒ȆӵӶۜஅ൲໤৘ࡑঔ୭

࠺໤ྴઠ

‫ٴ‬ତ

࠺࿂ୟȪԦȫ

‫װ‬࿂ୟȪԦȫ

ӱུ‫܁‬

ĸ

Ĳĭĸıķ

ķĭĴĺĸ

Ӳධ‫܁‬

ĳ

ĵıĺ

ĺĵĶ

ӳཤ‫܁‬

Ĵ

ĵĺĳ

ĲĭĳĶĳ

Ӵ༆‫܁‬

ĳ

ĸķĹ

ĲĭĶĵĹ

ӵۜஅ൲໤৘ࡑঔ୭˝൓

ĳ

ķĵı

ĲĭĴĺĲ

Ӷۜஅ൲໤৘ࡑঔ୭˞൓

ĵ

ĴĶĶ

ĲĭĵĳĶ

ӷۜஅછ‫ވ‬൳৘ࡑ৒

Ĵ

ĳĵĲ

ĶĶı

Ӹ‫ܥ‬٫൓

ĳ

ĴĸĹ

Ķıĵ

ӹ‫ࡏܓ‬࿪຦ࡩ൝

Ĳ

Ĳķı

Ĳķı

Ӻဏࣣ߿୆ྵ‫ڠش‬௙ࣣࡄ‫ݪ‬൓

Ĳı

Ĳĭıĸĳ

ĺĭĳĶĹ

ӻड୶౤ۜஅછࡄ‫ݪ‬൓

ĺ

ĺĸĴ

ĸĭĵĵĹ

Ӽۜஅ൲໤৘ࡑঔ୭ń൓

ĵ

ĸĴĹ

ĳĭĵĹĳ

ĺ

ĸĸı

ķĭĶĹĶ

ȁȪ྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜ‫ۯ‬ၑȫӽ྾‫ڠע‬έυϋΞͻͺࡄ‫ݪ‬ΓϋΗȜ൓ķĸմඤ଎ȁMap & Access

ਫ਼ ह ౷
ঢदസୌ
ঢྜྷ࿂

࿻௙ٛພ֭

ࣽ‫ݠ‬

ୄକ

઀࿤ࡔ

ೋ஌
֟࿐୫
ຸൽ

᧾࿤

₉

ঢ౻ന

࣭ၛ੏۪‫ܕ‬ພΓϋΗȜ߄၊ౣ‫ܢ‬ఱ‫ڠ‬ঢ‫ނ‬സ࣭ൽĲĸĲ࣢
ཅ୼‫פ‬
֟࿐Ŋń

ঢ‫ނ‬സ

ఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼૧ࢄ൴޼ঢ‫ࡔع‬಴

ఱिఱ‫ڠ‬ġ଑നġġ΅λϋΩΑ

ཤ୷ၖ

୷ၖಎ؇

ঢఱिߗࢽ

ྴ૰ࣞ௸ൽႹκΦτȜσ֟࿐ि‫୷ݢ‬ၖ஌

࣭ၛྦྷ௼‫ڠ‬ฎ໤‫܁‬࢖‫׬‬൐࢛

५ന

ঢ෿ന

ঢౠႹ

ྔ

ฎ

֟࿐ঌ

ŋœ൐٬ൽ஌

ಎ؇۪ે஌ྔฎܱැ࢖‫׬‬ಎ࣭ু൲৬ൽཤఱि‫࣐ݢ‬ঢ෿നिఱພ֭ஜ‫פ‬ि‫ނݢ‬സ஌

ྔฎܱැ࢖‫׬‬
‫ٸ‬
ਔൽ
Ⴙ

଑നŊń

ఱिκΦτȜσ
ֳ࿤༏

߃‫ܪ‬
ু൲৬ൽ

ධ֟࿐

ঢ෿ന

ঢ࿝૯ঌ

ঢઐࡔ

࢐೒մඤ
ঢदസୌ
ఱिఱ‫ڠ‬ȁ଑ന΅λϋΩΑཤ୷ၖྔฎܱැ࢖‫׬‬୷ၖಎ؇ಎ࣭ু൲৬ൽ

ఱिߗࢽ

ঢ૧૰࡫

౷‫ئ‬ഘ
ࢄ൴޼஌

ྴ૰ࣞ௸ൽႹ

૧ఱिঢ‫ނ‬സ ঢ‫ނ‬സ५നि‫୷ݢ‬ၖ஌

ཤఱि‫࣐ݢ‬

ঢ༯೓

िఱພ֭ஜ

ུ஌

ൽ
൐٬

ঢ࿝૯ঌ

஌
૧ۚ

߃‫ুܪ‬൲৬ൽ

ఱि
Ȫ෿നȫ

ঢ૰࡫

೧‫ޘ‬
ఱि۪ે஌

߃ഘජၻ஌

ঢජၻ

̈́ͭ͊
ŋœ
ධ٬஌

૧ۚ஌

ഛؐ঳
िგ஌

κΦτȜσ

ঢ‫۾‬ୌ࣭षߗࢽȆგ‫ظ‬५ɜഩȁȁȁ৬ȁि‫ݢ‬ഩ৬୷ၖ஌ȁཤ୷ၖ‫ئפ‬৬ȁര༜Ĳĳ໦ɜκΦτȜσȁఱिκΦτȜσदസ஌ȁिఱພ֭ஜ‫ئפ‬৬ȁര༜ĳı໦ɜΨȁȁȁΑȁि‫ݢ‬ΨΑȁ୷ၖಎ؇อȁȶ઀࿤ࡔ൐࣐ȷ
Ȃȶཅ୼‫࣐פ‬ȷྌ͉ȶີআ‫غ‬ब࣐ȷिఱ࢛‫ئ‬৬ȁര༜Ķ໦ȁȁȁȁȁȁȁि‫ݢ‬ΨΑȁ୷ၖಎ؇อȁȶिఱུ໐ஜ࣐ȷྌ͉ȶ֟࿐๼༠ώ‫࣐ݚ‬ȷȁȁȁȁȁȁȁ߃ഘΨΑȁि‫֟ݢ‬࿐ঌ‫פ‬อȶिఱུ໐ஜ࣐ȷȪŋœ֟࿐‫ࠐפ‬ဇȫिఱུ໐ஜ‫ئ‬৬ȁര༜Ĳĳ໦ġķĹմ଑ന΅λϋΩΑඤ଎ᚤ⏕≀⑓◊✲ᡤ䜻䝱䞁䝟䝇䝬䝑䝥

8
䝞䝇೵
㜰኱ཱྀ

2
1

኱㜰䝰䝜䝺䞊䝹
㜰኱⑓㝔๓㥐

3

༓㔛㛛

ᮾ㛛
す㛛
䝞䝇೵
㜰኱ᮏ㒊๓

9

4

7

6
5

㜰ᛴ໭༓㔛㥐ṇ㛛୓༤グᛕබᅬ

1ᚤ⏕≀⑓◊✲ᡤ6་Ꮫ㒊㝃ᒓ⑓㝔

2ච␿Ꮫ䝣䝻䞁䝔䜱䜰◊✲䝉䞁䝍䞊7ᮏ㒊஦ົᶵᵓ

3

ᕤᏛ◊✲⛉

8

⏘ᴗ⛉Ꮫ◊✲ᡤ

4་Ꮫ⣔◊✲⛉

9ṑᏛ㒊㝃ᒓ⑓㝔5⏕࿨ᶵ⬟◊✲⛉

อ࣐ȁఱिఱ‫ڠ‬๷୆໤ພࡄ‫ݪ‬ਫ਼ࢩ༭տ֥ٛȁɧ565-0871 ଑നঌ५ന‫ݚ‬3๔1࣢
TELȪ06ȫ6877-5111ȪయນȫȁFAXȪ06ȫ6879-8266ȁURL http://www.biken.osaka-u.ac.jpķĺ